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Abstract 
Substance use, substance use disorders (SUDs), and psychiatric disorders are prevalent, comorbid 
and heritable. Substance use is common in people with psychiatric disorders, psychological distress, 
or somatic distress. These conditions may be further complicated by the tendency to use multiple 
substances. I hypothesised that shared genetic risk underlay these co-occurring conditions. I tested 
this hypothesis by investigating the common and specific genetic influences underlying the use of 
different substances, SUDs, and some common psychiatric disorders. 
Chapter 1 will give a background for the phenotypes and statistical methods used in the four results 
chapters. 
Chapter 2 estimated the genetic and environmental influence on the variation of four groups of 
disorders, including psychological distress, somatic distress, affective disorders, and substance use, 
by conducting twin modelling (N=1548~ 2132 twin individuals). Firstly, I modelled the four disorder 
groups separately with item response theory (IRT) to create an IRT theta score as a refined phenotype 
for each of them. These IRT scores and other relevant phenotypes were then analysed with univariate 
and multivariate twin modelling. I provided the first evidence that the psychological distress and 
somatic distress were heritable and that the covariation between these two subscales was largely 
explained by common genetic factors. In addition, I identified an independent pathway model that 
best explained the covariation between the four IRT scores. This model showed the covariation was 
largely explained by environmental factors (53%~ 64%) that were specific to each of the four 
phenotypes. Genetic factors common to the four phenotypes explained a small but non-negligible 
portion (3%~22%) of the covariation. 
Chapter 3 tested the associations between licit substance use and illicit substance use. I first 
calculated polygenic risk scores (PRS) using genome-wide association study (GWAS) meta-analysis 
summary statistics derived from a large discovery sample GWAS & Sequencing Consortium of 
Alcohol and Nicotine use (GSCAN; 258,797- 632,802 subjects) for four smoking and one alcohol 
phenotypes: regular smoking initiation (PRS-SI), age of initiation of regular smoking (PRS-AI), 
cigarettes per day (PRS-CPD), smoking cessation (PRS-SC), and drinks per week (PRS-DPW). These 
PRSs were then used to predict individual differences in a total of 22 substance use phenotypes in an 
independent target sample of 2,463 young Australian adults. PRS-SI explained variation in the 
liability of initiating cocaine (0.67%), amphetamine (1.54%), hallucinogens (0.72%), ecstasy (1.66%) 
and cannabis initiation (0.97%), as well as DSM-5 alcohol use disorder (0.72%). PRS-DPW explained 
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0.75%, 0.59% and 0.90% of the variation of initiating cocaine, amphetamine and ecstasy use 
respectively. This study provided the first evidence for genetic overlap between the polygenic risks 
for smoking or alcohol, and the risk of initiating major classes of illicit substances. 
Chapter 4 tested the associations between the same set of the five PRS used in Chapter 3 and 
individual differences in 15 licit substance use and common psychiatric disorders in 13,999 
Australian adults. Ten out of 75 pairwise-combinations of discovery and target phenotypes remained 
significant after correcting for multiple testing. PRS-SI  was positively associated in the independent 
target sample with smoking initiation, drinks per week, conduct disorder, and nicotine dependence 
defined by DSM-IV and FTND (R2 range: 1.98% ~ 5.09%). PRS-AI was negatively associated with 
DPW (R2: 3.91%). PRS-CPD was positively associated with DSM-IV nicotine dependence and 
conduct disorder (R2: 1.56% ~ 1.77%). PRS-DPW was positively associated with DPW only (R2: 
3.39% ~ 6.26%). A significant interaction between PRS and sex was detected in the associations 
between DPW and PRS-SI, PRS-AI or PRS-DPW. I provided the first evidence for the association 
between polygenic risk for smoking and risk for conduct disorder. 
Chapter 5 investigated the phenotypic associations, genetic correlations and causal associations 
between the initiation or use of four common substances alcohol, caffeine, cannabis, and nicotine. 
GWAS summary results for ten traits were derived or obtained from three large samples GSCAN, 
UK Biobank (UKB), and International Cannabis Consortium (ICC). After correcting for multiple 
testing, 33 of the 45 trait pairs were genetically correlated. Results from two-sample Mendelian 
randomisation (MR) estimators showed that most exposure and outcome traits were not causally 
associated. However, a causal relationship was found between regular smoking initiation and caffeine 
consumption, with two-fold increased prevalence of regular smoking initiation causally associated 
with an increase of 40.17 mg caffeine consumed. This association was robustly resistant to horizontal 
pleiotropy and SNP outliers. 
In conclusion, I showed that the association between psychological distress and somatic distress was 
largely due to genetic covariance. I identified shared genetic risk between the use of tobacco or 
alcohol, and the risk for initiating five different illicit substances, nicotine dependence, and conduct 
disorder. Using various MR approaches, I provided evidence for a positive causal effect of regular 
smoking initiation on caffeine consumption. These findings suggest that substance-substance or 
substance-disorder associations were partially driven by shared genetic aetiology, but I found little 
evidence for causality in most of the exposures and outcomes. 
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 Introduction 
Psychiatric disorders and substance use 
Psychiatric disorders and substance use are common, prevalent and heritable. Psychiatric disorders 
are generally characterised by abnormal thoughts, perceptions, emotions, behaviour and relationships 
with others. This can have a detrimental impact on various aspects of our life, from physical health, 
work, education, to even housing, driving, and parenting. Use or misuse of a substance, licit or illicit, 
is common in those with psychiatric disorders. This comorbid condition can be further complicated 
by the use of multiple substances. This thesis aims to explore genetic influences on the association 
between psychiatric disorders and substance use, and between the use of different substances in 
general populations. 
This introductory chapter will provide background information about the traits of interest, statistical 
methods used to analyse them, an overview for the data sources and the main aims of the four results 
chapters (Chapter 2 ~ Chapter 5). 
The burden of disease attributed to psychiatric disorders and 
substance use disorders 
The burden of disease is a measure for the impact of diseases, as assessed by the Global Burden of 
Diseases, Injuries, and Risk Factor Study (GBD), one of the largest global efforts to understand the 
impact of diseases worldwide since 1990 [1]. The burden is calculated as three health metrics: (1) 
years of life lost (YLL) due to premature mortality, which measures the time people lose when they 
die before attaining their ideal life expectancy, (2) years of life lived with disability (YLD), which 
calculates the amount of time in a year that people live with any health conditions, and (3) disability-
adjusted life years (DALY), which simply adds YLL and YLD together (metric definitions available 
at (http://www.healthdata.org/acting-data/what-we-measure-and-why). The DALY is becoming the 
principle metric of the GBD studies, because this metric allows the burden from all causes of illness, 
both fatal and non-fatal burden, to be compared across different diseases.  
The GBD released in 2010 was the first re-analysis that comprehensively estimated disease burden 
from GBD 1990, 2005 to 2010. Importantly, this GBD considered the uncertainty for each disease, 
comorbidity between diseases, and employed a systematic literature review to obtain all available 
epidemiological data; it also separated mental disorders and SUDs from neurological disorders [2,3]. 
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According to the GBD 2010, mental disorders and SUDs were the leading cause of YLDs worldwide, 
accounting for 7.4% (6.2–8.6) of global DALYs and 22.9% of global YLDs [4].  
More recently, the findings from the GBD 2015 [5] showed that the burden of mental and substance 
use disorders remained the leading contributor to non-fatal burden in Australia, explaining 24.3% of 
total YLD and 14.6% of total DALY. The period between 1990 and 2015 saw no significant change 
in the DALY rates but increased YLLs over time due to SUDs [6]. This is the background to my 
investigation of the genetic architecture of substance use, SUDs, common psychiatric disorders, as 
well as the causal relationship between the use of multiple substances in this thesis. 
Prevalence of substance use 
Caffeine is the most commonly consumed addictive substance, followed by nicotine, alcohol, and 
illicit psychoactive stimulants. Frary et al. (2005) found 87% of the US population consumed caffeine 
in forms of coffee, tea, or other caffeinated food. The 2014 global statistics on addictive behaviour 
revealed that 22.5% of adults (~1 billion) smoke tobacco products and that 4.9% of adults (240 
million) suffer from alcohol use disorder [8].  
The prevalence of substance use in Australia is largely consistent with the other first-world countries. 
Nearly 46% of the Australian population consumes coffee (survey result available at 
https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.007~2011-
12~Main%20Features~Non-alcoholic%20beverages~701). Tobacco and alcohol are commonly 
abused licit substances (SU) in Australia. Approximately 20% of Australians aged 14 or older have 
reported daily tobacco use, while 17% of the same age cohort have reported risky alcohol 
consumption at least once [9]. Cannabis is the most commonly used and abused illicit substance 
(Verweij et al., 2017), accounting for approximately 3.5% (174 million) prevalence in adults 
worldwide [8]. Use of illicit substances is particularly worrying to Australians. The findings from the 
GBD 2010 showed that Australia had a relatively higher prevalence of cannabis dependence [11], 
opioid dependence [12] and amphetamine dependence [13] than the other countries. 
Co-occurring use of different substances is common 
The use of multiple substances is common. Among current middle-aged alcohol dependents, 
approximately 90% of them smoke [14]. Smoking quantity and the rate of nicotine dependence are 
positively correlated with the amount of alcohol consumption and the presence of an alcohol use 
disorder [15]. The majority of cocaine users smoke cigarettes [16]. The vast majority of regular 
cocaine smokers also smoked marijuana, tobacco or both [17]. Co-occurring use and misuse of 
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cannabis and tobacco are very common (reviewed by Agrawal et al. 2012). The majority of 
methamphetamine users smoke tobacco [19]. Alcohol and methamphetamine are commonly co-used 
[20]. While there has been an increasing research effort on the role of genetic influence on substance 
use (Agrawal et al., 2012a; Agrawal et al., 2012b; Cross et al., 2017; Weinberger and Sofuoglu, 2009; 
Yang et al., 2010), it remains unclear the extent to which the co-occurring conditions are due to 
genetic overlap. 
Why are comorbid psychiatric disorders and substance use 
disorders so common? 
Over the past 20 years, psychiatric disorders and substance use disorders have been commonly found 
to be comorbid disorders. For example, individuals with mood disorders were twice as likely to use 
drugs compared to those without mood disorders [25]. A large community survey in the US revealed 
that among individuals with major depression 16.5% had an alcohol use disorder (AUD) and 18% 
had a drug use disorder [26]. Comorbidity of mental disorders and substance misuse, which results 
in considerable disability, occurred in 12% of Australian patients attending general practice [27]. 
According to the National Survey on Drug Use and Health (NSDUH) in 2014, an estimated 43.6 
million (18.1%) Americans aged ≥ 18 years experienced some forms of mental illness. In 2015, 20.2 
million adults (8.4%) had a SUD. Of these, 7.9 million people had both a mental disorder and 
substance use disorder [28]. 
The co-occurring conditions may be explained by common risk factors, such as (1) increased risk for 
one disorder by another disorder, (2) overlapping neuronal circuits in mental disorders and SU, (3) 
underlying genetic risk factors common to both groups of disorders, and (4) confounded diagnosis of 
one disorder by another disorder [29]. Particularly interesting is the possibility that the comorbidity 
may be influenced by common genetic risk factors and environmental risk factors, which can be tested 
by genetic association studies [30–35]. Having reviewed 94 articles, Cerdá and colleagues reported 
that the relationship between conduct disorder and substance abuse were influenced by genetic and 
unique environmental factors. Another review by Tsuang et al. (2012), based on both behavioural and 
molecular genetic evidence, concluded that nicotine dependence and depression were likely to be 
influenced by common genetic mechanisms. The nature of the psychiatric comorbidity, however, 
remains understudied. 
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Statistical methods used in this thesis  
To better understand the genetic architecture of substance use and psychiatric disorders, I applied a 
variety of statistical methods to raw data on phenotypes of interest, or to summary statistics from 
genome-wide association studies (GWAS). All phenotypes analysed in this thesis were self-reported 
measures collected in mailed, telephone, or online surveys. Classic test theory (CTT) and item 
response theory (IRT) modelling are two commonly used methods applied to survey data involving 
a series of related items. Twin design was used to partition the variation of a single phenotype, or the 
covariation between multiple phenotypes into genetic and environmental components. GWAS 
analysis was used to associate a phenotype and single nucleotide polymorphism (SNP) genotype. 
Polygenic risk score analysis was used to test the association between a phenotype and genotype that 
sums up risk alleles from clumped SNPs. Linkage disequilibrium (LD) score regression [37] was used 
to calculate SNP-based heritability or genetic correlation between GWAS conducted separately for 
two different phenotypes. Two-sample Mendelian randomisation (MR) was used to investigate the 
causal relationship between an exposure and an outcome variable measured in two non-overlapping 
samples, using genetic instrumental variables that were associated with the exposure.  
Classical test theory 
The origin of classical test theory  
According to [38], classical test theory (CTT) can be traced back to Charles Spearman’s work on 
determining and measuring general intelligence [39]. Spearman showed how to correct a correlation 
coefficient for attenuation due to measurement error and how to index reliability needed for making 
the correction. 
What is classical test theory? 
Classical test theory (CTT) is a psychometric theory that assumes a person’s observed score on a test 
is the sum of his/her true score and an error score. The true score reflects the construct of interest (e.g. 
intelligence, depression) while the error score reflects the error in the measurement of the construct 
of interest (e.g. misunderstanding of questions, chance responses due to guessing). Suppose test-
takers who knew exactly 80% (i.e. their true scores) of a subject covered in a course ended up scoring 
75% to 85% (i.e. their observed scores). The 5% discrepancy from their true scores is the error (score). 
Hypothetically, their observed scores should be equal to their true scores if the test is taken for an 
infinite number of times. Under the CTT, item scores are usually summed to generate a total score 
without weighting or standardization [40]. 
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The CTT poses a number of problems. Each item is assumed to equally contribute to the total score. 
Without attaching different weights to each item, the total score is simply the sum of the scores from 
individual items, irrespective of how well each item correlates with the underlying construct. In 
addition, it is very difficult to equate scores that a respondent receives on multiple tests, which poses 
a problem for longitudinal studies. The usual approach to equating scores is to convert the scores to 
t- or z-scores or to use percentile equating. However, this approach requires that all the sum scores 
are normally distributed. The limitations of CTT have been discussed in the book by Streiner et al. 
2014.  
Item response theory (IRT) 
What is item response theory? 
While CTT mainly focuses on the test-level information, item response theory (IRT) primarily 
focuses on item-level information [42]. The IRT shows the relationship between the level of a latent 
trait and responses to individual questions (items) of the scale.  
It is important to note that IRT is primarily developed in the field of education. Different terminology, 
however, may be used in other fields. The underlying construct of interest is often described as a 
person’s ability in the context of educational measurements (e.g. reading comprehension in the verbal 
section of the Graduate Record Examination). However, the underlying construct of interest is best 
described as a latent trait (e.g. level of depression) rather than ability in the context of mental health 
assessment [43]. Item difficulty, taken from educational psychology, maybe better described as item 
severity in the health-care setting [44].  
In IRT models, the relationship between the level of a person’s latent trait and their probability of 
endorsing a particular response option of an item is graphically characterised by the item response 
function (IRF), also known as item characteristic curves (ICC), or item response step function for 
polytomous items (IRSF). Hambleton and Jones (1993) compared CTT with IRT with respect to 
assumptions, model linearity, level of information, levels of latent traits, relationship between items 
and trait level, sample sizes, and so on [45]. 
Assumptions in IRT 
Three assumptions underlying IRT models are unidimensionality, local independence, and 
monotonicity of IRFs. Unidimensionality means that all items in a scale measure a single latent trait, 
and the amount of the trait is the only factor influencing the probability of endorsing an item [46]. 
Local independence, or conditional independence, means that for people at the same level of a trait, 
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the probability of answering any question in the positive direction should not be influenced by the 
probability of answering any other questions positively. If these two assumptions are met, the 
relationship between a person’s responses to the items and their trait level can be described by an 
IRF. The third assumption, monotonicity of IRFs, means the probability P(θ) is monotonically non-
decreasing along θ. 
Parametric IRT versus Nonparametric IRT 
In a parametric IRT model, IRFs are assumed to be logistic, hence always monotonic. That is, the 
IRF increases first slowly, then rapidly, and slowly again. Parametric IRT models include 1-parameter 
IRT models (1-PL IRT), 2-parameter IRT models (2-PL IRT) and 3-parameter IRT models (3-PL 
IRT). The 1-PL IRT, also called the Rasch model, holds the item discriminability constant and only 
the item difficulty is estimated for each item. The 2-PL IRT models item discriminability and 
difficulty. The 3-PL IRT further includes a guessing parameter (pseudo-chance-level parameter). For 
example, students with lower ability may correctly guess on a multiple-choice test item. Similarly, 
participants could randomly answer the items in a survey, likely due to boredom or incomprehensible 
questions.  
Non-parametric IRT (NIRT) models, however, carry no assumptions about the underlying shape of 
the IRF [47]. Items are allowed to have IRFs that are not in a non-decreasing shape, allowing the 
better fit to the data with the NIRT models. In addition, NIRT models do not constrain the IRF to be 
monotonic and whether this IRT assumption holds can be investigated. In this thesis, the SPHERE-
12 was validated using the nonparametric graded response model (np-GRM), which is the most 
general NIRT model, while having the simplest definition of its IRF. 
Classical twin studies 
Univariate twin modelling 
In a univariate twin study, the goal is usually to estimate the relative contribution of additive genetic 
factors to the variation of a phenotype of interest, also known as heritability, using data from groups 
of monozygotic (MZ) twins and dizygotic (DZ) twins. This design assumes that MZ twins share 100% 
of their genes whereas DZ twins share on average only 50% of their genes. If the trait correlates 
between MZ twins (rMZ) to a greater extent than the trait correlation between DZ twins (rDZ), it 
usually implies that the addictive genetic factor explains a significant portion of the trait variation. 
The heritability is then calculated as twice the difference between rMZ and rDZ using the most 
parsimonious model.  
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Multivariate twin modelling 
When multiple traits are of interest, multivariate twin models can be used to partition the covariation 
between these traits into sources of genetic and environmental factors that are common to these traits, 
or that are specific to each of them. Various multivariate models can be found in a book chapter by 
Posthuma (2009) [48]. 
Genome-wide association studies  
The GWAS analysis tests the association between a phenotype and SNPs. Given it is usually assumed 
the test is conducted approximately one million times, one SNP at a time, across the whole genome, 
the significance level is usually adjusted as 5e-8 (i.e. nominal p value of 0.05 divided by one million). 
It should be noted that different software is available. For instance, raremetalworker can be used on 
subjects who are related or unrelated to each other (software available at 
https://genome.sph.umich.edu/wiki/RAREMETALWORKER). For unrelated individuals, plink [49] 
is commonly used for binary phenotypes in a case-control setting, whereas BOLT-LMM is commonly 
used for continuous traits [50]. 
SNP-based heritability  
While twin-based heritability is estimated based on the phenotypic difference between twin groups, 
SNP-based heritability is estimated using SNP data from a GWAS. The term SNP- heritability refers 
to the proportion of phenotypic variance that is explained by a given set of SNPs. Linkage 
disequilibrium score regression (LDSC) and genome-based restricted maximum likelihood 
(GREML) are common estimators for calculating SNP-heritability. Although the accuracy of 
heritability estimates can differ between LDSC and GREML, selecting a suitable estimator usually 
depends on the data source. LDSC maybe more popular than GREML because it simply requires 
GWAS summary results. The GREML estimator, however, requires individual-level information on 
a phenotype and the genetic relationship between subjects. Unfortunately, these two pieces of 
information are not always accessible to researchers. The LDSC estimator was used in Chapter 5. 
Polygenic risk scoring 
Polygenic risk score (PRS) analysis usually follows up a completed GWAS. Note that different names 
can be used for the PRS in literature, such as genetic (risk) scores, genome-wide (risk) scores, and 
polygenic scores. In PRS studies, a discovery sample refers to the training GWAS whereas a target 
sample refers to the testing dataset consisting of individuals, their SNP genotype (or dosage) and 
phenotypes of interest. The SNP genotype is usually imputed and dosage is given to an SNP based 
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on the probabilities of the three possible genotypes at the SNP locus. A risk score at an SNP is then 
calculated by multiplying the dosage by the effect size of the SNP in the discovery GWAS sample. 
Effect size β is used if the GWAS is conducted on a continuous trait. When the GWAS is conducted 
on a binary trait, the effect size can be obtained by log-transforming the odds ratio. Finally, risk scores 
are summed up across all the selected SNPs that are carried by an individual, resulting in one PRS 
per individual in the target sample. This individual-level PRS can then be used to predict the 
phenotypes of interest.   
Two-sample Mendelian randomisation 
What is Mendelian randomisation? 
Mendelian randomisation studies rely on the use of genetic variation as an instrumental variable (IV) 
to estimate the causal effect of an exposure on a related outcome. The IV is simply a third variable 
that is associated with an environmentally modifiable exposure, but not associated with any 
confounder of the exposure-outcome association, nor is there any causal pathway from the IV to the 
outcome other than via the exposure [51]. 
Mendelian randomisation versus randomised controlled trial 
MR can be thought of a study design that mimics a natural randomised controlled trial (RCT). In an 
RCT, subjects are randomly assigned to the experimental group receiving the intervention that is 
being tested, or the other group receiving a placebo (control group) or an alternative treatment 
(comparison group). The two groups are then followed up to see if there is a difference in their 
outcome. The MR studies, however, are usually applied in a setting in which conducting an RCT on 
human subjects is unethical or impractical, say assessing the effect of smoking on lung diseases. 
The principle underlying MR originates from Mendel’s law of independent assortment (segregation), 
which assumes that the alleles of two or more different genes are independently sorted into gametes 
during meiosis, and therefore the inheritance of one trait is independent of the inheritance of other 
traits. While the allelic segregation is analogous to the subject randomisation process in the RCT, the 
allelic randomisation occurs at conception and the causal effect estimated in an MR study represents 
the long-term effect of the exposure [52]. Evans and Davey Smith (2015) have compared findings 
from MR studies with those from RCTs for some common human diseases [52], a good starting point 
for researchers who are running MR for the first time. 
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Mendelian randomisation versus Observational studies 
Observational studies are known to have limited ability to identify whether exposure is causally 
related to an outcome. Associations found in an observational study are likely to be affected by 
residual confounding and reverse causation. Although it is possible to adjust confounding for factors 
that are identified and measured, some degree of residual confounding will always remain [53]. 
Reverse causation is an effect of the outcome on the studied exposure.  
Unlike the traditional observational studies, MR is designed to leverage genetic variation and use 
genetic variants as an instrumental variable (i.e. proxy) for an environmentally modifiable exposure, 
rather than directly measuring the exposure. Because genetic variants were allocated to the gametes 
before the birth of an individual, using the variants as the proxy, as Smith and Ebrahim described 
[54], will not be confounded in the way that the exposure and outcome are measured in traditional 
observational associations. MR can circumvent both residual confounding and reverse causation. This 
random allocation of genetic variants from parents to their offspring means these variants will 
generally be unrelated to other factors that affect the outcome [55]. Moreover, associations between 
the genotype and the outcome will not be influenced by reverse causation because diseases do not 
affect genotype [55]. 
Assumptions in Mendelian randomisation 
Mendelian randomisation studies that use genotype as an instrumental variable are expected to fulfil 
three IV assumptions [56]: (1) the genotype is associated with the exposure; (2) the genotype is 
associated with the outcome through the studied exposure only, also known as the exclusion 
restriction assumption; and (3) the genotype is independent of other factors which affect the outcome, 
also known as the independence assumption. Potential threats to the validity of these assumptions, 
such as linkage disequilibrium, pleiotropic effects, and population stratification have been discussed 
in details [55,57]. MR is increasingly used in etiological studies; however, various statistical models 
have been proposed to refine IV estimation of causality (see Boef et al. 2015 for a review of MR 
studies published between 2003 and 2013). 
What is two-sample Mendelian randomisation? 
The two-sample Mendelian randomisation method [58] typically uses data from GWASs that are 
conducted in two non-overlap samples of the same ancestry. This method is efficient because 
individual-level data are not required, yet GWAS summary results are increasingly available from 
larger samples. It should be noted that a variety of two-sample MR estimators exist and researchers 
usually seek consistent causal estimates from these methods. Usually, the inverse variance weighted 
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(IVW) estimator is used to give a first indication of whether there is a causal effect, and then the 
different sensitivity analyses, with different underlying assumptions, are used to examine how robust 
the IVW estimates are. The rationale for this analytical flow is that multiple genetic variants are 
usually used as IVs in the context of a two-sample MR but it is implausible that every IV can meet 
all the assumptions required. 
Data sources 
I categorised the traits analysed in this thesis into five groups: psychological distress, somatic distress, 
psychiatric disorders, licit substance use (disorders), and illicit substance use (disorders). These traits 
were (1) self-report phenotypes collected through surveys from two Australian cohorts at QIMR 
(19Up and adults), UK Biobank, or (2) GWAS summary results obtained from International Cannabis 
Consortium (ICC), and GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN). 
Caution was taken to keep these samples non-overlapping in the chapters that used polygenic risk 
score analysis and two-sample MR. These traits are listed in Table 1-1.   
Table 1-1 Phenotypes analysed in the result chapters and the sources of data. Letters under 
the Chapter header indicate the source of data where the phenotype was recorded: a for 
QIMR 19up (sample size: 1548- 2132 twins), b for QIMR adults (sample size: 13,999 twins 
and their families), c for GSCAN (258,797- 632,802 subjects), d for UK Biobank (sample 
size: 25,153-296,735 subjects), and e for ICC (sample size: 164,742 subjects).  
Trait group Trait Chapter 
2 3 4 5 
Psychological distress IRT score a    
Somatic distress IRT score a    
Psychiatric disorders DSM-IV depressive disorder   b  
 DSM-5 depressive episodes a    
 DSM-5 major depressive disorder a    
 DSM-5 agoraphobia a    
 DSM-5 panic attack     
 DSM-IV panic disorder   b  
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 DSM-5 panic disorder a    
 DSM-5 social anxiety a    
 DSM-IV social phobia   b  
 DSM-IV Mania   b  
 DSM-5 manic episodes a    
 DSM-IV conduct disorder   b  
 DSM-IV antisocial personality disorder   b  
Licit substance use 
(disorder) 
Alcohol initiation a  bc  
 Drinks per week  c bc c 
 Estimated standard drinks per week    d 
 DSM-IV Alcohol abuse  a   
 DSM-IV Alcohol dependence  a b  
 DSM-5 alcohol use disorder a a   
 Regular smoking initiation a c bc c 
 Age at starting regular smoking  c bc c 
 Cigarettes per day  c bc cd 
 Pack years of smoking    d 
 Smoking cessation  c bc c 
 DSM-IV nicotine dependence   b  
 FTND-based nicotine dependence   b  
 Caffeine consumed per day through regular coffee 
or tea 
   d 
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Illicit substance use 
(disorder) 
Cocaine initiation a a   
 Amphetamine initiation a a   
 Inhalant initiation a a   
 Sedative initiation a a   
 Hallucinogen initiation a a   
 Opioid initiation a a   
 Ecstasy initiation a a   
 Prescription pain killer initiation  a   
 Prescription stimulant initiation a a   
 Cannabis initiation  a  e 
 DSM-IV Cannabis abuse  a   
 DSM-IV Cannabis dependence  a   
 DSM-5 cannabis use disorder a a   
 
Main aims of results chapters 
The main aim of this thesis was to better understand the genetic architecture of comorbidity between 
psychiatric disorders, substance use behaviour, and substance use disorders. A variety of genetic 
association approaches were applied to two phenotypically associated traits to answer a series of 
questions, including how the two traits were genetically correlated, whether common genetic variance 
could explain their association, or whether causality could be established between these phenotypes 
and could explain their covariation. This thesis consists of four results chapters, each representing a 
manuscript that is published or accepted by a journal. Chapter 2 addressed the nature-versus-nurture 
question by first estimating the genetic contribution to the variation of a single phenotype, and then 
by estimating the relative contribution of genetic and environmental influence to the covariation 
between multiple phenotypes. Chapter 3 and Chapter 4 addressed the question of whether common 
genetic risk factors could explain the associated traits. I first constructed polygenic risk scores (PRSs) 
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for individuals in the 19Up young adult sample and QIMR adult sample using the very large GSCAN 
GWAS meta-analysis (excluding Australian samples, to ensure the independence of prediction at 
target samples) on tobacco or alcohol use. The PRSs were then used to predict individual differences 
in the initiation of illicit substances (Chapter 3), licit substance use, substance use disorders, and 
psychiatric disorders (Chapter 4). Chapter 5 answered the question of whether causality could be 
established between traits that were found genetically correlated. I applied a variety of two-sample 
Mendelian randomisation approaches to traits related to the quantitative use or initiation of substance 
use behaviour. 
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Abstract 
Psychological distress (PSYCH), somatic distress (SOMA), affective disorders (AD), and substance 
use (SU) frequently co-occur. The genetic relationship between PSYCH and SOMA, however, 
remains understudied. We examined the genetic and environmental influences on these two disorders 
and their comorbid AD and SU using structural equation modelling. Self-reported PSYCH and 
SOMA were measured in 1,548 twins using the two subscales of a 12-item questionnaire, the Somatic 
and Psychological Health Report. Its reliability and psychometric properties were examined. Six ADs, 
involvement of licit and illicit substance, and two SU disorders were obtained from 1,663–2,132 twins 
using the World Mental Health Composite International Diagnostic Interview and/or from an online 
adaption of the same. SU phenotypes (heritability: 49–79%) were found to be more heritable than the 
affective disorder phenotypes (heritability: 32–42%), SOMA (heritability: 25%), and PSYCH 
(heritability: 23%). We fit separate non-parametric item response theory models for PSYCH, SOMA, 
AD, and SU. The IRT scores were used as the refined phenotypes for fitting multivariate genetic 
models. The best-fitting model showed the similar amount of genetic overlap between PSYCH–AD 
(genetic correlation rG= 0.49) and SOMA–AD (rG=0.53), as well as between PSYCH–SU (rG= 0.23) 
and SOMA–SU (rG= 0.25). Unique environmental factors explained 53% to 76% of the variance in 
each of these four phenotypes, whereas additive genetic factors explained 17% to 46% of the variance. 
The covariance between the four phenotypes was largely explained by unique environmental factors. 
Common genetic factor had a significant influence on all the four phenotypes, but they explained a 
moderate portion of the covariance. 
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Introduction 
Psychological Distress and Somatic Distress 
Psychological distress (PSYCH) and somatic distress (SOMA) commonly co-occur [59–62]. PSYCH 
can be described as a negative feeling that affects a person’s life. This discomfort is usually 
manifested as anxiety, frustration, hopelessness, sadness, or worthlessness. SOMA, also known as 
somatoform disorder or somatization syndrome, can involve various bodily discomforts such as 
prolonged fatigue, pain, tiredness, or sleep disturbance [63,64]. The prevalence of PSYCH and 
SOMA tends to vary across studies, likely due to the heterogeneous definition of the distress and the 
group from which the distress is measured. An analysis of five Australian National Health Surveys 
found that a high level of PSYCH affected 11.1–13.4% of the population aged 18–65. This prevalence 
remained fairly stable from 2001 to 2014 [65]. In primary care settings, approximately 9.5% of 
Australian general practice attendees had a very high level (K10 ≥ 30) of PSYCH [59]. Somatization 
syndromes based on the Patient Health Questionnaire, on the other hand, occurred in 9.3% of the 
German general population [66]. A higher prevalence has been reported in clinical samples, with 
16.1% of Dutch general practice participants reporting somatoform disorders as classified in the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [60], and 18.5% of Australians 
being classified as somatisers [59]. Despite the varying prevalence, a common finding in the studies 
is a high comorbidity of PSYCH, anxiety/depressive disorder, and somatoform disorders [59,60,67–
71]. A higher level of distress, as measured by the 10-item Kessler Psychological Distress Scale [72], 
is associated with a higher probability of meeting criteria for a mental disorder or substance use (SU) 
disorder [73,74].  
SPHERE-12 for Measuring PSYCH and SOMA 
The 12-item Somatic and Psychological Health Report (SPHERE-12) is shortened from the original 
34-item SPHERE for screening mental illnesses that are commonly found in primary care settings 
and for use in research [75]. The SPHERE-12 questionnaire consists of two six-item sub-scales: the 
PSYCH-6, measuring PSYCH, and the SOMA-6, measuring SOMA. 
Short questionnaires can be advantageous as short instruments with 12 or fewer items, such as the 
Beck Depression Inventory-Short Form (BDI-SF; Beck & Steer, 1993), Patient Health Questionnaire-
9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001), and K10 [72], have been shown to be as accurate as 
longer questionnaires that contain 15 or more items [78] in detecting depression [79]. In addition, 
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they can be completed in a shorter time with lower participant burden and higher completion rates. 
Few studies have focused on PSYCH and SOMA measured with the SPHERE scale [80,81]. 
Classical Twin Studies 
The classical twin study provides a unique opportunity to understand the extent to which a trait or a 
group of related traits is governed by nature or nurture. This method is commonly used to estimate 
the relative importance of genetic or environmental influences on comorbid disorders [82–87]. Twin 
studies typically employ standard error of the mean (SEM), which provides various models to 
partition the variation of a single phenotype, or the covariance of multiple phenotypes, into additive 
genetic component and environmental component. Multivariate twin studies typically find that 
psychiatric disorders are influenced by both genetic and environmental factors [88,89]. 
The Genetic Relationship Between PSYCH and SOMA 
Few studies have examined the genetic aetiology of PSYCH and SOMA [90–94]. Moderate 
heritability has been estimated for PSYCH (0.18– 0.4) and SOMA (0.32–0.43). A high genetic 
correlation (0.84) has been found between PSYCH and SOMA in Australian adolescents and young 
adults  [92], suggesting a large overlapping genetic effect on these two phenotypes. Little is known 
about the genetic relationship between PSYCH, SOMA, and the more severe mental disorders and 
SU. 
Aims 
The objectives of this study were to (1) validate the PSYCH6 and SOMA-6 sub-scales; (2) estimate 
the heritability for the PSYCH-6 and the SOMA-6, as well as CIDI-based assessment of affective 
disorders (AD) and SU; and (3) examine the overlapping genetic influence on the PSYCH-6, SOMA-
6, AD, and SU. We examined the internal consistency and reliability of the PSYCH-6 and SOMA-6. 
We applied the item response theory (IRT) modelling to create refined phenotypes that estimate the 
normalized liability to PSYCH, SOMA, AD, and SU. We estimated the heritability for individual 
AD, SU phenotypes, as well as the IRT theta scores for the four scales (PSYCH-6–IRT, SOMA-6– 
IRT, AD–IRT, and SU–IRT). Finally, we investigated the genetic and environmental influences on 
the covariance between these four IRT scores. 
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Materials and methods 
The 19Up Study 
The Brisbane Longitudinal Twin Study (BLTS, Wright & Martin, 2004) has collected a 
comprehensive array of neurobiological correlates, environmental risk factors, and 
endophenotypes for psychiatric disorders, since its inception in 1992 at QIMR Berghofer 
Medical Research Institute. The current study used data collected in one of the BLTS studies, 
19Up (see Figure 2-1 for details of data collection; Couvy-Duchesne et al., 2018; Nathan A. 
Gillespie et al., 2013). 
 
Figure 2-1 Timeline of data collection of psychological distress, somatic distress, and CIDI-
based psychiatric diagnoses in the 19Up study 
PSYCH and SOMA were assessed with the SPHERE12 questionnaire when the participants were on 
average 26 years old. The SPHERE-12 data were available from all the three waves of the 19Up: 
NU1, NU2, and NU3. In addition, the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5; American Psychiatric Association, 2013) diagnoses were made using an online 
version of the Composite International Diagnostic Interview (CIDI; World Health Organization, 
1990). The CIDI-based diagnoses were collected in NU2 and NU3. The 19Up study was approved 
by the QIMR Human Research Ethics Committee. Data were stored in compliance with national 
regulations regarding personal data protection. Informed consent was obtained from all the 
participants. 
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Participants 
Detailed descriptions of participation rates, sample demographics, and the prevalence of mental or 
SU disorders in the 19Up cohort have been published [96]. The current study only used the data 
collected from twin individuals. The SPHERE-12 sample was comprised of 1,548 twin individuals. 
Their mean age was 25.3 years (age range: 18.4–38.4) and the sex ratio was 56.9% females. The CIDI 
sample was composed of measurements from 2,132 twin individuals. Their mean age was 26.1 years 
(age range: 18.7–38.6) and the sex ratio was 57.8% females. The number of complete twin pairs and 
twin individuals are shown for each study wave and zygosity group in Table 2-1.
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Table 2-1 Number of complete twin pairs and individual twins (parenthetical) in each zygosity and sex group and across all the groups 1 
(sum) from different waves of (1) SPHERE12 questionnaire, (2) diagnostic interviews, and (3) twins who are in both samples (overlapped). 2 
SPHERE12 data were collected from three waves NU1, NU2, and NU3. Diagnostic data were collected from two waves NU2 and NU3.  3 
 SPHERE12  Diagnoses  Overlapped 
zygosity  NU1 NU2 NU3 All waves  NU2 NU3 all waves  all waves 
Monozygotic females  43 ( 98 ) 34 ( 109 ) 65 ( 178 ) 160 ( 385 )  47 ( 144 ) 151 ( 380 ) 232 ( 524 )  154 ( 376 ) 
 
Monozygotic males  14 ( 46 ) 25 ( 86 ) 46 ( 146 ) 102 ( 278 )  27 ( 96 ) 89 ( 265 ) 139 ( 361 )  93 ( 265 ) 
 
Dizygotic females  27 ( 76 ) 13 ( 54 ) 42 ( 125 ) 101 ( 255 )  17 ( 64 ) 127 ( 318 ) 166 ( 382 )  96 ( 248 ) 
 
Dizygotic males  10 ( 41 ) 10 ( 48 ) 22 ( 97 ) 60 ( 186 )  12 ( 57 ) 71 ( 216 ) 100 ( 273 )  52 ( 170 ) 
 
Dizygotic opposite sexes  43 ( 113 ) 20 ( 110 ) 64 ( 221 ) 160 ( 444 )  26 ( 126 ) 155 ( 466 ) 219 ( 592 )  144 ( 421 ) 
 
sum  137 ( 374 ) 102 ( 407 ) 239 ( 767 ) 583 ( 1548 )  129 ( 487 ) 596 ( 1645 ) 860 ( 2132 )  539 ( 1480 ) 
 
 4 
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Measures 5 
Following standard administration procedures, respondents were asked to rate each SPHERE-12 item 6 
on the extent it had troubled them over the previous two weeks: sometimes or never having the 7 
problem (coded as 0), often (coded as 1), and most of the time (coded as 2). Internal consistency of 8 
the SPHERE-12 questionnaire was assessed using Cronbach’s alpha [100] both item by item and for 9 
the whole scale without excluding any items. A small proportion of the participants answered the 10 
SPHERE12 questions in two or three waves, enabling us to evaluate the test-retest reliability of the 11 
questionnaire between (1) NU1 and NU2, (2) NU2 and NU3, and (3) NU1 and NU3. There were 132 12 
participants in both NU1 and NU2, 20 participants in both NU2 and NU3, and 22 participants in both 13 
NU1 and NU3. SPHERE data used for the item-by-item assessment of internal consistency consisted 14 
of 2,122– 2,126 twins and siblings. Phenotypes used in our univariate and multivariate genetic 15 
modelling were composed of measurements per twin individual. For twins with multiple 16 
measurements, their earliest wave was used. 17 
The CIDI was used to assess various lifetime DSM-5 psychiatric criteria to obtain diagnostic 18 
classifications relevant to AD or SU. The AD included agoraphobia, depressive episodes, major 19 
depressive disorder (MDD), panic attack (PA), panic disorder (PD), and social anxiety. The SU 20 
phenotypes included ever using alcoholic beverages, tobacco products, cannabis, non-medical use of 21 
prescription drugs (e.g., pain killers, stimulants), or illicit drugs, such as cocaine, amphetamine, 22 
inhalants, sedatives or sleeping pills, hallucinogens, opioids, and party drugs (e.g., MDMA, ketamine, 23 
or gamma-hydroxybutyrate), as well as alcohol-use disorder (AUD), and cannabis-use disorder 24 
(CUD). We selected six binary AD diagnoses and three ordinal SU diagnoses to construct the AD 25 
and SU scale. 26 
Non-Parametric Item Response Theory Modeling 27 
We employed the non-parametric IRT to evaluate item properties within each psychiatric domain or 28 
scale (i.e., PSYCH-6, SOMA-6, AD, and SU). One advantage of IRT is that item difficulty and item 29 
discriminability are used to weight the items when calculating the IRT score. In addition, IRT makes 30 
it possible to combine information from uniquely measured psychopathology [101]. Consequently, 31 
the IRT score can yield more precise estimation of the underlying trait than a summed score. This 32 
represents an improvement over the classical test theory, in which different items are usually assumed 33 
to have equal difficulty and discriminability and items’ properties cannot be evaluated.  34 
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IRT models can be categorized as parametric IRT or non-parametric IRT. The parametric IRT 35 
assumes a logistic shape on item-response step functions (IRSFs). This more restricted method can 36 
lead to the rejection of useful items when the assumption is violated. Non-parametric IRT, however, 37 
does not impose a logistic shape on the IRSFs. This flexible method has become increasingly popular 38 
in modelling various scales, such as personality [102], quality of life [103], psychopathology (e.g., 39 
Khan, Lewis, & Lindenmayer, 2011; Meijer & Baneke, 2004), and mental health [106]. 40 
In IRT, the family of graded response models (GRMs; Samejima, 1968) is suitable for analyzing 41 
polychotomous items collected using response scales [108,109]. IRT models the probability of 42 
answering each option in an item as a function of the underlying trait (e.g., level of depression or 43 
somatization). Such conditional probabilities are often referred to as IRSFs. Here, we used non-44 
parametric GRM (np-GRM) that makes no assumptions about the underlying shape of the IRSF [103]. 45 
This model allows the checking of a fundamental requirement in IRT and scale construction — the 46 
probability of reporting a symptom is a strictly growing function of the latent score (hypothesis of 47 
monotonicity of IRSF). In practice, this ensures that the ordering of respondents on the score reflects 48 
the true ordering on the latent trait [110]. 49 
The np-GRM employs a kernel-smoothing technique to model the relationship between the level of 50 
underlying trait and the probability of choosing a particular option for a questionnaire [111]. We 51 
visually examined the IRSF of every item for determining items that were included in the final scales. 52 
Items were included in the np-GRMs if they were monotonically increasing. The PSYCH-6 53 
(questions 1–6 in Table 2-2) and the SOMA-6 (questions 7–12 in Table 2-2) included every item in 54 
their np-GRMs. The AD scale included the aforementioned six binary DSM-5 diagnosis items. The 55 
SU scale included three ordinal diagnoses: AUD, CUD, and degree of drug use. The degree of drug 56 
use was derived from ever using any illicit substance aforementioned. This variable was coded as 0 57 
for never using any of the nine drugs, 1 for ever using any one of them, 2 for ever using any two of 58 
them, and 3 for ever using 3 or more of them. The IRT scaling provided a better distributional shape, 59 
with reduced skewness and kurtosis relative to the scaling of the PSYCH-6 and the SOMA-6 summed 60 
scores (Figure S2-1).61 
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Table 2-2 Internal consistency assessed with Cronbach's alpha coefficients and test-retest reliability assessed with intraclass correlation 62 
coefficients (ICC 95% CI) for individual SPHERE12 questionnaire item. Psychological distress subscale included item 1-- item 6. Somatic 63 
distress subscale included item 7- item 12.  64 
 Test-retest reliability 
 Internal consistency  NU1-NU2 (N=132,df=131)  NU2-NU3 (N=20,df=19)  NU1-NU3 (N=22,df=21) 
SPHERE12 item 
Number 
of items 
Sample 
size 
Cronbach 
alpha  ICC (95% CI) F p value  ICC (95% CI) F p value  ICC (95% CI) F p value 
1. Feeling nervous or tense? 11 2,124 0.87  0.61 (0.49-0.71) 4.16 2.1E-15  0.52 (0.12-0.78) 3.17 0.0069  0.20 (-0.22-0.57) 1.50 0.17 
 
2. Feeling unhappy and depressed? 11 2,122 0.87  0.60 (0.48-0.70) 4.04 6.6E-15  0.57 (0.20-0.81) 3.70 0.0027  0.23 (-0.19-0.59) 1.61 0.14 
 
3. Feeling constantly under strain? 11 2,122 0.87  0.60 (0.48-0.70) 4.01 8.8E-15  0.57 (0.19-0.80) 3.68 0.0028  0.27 (-0.15-0.61) 1.75 0.1 
 
4. Everything getting on top of you? 11 2,122 0.87  0.59 (0.47-0.69) 3.92 2.2E-14  0.57 (0.18-0.80) 3.60 0.0032  0.26 (-0.17-0.60) 1.69 0.12 
 
5. Losing confidence? 11 2,122 0.87  0.61 (0.49-0.71) 4.11 3.3E-15  0.56 (0.18-0.80) 3.59 0.0033  0.22 (-0.20-0.58) 1.57 0.15 
 
6. Being unable to overcome difficulties? 11 2,122 0.87  0.62 (0.50-0.71) 4.26 7.2E-16  0.52 (0.12-0.78) 3.17 0.0068  0.22 (-0.20-0.58) 1.57 0.15 
 
7. Muscle pain after activity? 11 2,123 0.88  0.65 (0.54-0.74) 4.70 1.1E-17  0.62 (0.27-0.83) 4.33 0.001  0.25 (-0.17-0.60) 1.68 0.12 
 
8. Needing to sleep longer? 11 2,124 0.87  0.63 (0.52-0.73) 4.46 1.1E-16  0.55 (0.16-0.79) 3.41 0.0045  0.27 (-0.15-0.62) 1.76 0.099 
 
9. Prolonged tiredness after activity? 11 2,122 0.87  0.62 (0.50-0.71) 4.26 7.6E-16  0.55 (0.17-0.79) 3.49 0.0039  0.19 (-0.23-0.56) 1.48 0.18 
 
10. Poor sleep? 11 2,122 0.88  0.61 (0.50-0.71) 4.19 1.5E-15  0.50 (0.10-0.77) 3.01 0.0092  0.21 (-0.22-0.57) 1.52 0.17 
 
11. Poor concentration? 11 2,122 0.87  0.63 (0.51-0.72) 4.36 2.8E-16  0.57 (0.19-0.80) 3.64 0.0031  0.15 (-0.27-0.53) 1.36 0.24 
 
12. Tired muscles after activity? 11 2,126 0.88  0.64 (0.53-0.73) 4.62 2.6E-17  0.62 (0.26-0.83) 4.24 0.0012  0.25 (-0.18-0.60) 1.65 0.12 
 
total scores 12 2,122 0.88  0.62 (0.51-0.72) 4.31 4.7E-16  0.57 (0.19-0.80) 3.63 0.0031  0.23 (-0.20-0.58) 1.59 0.14 
 
Cronbach’s alpha coefficients for each item represents the effect of removing that item from the computation of the alpha coefficients (e.g. if item 1 is removed, the resulting value for the 
scale is 0.87, if item 2 is omitted, it is 0.87, etc) 
65 
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We attempted various data transformations for PSYCH6 and SOMA-6 measurements; however, a 66 
reverse J-shaped distribution was seen in all the transformed measurements. Even though IRT 67 
modelling attempts to put all data on a normal scale of liability with a limited number of items, it was 68 
not possible to remove all kurtosis and skewness, which is evident in the distribution of our data. We 69 
combined the PSYCH-6 and SOMA-6 measurements across the three waves, as we did not find 70 
significant differences in the IRT scores among the three study waves for the PSYCH-6 (Kruskal–71 
Wallis chi-squared = 3.4,511, df = 2, p value = .1781) and the SOMA-6 (Kruskal–Wallis chi-squared 72 
= 0.69,418, df = 2, p value = .7067). The IRSFs for the four scales, PSYCH-6 (Figure S2-2), SOMA-73 
6 (Figure S2-3), AD (Figure S2-4), and SU (Figure S2-5), are shown in the supplementary section. 74 
Basic Assumption Tests 75 
There are different zygosity and sex groups in the twin design [112]. For binary phenotypes, the 76 
differences in thresholds and covariances were examined between different zygosity and sex groups. 77 
For continuous phenotypes, the differences in means, variances, and covariances were examined 78 
across all the groups [112]. When no significant differences are found between the groups, means and 79 
variances can then be combined across the groups to estimate the underlying population mean and 80 
variance [112]. 81 
Univariate Twin Modeling 82 
The observed variance of the phenotypes was partitioned into (A) additive genetic, (D) dominant 83 
genetic, (C) common environmental, and (E) unshared environmental variation using a univariate 84 
ACE or ADE model. The ACE models were fit for the phenotypes where MZ correlations (rMZ) 85 
were smaller than twice the DZ correlations (rDZ). The ADE models were fit for the phenotypes 86 
where rMZ were greater than twice the rDZ. The presence of D effect was not significant, given large 87 
sample sizes are required to detect a significant D. 88 
Univariate twin models were fit separately for each continuous, binary, and ordinal phenotypes using 89 
the full information maximum likelihood (FIML) method, which allows the use of data from all 90 
available individuals (see the number of twins in Table 2-3), including those without cotwins and 91 
those with co-twins who had missing measures. The log-likelihood ratio test was performed to assess 92 
the fit of nested models. We regressed the IRT scores (PSYCH6–IRT, SOMA-6–IRT, AD–IRT, and 93 
SU–IRT) against covariates age of survey, sex, and study waves for obtaining their residuals. The 94 
four residualized IRT scores (PSYCH6r, SOMA-6r, ADr, and SUr) were used to fit multivariate twin 95 
models.96 
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Table 2-3 Maximum likelihood estimate beta (standard error) of age and sex, twin correlations (standard errors), and heritability (95% 97 
confidence interval) for affective disorders (AD), substance use (SU), psychological (PSYCH6) and somatic (SOMA6) distress subscales 98 
of the SPHERE12. Total number of subjects (N), number of complete MZ or DZ twin pairs (individuals) are given. rMZ and rDZ are shown 99 
as NC when these correlations are too small. The heritability is bolded when the AE models are significantly different from the E models. 100 
The heritability is shown as NC when both rMZ and rDZ are NC. 101 
 Beta of covariates  Monozygotic twins  Dizygotic twins  
Scale Phenotypes N  Age Sex (F vs M)  Pairs (Ind) rMZ  Pairs (Ind) rDZ  Heritability 
PSYCH6 IRT score 1548  -0.04 ( 0.01) -0.27 ( 0.11)  266 ( 666) 0.27 ( 0.06)  322 ( 882) 0.06 ( 0.05)  0.23 ( 0.13-0.33 ) 
 
 
SOMA6 IRT score 1548  -0.05 ( 0.01) -0.13 ( 0.10)  266 ( 666) 0.29 ( 0.05)  322 ( 882) 0.04 ( 0.06)  0.25 ( 0.15-0.35 ) 
 
 
AD AD-IRT 2132  0.01 ( 0.01) -0.54 ( 0.10)  374 ( 885) 0.34 ( 0.04)  491 (1247) 0.10 ( 0.05)  0.32 ( 0.23-0.39 ) 
 
 major depressive disorder 2132  -0.01 ( 0.04) 0.28 ( 1.54)  374 ( 885) 0.43 ( 0.09)  491 (1247) 0.17 ( 0.10)  0.41 ( 0.24-0.57 ) 
 
 agoraphobia 2132  0.01 0.64  374 ( 885) NC  491 (1247) NC  NC 
 
 depressive episodes 2132  -0.01 0.31  374 ( 885) 0.43 ( 0.09)  491 (1247) 0.16 ( 0.10)  0.41 ( 0.24-0.56 ) 
 
 panic attack 2132  -0.01 ( 0.13) 0.40 ( 7.01)  374 ( 885) 0.43 ( 0.10)  491 (1247) 0.04 ( 0.12)  0.37 ( 0.17-0.55 ) 
 
 panic disorder 2132  -0.01 0.47  374 ( 885) 0.39 ( 0.27)  491 (1247) NC  0.23 ( 0.00-0.68 ) 
 
 social anxiety 2132  0.01 ( 0.07) 0.26 ( 1.64)  374 ( 885) 0.44 ( 0.10)  491 (1247) 0.15 ( 0.10)  0.42 ( 0.23-0.58 ) 
 
 
SU SU-IRT 2132  0.05 ( 0.01) 0.70 ( 0.09)  374 ( 885) 0.49 ( 0.04)  491 (1247) 0.26 ( 0.04)  0.49 ( 0.42-0.56 ) 
 
 alcohol use 2132  0.02 ( 0.37) -0.15 ( 2.62)  374 ( 885) 0.71 ( 0.06)  491 (1247) 0.56 ( 0.08)  0.75 ( 0.64-0.84 ) 
 
 drug use ever 2132  -0.03 ( 0.31) -0.26 ( 2.87)  374 ( 885) 0.78 ( 0.04)  491 (1247) 0.44 ( 0.06)  0.79 ( 0.71-0.86 ) 
 
 cannabis use ever 1663  -0.03 -0.38  245 ( 648) 0.78 ( 0.05)  372 (1015) 0.38 ( 0.08)  0.78 ( 0.66-0.86 ) 
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 Beta of covariates  Monozygotic twins  Dizygotic twins  
Scale Phenotypes N  Age Sex (F vs M)  Pairs (Ind) rMZ  Pairs (Ind) rDZ  Heritability 
 
 tobacco use ever 2132  -0.03 ( 0.26) -0.32 ( 2.63)  374 ( 885) 0.65 ( 0.06)  491 (1247) 0.50 ( 0.06)  0.70 ( 0.60-0.78 ) 
 
 alcohol use disorder 2132  -0.03 ( 0.07) -0.43 ( 0.91)  374 ( 885) 0.43  491 (1247) 0.23  0.50 ( 0.40-0.59 ) 
 
 cannabis use disorder 2132  -0.04 -0.42  374 ( 885) 0.50  491 (1247) 0.21  0.74 ( 0.61-0.83 ) 
 
 
NC: not calculable 
102 
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Multivariate Twin Modeling 103 
Multivariate twin models allow us to estimate the relative contribution of genes and environment to 104 
the covariation between measures [113]. Our analytical flow started with fitting the fully saturated 105 
Cholesky decomposition (CD) for PSYCH-6r, SOMA-6r, ADr, and SUr, followed by the more 106 
parsimonious independent pathway (IP) models, and common pathway (CP) models. To make it 107 
easier for researchers who are not familiar with twin studies and SEM, we provided conceptual path 108 
diagrams for the quadrivariate CD (Figure S2-6), IP (Figure S2-7), and CP (Figure S2-8) model. SEM 109 
enables us to quantify the effect of a single latent variable on an observed variable. High magnitudes 110 
of path coefficients indicate that latent variables have a large effect on the observed variables. The 111 
relative contribution of different latent variables to the variation of an observed variable can be 112 
quantified by squaring the standardized path coefficients. The CD model assumes one A, one C, and 113 
one E factor influences each of the four observed variables. As this model does not carry an 114 
assumption about the underlying genetic and environmental architecture, it was used as the base 115 
model against its nested sub-models (e.g., Cholesky AE, Cholesky CE, and Cholesky E) and the more 116 
parsimonious IP and CP models were compared.  117 
The IP model hypothesizes that genes and environment exert differential influence on the covariance 118 
between phenotypes [114]. This model estimates one set of shared genetic factor (Ac), common 119 
environmental factors (Cc), and unshared environmental factors (Ec), which influence the covariation 120 
between the four phenotypes via separate paths to each of them. In addition, this model also estimates 121 
genetic factor (As), common environmental factors (Cs), and unshared environmental factors (Es) 122 
that are specific to each phenotype, to explain the remaining phenotype-specific variance.  123 
Nested within the IP model, the CP model is more parsimonious and restrictive than the IP model. 124 
This model hypothesizes that the covariation between the four phenotypes is influenced by common 125 
A, C, and E factors through a latent factor [114]. Similar to the IP model, the CP model estimates 126 
phenotype-specific variance with A, C, and E factors that are specific to each phenotype. More 127 
complicated models, such as the IP with two or three common genetic factors, were also explored. 128 
We interpreted the parameter estimates, such as phenotypic correlations (rP), genetic correlations (rG), 129 
environmental correlations (rE), and factor loading, from the best-fitting multivariate model. 130 
Statistical Software 131 
We used R [115] and SAS 9.4 [116] for statistical analyses, graph, and table generation. The following 132 
R packages were used: package psy [117] for internal consistency (Cronbach’s alpha coefficient), 133 
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package irr [118] for test-retest reliability, package KernSmoothIRT [119] for the np-GRM models, 134 
and package OpenMx [120] for twin modelling. Path diagrams were generated using Onyx [121]. 135 
Results 136 
Internal Consistency and Test-Retest Reliability of SPHERE-12 137 
Good internal consistency (Cronbach’s alpha: 0.87–0.88, Table 2-2) was seen in the SPHERE-12 138 
scale, with the scale hardly varying as each item was dropped in turn, suggesting a high level of 139 
homogeneity among these items. A normal distribution in the intervals, assessed with Shapiro–Wilk 140 
test, was found between NU2 and NU3 (W = 0.94, Pr < W: 0.27) and between NU1 and NU3 (W = 141 
0.94, Pr < W: 0.16), but not between NU1 and NU2 (W = 0.97, Pr < W: 0.004). Moderate intra-class 142 
correlations (ICC; Table 2-2) were found between NU1 and NU2 (ICC: 0.59–0.65, interval: 1.6 ± 0.3 143 
years, range: 0.2–2.5 years) and between NU2 and NU3 (ICC: 0.5–0.62, interval: 4.3 ± 0.8 years, 144 
range: 2.5–6.3 years). The ICC values were nonsignificant between NU1 and NU3 in each of the 12 145 
items and the total scores. 146 
Basic Assumption Tests 147 
For binary phenotypes, no significant birth-order effect on the thresholds was found (Figure S2-2: 148 
H1t). A zygosity effect (Figure S2-2: H2t) was found only in alcohol use. Significant differences 149 
between correlations of MZ twins (rMZ) and DZ twins (rDZ) were found in drug use ever, and 150 
cannabis use ever (Table 2-2: H3c). We found a significant familial aggregation effect (Table S2-2: 151 
H4c) in all the AD and SU phenotypes, except for agoraphobia and PD. 152 
For continuous phenotypes, we did not find a significant birth-order effect (Table S2-3: H1m) or 153 
zygosity effect (Table 2-3: H2m) on the means. Significant differences between rMZ and rDZ (Table 154 
2-3: H3c) were found in all the phenotypes, suggesting the presence of significant genetic effects in 155 
these phenotypes. A significant familiar aggregation effect on the covariance (Table 2-3: H4c) was 156 
found in all the phenotypes. 157 
Univariate Genetic Analyses 158 
As shown in Table S2-4, the results of the univariate genetic analyses revealed that the additive 159 
genetic (A) and unshared environmental (E) effect model best explained the variation in all the 160 
phenotypes (bolded AE models) except for AU and tobacco use ever. Table 2-3 shows the sample 161 
sizes, estimates of betas, twin correlations, and heritability from the best-fitting models for each of 162 
these phenotypes. We found a significant effect of age in all SU phenotypes, PSYCH6-IRT, and 163 
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SOMA-6-IRT, but not in any AD phenotypes. Sex had a significant effect on the variance of all the 164 
phenotypes except for SOMA-6-IRT. Significantly higher rMZ than rDZ was found in all the 165 
phenotypes except for agoraphobia and PD. Most AD phenotypes were moderately heritable, with 166 
heritability ranging from 37% for PA to 42% for social anxiety. The SU phenotypes were found to 167 
be more heritable than the AD phenotypes, with heritability ranging from 49% for AUD to 79% for 168 
ever using drugs. We were unable to estimate heritability for agoraphobia and PD as the low 169 
prevalence of these disorders resulted in a lack of discordant/concordant twin pairs, which resulted in 170 
insufficient information in the analyses. 171 
Multivariate Genetic Analyses 172 
Table S2-5 shows the model-fitting results for various multivariate models. Dropping the C 173 
component from the full Cholesky ACE model did not lead to a significant loss of model fit (Model 174 
2). Dropping the A component (Model 3), or A and C component (Model 4), however, led to 175 
significant losses of fit. We then fit alternative IP models with one common genetic factor (Model 5), 176 
IP with two common genetic factors (IP2A; Model 6), IP with three common genetic factors (Model 177 
7), as well as the CP model (Model 8). As none of these models led to significant loss of fit, we then 178 
explored the most parsimonious models from the IP model and IP2A model. To test the importance 179 
of the A, C, and E components, we fit a series of nested models by dropping these components from 180 
the common and the specific paths of the IP model (Models 10–17) and the IP2A model (Models 21–181 
28). The C component could be dropped from both the common and specific paths of the IP model 182 
(Model 17), as well as the IP2A model (Model 28), without significant loss of fit. Moreover, the 183 
IP_AE_AE model (Model 33) and the IP2A_AE_AE model (Model 34) had a lower AIC than the 184 
Cholesky AE model (Model 12). We present the parameter estimates from IP_AE_AE (Figure 2-2) 185 
as it had the lowest AIC. 186 
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Figure 2-2 Path diagram of an independent pathway (IP) model with standardized parameter 188 
estimates. The IP model has an additive genetic (Ac) factor and a unique environmental 189 
factor (Ec) that are common to all four phenotypes, as well as a genetic factor (As) and 190 
unshared environmental factor (Es) that are specific to each phenotype. All shared 191 
environmental influences have been dropped without worsening the model fit. Solid lines 192 
indicate significant paths and dotted lines indicate non-significant paths (95% confidence 193 
intervals include zero). Standardized path coefficients, their 95% confidence intervals (CIs), 194 
and percentage of variation of a phenotype explained by a factor are presented for 195 
significant paths. Non-significant paths are shown with path coefficients and 95% CIs. 196 
Table 2-4 shows rP, rG, and rE between any two of the four phenotypes. Significant rP’s were found 197 
between all the four phenotypes, with an average of 0.22 (range: 0.06– 0.51). Significant and higher 198 
rG, ranging from 0.15 to 0.85, was also found between the four phenotypes. The magnitude of rG 199 
between the PSYCH-6r and ADr was very close to that between the SOMA-6r and ADr. The same 200 
pattern was also seen when comparing the rG between PSYCH6r and SUr with the rG between the 201 
SOMA-6r and SUr. Significant rE was only found between the PSYCH-6r and the SOMA-6r, the 202 
PSYCH-6r and ADr, and the PSYCH-6r and SUr.203 
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Table 2-4 Estimates of phenotypic, genetic and environmental correlations (95% confidence intervals) between psychological (PSYCH6r) 204 
and somatic (SOMA6r) distress subscales of the SPHERE12, the affective disorders (ADr) and substance use (SUr) scales. Significant 205 
correlations that did not include zero in their confidence intervals are bolded. 206 
 Phenotypic correlation (95% CI)  Genetic correlation  (95% CI)  Environmental correlation  (95% CI) 
Phenotyp
e  PSYCH6r SOMA6r ADr SUr  PSYCH6r SOMA6r ADr SUr  PSYCH6r SOMA6r ADr SUr 
PSYCH6r  1     1     1    
 
SOMA6r  .51 (.47-.55) 1    .85 (.61-1.0) 1    .41 (.33-.49) 1   
 
ADr  .31 (.26-.36) .23 (.18-.27) 1   .49 (.27-.73) .53 (.31-.74) 1   .25 (.16-.33) .11 (.06-.21) 1  
 
SUr  .10 (.05-.15) .10 (.05-.15) .06 (.03-.11) 1  .23 (.04-.41) .25 (.04-.42) .15 (.02-.27) 1  .05 (-.0-.15) .02 (-.0-.11) .01 (-.0-.06) 1 
 
207 
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The common unshared environmental factor (Ec in Figure 2-2) had a significant influence on the 208 
PSYCH-6r, SOMA-6r, and ADr, explaining 5–73% of their variation. The specific environmental 209 
factors (Es) had a significant effect on SOMA-6r, ADr, and SUr, explaining 53–64% of their 210 
variations. In phenotypes with significant Ec and Es, the Es had a much larger contribution than the 211 
Ec. A different pattern was seen in the additive genetic influence. The common additive genetic 212 
factors (Ac) had significant loading onto each set of the four phenotypes, explaining 3–22% of their 213 
variations. The specific additive genetic factors (As), however, were allowed to load only onto ADr 214 
and SUr. The relative contribution of the As was two to four times larger than the Ac. 215 
Discussion 216 
This is the first study to investigate the overlapping genetic and environmental influences underlying 217 
the four comorbid disorders — PSYCH, SOMA, AD, and SU — in young Australian adults. We 218 
began our analytical flow with the validation of the SPHERE-12 instrument and then dissected the 219 
genetic and environmental influences using univariate and multivariate twin modelling. We found 220 
evidence for a small but significant genetic influence that was common to all the four phenotypes 221 
(Ac). The unshared environmental factors exerted a greater influence on the four phenotypes; 222 
however, these influences were largely specific to SOMA, AD, and SU. This suggests that the genetic 223 
and environmental influences on the four phenotypes may be best explained by one common genetic 224 
factor (Ac), one unshared environmental factor that is common to the PSYCH-6, the SOMA-6, and 225 
AD (Ec), and genetic (As) and unshared environmental factors (Es) that were specific to some 226 
phenotypes. 227 
Test-Retest Reliability of SPHERE-12  228 
The SPHERE-12 has proved to be a highly consistent and moderately reliable instrument in our young 229 
Australian sample, which is consistent with longer SPHERE questionnaires such as the SPHERE-21 230 
(Couvy-Duchesne, Davenport, Martin, Wright, & Hickie, 2017) and the SPHERE-34 [92]. Internal 231 
consistency (Cronbach’s alpha) was consistent between the PSYCH sub-scales (our PSYCH-6: 0.86; 232 
anxiety depression: 0.86–0.88; PSYCH-14: 0.87) and between SOMA sub-scales (our SOMA-6: 233 
0.81; chronic fatigue: 0.78–0.79; SOMA-10: 0.7), suggesting that the item reduction did not lower 234 
the consistency of the SPHERE questionnaire. 235 
Test-retest reliability, commonly assessed by ICC, reflects the variation in measurements taken 236 
during a test and a retest on the same subjects and under the same conditions [123]. The value of ICC 237 
can be influenced by factors such as variability among participants, sample sizes, and the time 238 
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between the test and the retest. The ICC of our PSYCH-6, 0.47–0.48, was consistent with the anxiety-239 
depression sub-scale, 0.47, reported by Couvy-Duchesne et al. (2017). However, the ICC in our 240 
SOMA-6 (ICC: 0.36–0.5) was lower than their chronic fatigue subscale (ICC: 0.57). The fact that our 241 
NU1–NU3 ICCs were non-significant and lower than NU1–NU2 ICCs and NU2– NU3 ICCs may be 242 
attributed to the long NU1–NU3 interval (mean interval: 5.4 ± 0.7 years, range: 4.4–6.8 years) or the 243 
stability of PSYCH-6 or SOMA-6 measurements over time. Longer test-retest intervals have been 244 
shown to increase inconsistency [124]. 245 
Univariate Findings 246 
Our heritability estimates were generally consistent with previous studies. Heritability estimates can 247 
vary between studies due to their variations in study designs, such as age groups, sample sizes, sexes, 248 
data collection methods (e.g., via self-reporting questionnaires or diagnostic interviews), and source 249 
of participants (e.g., community or clinical samples). Bearing in mind these differences, we checked 250 
to see whether our heritability estimates overlapped with the confidence intervals of heritability 251 
estimates reported from previous studies. 252 
We found low but significant heritable influences on the PSYCH and the SOMA. Our heritability 253 
estimates for the PSYCH-6–IRT (0.23, 95% CI [0.13, 0.33]) and the SOMA6–IRT (0.25, 95% CI 254 
[0.15, 0.35]) were consistent with heritability estimates for similar sub-scales in the oldest age groups 255 
[81]. They reported heritability 0.37 (95% CI [0.21, 0.51]) for anxiety-depression IRT scores at age 256 
17–19 and 0.27 (95% CI [0.11, 0.41]) for chronic fatigue at the same ages. 257 
We found moderate to high heritability estimates on the liability to AD and SU phenotypes (Table 258 
2-3). For AD diagnostic phenotypes, our heritability estimates were in accordance with previous 259 
studies. Sullivan et al. (2000) attributed on average 37% (range: 31–42%) of the variation in major 260 
depression to additive genetic factors by reviewing four community studies [125–128] and two 261 
clinical studies [126,129]. These reviewed studies employed various data collection methods, such as 262 
semi-structured interviews, mailed questionnaires, telephone interviews, or diagnostic assessments 263 
on probands with MDD. Rijsdijk et al. (2003) reported an estimate of 0.39–0.42 for severe depression, 264 
measured with GHQ, in female twins aged 18–79 (mean age: 47.7). Our heritability estimates for 265 
MDD (0.41, 95% CI [0.24, 0.57]) and depressive episodes (0.41, 95% CI [0.24, 0.56]) fell within the 266 
range reported from these studies. Unfortunately, heritability for agoraphobia and PD was not 267 
estimable, given insufficient cases in MZ and DZ twins (Table S2-1). We, therefore, compared our 268 
heritability of PA with that of PD, as PA is one of the defining features of PD. Previous studies 269 
reported a considerable variation in the heritability of PD, ranging from 0.28 in female twins [131] to 270 
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0.48 from a meta-analysis [132] that combined data from five family studies and five twin studies. 271 
Our heritability of PA (0.37; 95% CI[0.17,0.55]) was within this range. To our knowledge, the 272 
heritability of DSM-5 social anxiety has not been reported. However, studies that assessed a relevant 273 
symptom, social anxiety disorder (SAD), with diagnostic interviews on twin samples have reported 274 
a considerable variation in their heritability estimates, ranging from 0.1 to 0.55 [133–137]. Our 275 
heritability estimate for social anxiety 0.42 (95% CI [0.23, 0.58]) was close to the upper range. 276 
For SU phenotypes, we found that 50–79% of the variation was attributable to the additive genetic 277 
influence, which is comparable with heritability estimates for SU. To our knowledge, this is the first 278 
twin study that reports a heritability estimate (0.78, 95% CI [0.66, 0.86]) for CUD using DSM-5 279 
diagnosis. A meta-analysis [138] reviewed 28 studies for heritability estimates for cannabis use 280 
initiation and problematic cannabis use; most of these phenotypes were defined by DSM-IV-TR [139]. 281 
They reported heritability estimates of 48% in male twins and of 40% in female twins for cannabis 282 
use initiation. Higher heritability was found in problematic cannabis use: 51% in men and 59% in 283 
women. Another study reported a heritability of 72% for the DSMIV [140] definition of cannabis 284 
abuse or dependence in young Australian adults [141]. A recent study found that 21% of the 285 
phenotypic variation in the DSM-5 CUD was attributable to the genomic variation in common SNPs, 286 
but this estimate was found to be non-significant [142]. It is worth noting that the diagnostic criteria 287 
for SU disorder differ between the DSM-IV and the DSM-5. The distinction between substance abuse 288 
and substance dependence in the DSM-IV has been replaced with a single SU disorder in the DSM-5 289 
[143]. Our heritability for AUD, 0.50 (95% CI [0.4, 0.59]), is similar to the best-fit estimate of 0.49 290 
(95% CI [0.43, 0.53]) reported by Verhulst et al. (2015). Another study reported a wide range of 291 
heritability (49–64%) for alcoholism [145]. For AU and tobacco use, dropping the A component did 292 
not lead to losses of fit, whereas dropping the C component led to losses of fit. With the lowest AIC, 293 
the resulting CE models best explained the variance of the two phenotypes. 294 
Multivariate Findings 295 
We found a strong genetic correlation (rG = 0.85) between the PSYCH-6r and the SOMA-6r, which 296 
is consistent with longer SPHERE sub-scales. Couvy-Duchesne et al., (2017) found high genetic 297 
correlations of 0.85–1.00 between anxiety-depression and chronic fatigue IRT scores in four younger 298 
age groups (<13, 13–15, 15–17, and 17– 19 years). Hansell et al. (2012) reported a high rG of 0.87 299 
between the PSYCH-14 and the SOMA-10 at mean age 15.5 years (age range: 12.0–25.6). Our 300 
results, together with these findings, suggest that the genetic overlap between PSYCH and SOMA 301 
remained consistently high in adolescents and young adults. It is interesting to note that the two 302 
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SPHERE sub-scales had a similar genetic overlap with ADr (rG = 0.49, 0.53) and SUr (rG = 0.23, 303 
0.25). Although the main objectives of this study were not to compare summed scores with IRT 304 
scores, we found a high rP between them in both the PSYCH-6 (rP: 0.81, 95% CI [0.79, 0.82]) and 305 
the SOMA-6 (rP: 0.82, [95% CI: 0.8, 0.84]). 306 
An important finding from our independent pathway model was that the genetic influence on the four 307 
phenotypes was through the actions of three sets of genetic factors. The first set, the common genetic 308 
factor (Ac), explained 3– 22% of the variance of the four phenotypes. The second and third sets were 309 
genetic factors (As) that were specific to ADr and SUr. For these two phenotypes, these As explained 310 
a larger proportion of their variance than the Ac. 311 
What are the implications of the common genetic influence underlying comorbid psychiatric 312 
disorders? Given the genetic factors derived from multivariate models are statistically defined as a 313 
hypothetical predictive construct [146], the genetic covariation does not directly map onto an 314 
inference about shared loci. However, the shared genetic construct suggests the potential utility of 315 
treatment approaches that target comorbid conditions in the absence of manifest comorbidity. 316 
Limitations 317 
The use of a genetically informative sample and comprehensive sets of phenotypes were the strength 318 
of this study; however, our results should be interpreted considering the following limitations. First, 319 
the low prevalence rates of agoraphobia and PD did not allow the estimation of their heritability. The 320 
estimation of heritability requires calculable rMZ and rDZ (i.e., neither zero nor negative). There 321 
were limited pairs of twins who were concordant for these disorders, meaning that we were unable to 322 
estimate the heritability for these phenotypes (Table S2-1). However, we included these items in our 323 
IRT modelling as they showed acceptable IRSF (Figure S2-4). Low prevalence is a common problem 324 
in these binary traits [147,148]. Second, our use of a cross-sectional design could limit the 325 
generalizability of our results beyond the age group 18–38 years. Third, we combined the PSYCH6 326 
and SOMA-6 measurement from all the study waves and sexes in order to obtain their genetic 327 
estimates in a sample as large as possible. This may have diluted the difference in variance and 328 
covariance components between the waves and between the sexes. Fourth, our study was well 329 
powered to reject the C component in favour of an AE source model but was insufficiently powered 330 
to distinguish the IP and CP structural models within the AE source model. Finally, although we 331 
found that unique environmental factors and additive genetic factors explained on average 67.5% and 332 
29.5% of the covariance between the four phenotypes, we do not know how these influences may 333 
change overage. For personality traits, genetic contribution tends to be stable over time, whereas new 334 
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environmental effects emerge over time [149]. Similar results have also been found on the genetic 335 
and environmental influences on subjective well-being [150]. To study the stability of genetic 336 
influence on common psychiatric disorders, future work needs to use a longitudinal twin design. 337 
Conclusions 338 
The present study shows that both nature and nurture play an important role in the liability to PSYCH, 339 
SOMA, AD, and SU in young adults. We found consistently high internal consistency between the 340 
12-item SPHERE and the longer SPHERE instruments. We examined the item properties for each of 341 
these four illnesses using non-parametric item response theory models. We found a high genetic 342 
overlap between PSYCH and SOMA. These shared genetic effects suggest the potential utility of 343 
treatment approaches that target comorbid conditions in the absence of manifest comorbidity. 344 
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Abstract 374 
Background: Co-morbid substance use is very common. Despite a historical focus using genetic 375 
epidemiology to investigate comorbid substance use and misuse, few studies have examined 376 
substance-substance associations using polygenic risk score (PRS) methods. 377 
Methods: Using summary statistics from the largest substance use GWAS to date (258,797- 632,802 378 
subjects), GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN), we 379 
constructed PRSs for smoking initiation (PRS-SI), age of initiation of regular smoking (PRS-AI), 380 
cigarettes per day (PRS-CPD), smoking cessation (PRS-SC), and drinks per week (PRS-DPW). We 381 
then estimated the fixed effect of individual PRSs on 22 lifetime substance use and substance use 382 
disorder phenotypes collected in an independent sample of 2463 young Australian adults using 383 
genetic restricted maximal likelihood (GREML) in Genome-wide Complex Trait Analysis (GCTA), 384 
separately in females, males and both sexes together. 385 
Results: After accounting for multiple testing, PRS-SI significantly explained variation in the risk of 386 
cocaine (0.67%), amphetamine (1.54%), hallucinogens (0.72%), ecstasy (1.66%) and cannabis 387 
initiation (0.97%), as well as DSM-5 alcohol use disorder (0.72%). PRS-DPW explained 0.75%, 388 
0.59% and 0.90% of the variation of cocaine, amphetamine and ecstasy initiation respectively. None 389 
of the 22 phenotypes including emergent classes of substance use was significantly predicted by PRS-390 
AI, PRS-CPD, and PRS-SC. 391 
Conclusions: To our knowledge, this is the first study to report significant genetic overlap between 392 
the polygenic risks for smoking initiation and alcohol consumption and the risk of initiating major 393 
classes of illicit substances. PRSs constructed from large discovery GWASs allows the detection of 394 
novel genetic associations. 395 
  396 
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Introduction 397 
Genetic Influence on Substance Use 398 
Based on non-molecular but genetically informative family and twin studies, it is widely accepted 399 
that licit and illicit substance use (SU) and substance use disorders (SUDs) are polygenic with 30–400 
80% heritability estimated across different substances as summarised by a comprehensive review 401 
(Kendler et al., 2012b). Twin studies have also shown that the genetic covariance between major licit 402 
and illicit substances use disorders can be explained by common genetic risks (Kendler et al., 2003; 403 
Kendler et al., 2012a), with some evidence suggesting that highly correlated (rG = 0.82) genetic risks 404 
underpinning legal (nicotine, alcohol and caffeine) and illegal (cannabis and cocaine) SUDs [153]. 405 
Recent meta-analyses of genome-wide association studies (GWAS) provide evidence that SU and 406 
SUDs support the conclusion these are polygenic genetic behaviours [154–157] with multiple genes 407 
of small effect contributing to the variation in the risk. Despite their complex polygenicity [158,159] 408 
the direct effects of individual SU and SUD loci and genes are becoming increasingly clear. Multiple 409 
loci have been associated with liability to consuming nicotine [160–162], alcohol [157,163–189], and 410 
cannabis [154,155,190,191], and SNPs related to multi-substance use [192] have now been identified. 411 
Given the availability of very large, informative GWAS summary statistics there now exists the 412 
opportunity to examine the degree to which the variation of SU and SUD risk can be explained by 413 
emerging allelic risks as opposed to statistical inference based on twin and family studies. 414 
Polygenic Risk of Substance Use 415 
A key implication of the recent molecular findings is that a complete list of true replicable signals is 416 
not required for GWAS to demonstrate significant concurrent or predictive criterion validity. The 417 
upper tails of well-powered GWAS summary test distributions are expected to be highly enriched 418 
with many true signals [193] that can be used to estimate individualized polygenic risk score for 419 
complex behaviours including SU and SUDs. 420 
Polygenic risk score (PRS) analysis aggregates the effects of thousands of genetic variants that are 421 
associated with a trait using a spectrum of significance levels. A PRS is calculated as a weighted sum 422 
of the number of risk alleles at the selected SNPs that are carried by an individual. The weight is 423 
obtained from the effect size (e.g. beta for a continuous trait; log transformation of the odds ratio for 424 
a binary trait) associated with the SNPs. These scores allow us to compare and correlate PRSs 425 
between different individuals or PRSs for different phenotypes. 426 
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A common problem in PRS methodology is that a PRS typically explains a small proportion, in 427 
comparison to twin estimates (Kendler et al., 2012b) of the variation of a target phenotype, which 428 
may be improved with larger-sized discovery sample from which the PRS is calculated. The criterion 429 
validity of PRS to predict a variety of important behavioural outcomes has clearly been demonstrated. 430 
For example, PRS based on much smaller discovery samples already predicts complex traits [194–431 
197] including cannabis use and cannabis use frequency [198]. A number of reports have also linked 432 
PRS for psychiatric disorders to SU and SUDs outcomes [199–203]. However, very few studies 433 
[203,204] have investigated the associations between PRSs for SU and SUDs, and none of these 434 
studies have leveraged the most recent and largest SU GWAS to date. With PRSs derived from a very 435 
large discovery sample GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN), 436 
the current study is likely to maximise the power to detect an association between PRSs and SU and 437 
SUDs. 438 
Aims 439 
This study aimed to establish the association between polygenic risks for licit substance use and the 440 
risk of self-report illicit substance use, alcohol use disorders (AUD) as well as measures of cannabis 441 
misuse in an Australian sample of young adults. 442 
Materials and Methods 443 
Our overall aim was to calculate the PRSs for five measures of tobacco and alcohol consumption, and 444 
then test their associations with self-reported illicit SU phenotypes while appropriately adjusting for 445 
multiple testing. PRSs are commonly calculated using independent SNPs that meet different 446 
association p-value thresholds, which allows us calculating PRS from SNPs that did not reach 447 
genome-wide significance. 448 
Target Sample and Measures 449 
Self-report measures of SU and SUDs were obtained from a sample of young adult Australian twins 450 
and their families who participated in the Brisbane Longitudinal Twin Study 19Up Project between 451 
2009 and 2016 [96,97] in Brisbane, Australia. Twins and their families were invited to participate in 452 
this project when they turned 19 or older. The 19Up study was approved by the QIMR Human 453 
Research Ethics Committee. Data were stored in compliance with national regulations regarding 454 
personal data protection. Informed consent was obtained from all the participants. 455 
Our target sample comprised 2463 individuals who were genotyped (mean age: 26.1 years; age range: 456 
18.7–38.6) at QIMR Berghofer. This included 1977 twin individuals (835 twin pairs), and 486 457 
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siblings from 1163 families. The Composite International Diagnostic Interview (CIDI; Kessler and 458 
Üstün, 2004) was used to identify Diagnostic and Statistical Manual of Mental Disorders (Fourth 459 
Edition, DSM-IV) diagnoses of lifetime use of an illicit substance (cocaine, amphetamine, inhalants, 460 
sedatives, hallucinogens, opioids, ecstasy, prescription painkillers, prescription stimulants, and 461 
cannabis), alcohol abuse, alcohol dependence, cannabis abuse, and cannabis dependence. The 462 
prevalence of the ten binary initiation phenotypes ranged from 5% for lifetime inhalants to 47% for 463 
lifetime cannabis use (Table 3-1). For the four abuse and dependence phenotypes, the prevalence was 464 
7% to 33%. Significantly different prevalence was seen between males and females in these 14 465 
phenotypes, except for sedative, opioid and painkiller initiation (Table 3-1). The DSM-5 AUD and 466 
CUD outcomes (0 = absent, 1 =mild, 2 = moderate, and 3 =severe) were constructed based on the 467 
number of symptoms identified, with two or three symptoms indicating a mild SUD, four or five 468 
symptoms indicating a moderate SUD, and six or more symptoms indicating a severe SUD. In 469 
addition to these two four-point scales, we derived binary phenotypes by dichotomising those who 470 
scored 0 or 1 and those who score 2 or 3.471 
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Table 3-1 Number of female and male participants surveyed for lifetime use of illicit substance and substance use disorders and result for 472 
Chi-Sqaure test of association between prevalence and sex. 473 
 Females  Males  Assoc: prevalence & sex (DF=1) 
Target phenotype  N (%) Cases (%)  N (%) Cases (%)  χ² p-value 
Ever used cocaine  1336 ( 58% ) 184 ( 14% )  976 ( 42% ) 238 ( 24% )  41.86 <.0001 
Ever used amphetamine  1335 ( 58% ) 235 ( 18% )  975 ( 42% ) 223 ( 23% )  9.51 0.0020 
Ever used inhalants  1331 ( 58% ) 45 (  3% )  972 ( 42% ) 72 (  7% )  18.06 <.0001 
Ever used sedatives  1334 ( 58% ) 177 ( 13% )  975 ( 42% ) 153 ( 16% )  2.51 0.1133 
Ever used hallucinogens  1334 ( 58% ) 139 ( 10% )  974 ( 42% ) 201 ( 21% )  45.97 <.0001 
Ever used opioids  1335 ( 58% ) 72 (  5% )  974 ( 42% ) 64 (  7% )  1.20 0.2725 
Ever used ecstasy  1337 ( 58% ) 318 ( 24% )  975 ( 42% ) 333 ( 34% )  29.46 <.0001 
Ever used prescription pain killers  1335 ( 58% ) 246 ( 18% )  974 ( 42% ) 179 ( 18% )  0.00 1.0000 
Ever used prescription stimulants  1334 ( 58% ) 151 ( 11% )  973 ( 42% ) 162 ( 17% )  13.18 0.0003 
Ever used cannabis  1106 ( 59% ) 450 ( 41% )  784 ( 41% ) 443 ( 57% )  45.42 <.0001 
Alcohol abuse  1368 ( 59% ) 386 ( 28% )  959 ( 41% ) 390 ( 41% )  38.76 <.0001 
Alcohol dependence  1368 ( 59% ) 305 ( 22% )  959 ( 41% ) 343 ( 36% )  50.25 <.0001 
DSM5 AUD (ctrl mild vs moderate severe)  1368 ( 59% ) 310 ( 23% )  959 ( 41% ) 352 ( 37% )  53.94 <.0001 
Cannabis abuse  1368 ( 59% ) 105 (  8% )  959 ( 41% ) 165 ( 17% )  49.00 <.0001 
Cannabis dependence  1368 ( 59% ) 61 (  4% )  959 ( 41% ) 91 (  9% )  22.55 <.0001 
DSM5 CUD (ctrl mild vs moderate severe)  1368 ( 59% ) 75 (  5% )  959 ( 41% ) 122 ( 13% )  37.20 <.0001 
474 
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Discovery Sample 475 
We used GWAS summary statistics from the global ‘GSCAN’ consortium [206] with the QIMR 476 
sample removed prior to constructing PRSs for four smoking and one alcohol-related discovery 477 
phenotypes: smoking initiation (SI) (N = 631,564, 52% smokers, 53.6% females); age of initiation of 478 
regular smoking (AI) (N = 258,251, 50.0% females); cigarettes per day (CPD) (N = 258,999, 55.1% 479 
females); smoking cessation (SC) (N = 312,273, 40% current smokers, 50.6% females); and drinks 480 
per week (DPW) (N = 527,402, 53.2% females). GWAS summary statistics for these five phenotypes 481 
were generated with sex as a covariate when possible. 2.3. Genetic Correlations Between Discovery 482 
Phenotypes 483 
Genetic correlations (rG) between discovery phenotypes were estimated using cross-trait LD score 484 
correlation (LDSC; Bulik-Sullivan et al., 2015). This method is suitable for our study as it requires 485 
only GWAS summary statistics, is not biased by sample overlap and estimates of rG between a binary 486 
and continuous trait without having to specify a scale. We merged each of the five GWAS files with 487 
the HapMap3 SNP list, converted the summary statistics into the LDSC format, and calculated the 488 
genetic correlation. The independent variables and weights for LD score regression were read from 489 
an LD score computed from the 1000 Genomes European data. 490 
Calculation of Polygenic Risk Scores 491 
Before estimating the PRS for the 19UP subjects we first ensured quality control (QC) of the 492 
discovery GWAS summary statistics SNPs by removing SNPs with more than one occurrence, 493 
keeping SNPs that began with “rs” in their variant IDs, removing SNPs from ambiguous strands (i.e. 494 
SNPs that had “A T”, “T A”, “C G” or “G C” in their reference alleles and alternative alleles), and 495 
excluding insertions or deletions. Next, we ensured QC for SNPs in the target BLTS cohort sample 496 
by retaining SNPs with minor allele frequencies between 0.01 and 0.99 and with genotype imputation 497 
R2 ≥ 0.6 (an indication of imputation quality across different platforms), and applying the same 498 
criteria as the QC used for the discovery sample SNPs. Thirdly, an inner join was then performed to 499 
obtain SNPs that were common to the discovery and target SNPs using chromosome number and base 500 
pair position (CHR: BP) as the merging key. Fourthly, we accounted for linkage disequilibrium (LD) 501 
by selecting one representative SNP per haplotype, a process known as LD-based SNP clumping. 502 
Specifically, we set the Rsquared threshold (plink –clump-r2) to 0.1, and the distance threshold (plink 503 
–clump-kb) to 10,000 kb. The number of SNPs that met our eight p-value thresholds of 5e-08, 1e-05, 504 
1e-03, 1e-02, 5e-02, 0.1, 0.5 and 1 was compared before (see QC in Table S3-1) and after (see LD in 505 
Table S3-1) clumping based on their linkage disequilibrium (LD) in individual autosomes. Across all 506 
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these autosomes (see Total in Table S3-1), less than 1% of SNPs were selected through LD-based 507 
clumping. The difference in the number of clumped SNPs tended to be small between the five 508 
discovery phenotypes at higher p-value thresholds, with 400,877- 403,341 clumped SNPs at p-value 509 
< 1, 280,074–281,387 clumped SNPs at p < 0.5, 86,672- 91,667 clumped SNPs at p < 0.1, 49,797-510 
55,505 clumped SNPs at p < 5e-02, 13,235- 18,428 clumped SNPs at p < 1e02. The PRS-SI at a p-511 
value threshold lower than 1e-03 had nearly twice the number of clumped SNPs compared to the four 512 
other discovery phenotypes constructed with the same p-value. Fifthly, we constructed PRSs from 513 
imputed genotype dosage by summing up allelic scores of the clumped SNPs across all the 514 
chromosomal blocks of 22 autosomes, resulting in one PRS per p-value threshold and individual in 515 
the target sample: 516 
ij
1
n
i j
j
PRS G
=
=    517 
where i is an individual, β is the effect size of an independent SNPj for a discovery phenotype, and 518 
Gij is the number of risk alleles at the SNPj in the individual i. The number of independent SNPs, 519 
denoted as n, varies with the discovery phenotypes and p-value thresholds. Before the PRS 520 
calculation, the genotypes had been imputed on the Michigan Imputation Server [207] using the 521 
Haplotype Reference Consortium [208] version r1.1 as the reference panel and then converted to 522 
plink dosage format at QIMR. Lastly, we standardised the PRSs and merged them back into the QIMR 523 
cohort who were assessed with SU and SUDs. 524 
Univariate Mixed Model That Models Familial and Cryptic 525 
Relatedness 526 
To estimate the proportion of variance in each target phenotype that was explained by the PRS, we 527 
performed linear mixed modelling using genetic restricted maximum likelihood (GREML) by the 528 
software GCTA [209]: 529 
Y X g=  + +   530 
where Y is a nx1 vector of either a binary phenotype or continuous phenotype with n being the number 531 
of individuals in the input data, X is a vector of fixed-effect covariates, and β is the effect estimate of 532 
the X. Considering the predictive power of our PRSs may be confounded by sex, we conducted the 533 
mixed modelling separately for males (M), females (F) and both sexes combined (F + M). The 534 
covariates used in the both-sex model included categorical covariates of study wave, sex, GWAS 535 
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array, and quantitative covariates, such as a single PRS, age, age2, age x sex, age2 x sex, and the first 536 
ten principal components derived from the SNP data. The two single-sex models used the same 537 
covariates except for sex, age x sex, and age2 x sex. 538 
The g and  denote the random genetic effect and error term respectively. The genetic effect has a 539 
known variance-covariance structure that is defined by the genetic relationship matrix (GRM), which 540 
estimates the genetic relatedness between individuals using SNP data. Although the GCTA-GREML 541 
is developed mainly for estimating SNP heritability, this method provides the additional functionality 542 
of estimating fixed effect parameters in a sample of related individuals. Our fixed effects were 543 
estimated using the GCTA –reml-est-fix option. We then derived an estimate of the association 544 
expressed as a proportion of the target phenotype (both binary and continuous) variance explained by 545 
PRS, R2 as 546 
2
2 ( )
PRS
PRS
Y
R SD
SD
 
=   
 
 547 
where PRS is the fixed effect estimate of a PRS, YSD is the standard deviation of a binary or 548 
continuous target phenotype Y, and ( )PRSSD  is the standard deviation of the PRS . Here, the R2 is 549 
defined as the square of the correlation between Y and PRS. We calculated two-sided p-values from 550 
at distribution in R. 551 
Multiple Testing 552 
We tested the association between each of the 22 target phenotypes and each of the 40 PRSs, giving 553 
a total of 880 association tests. To account for multiple testing (Table S3-2), we presented p-values 554 
adjusted for the effective number of independent target and discovery phenotypes (threshold T4) and 555 
Bonferroni-corrected p-values (threshold T5). Bonferroni correction is known to be extremely 556 
conservative and increase the likelihood of a type II error. We, therefore, interpreted our results based 557 
on the associations that remained significant after accounting for the T4 threshold, which was 558 
calculated as 559 
nom
eff t eff d
P
M − − 
 560 
Where Pnom is the nominal p-value, Meff-t is the effective number of independent target phenotypes, 561 
and Meff-d is the effective number of independent discovery phenotypes [210,211]. We estimated the 562 
Meff-t as 14 and Meff-d as five in females, males, and both sexes. 563 
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Statistical Software 564 
The pipeline of PRS calculation was coded in BASH [212] and R [213]. LD-based SNP clumping 565 
and PRS calculation were performed using Plink [49]. Univariate GREML was performed using 566 
GCTA [209]. We used R and Base SAS 9.4 [214] for data cleaning, statistical analyses, graph and 567 
table generation. 568 
Results 569 
Genetic Correlations Between Discovery Phenotypes 570 
Shown in Table 3-1, the five discovery phenotypes were significantly correlated with each other, with 571 
positive genetic correlation coefficients ranging between 0.08 and 0.43, and negative genetic 572 
correlation coefficients ranging between -0.69 and -0.15. AI negatively correlated with each of the 573 
other four phenotypes, suggesting that genetic liability to starting regular smoking at an early age 574 
could be related to the genetic liability to a higher chance of starting regular smoking (SI), smoking 575 
more cigarettes (CPD), or drinking more alcoholic beverage (DPW). There is also evidence for the 576 
genetic overlap between SI and CPD, SC and DPW. 577 
Associations Between PRS and the Self-reported SU and SUD Measures 578 
After correcting for multiple testing, significant predictors were only seen in PRS-SI, which explained 579 
the variance of six target phenotypes and in PRS-DPW explaining the variance of three target 580 
phenotypes. Percentage of variation explained by the PRSs (prediction R2) in these significant 581 
associations are shown in Figure 3-1. The associations that remained statistically significant after the 582 
Bonferroni-correction were found between PRS-SI and amphetamine initiation, ecstasy initiation, 583 
and alcohol abuse, as well as between PRS-DPW and ecstasy initiation. An overview of the results 584 
for the entire 880 substance-PRS associations is visualised for both sexes (Figure S3-1), males (Figure 585 
S3-2) and females (Figure S3-3).1 Effect sizes of PRSs were all positive in these associations 586 
(estimates highlighted in blue and bold-face, Table S3-3). The effect size estimates were similar in 587 
males and females (Table S3-3). Phenotypic correlations between individual target phenotypes and 588 
PRSs were generally very small, ranging between -0.3 and 0.37 (Table S3-4), with the highest 589 
correlation found between age at onset of cannabis dependence and PRS-DPW calculated at p value 590 
< 5e-08. 591 
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 592 
Figure 3-1 Percentage variance of liability to illicit substance use (disorder) explained by 593 
polygenic risk scores (PRS) for smoking initiation (PRS-SI) or drinks per week (PRS-DPW) 594 
in males (M), females (F) and both sexes (F + M). Bar height represents the percent of the 595 
variation in a target phenotype explained by a PRS. Associations that remained significant 596 
after accounting for multiple testing (adjusted p-value threshold: 7.14e-04) are shown as 597 
green in both sexes combined, as orange in females and as purple in females. Bars from 598 
non-significant associations are shown in a pale colour. Bar groups on the x-axis indicate 599 
the eight p-value thresholds at which the PRSs were calculated: 5e-08, 1e-05, 1e-03, 1e-600 
02, 0.05, 0.1, 0.5, and 1 (For interpretation of the references to colour in this figure legend, 601 
the reader is referred to the web version of this article).  602 
  603 
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Discussion 604 
This study aimed to examine the association between molecular-based estimates of polygenic risk for 605 
alcohol and nicotine use and self-report measures of common and emergent types of illicit substance 606 
use and misuse. The pattern of genetic correlations (positive rG range: 0.08∼0.43, negative rG range: 607 
-0.68∼-0.15, see Table 3-2), as estimated by cross-trait LD score regression, between the five 608 
discovery PRS was very similar to those observed in the full GSCAN full sample (rG range: -609 
0.71∼0.42, Liu et al., 2019). The highest rG was between AI and SI, along with moderate to weak 610 
correlations in nine other pairwise correlations. Among the SU phenotypes predicted by PRS-SI or 611 
PRSDPW were lifetime cocaine, amphetamine, hallucinogen, ecstasy, and cannabis use (Figure 3-1). 612 
The DSM-5 AUD was the only clinical SUD diagnosis that was predicted by PRS-SI. Importantly, 613 
none of the PRSs that were based only on SNPs that reached genome-wide significant (p-value < 5e-614 
08) significantly predicted any of the SU or SUD outcomes. However, significant associations were 615 
found when PRSs were based on less stringent p-values (5e-08 < p-value < 1). Despite the small-616 
sized target sample, the use of PRSs based on a large discovery GWAS samples has the power to 617 
predict, to some extent, individuals at risk of comorbid SU and progression to AUDs. 618 
Table 3-2 Genetic correlations (rG) between any two (trait1, trait2) of the five smoking and 619 
alcohol-related discovery phenotypes that were meta-analysed by genome-wide association 620 
studies. The rG, standard errors (SE) and p values were estimated by cross-trait L D score 621 
regression. These five phenotypes are smoking initiation (SI, binary), age at starting regular 622 
smoking (AI, continuous), cigarettes per day (CPD, continuous), smoking cessation (SC, 623 
binary), and drinks per week (DPW, continuous). 624 
Trait1 Trait2 rG SE p value 
AI CPD -0.381 0.037 <0.001 
AI DPW -0.15 0.031 <0.001 
AI SC -0.294 0.041 <0.001 
AI SI -0.685 0.024 <0.001 
CPD DPW 0.084 0.028 0.0030 
CPD SC 0.426 0.033 <0.001 
CPD SI 0.28 0.033 <0.001 
DPW SC 0.104 0.033 0.0016 
DPW SI 0.403 0.018 <0.001 
SC SI 0.39 0.029 <0.001 
Prediction by PRSs 625 
Although the range in variances explained by our PRSs was small (0.67%–1.66% in both sexes, 626 
0.00%∼2.21% in females, 0.58%∼1.80% in males, see Table S3-3), these estimates are 627 
commensurate with other studies that have used aggregated genetic risk based on well-powered 628 
GWAS discoveries to predict substance use and misuse. For example, GSCAN PRS for AI, CPD, SI 629 
and DPW explained between 1% and 4% of the variance in similar measures assessed by the Add 630 
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Health and Health and Retirement Study datasets [206]. Likewise, PRS based on a recent genome-631 
wide meta-analysis of alcohol dependence explained between 0.3% and 1.7% of the variance in 632 
alcohol use and misuse phenotypes in the large Avon Longitudinal Study of Parents and Children 633 
(ALSPAC), Generation Scotland (GS), and Collaborative Study on the Genetics of Alcoholism 634 
(COGA) samples [157]. 635 
We found that cannabis initiation was significantly predicted by the PRS-SI, but not by PRS-CPD or 636 
PRS-SC. In contrast, Vink et al., (2014) reported an association between cannabis initiation and a 637 
PRS for CPD, based on the Tobacco and Genetics Consortium (TAG), but not with a TAG-based 638 
PRS for SI (N = 69,409), or PRS for SC. Apart from the obvious discrepancy in the two discovery 639 
sample sizes, the differences in the prediction by the smoking-related PRSs predicts may be 640 
attributable to the heterogeneity in terms of how the discovery GWAS consortia defined their 641 
phenotypes. For example, the GSCAN SI was a binary phenotype based on whether subjects had ever 642 
been a regular smoker, whereas the TAG-based SI used by Vink et al. was more strictly defined. The 643 
GSCAN CPD used the average number of cigarettes smoked per day scored on an ordinal scale with 644 
five response categories (1–5, 6–15, 16–25, 26–35, or 36 or more cigarettes smoked per day) whereas 645 
the CPD used by Vink et al. was the average or maximum number of cigarettes smoked per day from 646 
contributing studies. We cannot rule out the possibility that our study was underpowered to detect the 647 
effect of PRS-CPD on the initiation of cannabis, and even the other substances. 648 
Given the sample sizes and success of recent GWSA meta-analyses investigating alcohol use and 649 
misuse [157,206] our a priori expectation was that the PRS- DPW should have predicted the self-650 
reported measures of alcohol misuse. Instead, the PRS-DPW did not predict any alcohol-related 651 
disorders. In addition to the lack of power related to the BLTS sample size, this null finding could be 652 
attributable to the possibility that the PRS-DPW was assessing an unrelated genetic liability. Note 653 
that GSCAN DPW phenotype was based on either current or former drinkers, combined all types of 654 
liquor, or averaged across all assessments when based on longitudinal data [206]. Kendler et al. 655 
(2012a)  found that the DSM-IV syndrome of alcohol dependence does not reflect a single dimension 656 
but instead is best characterized by three distinct genetic factors: tolerance and heavy use; loss of 657 
control; and withdrawal symptoms [151]. Therefore, it is plausible that GSCAN-based PRS for DPW 658 
may be indexing the genetics of tolerance and heavy use, which is in contrast to our measure of 659 
alcohol misuse that is more likely to be indexing genetic risks related to loss of control and 660 
withdrawal. 661 
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The pattern of non-significant associations between the alcohol and nicotine-based PRS and the non-662 
medical use of prescribed or over the counter analgesics is commensurate with our recent twin 663 
modelling exploring the aetiology of this emergent class of SU. Briefly, we have found that apart 664 
from opioids, broadly defined non-medical use of analgesics is genetically correlated (rg = 0.44) but 665 
mostly distinct from the genetic risks underpinning lifetime nicotine use (Gillespie et al., submitted). 666 
In terms of diagnostic outcomes, non-medical use of analgesics was only partially genetically 667 
correlated with either alcohol use disorder (rG = 0.24) and nicotine dependence (rG = 0.32; Gillespie 668 
et al., submitted), which suggests that most of the genetic risks in non-medical use of analgesics are 669 
variable specific. 670 
Limitations 671 
Our results must be interpreted in the context of the following two limitations. First, the discovery 672 
sample was based predominately on Caucasian ancestral groups. Consequently, the significant PRS-673 
phenotype correlations observed here may not apply to other ethnic groups especially those with 674 
different haplotype structures. The need to collect genetic data from non-European-ancestry 675 
populations has been recently discussed [217–219]. Second, the significant associations between 676 
genetic risks for alcohol- and nicotine-related phenotypes and self-report measures of SU and SUDs 677 
do not imply causation. Third, our PRSs explained a relatively small proportion of the genetic 678 
variance, a common problem in addiction studies [204,220] that uses the PRS approach. Although it 679 
is premature to discuss the clinical utility of PRSs in genetic risk prediction for substance use, the 680 
PRS method has been shown to improve risk prediction in other diseases, such as prostate cancer 681 
[221], when it is combined with a conventional risk factor family history. As discovery sample sizes 682 
increase and the PRS approach continues to refine, the PRS predictor can prove useful in 683 
discriminating patients in the top and bottom risk deciles [219]. 684 
Significance of this Study  685 
The current results lend support for there being shared genetic risks between initiation of tobacco and 686 
various addictive substances (e.g. cocaine, amphetamine, hallucinogens, ecstasy, and cannabis), as 687 
well as between alcohol consumption and several of these substances. Twin studies show that 688 
common genetic factors tend to exert a varying degree of influence on the covariation of tobacco and 689 
cannabis use and misuse at different stages of the involvement of these two substances [222,223], 690 
with the stronger influence at the earlier stages (e.g. initiation) than the later stages (e.g. progression) 691 
of the use. Taken together with our finding, this stage-dependent genetic relationship may be 692 
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generalised to tobacco and other addictive substances (i.e. cocaine, amphetamine, hallucinogens, 693 
ecstasy). 694 
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Abstract 740 
Background Substance use, substance use disorders (SUDs), and psychiatric disorders commonly 741 
co-occur. Genetic risk common to these complex traits is an important explanation; however, little is 742 
known about how polygenic risk for tobacco or alcohol use overlaps the genetic risk for the comorbid 743 
SUDs and psychiatric disorders.  744 
Methods We constructed polygenic risk scores (PRSs) using GWAS meta-analysis summary 745 
statistics from a large discovery sample, GWAS & Sequencing Consortium of Alcohol and Nicotine 746 
use (GSCAN), for smoking initiation (SI; N = 631,564), age of initiating regular smoking (AI; N 747 
=258,251), cigarettes per day (CPD; N = 258,999), smoking cessation (SC; N = 312,273), and drinks 748 
per week (DPW; N = 527,402). We then estimated the fixed effect of these PRSs on the liability to 749 
15 phenotypes related to tobacco and alcohol use, substance use disorders, and psychiatric disorders 750 
in an independent target sample of Australian adults.  751 
Results After adjusting for multiple testing, 10 of 75 combinations of discovery and target phenotypes 752 
remained significant. PRS-SI (R2 range: 1.98%–5.09 %) was positively associated with SI, DPW, 753 
and with DSM-IV and FTND nicotine dependence, and conduct disorder. PRS-AI (R2: 3.91 %) 754 
negatively associated with DPW. PRS-CPD (R2: 1.56 %–1.77 %) positively associated with DSM-755 
IV nicotine dependence and conduct disorder. PRSDPW (R2: 3.39 %–6.26 %) positively associated 756 
with only DPW. The variation of DPW was significantly influenced by sex*PRS-SI, sex*PRS-AI and 757 
sex*PRS-DPW. Such an interaction effect was not detected in the other 14 phenotypes. 758 
Conclusions Polygenic risks associated with tobacco use are also associated with liability to alcohol 759 
consumption, nicotine dependence, and conduct disorder. 760 
Introduction 761 
Common genetic risk underlying substance use and psychiatric 762 
disorders 763 
Tobacco smoking and alcohol use are among the most important risk factors contributing to the global 764 
burden of diseases. These two addictive substances together were responsible for 255.9 million 765 
disability-adjusted life-years (DALYs) in 2015 [224]. Use or misuse of these two substances 766 
commonly occurs in people with substance use disorders (SUDs) or psychiatric disorders [225–227]. 767 
One of the possible explanations for the co-occurring conditions is that genetic predisposition to 768 
substance use (SU) overlaps genetic predisposition to a co-occurring or comorbid disorder [228]. This 769 
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theory is commonly tested by computing genetic correlations between two traits using twin designs 770 
[229] or genome-wide association study (GWAS) summary statistics (e.g. Linkage disequilibrium 771 
(LD) score regression). 772 
GWAS findings on the liability to licit substance use 773 
Recent meta-analyses of genome-wide association studies (GWAS) provide additional evidence that 774 
SU and SUDs are highly polygenic [154–157] with multiple genetic variants of small effect 775 
contributing to the variation of the risk. Despite their complex genetic architecture [158,159] the 776 
direct effects of individual SU and SUD loci and genes are becoming clearer. For instance, multiple 777 
loci have been associated with the liability of consuming nicotine [160–162,206], alcohol [157,164–778 
166,169,172,176–178,183,186–189,206], and a combination of SU and SUDs [192]. Among the 779 
largest GWAS meta-analytic results to date, Pasman et al. have identified 35 significant genes in 16 780 
regions associated with lifetime cannabis use [155]. Liu et al. identified 566 genetic variants in 406 781 
loci associated nicotine initiation, cessation, cigarettes per day and drinks per week [206]. Both 782 
Walters and Liu et al. replicated the association with the alcohol metabolism gene ADH1B reported 783 
by others [157,206]. Based on the increasing number of identified loci each with very small effects 784 
plus the observation that most of the variance in SNP heritabilities is accounted for by variants below 785 
standard GWAS thresholds, these GWAS and meta-analytic results are consistent with SU and SUDs 786 
traits being highly polygenic. Findings from these GWAS pave the way for subsequent analysis on 787 
identifying common genetic risk underlying substance use and associated phenotypes.  788 
What is polygenic risk scoring? 789 
Polygenic risk score (PRS) analysis is usually conducted as one of the post-GWAS analyses.  The 790 
PRS analysis aggregates the effects of thousands of genetic variants that are associated with a trait 791 
using a spectrum of significance levels. A PRS is calculated as a weighted sum of the number of risk 792 
alleles at the selected single-nucleotide polymorphism (SNPs) that are carried by an individual. The 793 
weight is obtained from the effect size (e.g. beta for a continuous trait; the log-transformed odds ratio 794 
for a binary trait) associated with each SNP in the discovery GWAS. PRSs are typically calculated 795 
using independent SNPs that meet association p-value thresholds ranging from formal genome-wide 796 
significance (association p values < 5x10-8) to less stringent thresholds (association p values < 10-5 to 797 
< 1 including all SNPs). These scores allow us to compare and correlate PRSs between different 798 
individuals or PRSs constructed for different phenotypes. 799 
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Polygenic risk of substance use 800 
The criterion validity of PRS to predict a variety of important behavioural outcomes has clearly been 801 
demonstrated. For example, PRSs based on much smaller discovery samples are already capable of 802 
predicting complex traits [194–197] including cannabis use and cannabis use frequency [198]. Liu et 803 
al. reported that PRS based on the GSCAN summary statistics significant predicted nicotine and 804 
alcohol use in the independent Add Health and Health and Retirement Study datasets [206]. Likewise, 805 
Walters et al.'s alcohol dependence GWAS results significantly predict out of sample alcohol misuse 806 
[157]. These findings combined with the repeatedly observed genetic correlations based on linkage 807 
disequilibrium score regression (LDSC) between licit and illicit substance use and misuse traits 808 
[155,157,206,230,231] are consistent with twin-based genetic epidemiological results [151] arguing 809 
that familial aggregation in comorbid substance use is best explained by common genetic risk factors. 810 
Given the availability of summary statistics based on the world’s largest GWAS to identify loci 811 
associated with nicotine and alcohol phenotypes (GWAS & Sequencing Consortium of Alcohol and 812 
Nicotine use, GSCAN; Liu et al., 2019), there exists the opportunity to examine the degree to which 813 
individual differences in SU and SUD risk can be explained by loci identified by GSCAN. 814 
Aims 815 
We hypothesised that shared genetic risk is underlying use of alcohol, nicotine, alcohol or nicotine 816 
use disorders, and even psychiatric disorders. We tested this hypothesis by testing the associations 817 
between GSCAN PRSs and individual differences in the liability to SUDs and psychiatric disorders 818 
in an independent sample of Australian adults while adjusting for multiple testing. In sample sizes up 819 
to 1.2 million individuals, the GSCAN consortium has identified 566 loci that are associated with 820 
nicotine and alcohol use [206]. With PRSs derived from this very large discovery sample, the current 821 
study is likely to maximise the power to detect an association between PRSs, and related traits. We 822 
focused our risk prediction on not only SUDs but also psychiatric traits because they are commonly 823 
comorbid with SU or SUDs [14,15,232,233]. 824 
Material and methods 825 
Design 826 
We constructed PRSs for individuals in an independent sample using recently published GWAS meta-827 
analytic summary statistics for tobacco and alcohol use (see discovery sample for details). We then 828 
tested associations between these PRSs and the liability of SUDs, and psychiatric disorders. 829 
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Discovery sample 830 
We obtained GWAS meta-analysis summary statistics from GSCAN [206], an international meta-831 
analysis that aggregated genetic association findings from over 30 contributing studies and over one 832 
million participants to find genetic variants associated with smoking and drinking. This meta-analysis 833 
was performed for four tobacco and one alcohol-related phenotypes in a sample that excluded the 834 
contribution of QIMR samples and 23andMe before we constructed PRSs for: smoking initiation (SI; 835 
N=631,564; 52% smokers; 53.6% females); age of initiation of regular smoking (AI; N=258,251; 836 
50.0% females); cigarettes per day (CPD; N=258,999; 55.1% females); smoking cessation (SC; 837 
N=312,273; 40% current smokers; 50.6% females); and drinks per week (DPW; N=527,402; 53.2% 838 
females). We ensured that the discovery sample did not overlap the target sample (see next section). 839 
Non-independence of these two samples can inflate the prediction R-squared for the target sample 840 
[234]. 841 
Target sample and outcome measures 842 
Participants in our target sample were drawn from a pool of Australian twins who were initially 843 
recruited through the Australian Twin Registry (ATR; Hopper, 2002), and other members of their 844 
families. The ATR is a volunteer registry that recruited participants through the media, schools and a 845 
variety of other sources [236]. Response rates [237], sampling bias [238], and sample 846 
representativeness [239] have been previously examined for the ATR sample. Target phenotypes 847 
related to substance use and psychiatric disorders were selected from 15,440 individuals who were 848 
part of three coordinated studies: (1) the Nicotine Addiction Genetics [240,241] study, which targeted 849 
families based on heavy smoking index cases identified in earlier interviews and questionnaires [242], 850 
(2) the Australian Alcohol Extreme Discordant and Concordant Sibship (OZALC-EDAC; Hansell et 851 
al., 2008) study, which ascertained index cases with a history of heavy drinking or alcohol 852 
dependence, and (3) the Australian Alcohol Large Sibship (OZALC-BIGSIB) study, designed to 853 
study families with five or more offspring sharing both biological parents and unselected for 854 
phenotype [176,236,243]. Our final target sample consisted of 13,999 individuals (59.0% females, 855 
median age: 42 years, age range: 20 ~ 89 years) who were genotyped and not ancestry outliers, 856 
including 6,578 twins, their 23 spouses, and their 7398 family members (2,047 parents, 5200 siblings, 857 
and 151 offspring). Diagnostic phone interviews modified from the Semi-Structured Assessment for 858 
the Genetics of Alcoholism (SSAGA; Bucholz et al., 1994; Hesselbrock et al., 1999) were used to 859 
collect data through a computer-assisted telephone interview (CATI) program. These CATI 860 
interviews assessed a wide range of variables across tobacco use, specific phobia and social phobia, 861 
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alcohol and drug dependence, mental, conduct, and anti-social personality disorders. This project was 862 
approved by the QIMR Human Research Ethics Committee. Data were stored in compliance with 863 
national regulations regarding personal data protection. Informed consent was obtained from all the 864 
participants. 865 
Fifteen target phenotypes (i.e. outcome measures) used in this study included six self-reported 866 
phenotypes that were identical to those used in GSCAN discovery analyses: (1) smoking initiation 867 
(SI); (2) age at starting regular smoking (AI); (3) cigarettes per day (CPD); (4) smoking cessation 868 
(SC); (5) drinking initiation (DI); (6) drinks per week (DPW), and nine binary outcomes: (7) alcohol 869 
dependence defined by the fourth edition of Diagnostic and Statistical Manual of Mental Disorders 870 
(DSM-IV; American Psychiatric Association, 1994); (8) DSM-IV nicotine dependence; (9) nicotine 871 
dependence defined by the Fagerström Test for Nicotine Dependence (FTND; Heatherton et al., 872 
1991); (10) DSM-IV conduct disorder (CD); (11) DSM-IV antisocial personality disorder (ASPD); 873 
(12) DSM-IV major depressive disorder (MDD); (13) DSM-IV panic disorder; (14) DSM-IV social 874 
anxiety disorder (SAD); and (15) a screen for mania. The nine binary outcomes were calculated 875 
according to the DSM-IV criteria. Definitions of the 15 phenotypes were provided in the supporting 876 
information (see Supporting S4-1 for the definitions of six self-reported phenotypes and Supporting 877 
S4-2 for the definitions of nine binary phenotypes). The prevalence of the three self-reported binary 878 
phenotypes ranged from 44% for smoking cessation to 80% for drinking initiation. Lower prevalence 879 
of the nine binary phenotypes ranged from 1% for mania screen to 39% for DSM-IV nicotine 880 
dependence (Table 4-1). Significantly different prevalence was seen between males and females in 881 
these 12 phenotypes, except for mania screen.882 
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Table 4-1 Summary of outcome variables related to use of licit substance, substance use disorders, and psychiatric disorders in Australian 883 
adults aged between 20 and 89 years. For binary outcomes (Type=binary), the number of individuals with non-missing data and prevalence 884 
was presented separately in females (F), males (M) and both sexes together (F+M). The sex difference was tested using Chi-squared test 885 
of association. For continuous outcomes (Type=continuous), the number of individuals with non-missing data, median and interquartile 886 
range (IQR) were presented. The sex difference was tested using the Wilcoxon rank-sum test with continuity correction. 887 
 888 
 Females  Males  F+M  Sex differences 
Type Target phenotypes  Num Summary  Num Summary  Num Summary  Test stat p value 
binary Smoking initiation  7,640 Prevalence:  52%  5,193 Prevalence:  64%  12,833 Prevalence:  57%  167.1 <.0001 
 Smoking cessation  2,894 Prevalence:  45%  2,635 Prevalence:  41%  5,529 Prevalence:  43%  11.51 0.0007 
 Drinking initiation  7,594 Prevalence:  76%  5,276 Prevalence:  86%  12,870 Prevalence:  80%  173.1 <.0001 
 DSM-IV alcohol dependence  3,946 Prevalence:  17%  3,290 Prevalence:  33%  7,499 Prevalence:  24%  254.3 <.0001 
 DSM-IV nicotine dependence  3,893 Prevalence:  38%  3,435 Prevalence:  40%  7,603 Prevalence:  39%  4.68 0.0304 
 FTND-based nicotine dependence  3,893 Prevalence:  25%  3,435 Prevalence:  32%  7,603 Prevalence:  28%  43.65 <.0001 
 DSM-IV conduct disorder  3,874 Prevalence: 1.8%  3,247 Prevalence: 4.9%  7,383 Prevalence: 3.2%  55.18 <.0001 
 DSM-IV antisocial personality 
disorder 
 3,947 Prevalence: 0.8%  3,291 Prevalence: 3.8%  7,501 Prevalence: 2.1%  75.83 <.0001 
 DSM-IV major depressive 
disorder 
 3,889 Prevalence:  36%  3,252 Prevalence:  25%  7,402 Prevalence:  31%  90.60 <.0001 
 DSM-IV panic disorder  3,941 Prevalence: 5.5%  3,283 Prevalence: 3.5%  7,487 Prevalence: 4.5%  16.11 <.0001 
 DSM-IV social anxiety disorder  3,944 Prevalence:  20%  3,286 Prevalence:  17%  7,493 Prevalence:  19%  11.25 0.0008 
 Mania screen  3,091 Prevalence: 1.2%  2,629 Prevalence: 1.0%  5,977 Prevalence: 1.1%  0.26 0.6090 
continuous Drinks per week  5,446 Median: 5, IQR: 8  4,450 Median:12, IQR:16  9,896 Median: 7, IQR:12  174E5 <.0001 
 Age at starting regular smoking  2,344 Median:16, IQR: 3  1,593 Median:16, IQR: 4  3,937 Median:16, IQR: 3  166E4 <.0001 
 Cigarettes per day  2,461 Median: 4, IQR: 1  1,687 Median: 4, IQR: 2  4,148 Median: 4, IQR: 1  239E4 <.0001 
 889 
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Construction of polygenic risk scores 890 
Our quality control (QC) procedure for the discovery and target sample SNPs is discussed in detail 891 
elsewhere [248]. We performed LD-based clumping on the QCed SNPs that were common to both 892 
samples. PRSs were calculated using the clumped SNPs that met eight association p-value thresholds 893 
of 5x10-8, 10-5, 10-3, 10-2, 5x10-2, 0.1, 0.5 and 1 (i.e. all SNPs), and were standardised to a mean of 894 
zero and a standard deviation of one, resulting in one standardised PRS per p-value threshold and 895 
individual in the target sample. 896 
Univariate mixed modelling 897 
Linear mixed models were constructed using genetic restricted maximum likelihood (GREML) in the 898 
GCTA [209] software package to obtain the effect estimates of PRSs on the individual differences in 899 
SU, SUD, and psychiatric disorders: 900 
Y X g=  + +   901 
where Y is a n x1 vector of either a binary phenotype or continuous phenotype with n being the 902 
number of individuals in the input data, X is a vector of fixed-effect covariates, and β is the effect 903 
estimate of the X. In addition to PRSs, covariates were included to control for the effects of 904 
categorical variables to capture sex (males coded as 1; females coded as 2), GWAS array, quantitative 905 
variables to capture the interaction between PRS and sex (PRS*sex), age, age2, age*sex, age2*sex, 906 
and the first ten principal components derived from the SNP data (to control for population 907 
stratification). The 𝑔 and 𝜖 denote the random genetic effect and error term respectively. Given that 908 
our target sample consisted of twins and their relatives, it is important to account for cryptic 909 
relatedness in the estimation. The genetic effect has a known variance-covariance structure that is 910 
defined by a genetic relationship matrix (GRM), which estimates the genetic relatedness between 911 
individuals using the SNP data. In addition to the modelling with sex*PRS interaction, we conducted 912 
additional modelling by stratifying the target sample by sex. This design was used in our earlier study 913 
[248] and may allow us to compare the PRS predictive performance between the two designs.  914 
The fixed effect estimates from the GCTA-GREML analysis were used to calculate the proportion of 915 
variance of target phenotypes explained by PRSs, R2, as 916 
2
2 ( )
PRS
PRS
Y
R SD
SD
 
=   
 
 917 
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where PRS is the regression coefficient of a PRS, YSD is the standard deviation of a binary or 918 
continuous target phenotype Y, and ( )PRSSD  is the standard deviation of the PRS . The R2 is defined 919 
as the square of the correlation between Y and PRS. We calculated two-sided p-values from a t-920 
distribution in R. 921 
Types of associations between PRS and target phenotypes 922 
To make it easy to interpret results from a large number of associations, we divided the 75 923 
combinations based on the five GWAS discovery phenotypes and 15 target phenotypes into four 924 
groups: (1) same-trait associations where discovery and target phenotypes are identical (e.g. 925 
smoking initiation and smoking initiation; five associations), (2) cross-trait associations between 926 
use of same substances where discovery and target phenotypes are different traits but based on the 927 
same substances (e.g. smoking initiation and cigarettes per day; 22 associations), (3) cross-trait 928 
associations between use of different substances where discovery and target phenotypes are based 929 
on different substances (e.g. smoking initiation and drinks per week in active drinkers; 18 930 
associations), and (4) other cross-trait associations where target phenotypes are non-substance traits 931 
(e.g. DSM-IV conduct disorder and smoking initiation; 30 associations). 932 
Multiple testing 933 
We tested the association between each of the 15 target phenotypes and each of the 40 PRSs, giving 934 
a total of 600 association tests (i.e. 15 target phenotypes * 5 discovery phenotypes * 8 p value 935 
thresholds). To account for multiple testing, we presented p-values adjusted for the effective number 936 
of independent target and discovery phenotypes (p < 7.14 x 10-4, see threshold T4 in Table S4-1). 937 
Details of the multiple testing were provided in the supplementary document (Supporting S4-3). 938 
Statistical software 939 
The data processing and computing for  PRS calculation were coded in Bash [212] and R [213]. LD-940 
based SNP clumping and PRS calculation were performed using Plink 1.90b3.38 [49]. Univariate 941 
GREML was performed using GCTA [209]. We used R and Base SAS 9.4 [249] for cleaning data, 942 
conducting statistical analyses, and generating graphs and tables. 943 
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Results 944 
Predictive performance of PRSs 945 
In our models that contained sex*PRS interaction, 10 of the 75 target-PRS associations remained 946 
significant after correcting for multiple testing at the T4 threshold. Our five PRSs significantly 947 
predicted five target phenotypes, including smoking initiation, drinks per week, DSM-IV and FTND-948 
based nicotine dependence, and DSM-IV conduct disorder, explaining 1.56% to 6.26% of their 949 
variance. The five PRSs were not associated with the other ten outcomes, such as age at starting 950 
regular smoking, cigarettes per day, smoking cessation, drinking initiation, DSM-IV alcohol 951 
dependence, antisocial personality disorder, major depressive disorder, panic disorder, social anxiety 952 
disorder, and mania screen. In terms of the number of target phenotypes predicted, PRS-SI was the 953 
most predictive, explaining five target phenotypes. The other four PRSs predicted one or two 954 
phenotypes. Significant sex*PRS were identified in the associations between (1) PRS-SI and DPW, 955 
(2) PRS-AI and DPW, and (3) PRS-DPW and DPW (Table S4-2). The main effect of the PRSs was 956 
larger in same-trait analyses (panel 1 and 2, Figure 4-1) than the cross-trait analyses (panel 3 to 10, 957 
Figure 4-1). The R2 generally increased with less stringent p value thresholds at which the PRSs were 958 
calculated against (Figure 4-1).  959 
Our models that stratified the target sample by sex identified 26 of the 75 target-PRS associations 960 
after correcting the results with the same significance threshold. We provided the number of 961 
significant associations in Table S4-3 and the fixed effect estimates of the PRSs in Table S4-4. 962 
89 
 
 963 
Figure 4-1 Proportion of variance of target phenotypes (Y) explained by polygenic risk 964 
scores (PRS, X). Bar height represents the percentage of the phenotypic variation explained 965 
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by a PRS. Associations that remained significant after accounting for multiple testing 966 
(adjusted p-value threshold: 7.14 x10-4) are shown as green whereas associations that did 967 
not survive multiple testing are shown in a pale colour. Bar groups on the x-axis indicate the 968 
eight p-value thresholds at which the PRSs were calculated: 5 x10-8, 10-5, 10-3, 10-2, 0.05, 969 
0.1, 0.5, and 1.  970 
Same-trait associations 971 
In the same-trait analyses, significant effects of PRSs were only identified from PRS-SI (panel 1, 972 
Figure 4-1) and PRS-DPW (panel 2, Figure 4-1). Sex*PRS-DPW negatively influenced the variance 973 
of DPW (β= -1.396, SE=0.354, p value= 0.00008, R2= 2.94%), suggesting the greater influence of 974 
increased PRS-DPW on the variation of DPW in males than females.  975 
Cross-trait associations between the use of same substances 976 
In cross-trait analyses based on the same substances, we found that higher PRS-SI, PRS-CPD and 977 
PRS-SC were associated with higher liability to DSM-IV and FTND-based nicotine dependence. 978 
PRS-SI showed a similar prediction pattern in the two nicotine dependence phenotypes (panel 3 & 5, 979 
Figure 4-1), with a significant effect only seen in the PRSs calculated using SNPs at or higher than 980 
10-2. A significant effect of PRS-CPD was only found in the PRS calculated using all SNPs (β=0.06, 981 
SE=0.018, p value=0.00068, R2=1.56%; panel 4, Figure 4-1). Significant effect of PRS-SC on FTND-982 
based nicotine dependence was only seen from SNPs at p value < 10-5 (β=0.059, SE=0.017, p 983 
value=0.00044, R2=1.7%; panel 6, Figure 4-1). Finally, we found no significant sex*PRS effect on 984 
these four associations. 985 
Cross-trait associations between the use of different substances 986 
In cross-trait analyses based on different substances, we found that higher risk of DPW was 987 
significantly associated with higher PRS-SI but with lower PRS-AI. PRS-SI calculated at all the eight 988 
p value thresholds significantly predicted DPW, explaining 3.01% to 4.39% of the trait variation 989 
(panel 7, Figure 4-1). Significant sex*PRS-SI effect on DPW was found in PRS-SI calculated at p 990 
value < 5x10-8 (β=-1.26, SE=0.353, p value=0.00036, R2=2.4 %; Table S4-2) and < 10-5 (β=-1.361, 991 
SE=0.355, p value=0.00013, R2=2.77%; Table S4-2), indicating greater influence of PRS-SI on DPW 992 
in males compared to females. Both PRS-AI (β=-2.714, SE=0.583, p value < 0. 00001, R2= 3.91%; 993 
Table S4-2) and sex*PRS-AI (β=1.307, SE=0.36, p value=0.00029, R2=2.48%; Table S4-2) 994 
significantly predicted DPW based on PRS-AI calculated at p value < 10-5suggesting that polygenic 995 
risk for starting regular smoking at an earlier age was associated with higher DPW but this association 996 
was stronger in females than males. 997 
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Cross-trait associations between SU and psychiatric disorders  998 
In the other cross-trait analyses, higher liability to DSM-IV conduct disorder was associated with 999 
higher PRS-SI (panel 9, Figure 4-1) and PRS-CPD (panel 10, Figure 4-1). The effect sizes were 1000 
generally smaller than 0.03. We had no evidence for significant sex*PRS effect in these associations. 1001 
Discussion 1002 
This study examined the association between SNP-based polygenic risk for tobacco or alcohol 1003 
consumption and the risk of SUs, SUDs, and psychiatric disorders. Our results lend support to genetic 1004 
risk factors that were common between cigarette smoking, and nicotine dependence, or conduct 1005 
disorder. PRS for smoking initiation (PRS-SI) was the most predictive among our five PRSs, 1006 
explaining not only the liability of smoking phenotypes expectedly but also alcohol consumption and 1007 
conduct disorder. Our PRSs showed higher prediction R2 in the same-trait associations (2.46% ~ 1008 
6.26%) than cross-trait associations (1.56% ~ 4.39%). Finally, we reported the first evidence for 1009 
PRS*sex interactions influencing the variation in alcohol consumption measured by the number of 1010 
drinks per week.  1011 
Same-trait associations 1012 
Given the very large sample sizes in the GSCAN discovery GWAS meta-analyses, our a priori 1013 
expectations were that all same-trait associations would be significant. This was not the case for 1014 
associations based on PRS-AI, PRS-CPD, and PRS-SC. One possible explanation could be the fewer 1015 
identified loci associated with AI, SC and CPD than the other two discovery phenotypes DPW and 1016 
SI (see Fig. 2, [206]). Second, pleiotropy across the five discovery phenotypes may partly explain the 1017 
difference in the prediction result. Every locus associated with AI was found to be pleiotropic for the 1018 
other four phenotypes. Only two non-pleiotropic loci were found in SC, followed by eight in CPD, 1019 
23 in DPW and 138 in SI [206]. Third, the inclusion of sex*PRS interaction in our models may 1020 
undermine the predictive performance of PRS-CPD on CPD. However, our additional analyses based 1021 
on models that were fitted separately in three sex subgroups identified a significant association 1022 
between PRS-CPD and CPD (Table S4-4). Liu et al. (2019) reported that GSCAN PRS for AI, CPD, 1023 
SI, SC, and DPW explained between 1% and 4% of the variance in similar measures. However, their 1024 
estimates were derived using pseudo-R2 and did not include sex*PRS interaction as a covariate. 1025 
Finally, our PRS-DPW explained up to 6.26% of the variance of DPW, exceeding 2.4% by GSCAN 1026 
PRS for DPW in the independent AddHealth sample [206]. We attributed the performance of our 1027 
PRS- DPW to predict variance out-of-sample to the fact that the GSCAN meta-analysis was very 1028 
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culturally heterogeneous and included cohorts with varying drinking behaviours and modes of 1029 
phenotypic assessment. In contrast, our Australian sample was carefully phenotyped.  1030 
Cross-trait associations between the use of same substances 1031 
Our PRS-CPD significantly predicted the liability to DSM-IV nicotine dependence, but not smoking 1032 
initiation nor age at the initiation. An earlier longitudinal study [250] associated polygenic risk score 1033 
for cigarettes per day with various stages of smoking behaviour in New Zealanders aged 11 to 38 1034 
years using six top SNPs to construct the PRS. We found that PRS-CPD was not associated with 1035 
smoking initiation nor with the time of the initiation; however, individuals at higher PRS-CPD were 1036 
more likely to become nicotine dependent. Our results largely agree with the findings reported by 1037 
Belsky et al. (2013) [250]. 1038 
Cross-trait associations between the use of different substances 1039 
We found that PRS-SI and PRS-AI, but not PRS-CPD or PRS-SC, significantly predicted the 1040 
variation of alcohol consumption, measured by a weekly number of drinks consumed. In contrast, 1041 
Vink et al., (2014) reported an association between a number of glasses alcohol per week and a PRS 1042 
for CPD, based on the Tobacco and Genetics Consortium (TAG; Tobacco and Genetics Consortium, 1043 
2010), but not with a TAG-based PRS-SI, nor PRS-SC [204]. Aside from the size differences in the 1044 
two discovery samples, the differences in the prediction for the smoking-related PRSs may be 1045 
attributable to the heterogeneity in terms of how the discovery GWAS consortia defined their 1046 
phenotypes. For example, the GSCAN-based SI dichotomised subjects as ever being regular smokers 1047 
or not, whereas the TAG-based SI classified subjects as ever smoking ≥ 100 or < 100 cigarettes, 1048 
which may be more strictly defined than our SI. The GSCAN-based CPD recorded the average 1049 
number of cigarettes smoked daily or binned the number of cigarettes in an ordinal scale (1-5, 6-15, 1050 
16-25, 26-35, or 36 or more cigarettes smoked per day) while the TAG-based CPD was defined as 1051 
the average or a maximum number of cigarettes smoked daily. While CPD and DPW are genetically 1052 
correlated with LDSC (rG=0.07, [206]; rG=0.44, [251]), we found no evidence for the association 1053 
using PRS method. 1054 
Cross-trait associations between substance use and psychiatric 1055 
disorders 1056 
We found evidence that DSM-IV conduct disorder was positively associated with PRS-SI, or PRS-1057 
CPD, but not with PRS-AI, PRS-SC, nor PRS-DPW. To the best of our knowledge, this is the first 1058 
study that associated polygenic risk for smoking with the liability of conduct disorder. Grant et al. 1059 
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(2015) found in their twin study that shared genetic liability explained the comorbidity between 1060 
nicotine dependence and conduct disorder [252]. Given that our PRS-SI and PRS-CPD predicted both 1061 
nicotine dependence (ND) and conduct disorder (CD), it may be reasonable to expect an association 1062 
between polygenic risk for ND and the liability to CD.  1063 
None of our PRSs significantly predicted the risk of antisocial personality disorder. One possible 1064 
explanation was that the low prevalence of this disorder, 0.8% in females and 3.8% in males, provided 1065 
insufficient variation for the PRS effect to be detected. Using the LDSC method, Tielbeek et al. (2018) 1066 
found a significant genetic correlation (rG = 0.59, p = 0.036) between antisocial behaviour 1067 
(N=31,968) and cigarettes per day (N=38,181) [253]. However, they inferred that the genetic variance 1068 
of antisocial behaviour that is overlapping CPD could be very low.  1069 
None of our associations between PRSs and DSM-IV major depressive disorder, panic disorder, SAD 1070 
or mania screen survived multiple testing. While genetic correlations of smoking phenotypes with 1071 
major depressive disorder were reported from twin studies [254] and LDSC-based studies [206,255], 1072 
we are unaware of other studies that have tested the associations using PRSs. 1073 
The role of PRS*sex interaction in smoking and alcohol consumption 1074 
We included the sex*PRS interaction in our PRS-phenotypic associations to control its effect on the 1075 
PRS prediction. The main advantage of incorporating this interaction term was that our models can 1076 
be tested on the full dataset, which can be more statistically powerful than splitting the data by sex 1077 
and testing the effect of PRSs in each subgroup [256]. Moreover, including the interaction allowed 1078 
us to identify its confounding effect on the PRS risk prediction. For example, the association between 1079 
PRS-CPD and CPD was significant (Table S4-4) in our additional analysis but not in our main 1080 
analysis (Table S4-2). Note that adding the interaction term may be a problem in a small target sample 1081 
(e.g., [257]). 1082 
However, we noted some impact of the practice of incorporating sex*PRS. Firstly, the number of 1083 
significant target-PRS associations was reduced from 26 to 10. Second, larger effect sizes, standard 1084 
errors (SE) and higher prediction R2 of our PRSs were found in models with the interaction term (β 1085 
range: -2.71 ~ 3.382; SE range: 0.007~ 0.594; R2 range: 1.56% ~ 6.26%) compared to models without 1086 
the interaction term (β range: -1.39 ~ 1.85; SE range: 0.002 ~ 0.372; R2 range: 0.17% ~ 3.69%).  1087 
Limitations 1088 
Our results should be interpreted in the context of the following limitations. First, our discovery 1089 
sample was based predominantly on Caucasian ancestry. Consequently, the significant PRS-1090 
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phenotype associations observed here may not be generalised in other ethnic groups. While we found 1091 
significant associations between PRS-CPD and DSM-IV nicotine dependence in Australians, a 1092 
similar association was found to be non-significant in native Americans [258]. Next, our disorder 1093 
outcomes from the NAG, OZALC-EDAC, and OZALC-BIGSIB study were defined by DSM-IV. 1094 
Significant changes were made in the diagnostic criteria of substance use disorders [259], as well as 1095 
psychiatric disorders [260]  from DSM-IV to the DSM-5  may not allow our results to be directly 1096 
compared with studies based on the DSM-5 outcomes. Thirdly, we reported the genetic overlap 1097 
between polygenic risk for alcohol- and nicotine-related phenotypes and self-reported measures of 1098 
SU, SUDs, and diagnoses. However, these associations do not imply causation. Fourthly, our PRSs 1099 
explained a relatively small proportion of the genetic variance, especially in the non-SU phenotypic 1100 
outcomes. This is a common problem in addiction studies [204,220,261–263] that rely on PRS 1101 
approaches. Although it remains challenging to discuss the clinical utility of PRSs in genetic risk 1102 
prediction for substance use, the PRS method does improve risk prediction in other diseases, such as 1103 
prostate cancer [221], coronary artery disease [264]. PRS prediction may prove useful for 1104 
discriminating patients at the top and bottom deciles of risk [219] through larger GWAS discovery 1105 
samples and use of multi-polygenic scores derived from related traits [265].  1106 
Implications 1107 
While the use of PRS is currently limited to a research context, the possibility of adapting PRS for 1108 
clinical use is being actively discussed [219,266,267]. We demonstrated the genetic overlap between 1109 
smoking PRSs and alcohol consumption, nicotine dependence, or conduct disorder.  To clinicians, a 1110 
calculated PRS in smokers may be used jointly with existing screening tools to identify individuals 1111 
at high risk of risky alcohol consumption, nicotine addiction or conduct problems. To geneticists, 1112 
future studies that aim at maximising risk prediction may consider including genotype-by-sex, or/and 1113 
genotype-by-age interaction [268] in their models. 1114 
Conclusion 1115 
In conclusion, using PRSs derived from the very large GSCAN consortium, we identified shared 1116 
genetic aetiology between smoking or alcohol consumption, and smoking initiation, alcohol 1117 
consumption, nicotine dependence, or conduct disorder. 1118 
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Abstract 1164 
Background Caffeine, alcohol, nicotine and cannabis are commonly used psychoactive substances. 1165 
While the use of these substances has been previously shown to be genetically correlated, causality 1166 
between these substance use (SU) traits remains unclear. We aimed to revisit the genetic relationships 1167 
among different measures of SU using genome-wide association study (GWAS) summary statistics 1168 
from the UK Biobank (UKB), International Cannabis Consortium (ICC), and GWAS & Sequencing 1169 
Consortium of Alcohol and Nicotine use (GSCAN).  1170 
Methods We obtained GWAS summary statistics from the aforementioned consortia for ten SU traits 1171 
including various measures of alcohol consumption, caffeine consumption, cannabis initiation and 1172 
smoking behaviours.  We then conducted SNP-heritability (h2) estimation for individual SU traits, 1173 
followed by genetic correlation analyses and two-sample Mendelian randomisation (MR) studies 1174 
between SU trait pairs. 1175 
Results SNP h2 of the ten traits ranged from 0.03 to 0.11. After multiple testing correction, 29 of the 1176 
45 trait pairs showed evidence of being genetically correlated. MR analyses revealed that most SU 1177 
traits were not causally associated with each other. However, we found evidence for an MR 1178 
association between regular smoking initiation and caffeine consumption (40.17 mg; 95% CI: [ 24.01, 1179 
56.33] increase in caffeine intake per doubling of odds in smoking initiation). Our findings were 1180 
robust against horizontal pleiotropy, SNP-outliers, and the direction of causality was consistent in all 1181 
MR analyses. 1182 
Conclusions Most of the substance traits were genetically correlated but there is little evidence to 1183 
establish causality apart from the relationship between smoking initiation and caffeine consumption. 1184 
Keywords 1185 
Substance use, genetic instruments, tobacco, coffee, tea, single nucleotide polymorphism, two-sample 1186 
Mendelian randomisation 1187 
Introduction 1188 
Observational associations between use of substances 1189 
Caffeine, alcohol, nicotine and cannabis are among the most commonly used psychoactive substances 1190 
worldwide [8]. Observational studies frequently associate the use of two or more of these substances. 1191 
High phenotypic correlations are found between the use of caffeine, alcohol, nicotine and cannabis 1192 
99 
 
[269] during adolescence. Smoking initiation is positively associated with coffee consumption 1193 
[270,271]. Cannabis use is associated with increased alcohol consumption [272], but also with less 1194 
success in quitting tobacco smoking [273].  1195 
Genetic associations between use of substances 1196 
Genetic influence plays an important role in the use of multiple substances. Twin studies reported a 1197 
wide range of heritability estimates on substance use: 0.39 ~ 0.51 for coffee consumption [274,275], 1198 
0.44~ 0.48 for the initiation of cannabis use [276,277], 0.44~ 0.75 for the initiation of smoking [278–1199 
280], and 0.24~ 0.53 for a range of alcohol consumption and alcohol use disorder phenotypes 1200 
[278,281–283].  1201 
Recent genetic association studies based on the variation in single nucleotide polymorphisms (SNPs) 1202 
provide the support that the genes underlying use of one substance are overlapping with those 1203 
underlying use of other substances.. For instance, coffee consumption [284] is genetically correlated 1204 
with various dimensions of cigarette smoking, including smoking initiation (rG: 0.28), persistence 1205 
(rG: 0.25) and number of cigarettes per day (rG: 0.44; [251,285]). The number of drinks consumed 1206 
per week is also correlated with different stages of smoking, such as initiation (rG: 0.40 [257]), 1207 
cigarettes per day (rG ranging from 0.07 [206] to 0.44 [251], and smoking cessation (rG: 0.104 [257]). 1208 
Lifetime cannabis use is also genetically correlated with smoking initiation, alcohol consumption, 1209 
and alcohol dependence [286]. While these studies were able to demonstrate the common genetic 1210 
influences underlying substance use, it remains unclear whether the co-occurring conditions are 1211 
driven by pleiotropy (i.e., the same set of genes influences multiple traits) or causality (i.e., one trait 1212 
is causally associated with the other).  1213 
Causality in the genetic risk of substance use 1214 
Mendelian randomisation (MR) studies typically use genetic variants as instrumental variables (IVs) 1215 
to estimate the causal effect of an exposure on a related outcome [287]. Given that variation in 1216 
substance use behaviour is heritable, we can identify suitable genetic instruments through large scale 1217 
GWAS studies to perform causal inferences. MR is subject to three assumptions [51]: (1) the genetic 1218 
instrument should be reliably associated with the exposure, (2) the instrument should not be 1219 
associated with (un)measured confounders, and (3) the instrument should not influence the outcome 1220 
other than through the exposure.. Among a variety of MR approaches available in the literature, the 1221 
two-sample MR approach [58] is particularly efficient when individual-level data on both the 1222 
exposure and outcome traits are unavailable in the same set of individuals. Two-sample MR allows 1223 
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higher statistical power to be leveraged across larger genome-wide association study (GWAS) 1224 
datasets for both the exposure and the outcome. 1225 
The intertwining causal relationship between the use of different substances has been examined by 1226 
only a few studies [288,289]. While higher smoking heaviness was shown to be associated with higher 1227 
coffee consumption in current smokers (N=10951~16243) via MR [288], a more recent and larger 1228 
MR study found little evidence for the causal associations between alcohol (N=112,117), caffeine 1229 
(N=92,501), cannabis (N=32,330) and nicotine use (N=38,181 in cigarettes per day; N=74,035 in 1230 
smoking initiation) [289]. However, the power in this study to detect subtle effect sizes remains 1231 
limited.  1232 
Aims 1233 
In this study, we aim to revisit the genetic relationships among different measures of substance use 1234 
using GWAS summary statistics from larger samples which recently became available. After removal 1235 
of sample overlap (e.g., 23andme and UKB), sample sizes range from N=25,153 to N= 296,735. We 1236 
investigated genetic correlations between ten phenotypes representing the initiation or use of alcohol, 1237 
caffeine, cannabis and nicotine through large scale studies conducted in the UK Biobank (UKB) 1238 
cohort, International Cannabis Consortium (ICC; [286]), and GWAS & Sequencing Consortium of 1239 
Alcohol and Nicotine use (GSCAN; [206]). We then investigated the causal associations between 1240 
some of these traits using two-sample MR. 1241 
Materials and methods 1242 
Measures 1243 
GWAS summary statistics were available for ten traits from three samples, including (1) number of 1244 
drinks consumed per week (GSCAN), (2) estimated standard drinks per week (UKB), (3) caffeine 1245 
consumption (mg/day) per day (UKB), (4) cannabis initiation (ICC), (5) regular smoking initiation 1246 
(GSCAN), (6) age at initiating regular smoking (GSCAN), (7,8) cigarettes smoked per day (GSCAN, 1247 
UKB), (9) pack-years of smoking (UKB), and (10) smoking cessation (GSCAN). Note that among 1248 
the ten traits, we included two similar traits for quantitative use of alcohol (i.e., number of drinks 1249 
consumed per week, and estimated standard drinks per week) and two identical traits for quantitative 1250 
smoking measured separately in the GSCAN and UKB for internal validation. We provided the 1251 
definitions of the ten traits in Table 5-1. See definitions of substance use phenotypes in the  Supporting 1252 
S5-1.1253 
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Table 5-1 Sources (Sample), definitions, types and sample sizes of substance use traits used in genetic associations. Genetic analyses, 1254 
including SNP-based heritability estimation, genetic correlation, and two-sample Mendelian randomisation, were conducted using GWAS 1255 
summary statistics in the UKB, ICC and GSCAN samples. UKB: UK Biobank. ICC: International Cannabis Consortium. GSCAN: GWAS & 1256 
Sequencing Consortium of Alcohol and Nicotine use. 1257 
Substance Sample Traits Type Trait definition Sample size 
nicotine GSCAN Age of initiation of regular smoking continuous Age of initiating regular smoking 119,239 
nicotine GSCAN Cigarettes smoked per day continuous Cigarettes smoked per day using averaged number or 
5 response categories: 1-5, 6-15, 16-25, 26-35, or 36+ 
122,027 
alcohol GSCAN Drinks consumed per week continuous Number of drinks consumed per week in ever 
drinkers 
185,828 
nicotine GSCAN Smoking cessation binary Current smokers versus former smokers 125,361 
nicotine GSCAN Regular smoking initiation binary Ever versus never smoked regularly. A regular 
smoker was defined as having smoked > 100 
cigarettes during lifetime, ever having smoked every 
day for at least one month, or simply ever smoking 
regularly 
207,726 
cannabis ICC Cannabis initiation binary Ever versus never taken cannabis 164,741 
caffeine UKB Caffeine consumed per day continuous Caffeine consumed per day through regular coffee 
and tea (mg/day; UKB Data-Field: 1488, 1498, 1508) 
168,919 
nicotine UKB Cigarettes smoked per day continuous Number of cigarettes currently smoked daily (UKB 
Data-Field: 3456) 
25,153 
alcohol UKB Estimated standard drinks per week continuous Number of standard drinks consumed per week based 
on alcohol intake frequency, types of alcoholic 
beverage and intake quantity 
296,735 
nicotine UKB Pack years of smoking continuous Pack years of smoking in ever or current cigarette 
smokers (UKB Data-Field: 20161) 
186,411 
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Analyses 1258 
In this study, we estimated SNP heritability (SNP h2), examined pairwise genetic correlations, and 1259 
then followed up with a two-sample MR analysis to evaluate evidence for causality. We curated each 1260 
GWAS dataset and removed all sample overlap by removing overlapping individual studies to avoid 1261 
biased causal estimates from the MR analysis. The details of these analyses are described below. 1262 
Genome-wide association studies (GWAS) 1263 
     The UKB cohort was the largest contributor to both the GSCAN and ICC consortia. To avoid 1264 
potential inflation of causal estimates in the two-sample MR framework due to sample overlap, we 1265 
obtained revised GWAS estimates for substance use phenotypes reported in the GSCAN and ICC 1266 
studies upon removal of UKB and 23andMe participants. Firstly, the five GSCAN meta-analytic 1267 
GWAS from previous work [206] was repeated after removing all contributing UKB participants, the 1268 
23andMe participants, and participants from studies that overlapped the ICC sample. Next, GWAS 1269 
for cannabis initiation was re-conducted after removing the 23andMe participants in the ICC cohort. 1270 
Because the ICC contained fewer individuals than GSCAN and UKB, we prioritised to retain as many 1271 
cases from the ICC. Thirdly, we identified 153,501 UKB participants who responded to the survey 1272 
concerning their lifetime use of cannabis and excluded these participants from our UKB GWASs on 1273 
four continuous traits, including cigarettes per day, pack-years of smoking, estimated standard drinks 1274 
per week, and caffeine consumed per day. The UKB GWAS was conducted using a Bayesian linear 1275 
mixed model implemented via the BOLT-LMM software (version 2.3; [50]), which takes cryptic 1276 
relatedness between participants into account. Covariates included age at recruitment, sex, and the 1277 
first ten ancestral principal components (PCs). SNPs with ambiguous strands and/or a minor allele 1278 
frequency (MAF) < 0.01 were excluded. Our leave-one-study-out approach in deriving the genetic 1279 
summary statistics allowed two-sample MR analyses to be conducted without worrying about 1280 
potential bias due to sample overlap. All individuals in the three independent samples ICC, GSCAN 1281 
and UKB were of European ancestry. 1282 
Heritability estimation and genetic correlations 1283 
SNP-h2 was estimated for the ten traits using LD-Score Regression (LDSC; [37]), which is based on 1284 
GWAS summary statistics. Bivariate genetic correlations [290] were then calculated using the same 1285 
software between all possible pairs of traits, giving a total of 45 combinations of tests. Our pairwise 1286 
genetic correlation results were adjusted using Bonferroni correction with the threshold 0.001 1287 
(0.05/45). More details on the SNP-h2 estimation and the calculation of genetic correlations are 1288 
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provided in the supporting information See procedure for heritability estimation and genetic 1289 
correlation analyses (Supporting S5-2). 1290 
Mendelian Randomization 1291 
Mendelian randomisation (MR) analyses rely on the use of genetic instruments to estimate the causal 1292 
effect of an exposure on a related outcome. The two-sample MR method [58] typically uses data from 1293 
GWASs that are conducted in two non-overlapping samples of the same ancestry. This method is 1294 
efficient because individual-level data are not required, yet GWAS summary results are increasingly 1295 
available from larger studies.  1296 
We selected genetic instruments from GWAS data on cannabis initiation, regular smoking initiation, 1297 
estimated standard drinks per week and caffeine consumption (as exposures). Traits that had their 1298 
GWAS performed on stratified samples (i.e. traits that can only be assessed in a subset of the 1299 
population, such as the number of cigarettes per day in smokers) were not considered in the analysis 1300 
due to the potential presence of collider bias when interpreting these findings unless the number of 1301 
non-users is negligibly low. A more detailed explanation was provided in the supporting information. 1302 
See the section avoiding collider bias in Mendelian randomisation findings (Supporting S5-5).  1303 
For the MR analyses, we used linkage disequilibrium (LD) based clumping to obtain a set of 1304 
independent (genome-wide) significant SNPs in each dataset using the following criteria: (1) LD R-1305 
squared between instruments < 0.01, (2) minimal distance of 10,000 kb. The clumping procedure was 1306 
performed in the software package PLINK (version: 1.90 beta) [49]. Following the previously 1307 
reported procedure [289], we defined our MR instruments on each of the four exposures at two 1308 
association criteria: (1) one set of instruments associated with the exposure of interest at p-value < 1309 
5e-8 and (2) the other at a less stringent threshold of p-value < 1e-5. MR analyses were conducted for 1310 
each exposure-outcome pair using both sets of instruments.  1311 
For the first set of the instruments, we calculated the proportion of phenotypic variance explained by 1312 
the instruments (R2) for each of the four exposure traits (i.e., regular smoking initiation, cannabis 1313 
initiation, number of standard drinks per week, and caffeine consumption). The R2 of our instruments 1314 
ranged from 0.004 to 0.02 (Regular smoking initiation: 8 SNPs, R2= 0.004; Cannabis initiation: 4 1315 
SNPs, R2= 0.02; Caffeine consumption: 22 SNPs, R2= 0.011; Estimated standard drinks per week: 1316 
37 SNPs, R2= 0.008; See Table S5-3). See the section “strength of genetic instruments” in the 1317 
supporting information for the calculation of the R2 (Supporting S5-3) 1318 
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We conducted two-sample MR analysis using the R package TwoSampleMR curated from the MR-1319 
Base platform [291]. First, we harmonised each pair of clumped exposure and raw outcome GWAS, 1320 
which ensures that the effect of an SNP on the exposure trait and the effect of that SNP on the outcome 1321 
trait correspond to the same allele. Next, the causal associations were then evaluated using the fixed 1322 
effect inverse-variance weighted (IVW) estimator [292] from exposure to an outcome, and in the 1323 
other direction if reverse causality could exist. We tested the association in a total of 23 pairs of 1324 
exposure and outcome traits. Multiple testing correction was applied using Bonferroni correction with 1325 
a threshold of 0.002 (0.05/23). For binary exposures, we presented the causal estimates to reflect an 1326 
average change in the outcome per doubling of odds in the prevalence of the exposure. 1327 
Sensitivity analyses 1328 
We reported our main MR findings using estimates derived from the IVW estimator. Subsequently, 1329 
we conducted different sensitivity analyses, with different underlying assumptions, to examine how 1330 
robust the IVW estimates are. These alternative MR methods make weaker assumptions on 1331 
instrument validity and horizontal pleiotropy than the IVW method which in turn allows further 1332 
triangulation of causality [293,294]. In brief, for each exposure-outcome pair, we conducted 1333 
heterogeneity tests, MR-Egger regression, weighted median, and weighted mode in addition to the 1334 
IVW estimator. Cochran’s Q statistics were derived from the IVW or MR-Egger estimates to detect 1335 
the presence of heterogeneous causal effects among the genetic instruments, an indication of potential 1336 
violations of the third assumption (i.e. horizontal pleiotropy) [295]. MR-Egger regression [296,297] 1337 
relaxes the third assumption of the IVW analysis that the average pleiotropic effect is zero by allowing 1338 
a non-zero intercept. A non-zero intercept means that the IVW estimate is biased [293]. The weighted 1339 
median method [298] allows up to 50% of the instruments to be invalid. The weighted mode method 1340 
relaxes the third assumption differently from the MR-Egger regression and weighted median and is 1341 
recommended to be used in combination with other sensitivity analyses [299]. 1342 
To evaluate bias due to heterogeneity of causal effect among instruments, we further applied two 1343 
additional analyses: the leave-one-out MR analysis [300], and the Mendelian randomization 1344 
pleiotropy residual sum and outlier (MR-PRESSO; [294]), where the lack of presence of 1345 
heterogeneity would suggest that MR estimates are unlikely to be driven by SNP outliers. The 1346 
rationale behind each of these six sensitivity analyses is further elaborated in the supporting 1347 
information See the section Procedure for two-sample Mendelian randomisation analyses (Supporting 1348 
S5-4).  1349 
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Scaling differences between the exposure and outcomes used in the MR analyses were removed. See 1350 
the section Effect estimate conversion in the supporting information for details (Supporting S5-8). 1351 
Results 1352 
SNP heritability and genetic correlations 1353 
The ten substance use traits show strong evidence of being heritable, with SNP h2 estimates ranging 1354 
from 0.033 to 0.109 (Table S5-1). We observe strong evidence of genetic overlap in 29 out of the 45 1355 
trait pairs (Figure 5-1; Table S5-2) after accounting for multiple testing, with positive correlation 1356 
coefficients ranging from 0.157 to 0.941 and negative correlation coefficients ranging from -0.821 to 1357 
-0.196. Negative coefficients were only seen in the correlations between age of initiation of regular 1358 
smoking and the other nine traits (see Figure 5-1). 1359 
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 1360 
Figure 5-1 Genetic correlation coefficients between any two of the ten GWAS on substance use or 1361 
initiation from three samples. Sizes of coloured squares are in proportion to the magnitude of the 1362 
correlations that remained significant after the correction for multiple testing. Correlations that did 1363 
not survive multiple testing are shown in white background. Abbreviated sample names: (1) 1364 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: International 1365 
Cannabis Consortium, (3) UKB: UK Biobank. Abbreviated trait names: (1) DPW: Drinks 1366 
consumed per week, (2) ESDPW: Estimated standard drinks per week, (3) caffeine: Caffeine 1367 
consumed per day, (4) CI: Cannabis initiation, (5) SI: Regular smoking initiation, (6) AI: Age at 1368 
initiation of regular smoking, (7) CPD: Cigarettes smoked per day, (8) PYOS: Pack years of 1369 
smoking, and (9) SC: Smoking cessation. 1370 
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Two-sample Mendelian randomisation analyses and sensitivity analysis 1371 
For each exposure investigated, we adopted two sets of instruments: (i) instruments including SNPs 1372 
with genome-wide significance (SNP-exposure) to control for weak instrument bias; (ii) a less 1373 
stringent set of instruments defined at SNP-exposure p-value<1e-5 to leverage better trait prediction 1374 
using more SNPs. 1375 
Based on the MR associations evaluated at both genome-wide and suggestive exposure sets,      regular 1376 
smoking initiation and caffeine consumption were the only exposure-outcome pair that showed 1377 
evidence for a causal association across both instrument thresholds (Table S5-4). The effect estimates 1378 
were broadly similar across other MR models (Table S5-4), with minimal evidence of bias due to 1379 
SNP heterogeneity (MR-PRESSO global test: Table S5-5; leave-one-out analysis: Table S5-6) or 1380 
directional pleiotropy (MR Egger intercept p-value 0.85), ensuring the robustness of the IVW finding 1381 
for regular smoking initiation on caffeine consumption (Table 5-2). In our reverse direction of MR 1382 
analysis, we did not observe evidence for a causal effect of caffeine consumption on regular smoking 1383 
initiation (Table S5-4).  1384 
To benchmark the MR results, we performed phenotypic associations. See the section Phenotypic 1385 
associations and definitions of some covariates used in phenotypic associations in the supporting 1386 
information for details and Table S5-7 for results. 1387 
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Table 5-2 Two-sample Mendelian randomisation results on the causal associations between the initiation of regular smoking and caffeine 1388 
consumption. Independent SNPs associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number 1389 
of independent SNPs used in each exposure-outcome pair. p1: Significance threshold for index SNPs. Heterogeneity tests were available 1390 
from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the estimates from the MR estimators. These 1391 
estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) GSCAN: 1392 
GWAS & Sequencing Consortium of Alcohol and Nicotine Use, (2) UKB: UK Biobank. The significance threshold was 0.002173913 1393 
(0.05/23). Details of multiple testing correction were provided in the method section. MR analyses that survived heterogeneity tests (i.e. Q 1394 
p value >= 0.05) and multiple testing are shown in blue and boldface. Full results for all the exposure and outcome traits are shown in Table 1395 
S5-4. 1396 
 1397 
 1 
 Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
No. Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
1 GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 IVW 1.1E-01  15.28 [ 8.389 , 22.16 ] 1.38E-05 
2 GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 Egger 9.5E-02  9.686 [ -18.4 , 37.74 ] 5.01E-01 
3 GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 W Median   14.12 [ 5.076 , 23.16 ] 2.21E-03 
4 GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 W Mode   12.33 [ -9.36 , 34.02 ] 2.69E-01 
5 GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 IVW 8.9E-01  40.17 [ 24.01 , 56.33 ] 1.10E-06 
6 GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 Egger 8.1E-01  57.69 [  -111 , 226.2 ] 5.32E-01 
7 GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 W Median   38.67 [ 18.27 , 59.07 ] 2.03E-04 
8 GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 W Mode   37.92 [ 7.917 , 67.92 ] 4.80E-02 
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Discussion 1398 
In this study, we comprehensively evaluated the genetic relationships between the use or initiation of 1399 
ten traits measuring different aspects of use for four commonly used substances alcohol, caffeine, 1400 
cannabis and nicotine. Our pairwise genetic correlation results showed significant genetic overlap 1401 
between most of the trait pairs (29 out of the 45). We further investigated the causal associations 1402 
between regular smoking initiation, cannabis initiation, caffeine consumption, or the number of 1403 
standard drinks per week (as exposures) and the other substance use traits (as outcomes) using various 1404 
two-sample MR methods and sensitivity analyses. We found evidence for a positive causal effect of 1405 
regular smoking initiation on caffeine consumption, with two-fold increased prevalence of smoking 1406 
initiation associated with increased consumption of caffeine up to 40.17 mg, an equivalent to the 1407 
caffeine in about half a cup of coffee. 1408 
Genetic correlations 1409 
The observed pattern of genetic correlations was consistent with previous studies on smaller GWAS 1410 
samples [251,285]. Substantial genetic overlap was detected between pack-years of smoking and each 1411 
of the other nine traits. To our knowledge, past studies have not reported LD-based genetic correlation 1412 
between this trait and alcohol, caffeine or cannabis use. Similarly, regular smoking initiation was 1413 
correlated with almost every other trait, except for cigarettes per day in the UKB sample. However, 1414 
regular smoking initiation was genetically correlated with cigarettes per day in GSCAN. These 1415 
inconsistent correlations were likely due to the sample size difference between the UKB (N= 25,153) 1416 
and GSCAN (N=122,027).  1417 
We found moderate genetic correlations between regular smoking initiation and cannabis initiation 1418 
(rG: 0.4), and between GSCAN cigarettes per day and caffeine consumed per day (rG: 0.41), but no 1419 
significant genetic correlation between cannabis initiation and caffeine consumption (rG: -0.02; Table 1420 
S5-2). Likewise, Nivard et al. (2016) observed a high genetic correlation between cannabis initiation 1421 
and smoking initiation (rG: 0.83; SE: 0.15), between cigarettes per day and coffee consumption (rG: 1422 
0.44; SE: 0.17), but limited evidence for genetic overlap between coffee consumption and cannabis 1423 
initiation [251]. Treur et al 2017 reported an rG of 0.28 between smoking initiation and coffee use 1424 
[285]. The pattern in our genetic correlations was similar to those studies, but our correlation 1425 
coefficients were slightly lower than their estimates. We detected a modest genetic correlation 1426 
between regular smoking initiation and cannabis initiation; however, this result would require further 1427 
validation. Moreover, our analyses revealed substantial overlap in the genetic architecture between 1428 
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alcohol consumption and smoking-related traits, such as regular smoking initiation, and pack-years 1429 
of smoking. 1430 
Genetic evidence for a causal association between liability to smoking 1431 
initiation and caffeine consumption 1432 
Although we observed an abundance of genetic correlations between regular smoking initiation and 1433 
several other substance use traits, we only detected evidence supporting a causal association between 1434 
regular smoking initiation and caffeine consumption via MR. Our MR analysis showed that genetic 1435 
liability to initiating regular smoking causally influenced caffeine consumption, with a doubling in 1436 
odds of regular smoking initiation associated with increased consumption of caffeine up to 40.17 mg. 1437 
While strong evidence for this causality was only seen in the weighted median model (Table S5-4) 1438 
but not in the other two sensitivity analyses MR-Egger regression (Table S5-4) and weighted mode 1439 
(Table S5-4), the direction of causality was similar across all the MR estimators. Our results yield 1440 
similar conclusions to findings from Bjørngaard et al. (2017) where the authors reported that each 1441 
additional cigarette consumed per day was associated with 0.1 more cups of coffee intake [288]. 1442 
It is important to note that our genetic causality analyses do not warrant a definitive conclusion on 1443 
(non-)causality due to existing shortfalls of our study design. Firstly, genetic correlation analyses 1444 
conducted using the LD-score regression technique assumes a strong degree of polygenicity (such 1445 
that LD-scores are informative) for each of the trait evaluated. Whilst our MR-approach complements 1446 
the LD-score restriction on polygenicity as long as instruments explain sufficient phenotypic 1447 
variance, MR analyses typically require large sample sizes to enable an adequately powered analysis. 1448 
Finally, causal estimates derived via MR assumes a lifelong predisposition of the exposure. These 1449 
findings are not necessarily compatible with results from intervention studies (such as RCTs) that 1450 
evaluate a temporal change in substance use on the outcome of interest. In lieu of these limitations, 1451 
the wide CIs around some of the MR findings would remain consistent with a clinically relevant 1452 
causal effect.  1453 
It remains unclear which biological mechanism underlies the positive causal association between 1454 
regular smoking initiation and caffeine consumption. One possible biological explanation pertains to 1455 
the cytochrome P450 1A2 (CYP1A2) enzyme that is induced by tobacco smoking[301]. Caffeine is 1456 
primarily metabolised by the CYP1A2 enzyme [301], which can be induced by cigarette smoking via 1457 
the aryl hydrocarbon receptor (AHR; [302]). Smoking accelerates caffeine metabolism [303,304] and 1458 
ultimately increases caffeine consuming behaviour. While the pleiotropic function of CYP1A2 might 1459 
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explain the postulated link between smoking and caffeine intake, none of our instruments for smoking 1460 
was located in or nearby CYP1A2 nor AHR, making this explanation unlikely. Future functional 1461 
work is needed to elucidate complex biological interaction between these smoking-associated 1462 
variants and CYP1A2 activity or whether there exist alternative causal pathways yet to be explored. 1463 
Conclusion 1464 
Our study utilised large scale phenotypic and genetic data to re-evaluate the relationship between 1465 
alcohol, caffeine, cannabis and nicotine initiation with greater precision. Our findings support the 1466 
notion that genetic liability to initiating regular smoking causally influenced caffeine consumption. 1467 
Future studies are warranted to investigate the mechanisms underlying these conditions to understand 1468 
substance use behaviours. 1469 
Disclosure of Interests 1470 
none 1471 
Conflict of Interest 1472 
none 1473 
  1474 
112 
 
6 1475 
General discussion  1476 
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 General Discussion 1477 
The main motivation of this thesis was to better understand the comorbidity between psychiatric 1478 
disorders, substance use behaviour, and substance use disorders from a genetic perspective. I achieved 1479 
this aim by estimating the heritability of individual traits, examining the genetic correlations between 1480 
them, predicting them with polygenic risk scores, and investigating the causal relationship between 1481 
traits that were genetically correlated. My data covered a comprehensive set of individual-level 1482 
phenotypes measured in two Australian samples and UK Biobank, as well as GWAS summary results 1483 
obtained from other larger samples, including GSCAN, the International Cannabis Consortium (ICC), 1484 
and UK Biobank (UKB). In this general discussion chapter, I will summarise the main aims and 1485 
findings in the result chapters, discuss the limitations of the data and methods, and future directions. 1486 
Main aims and findings of result chapters 1487 
In Chapter 2, my univariate twin modelling aimed to find the most parsimonious models that 1488 
explained the variation of the phenotypes of interest. The model fit of the AE models was not 1489 
statistically different from that of the full models ACE or ADE in most of the phenotypes, except for 1490 
two binary phenotypes tobacco use ever and alcohol use (see Table S2-4). Hence, the AE models 1491 
were chosen as the most parsimonious models for all the phenotypes including the two binary 1492 
phenotypes even though in some cases the point estimates of the C component were substantial. 1493 
I estimated the genetic and environmental influence on the variation of four groups of disorders, 1494 
including psychological distress (PSYCH6), somatic distress (SOMA6), affective disorders (AD), 1495 
and substance use (SU), by conducting twin modelling in young Australian adults (N= 1548~ 2132 1496 
twin individuals). I created item response theory (IRT) theta scores for each of the four groups. 1497 
Univariate findings showed low heritability estimates in PSYCH6-IRT (h2: 0.23) and SOMA6-IRT 1498 
(h2: 0.25), moderate heritability in affective disorders and AD-IRT (h2 range: 0.32 ~ 0.42), and higher 1499 
heritability in SU and SU-IRT (h2 range: 0.49 ~ 0.79). I provided the first evidence that DSM-5 1500 
cannabis use disorder (h2: 0.78, 95% CI [0.66, 0.86]) and DSM-5 social anxiety (h2: 0.42, 95% CI 1501 
[0.23, 0.58]) were heritable.  1502 
Multivariate findings showed that an independent pathway model (Figure 2-2) best described how 1503 
the covariation of the four IRT scores could be explained by genetic and environmental factors. 1504 
Importantly, genetic factors that were specific to ADs (explained 22% of variance) or SU (explained 1505 
43% of variance) exerted relatively greater influence than genetic factors that were common to ADs 1506 
(explained 10% of variance) and SU (explained 3% of variance). This finding justified the need to 1507 
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subsequently examine the genetic overlap between the use of different substances in Chapters 3, 4 1508 
and 5  1509 
Chapter 3 tested the associations between licit substance use and illicit substance use in 2,463 young 1510 
Australian adults (QIMR 19Up). First, I constructed polygenic risk scores for tobacco and alcohol 1511 
consumption using GWAS meta-analysis from the GSCAN [206] consortium. This discovery sample 1512 
was composed of up to 1.2 million participants in its full sample, which remained the largest substance 1513 
use GWAS at the time that Chapter 3 was published. Next, I estimated the fixed effect of the PRSs 1514 
on individual differences in 22 phenotypes related to the initiation of illicit drugs and SUDs in an 1515 
independent sample. After the correction for multiple testing, PRS for regular smoking initiation 1516 
(PRS-SI) significantly predicted the variation of DSM-5 alcohol use disorder, and the initiation of 1517 
five illicit substances ecstasy, amphetamine, cannabis, hallucinogens, and cocaine (Figure 3-1). 1518 
Moreover, the initiations of ecstasy, amphetamine, and cocaine were also predicted by PRS for 1519 
weekly alcohol consumption (PRS-DPW). While Chapter 3 identified some new associations 1520 
between the PRSs and illicit substance initiation, it remained unclear whether the trait variation could 1521 
also be influenced by the interaction between sex and SNP genotype.  1522 
In Chapter 4, I tested the associations between the same set of PRSs and individual differences in 1523 
licit substance use and common psychiatric disorders in 13,999 Australian adults (QIMR adult 1524 
cohort). The use of this large sample permitted a comparison in the PRS prediction between models 1525 
that included sex-PRS interaction as the primary analysis, and models that stratified the sample by 1526 
sex as a secondary analysis (similar to the design in Chapter 3). Higher prediction R2 but fewer 1527 
associated PRS-phenotype pairs were found in the primary analysis than the secondary analysis. PRS 1528 
for regular smoking initiation (PRS-SI) remained the most predictive, significantly explaining the 1529 
variation of regular smoking initiation, drinks per week, DSM-IV and FTND-based nicotine 1530 
dependence, and conduct disorder. The highest prediction R2 was found in the association between 1531 
PRS-SI and SI (R2: 5.09%) and between PRS-DPW and DPW (R2: 6.26%). A significant effect of 1532 
the sex-PRS interaction was only detected in the associations that involved weekly alcohol 1533 
consumption (DPW).  1534 
The context of this chapter needs to be understood. When I did this work and published it, the use of 1535 
PRS was still relatively new and the mere demonstration that I could obtain an out-of-sample 1536 
prediction of these previously measured phenotypes seemed noteworthy. From the perspective of 1537 
today, I agree that a join twin-family analysis of the phenotypes including PRS as fixed effects would 1538 
be worthwhile but this would be a lot more work and beyond the scope of the chapter and this thesis. 1539 
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Chapter 5 investigated whether certain genetically correlated traits can be explained by causality. 1540 
Firstly, I tested the phenotypic associations between substance use traits available in the UK Biobank. 1541 
Secondly, I estimated SNP heritability in GWAS summary results on ten traits obtained from 1542 
GSCAN, ICC, and UKB. Thirdly, I estimated genetic correlations between any two of the ten traits, 1543 
giving a total of 45 tests. Lastly, I examined the causal relationship between the ten traits using two-1544 
sample Mendelian randomisation (MR) methods. After the correction of multiple testing, 29 of the 1545 
45 trait pairs were genetically correlated. Among these trait pairs, a causal relationship was only 1546 
found between regular smoking initiation and caffeine consumption. Both inverse variance weighted 1547 
(IVW) and weighted median estimators pointed to a positive effect of regular smoking initiation on 1548 
caffeine consumption but not in the other direction from caffeine consumption to regular smoking 1549 
initiation. I found limited evidence that this causal association was driven by horizontal pleiotropy, 1550 
outlier SNPs, nor by single SNPs associated with the exposure (i.e. regular smoking initiation). Key 1551 
findings from the four result chapters are summarised in Table 6-1 1552 
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Table 6-1 Summary of aims and findings from result chapters (Chapter 2 to 5) 1553 
Chapter Aims Findings 
Chapter 2 The Genetic 
Relationship Between 
Psychological Distress, Somatic 
Distress, Affective Disorders, and 
Substance Use in Young 
Australian Adults: A Multivariate 
Twin Study 
• Validate the PSYCH6 and SOMA6 subscales of 
SPHERE12. 
• Construct an IRT score for PSYCH6, SOMA6, AD, 
and SU 
• Estimate heritability (h2) of PSYCH6, SOMA6, and 
various psychiatric disorder and substance use 
phenotypes 
• Estimate the relative contribution of genetic and 
environmental factors to the covariation between the 
four IRT scores 
• Cronbach’s alpha range: 0.87-0.88 for each item of 
SPHERE-12 (Table 2-2) 
• Intraclass correlation coefficient range: 0.5-0.65 
for each item of SPHERE-12 (Table 2-2) 
• h2 = 0.23 for PSYCH6-IRT, h2 = 0.25 for SOMA6-
IRT, h2 range: 0.32 ~ 0.42 for affective disorders, 
h2 range: 0.49 ~ 0.79 for substance use traits (Table 
2-3) 
• Genetic correlation between PSYCH6-IRT and 
SOMA6-IRT: 0.85 (Table 2-4) 
• Common genetic factors explained 3% ~ 22% of 
variations between PSYCH6-IRT, SOMA6-IRT, 
AD-IRT, and SU-IRT (Figure 2-2) 
Chapter 3 Association between 
polygenic risk for tobacco or 
alcohol consumption and liability 
• Estimate genetic correlation coefficients (rG) 
between five smoking and alcohol-related discovery 
phenotypes regular smoking initiation (SI), age of 
initiation of regular smoking (AI), cigarettes per day 
• Positive rG range: 0.08~ 0.43; Negative rG range: 
-0.69 ~  -0.15 (Table 3-2) 
• PRS-SI explained variation in the risk of cocaine 
(0.67%), amphetamine (1.54%), hallucinogens 
(0.72%), ecstasy (1.66%) and cannabis initiation 
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to licit and illicit substance use in 
young Australian adults 
(CPD), smoking cessation (SC), and drinks per week 
(DPW) 
• Construct polygenic risk scores (PRS) for the five 
phenotypes for QIMR cohort using meta-analysed 
GWASs from the independent discovery sample. 
• Test the association between the PRSs and use of 
illicit substances 
(0.97%), and DSM-5 alcohol use disorder (0.72%) 
(Figure 3-1)  
• PRS-DPW explained 0.75%, 0.59% and 0.90% of 
the variation of cocaine, amphetamine and ecstasy 
initiation (Figure 3-1). 
Chapter 4 Associations between 
polygenic risk for tobacco and 
alcohol use and liability to 
psychiatric disorders in an 
independent sample of 13,999 
Australian adults 
• Estimate the fixed effect of GSCAN PRSs 
(constructed in Chapter 3) on the liability to 15 
phenotypes related to tobacco and alcohol use, 
substance use disorders, and common psychiatric 
disorders. Discuss the results from four different 
types of associations: (1) same-trait associations 
where discovery and target phenotypes were 
identical, (2) cross-trait associations where target and 
discovery phenotypes were based on the same 
substance, (3) cross-trait associations where target 
and discovery phenotypes were based on different 
substances, and (4) cross-trait associations where 
target phenotypes were psychiatric disorders. 
• In same-trait associations, PRS-SI and PRS-DPW 
explained maximally 5.09% and 6.26% of the 
variation of SI and DPW, respectively (Figure 4-1) 
• In cross-trait associations between use of same 
substances, higher PRS-SI, PRS-CPD and PRS-SC 
were associated with higher liability to DSM-IV 
and FTND-based nicotine dependence (Figure 
4-1). 
• In cross-trait associations between use of different 
substances, high DPW was significantly 
associated with increased PRS-SI and decreased 
PRS-AI (Figure 4-1). 
• In cross-trait associations between SU and 
psychiatric disorders, higher liability to DSM-IV 
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conduct disorder was associated with increased 
PRS-SI and PRS-CPD (Figure 4-1) 
Chapter 5 Investigating the genetic 
and causal relationship between 
initiation or use of alcohol, 
caffeine, cannabis and nicotine 
• Estimate SNP-based heritability (h2) for GWAS for 
10 substance use phenotypes obtained from the UK 
Biobank, GSCAN and International Cannabis 
Consortium (ICC). 
• Estimate genetic correlation coefficients between any 
two of these 10 substance use phenotypes, giving a 
total of 45 tests.  
• Examine the causal associations in a total of 23 pairs 
of exposure and outcome traits. 
• Further investigate the relationship between causally 
associated exposure and outcome traits by examining 
horizontal pleiotropy with MR-Egger intercept, 
outlier exposure SNPs with MR-PRESSO, and 
whether the association was driven by single SNPs 
with leave-one-out analysis. 
• Moderate SNP h2 was found in the 10 traits, with 
h2 ranging from 0.033 in the age of initiation of 
regular smoking, to 0.109 in regular smoking 
initiation (Table S5-1). 
• 29 out of 45 genetic correlations remained 
significant after adjustment for multiple testing, 
with positive coefficients ranging from 0.157 to 
0.941, and negative coefficients ranging from -
0.821 to -0.196 (Table S5-2). 
• The positive causal effect of regular smoking 
initiation on caffeine consumption was identified 
by inverse variance weighted (Table S5-4) and 
weighted median (Table S5-4) estimators. No 
reverse causality was found (in Table S5-4).  
• Little evidence that the SI-ECCPD association was 
driven by horizontal pleiotropy (MR-Egger 
intercept: -0.51; SE: 2.50; p value: 0.845). No 
outlier SNPs were identified by MR-PRESSO 
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(Table S5-5). The SI-ECCPD association was not 
driven by single SNPs associated with the 
exposure (Table S5-6). 
1554 
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Limitations 1555 
Genetic architecture of psychological distress and somatic distress 1556 
The genetic architecture of psychological distress, measured by the PSYCH6 subscale, and somatic 1557 
distress, measured by the SOMA6, still need to be studied in a larger sample that I had available. To 1558 
attempt to identify loci associated with these two traits, I conducted a GWAS in a larger sample than 1559 
the Chapter 2 sample. I generated IRT scores for PSYCH6 and SOMA6 in a pooled sample that 1560 
binned six QIMR studies, including (1) Genetics of Laterality, Smell, Taste and Reading (study code: 1561 
TA), (2) Memory, Attention and Problem-Solving in Adolescent Twins (study code: TM), (3) 25Up 1562 
(study code: TU), (4) Melanocytic Naevi in Adolescent Twins (study code: TW1, TW2), and the (5) 1563 
19Up (study code: NU) cohort. I then conducted a GWAS analysis on the pooled sample of 3,423 1564 
twin individuals using the raremetalworker software package while controlling for the relatedness 1565 
between these individuals. While the heritability estimates (PSYCH6-IRT: 0.26; SOMA6-IRT: 0.28) 1566 
were close to those estimated with univariate twin modelling in Chapter 2 (N=1,548 twin individuals; 1567 
PSYCH6-IRT: 0.23; SOMA6-IRT: 0.25), no SNPs surpassed the genome-wide significance threshold 1568 
(see Figure S6-1, Figure S6-2). To date, no GWAS results have been reported for the PSYCH6 and 1569 
SOMA6. Although these two subscales have been developed since 2001 [311], they are mainly used 1570 
in Australia. No data (both genotype and phenotypes) were currently available from other studies. 1571 
 1572 
Improve measures for substance use 1573 
In this thesis, substance use was mainly assessed with self-reported measures, which are known to 1574 
suffer various errors of representation and measurement [312]. To accurately assess the quantitative 1575 
use of substances, it is necessary to consider assessment with biomarkers in a subset of conventional 1576 
substance use survey participants. In this section, I will discuss the limitations with self-report 1577 
measures, suggest biomarkers of substance exposure as better phenotypes, and highlight the findings 1578 
in few genetic association studies that used the biomarkers.  1579 
What are the problems with self-report measures for nicotine exposure? 1580 
Quantitative or frequency of substance use is commonly assessed with questions that ask for average 1581 
amounts of use. For instance, GSCAN’s cigarettes per day variable (Chapter 3, Chapter 4 and Chapter 1582 
5) came from data that collapsed average numbers of cigarettes smoked per day, and categories 1583 
representing a number range of cigarettes smoked per day. Surprisingly, polygenic risk scores 1584 
calculated for this measure (PRS-CPD) did not significantly explain the variation of the initiation of 1585 
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any of nine different illicit substances in the 19Up cohort (Chapter 3), nor did the PRS-CPD predict 1586 
the identical trait CPD in a five-time larger sample than the 19Up (Chapter 4). In Chapter 5, I was 1587 
unable to assess the phenotypic association of UK Biobank cigarettes per day (CPD) with other 1588 
substance use traits due to the high degree of missingness in the CPD. These findings suggested that 1589 
self-reported cigarettes per day itself are unlikely to accurately capture nicotine intake.  1590 
Johnson (2014) in a review article pointed out that self-reported measures possessed at least three 1591 
problems. Questionnaire items are typically concerned about averaged consumption amount; in 1592 
reality, drug consumption behaviour tends to be more variable than are assumed by the questions 1593 
[313,314]. Respondents can find it difficult answering the question when they had changed their 1594 
consumption pattern during the survey [315], which can result in nonresponse errors. Moreover, most 1595 
of the self-reported measures, including the quantity-frequency measures, can be limited by recall 1596 
bias [316].  1597 
Potential biomarkers of nicotine exposure 1598 
Biomarkers for nicotine exposure, including cotinine, and carbon monoxide are considered as the 1599 
gold standard for assessing nicotine exposure, but they are rarely used as outcome variables in genetic 1600 
association studies (see a review by [317]. Cotinine, a major metabolite of nicotine, is a relatively 1601 
stable compound, with a half-life of 15 to 20 hours [318]. Its concentration reflects not only recent 1602 
nicotine intake but also a cumulative intake of about seven days. Urinary or serum concentrations of 1603 
cotinine can separate smokers from non-smokers [319–321]. Keskitalo et al. (2009) showed that both 1604 
self-reported CPD and serum cotinine concentration were significantly associated with the genotypic 1605 
variation in a cluster of three nicotinic acetylcholine receptor genes [322]. Importantly, a single SNP 1606 
rs1051730 from the cluster captured a nearly five-time larger proportion of the variation in cotinine 1607 
concentration (R2: 4.3%) than the self-reported CPD (R2: 0.9%). Cotinine is further metabolised into 1608 
multiple compounds, including 3-hydroxycotinine. The rate of 3-hydroxycotinine to cotinine, also 1609 
known as nicotine metabolite rate (NMR) has also been used as a biomarker for nicotine exposure. 1610 
Loukola et al (205) conducted the first meta-analytic GWAS in NMR in 1518 participants [323]. 1611 
They showed that the detected variants explained up to 31% of the variance of NMR. 1612 
Carbon monoxide (CO) is one of the by-products of cigarette combustion. The concentration of 1613 
exhaled CO can distinguish non-smokers from smokers [324]. Non-smokers typically have exhaled 1614 
CO ≤ 5 ppm [324,325]. Moreover, levels of exhaled CO are highly correlated with the number of 1615 
cigarettes consumed per day [325]. Bloom et al (2014) conducted separate GWAS analyses on 1616 
exhaled CO, self-reported CPD and FTND-based nicotine dependence [326] in 1521 participants. 1617 
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Interestingly, the variant rs16969968 reached GWAS significance in the exhaled CO GWAS, but not 1618 
in the other two GWASs.  1619 
What are the problems with self-reported measures for coffee intake or caffeine 1620 
consumption? 1621 
It is challenging to accurately quantify caffeine intake with self-reported measures. First, the actual 1622 
caffeine amount varies considerably with sources of beverages, such as coffee, tea, soda, and energy 1623 
drinks. Moreover, brands of beverage, coffee or tea, and serving sizes, and brew time also affect 1624 
caffeine content [327]. Addicott et al. (2009) compared caffeine exposure estimated from two self-1625 
reported methods, interview and diary, against salivary caffeine concentration in a subset of 1626 
participants [328]. They reported that while both self-report methods were shown to be good 1627 
predictors for actual caffeine concentrations, subjects with high caffeine users (> 600 mg/day) needed 1628 
to be verified with more than one measure. In addition, epidemiological studies often classified 1629 
caffeine consumption into multiple categories using varying cut-off points (See Table 2 in Addicott 1630 
et al., 2009). This inconsistency makes it difficult to compare the findings across studies.  1631 
In Chapter 5, I calculated the caffeine consumption variable from both coffee and tea drinkers to 1632 
improve the power to detect a causal effect on caffeine consumption. The self-reported number of 1633 
cups of regular coffee and tea daily in the UK Biobank participants were multiplied with an assumed 1634 
amount of caffeine per cup (coffee: 75mg; tea: 40mg) to give a total amount of estimated caffeine 1635 
consumed per day. This variable was not phenotypically associated with smoking initiation (Model 1636 
3, Table S5-1), contradicting the findings from other observational studies that frequently reported 1637 
higher odds of consuming coffee in smokers than non-smokers [305–308]. However, previous studies 1638 
were inconsistent with the association between tea consumption and smoking initiation 1639 
[305,307,309]. If smoking initiation is truly associated with lower odds of tea consumption [307], my 1640 
lack of association between caffeine consumption and smoking initiation could be explained by the 1641 
coffee effect cancelling out that of tea. 1642 
Biomarkers of coffee intake or caffeine consumption 1643 
Considerations need to be taken when choosing a suitable biomarker of coffee intake or caffeine 1644 
consumption. First, a biomarker approach needs to be compared with the self-reported approach, 1645 
which is still the most popular method for assessing caffeine intake. This has been demonstrated in 1646 
studies that compared self-reported consumption with serum metabolites [329], or with urinary 1647 
excretion of caffeine metabolites [330,331]. Second, it is important to examine the specificity of a 1648 
biomarker in the populations. For instance, caffeine and ferulic acid may not be considered as 1649 
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biomarkers of coffee consumption, because the concentrations of these two compounds can be 1650 
confounded by dietary sources other than coffee, such as tea, soda or chocolate for caffeine and 1651 
wholegrain cereals for ferulic acid. Trigonelline and cyclo(isoleucylprolyl), on the other hand, can be 1652 
candidate biomarkers considering their high specificity for coffee [332].  1653 
Genetic associations in diverse populations and ethnicity 1654 
All the participants analysed in my four results chapters were of European ancestry. Consequently, 1655 
the findings could only be applied to populations of the same ancestry. It would be worthwhile to 1656 
examine how substance use PRS perform and whether the causality can be also observed in other 1657 
ancestry groups, such as individuals of Asian or African ancestry. The failure to consider diverse 1658 
populations in genomics work is a significant problem plaguing the field [333–335]. It is important 1659 
to consider diverse populations in the study design, even if this results in a lack of genetic risk 1660 
prediction or a likely reduction in the variance accounted for.  1661 
Future studies 1662 
Applying Mendelian randomisation to substance use research 1663 
While MR approaches are increasingly used to relate substance exposure to disease outcomes [336–1664 
341], few MR studies have focused on substance use as an outcome [288,289,342]. These studies 1665 
detected a causal effect of smoking heaviness, measured with cigarettes per day, on caffeine 1666 
consumption [288], but not on alcohol consumption [342]. What are the important points to note 1667 
about conducting an MR? Firstly, when running two-sample MR, it is important to ensure that 1668 
exposure and outcome traits of interest are from two non-overlap samples. This can be achieved by 1669 
asking the data providers to individually list contributing subsamples to both the exposure and 1670 
outcome samples, to remove overlapped individuals from the larger sample, and to rerun the GWAS 1671 
analysis. 1672 
Secondly, the exposure and outcome traits should represent a logical sequence. For example, smoking 1673 
initiation as exposure could lead to quantitative consumption of cigarettes as an outcome, but not vice 1674 
versa. Thirdly, the causal effect is interpreted as one unit change of the exposure on one unit change 1675 
of the outcome. Therefore, a  binary exposure of interest should represent a dichotomisation of 1676 
continuous underlying risk [343]. For example, the GSCAN regular smoking initiation variable was 1677 
dichotomised on one of the three conditions, ever smoking ≥ 100 cigarettes, ever smoking every day 1678 
for at least one month, and ever smoking regularly. This binary variable represents an acceptable 1679 
exposure for MR if all these three conditions represent continuous progress from smoking the first 1680 
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cigarette. Fourthly, the MR results should be interpreted on a meaningful scale of the exposure. The 1681 
caffeine consumption was originally in milligrams, but I had to convert its causal estimates to 1682 
represent one cup of coffee or tea consumption. Finally, the inverse variance weighted (IVW) 1683 
estimator is usually conducted to give a first indication of whether there is a causal effect, and then 1684 
different sensitivity analyses, with different underlying assumptions, are applied to examine how 1685 
robust the IVW estimates are. If all the approaches provide consistent causal estimates, one can be 1686 
more confident that a true causal effect exists [344]. 1687 
Improve polygenic risk prediction 1688 
Increasing the proportion of trait variance explained by a polygenic predictor is usually the goal in 1689 
many genetic association studies because PRS constructed for single substance use traits typically 1690 
explain a small proportion of the variation of a target phenotype even when a well-powered discovery 1691 
GWAS is used [157,206]. In Chapter 3, PRS for regular smoking initiation (PRS-SI) was shown to 1692 
be the most predictive among the five GSCAN PRSs. However, this PRS explained only 0.67% ~ 1693 
1.66% of the variance of initiating five different illicit substances. Although larger prediction R2 was 1694 
seen when PRS-SI (R2: 5.09%) and PRS-DPW (R2: 6.26%) were used to predict the variation of the 1695 
identical traits (Chapter 4), a cross-trait prediction is usually the research interest.  1696 
What can be done to increase the risk prediction R2? While substance use studies usually conclude 1697 
with a need to increase sample sizes or to improve measurement for substance use (e.g. use 1698 
biomarkers aforementioned) [156], it is now possible to employ new analytical approaches to achieve 1699 
this goal. For example, a recent study that used a multi-trait analysis of GWAS on correlated traits 1700 
(MTAG) has been shown to identify as many loci as individual univariate GWASs and to increase 1701 
the variance explained by PRS by about 25% [345]. It would be interesting to combine GWAS 1702 
summary results of the GSCAN regular smoking initiation, cigarettes per day, and smoking cessation 1703 
variables using MTAG, then to calculate a PRS for the combined smoking GWAS, and finally to 1704 
compare the risk prediction on the same traits in Chapter 4 with the three separate PRSs (i.e. PRS-SI, 1705 
PRS-CPD, and PRS-SC).  1706 
Another possibility is to include the interaction between genes and environmental factors in the 1707 
prediction model. The gene-by-environment interaction (GxE) occurs when the effect of genetic 1708 
variants on a trait differ in different environments [346]. Environmental factors, such as family, peer 1709 
influence, and socioeconomic status, are known to influence substance use [347–349]. In a recent 1710 
review, Pasman et al (2016) examined the quality of three types of studies that investigated GxE in 1711 
alcohol, tobacco, and cannabis use [350]. The highest quality was found in studies that used polygenic 1712 
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risk scores (PRS) as the measure for polygenic risk as compared with the other studies that used 1713 
haplotype or candidate gene scores. Importantly, the authors emphasised the need to use a good study 1714 
design, phenotypical measure, and to replicate the GxE that was previously reported.  1715 
Are there substance use genes beyond metabolism? 1716 
While reviewing existing literature, one may raise a question of whether there are substance use genes 1717 
that are responsible for the behaviour or physiological function preceding the drug consumption. To 1718 
date, GWASs of alcohol or nicotine use have identified abundant genetic variants that are related to 1719 
the metabolism of the substances and neurobiological mechanisms related to the development of 1720 
addiction [156]. However, twin studies have shown that impulsivity and alcohol dependence are 1721 
genetically correlated [351]. A recent GWAS on risk-taking has also been genetically correlated with 1722 
smoking and cannabis initiation [352]. Kreek et al. (2005) reviewed a comprehensive set of candidate 1723 
gene association studies on impulsivity, risk-taking, stress responsivity, and addiction. They 1724 
suggested that genetic influences on impulsivity and risk-taking contribute more to the initiation stage 1725 
and the progression to regular use of substance than to the addiction and relapse stage [353]. However, 1726 
it should be noted that the candidate gene approach is heavily criticised [354]. It would be interesting 1727 
and immediately doable to further examine the genetic overlap using the recently published GSCAN 1728 
GWAS on nicotine and alcohol use [206] and GWAS on risk tolerance and risk behaviour [355]. The 1729 
full samples in these two studies were consisted of over one million individuals. A follow-up two-1730 
sample MR can be conducted to detect whether there is a causal relationship between personality 1731 
traits (e.g. impulsivity, risk-taking and novelty-seeking) and substance use traits, preferably measured 1732 
with the aforementioned biomarkers. Lastly, it would be also important to continue identifying novel 1733 
loci for these correlated traits, which can be achieved by conducting a multivariate GWAS on the 1734 
personality and substance use traits. 1735 
Implications for preventing substance initiation 1736 
What could policymakers learn from the findings of this thesis? Substance control measures should 1737 
be made considering associated substances together rather than separately. I showed that regular 1738 
smoking initiation was strongly associated with the initiation of illicit substances (Chapter 3) and the 1739 
consumption of alcohol (Chapter 4), which implies that preventing regular smoking can be an 1740 
important measure to reduce the risk of initiating other drugs. A recent study has shown that novel 1741 
warnings on a cigarette stick can be more engaging and effective than the current warnings on a 1742 
cigarette pack [356]. Would it reduce the desire to light up a cigarette when smokers see “genetic risk 1743 
to initiating other substances” printed on their cigarette sticks? 1744 
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Conclusion 1745 
This thesis provided a better understanding of the genetic influence on the use and abuse of various 1746 
substances, and some of the common psychiatric disorders. It showed that shared genetic risk could 1747 
explain the use of different substances, but most of the substance-substance associations were not 1748 
causal. It also discussed the problems with the commonly used self-reported measures for substance 1749 
exposure and suggested the use of biomarkers as better phenotypes.   1750 
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Chapter 4 3016 
Supporting S4-1 Definitions of six self-reported phenotypes. Six self-reported phenotypes 3017 
used in this study were identical to those used in GSCAN discovery GWAS meta-analyses (Official 3018 
website: https://ibg.colorado.edu/mediawiki/images/d/da/GSCAN_GWAS_Phenotype_Definitions-3019 
2-24-2016.pdf) 3020 
Phenotype name Explanation Type 
Smoking initiation ever versus never being a regular smoker binary 
Age at starting regular 
smoking 
The age at which an individual first became a regular 
smoker 
continuous 
Cigarettes per day Average number of cigarettes smoked per day 
Number of cigarettes smoked per day in 5 response 
categories: 1-5, 6-15, 16-25, 26-35, or 36+ 
continuous 
Smoking cessation Current versus former smoker binary 
Drinking initiation Ever consumed alcoholic beverage in one’s lifetime binary 
Drinks per week Number of drinks consumed per week in those who 
were active drinkers 
continuous 
 3021 
Supporting S4-2 Definitions of nine binary phenotypes. Diagnostic criteria and case 3022 
definitions for the nine DSM-IV based [246] disorders are provided in the following:  3023 
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1. DSM-IV alcohol dependence. The assessment for this disorder was contingent upon regular 3024 
drinking. Respondents with three or more out of seven symptoms occurring within a year were 3025 
classed as cases [252]. The seven diagnostic criteria for DSM-IV alcohol dependence are 3026 
1.1. Tolerance, as defined by either of the following: 3027 
1.1.1. A need for markedly increased amounts of alcohol to achieve intoxication or desired 3028 
effect. 3029 
1.1.2. Markedly diminished effect with continued use of the same amount of alcohol. 3030 
1.2. Withdrawal, as defined by either of the following: 3031 
1.2.1. The characteristic withdrawal syndrome for alcohol (refer to DSM-IV for further 3032 
details). 3033 
1.2.2. Alcohol is taken to relieve or avoid withdrawal symptoms. 3034 
1.3. Alcohol is often taken in larger amounts or over a longer period than was intended. 3035 
1.4. There is a persistent desire or there are unsuccessful efforts to cut down or control alcohol 3036 
use. 3037 
1.5. A great deal of time is spent in activities necessary to obtain alcohol, use alcohol or recover 3038 
from its effects. 3039 
1.6. Important social, occupational, or recreational activities are given up or reduced because of 3040 
alcohol use. 3041 
1.7. Alcohol use is continued despite knowledge of having a persistent or recurrent physical or 3042 
psychological problem that is likely to have been caused or exacerbated by the alcohol 3043 
(e.g., continued drinking despite recognition that an ulcer was made worse by alcohol 3044 
consumption). 3045 
2. DSM-IV nicotine dependence. The assessment for this disorder was contingent upon regular 3046 
smoking. Respondents who had three or more out of seven symptoms occurring within a year 3047 
were defined as cases [240]. The seven diagnostic criteria [357] are: 3048 
2.1. Spent great deal of time getting, using, or getting over effects of cigarettes 3049 
2.2. Used cigarettes more often or in larger amounts than intended 3050 
2.3. Built up a tolerance so that the same amount of cigarettes had less effect than before 3051 
2.4. Cigarette use kept you from working, going to school, taking care of children, or engaging 3052 
in recreational activities 3053 
2.5. Cigarette use caused emotional or psychological problems 3054 
2.6. Cigarette use caused health problems 3055 
2.7. Wanted or tried to stop or cut down on your cigarette use 3056 
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3. FTND-based nicotine dependence. The assessment for this disorder was contingent upon 3057 
regular smoking. The FTND-based nicotine dependence is a continuous scale consisting of 3058 
six items. A total score ranges between 0 and 10. Respondents with total FTND scores at or 3059 
higher than four were coded as cases (Agrawal et al., 2009). The six items are: 3060 
3.1. How soon after waking up individuals smoke their first cigarette (shorter interval scored as 3061 
higher) 3062 
3.2. Whether individuals find it difficult to refrain from smoking in places where it is forbidden. 3063 
3.3. Which cigarette they would most hate to give up (the first one in the morning – higher score 3064 
– or “all the others”).  3065 
3.4. How much individuals smoke? 3066 
3.5. If they smoke more frequently during the first hours after getting up 3067 
3.6. If they smoke when they are so ill that they have to stay in bed for most of the day. 3068 
4. DSM-IV conduct disorder. Respondents who reported at least three out of 15 behaviours 3069 
associated with the DSM-IV criteria occurring within a year prior to age 18 were coded as cases 3070 
(Grant et al., 2015). The 15 behaviours are listed in Table 1 of the article by Knopik et al. 3071 
(2014) 3072 
5. DSM-IV antisocial personality disorder (ASPD). Case status was defined by the endorsement 3073 
of three or more of the seven DSM–IV ASPD criteria [359] as displayed under Criterion A in 3074 
the statistical manual [360]. These seven diagnostic criteria are 3075 
5.1. Failure to conform to social norms with respect to lawful behaviours as indicated by 3076 
repeatedly performing acts that are grounds for arrest.  3077 
5.2. Deception, as indicated by repeatedly lying, use of aliases, or conning others for personal 3078 
profit or pleasure.  3079 
5.3. Impulsivity or failure to plan ahead.  3080 
5.4. Irritability and aggressiveness, as indicated by repeated physical fights or assaults.  3081 
5.5. Reckless disregard for safety of self or others.  3082 
5.6. Consistent irresponsibility, as indicated by repeated failure to sustain consistent work 3083 
behaviour or honour financial obligations.  3084 
5.7. Lack of remorse, as indicated by being indifferent to or rationalizing having hurt, 3085 
mistreated, or stolen from another 3086 
6. DSM-IV major depressive disorder (MDD). MDD was defined as having at least five of 3087 
the following nine symptoms [361]: 3088 
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6.1. Depressed mood or irritable most of the day, nearly every day, as indicated by either 3089 
subjective report (e.g., feels sad or empty) or observation made by others (e.g., appears 3090 
tearful).  3091 
6.2. Decreased interest or pleasure in most activities, most of each day.  3092 
6.3. Significant weight change (5%) or change in appetite.  3093 
6.4. Change in sleep: Insomnia or hypersomnia.  3094 
6.5. Change in activity: Psychomotor agitation or retardation.  3095 
6.6. Fatigue or loss of energy.  3096 
6.7. Guilt/worthlessness: Feelings of worthlessness or excessive or inappropriate guilt. 3097 
6.8. Concentration: diminished ability to think or concentrate, or more indecisiveness. 3098 
6.9. Suicidality: Thoughts of death or suicide, or has suicide plan 3099 
7. DSM-IV panic disorder. Because the prevalence of panic disorder was too low in the sample 3100 
to provide reliable estimates of risk. History of panic attack was used, defined as having at least 3101 
two attacks with at least four out of 13 panic symptoms which began suddenly and reached a 3102 
peak within 10 minutes [361]. The 13 symptoms include: 3103 
7.1. Palpitations, pounding heart, or accelerated heart rate 3104 
7.2. Sweating 3105 
7.3. Trembling or shaking 3106 
7.4. Sensations of shortness of breath or smothering 3107 
7.5. Feeling of choking.  3108 
7.6. Chest pain or discomfort.  3109 
7.7. Nausea or abdominal distress.  3110 
7.8. Feeling dizzy, unsteady, lightheaded, or faint.  3111 
7.9. Derealization (feelings of unreality) or depersonalization (being detached from oneself). 3112 
7.10. Fear of losing control or going crazy 3113 
7.11. Fear of dying 3114 
7.12. Paresthesias (numbness or tingling sensations). 3115 
7.13. Chills or hot flushes  3116 
8. DSM-IV social phobia. This disorder was assessed with the DSM-IV criteria. 3117 
9. Mania. This is a non-diagnostic screen for manic behaviours. An abbreviated assessment of 3118 
mania was given. This section, though nondiagnostic, was considered “positive” for mania if the 3119 
subject reported a week or more of euphoria and psychiatric treatment for this condition. The 3120 
assessment was similar to that described in Bierut et al. (1999). 3121 
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Supporting S4-3 Multiple testing. We interpreted our results based on the associations that 3122 
remained significant after accounting for the T4 threshold, calculated as 3123 
 3124 
Where Pnom is the nominal p-value, Meff-t is the effective number of independent target phenotypes, 3125 
and Meff-d is the effective number of independent discovery phenotypes [210,211]. We estimated the 3126 
Meff-t as 10 and Meff-d as five.3127 
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Chapter 5 3128 
Supporting S5-1 Definitions of substance use phenotypes. 3129 
Sample Phenotype name 
(Type) 
Explanation 
GSCAN Regular smoking 
initiation (binary) 
Cases are those who report ever being a regular smoker in their life (current or former). Controls are those who 
denied ever being a regular smoker in their life. This phenotype is not available in studies that only address current 
smoking and ignore former smoking. This phenotype does not include information about pipes, cigars, chew, or 
other non-cigarette forms of tobacco use.  
This phenotype can be measured in a variety of ways:  
1. Have you smoked over 100 cigarettes over the course of your life?  
2. Have you ever smoked every day for at least a month?  
3. Have you ever smoked regularly?  
4. Do you smoke? 
Official website for the definitions of GSCAN phenotypes is available at 
https://ibg.colorado.edu/mediawiki/images/d/da/GSCAN_GWAS_Phenotype_Definitions-2-24-2016.pdf 
 Age at starting 
regular smoking 
(continuous) 
The age at which an individual first became a regular smoker. This variable does not include information about 
pipes, cigars, chew, or other non-cigarette forms of tobacco use.  
This can be measured in a variety of ways:  
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1. At what age did you begin smoking regularly?  
2. “How long have you smoked?” combined with “What is your current age?” 
 Cigarettes per day 
(continuous) 
Average number of cigarettes smoked per day, either as a current smoker or former smoker. Individuals who either 
never smoked, or on whom there is no available data (e.g., someone was a former smoker but former smoking was 
never assessed) will be set to missing. This variable does not include information about pipes, cigars, chew, or other 
non-cigarette forms of tobacco use. For studies that collect a quantitative measure of CPD, where the respondent is 
free to provide any integer (e.g., 13 CPD) we will bin responses as (1) 1-5 (2) 6-15 (3) 16-25 (4) 26-35 (5) 36+. For 
studies that already have pre-defined bins, which are different from ours, we will prefer their existing bins.  
 
Cigarettes per arey is almost always measured with a single question:  
1. How many cigarettes do you smoke per day?  
2. How many cigarettes did you smoke per day? 
 smoking cessation 
(Binary) 
Current smokers coded as cases whereas former smokers coded controls. This variable does not include information 
about pipes, cigars, chew, or other non-cigarette forms of tobacco use.  
 
This variable was measured through a combination of questions, including 
1. Do you currently smoke? and Have you ever smoked regularly?  
2. Do you smoke? and Have you smoked over 100 cigarettes in your entire life? 
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 Drinks per week 
(continuous) 
The average number of drinks a subject reported drinking each week, aggregated across all types of alcohol. If a 
study recorded binned response ranges (e.g., 1-4 drinks per week, 5-10 drinks per week) the midpoint of the range 
was used (e.g. 2.5 DPW on average for those reporting drinking 1-5 DPW).  
This variable can be measured in a variety of ways:  
1. In the past week, how many alcoholic beverages did you have?  
2. Thinking about the past year, on the average how many drinks did you have each week? 
ICC Cannabis initiation 
(Binary) 
This variable was surveyed with the question “Have you taken CANNABIS (marijuana, grass, hash, ganja, blow, 
draw, skunk, weed, spliff, dope), even if it was a long time ago?” 
UKB Cannabis initiation 
(Binary)  
UKB Data-Field= 20453 
Definition is similar to the ICC cannabis initiation above 
 Cigarettes smoked 
per day 
(continuous)  
UKB Data-Field 3456 
Number of cigarettes currently smoked daily 
 Pack years of 
smoking 
(continuous) 
UKB Data-Field 20161 
Pack years calculated for individuals who have ever smoked according to data field Ever smoking status=1, using 
appropriate data: Current cigarette (either manufactured or hand-rolled) smokers who smoke most days (smoking 
data fields used: Field 3436 and Field 6183).  
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Past cigarette (either manufactured or hand-rolled) smokers who smoked most days (smoking data fields used: Field 
2867, Field 2897 and Field 2887).  
Current cigar/pipe smokers who smoked most days and previously smoked cigarettes (smoking data fields used: 
Field 3436, Field 6194 and Field 6183). The general definition of a pack year is the number of cigarettes smoked 
per day, divided by twenty, multiplied by the number of years of smoking. The number of years of smoking is 
calculated by substracting the age of starting smoking from the age smoking was stopped. Number of cigarettes per 
day / 20 * (Age stopped smoking - Age start smoking) The figure is adjusted for individuals who gave up smoking 
for more than 6 months, according to data fields 2907 or 3486 by subtracting six months from the number of years 
of smoking. Number of cigarettes per day / 20 * (Age stopped smoking - Age start smoking - 0.5) Note: Individuals 
who started and gave up smoking before 16 years of age were coded as NA. For individuals who started smoking 
before 16 but gave up after 16, their age start was set as 16. Individuals who reported starting and stopping smoking 
at the same age and reported giving up smoking for more than 6 months had pack-years set at 0. 
 Estimated standard 
drinks per week 
Information on quantity and frequency of alcohol consumpion, was obtained through self-report questionnaires in 
the UKB. Frequency of consumption (AC-Frequency) was assessed in 501,718 participants (UKB field IDs: 1558) 
with the item “About how often do you drink alcohol?”. Frequency was originally assessed at a scale ranging from 
1 (daily or almost daily) to 6 (never), but was recoded so that a lower score represented less frequent drinking. For 
individuals who reported multiple instances (via multiple visits) of alcohol intake, only the first assessment was 
used.  
In those who drank at least once or twice a week, information on quantity of consumption (AC-Quantity) was 
assessed (n=348,039). AC-Quantity was assessed based on the average weekly alcohol intake for five general 
169 
 
classes: red wine (1568), champagne plus white wine (1578), spirits (1598), beer plus cider (1558), and fortified 
wine (1608). The following item was used: “In an average WEEK, how many servings of {class of alcohol} would 
you drink?”. To combine the different classes of alcohol, we followed the procedures developed by Clarke et al. (2) 
with some minor changes, as discussed below. To calculate the total number of alcohol standard drinks, the number 
of reported drinks was multiplied with a conversion factor depending on the class of alcohol (Supplementary Table 
1). For the less-frequent drinkers, we repeated the same procedure using equivalent assessments available for their 
monthly (instead of weekly) quantity. These values were converted to weekly units by dividing by 4.3 (~30 days/7). 
The average value for total drinks/day was then calculated for each frequency category. We subsequently identified 
outliers as those who had a score that deviated >5 SD from the average in each female drinker category.  
 
We then imputed the missing values with the sex-specific average of total standard drinks/week for each of the 6 
frequency categories. This allowed us to utilise data from the maximum number of female participants for the 
GWAS analyses, further improving the statistical power to detect robust genetic instruments for alcohol intake. 
Finally, we selected only individuals of white-British ancestry based on clustering via ancestral principal 
components and performed the GWAS analyses as per description in the main text. Unlike Clarke et al., we did not 
include weight (in kg) as a covariate in the GWAS model. 
 Caffeine consumed 
per day through 
This variable was derived from intake of both regular coffee (UKB data field: 1508 and 1498) and tea (UKB data 
field: 1488), by multiplying cups of coffee by 75mg and cups of tea by 40mg, to give an approximate caffeine 
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regular coffee or tea 
in milligram  
consumption per day [363]. Participants who reported drinking decaffeinated coffee were not used for extracting 
number of cups of coffee. 
 3130 
Supporting S5-2 Procedure for heritability estimation and genetic correlation analyses.  3131 
GWAS of substance use were merged with the HapMap3 SNP list and then converted to the munged format in LD score correlation (LDSC) [364] 3132 
software package. The independent variable and weights for the LDSC were read from a LD score computed from the 1000 Genomes European data. 3133 
SNP heritability was then estimated in an observed scale for continuous munged GWAS or in a liability scale for binary munged GWAS. The LD score 3134 
intercepts, ranging between 0.955 and 1.028, were close to one and smaller than lambda GC (Table S1), indicating that confounding biases, such as 3135 
population stratification and cryptic relatedness, were adequately controlled [37]. Bivariate genetic correlations were then conducted using any two of 3136 
the 10 munged GWAS. 3137 
Supporting S5-3 Strength of genetic instruments.  3138 
We quantified the strength of genetic instruments used in the MR analysis as the proportion of phenotypic variance of an exposure that was explained 3139 
by a genetic instrument (SNP) was calculated as  3140 
𝑅𝑆𝑁𝑃
2 =
2 × 𝑀𝐴𝐹 × (1 − 𝑀𝐴𝐹) × 𝛽2
𝑣𝑎𝑟(𝑌)
 3141 
where MAF is minor allelic frequency, β is the log-transformed odd ratio of a SNP, Y is the exposure trait. The R2 of individual instruments were summed 3142 
giving a single R2 per exposure. Among the four exposures (i.e., regular smoking initiation from GSCAN, cannabis initiation from ICC, caffeine 3143 
consumption from UKB, and number of standard drinks per week from UKB), the MAF information was unavailable in GWAS summary statistics from 3144 
171 
 
GSCAN. We conducted additional GWAS analysis for body mass index (BMI) in the UKB using BOLT-LMM and merged the effect allelic frequency 3145 
(A1FREQ) back to GWAS for regular smoking initiation, and cannabis initiation. The A1FREQ was used as the MAF. 3146 
 3147 
Supporting S5-4 Procedure for two-sample Mendelian randomisation analyses.  3148 
The causal relationship between an exposure and outcome of interest was first explored using inverse-variance weighted (IVW) linear regression, a 3149 
conventionally used method that combines the ratio estimates from each genetic variant using a formula from the meta-analysis literature [365]. This 3150 
IVW method requires that all genetic variants are independent (i.e. uncorrelated), are valid instrumental variables, and that Instrument Strength 3151 
Independent of Direct Effect (InSIDE) assumption is met. However, when multiple variants are used, it is highly implausible that all the variants satisfy 3152 
the instrumental variable assumptions. Therefore, we further conducted sensitivity analyses [300], which rely on a less stringent set of assumptions than 3153 
the conventional MR analysis, or the IVW. 3154 
Four sensitivity analyses were applied: (1) heterogeneity test, (2) MR-Egger regression, (3) weighted median, and (4) weighted mode estimator. The 3155 
heterogeneity test uses Cochran’s Q statistic to test for the presence of heterogeneity. The presence of heterogeneity provides evidence of horizontal 3156 
pleiotropy. MR-Egger regression [296,297] relaxes the assumption of the IVW analysis that the average pleiotropic effect is zero by allowing a non-zero 3157 
intercept. An intercept term different from zero indicates that either the InSIDE assumption is violated, or the average pleiotropic effect differs from zero 3158 
[293], also known as directional pleiotropy or horizontal pleiotropy. Weighted median [298] requires at least > 50% of the genetic variants to be valid 3159 
instrumental variables [300]. The performance of weighted mode MR estimator was evaluated by Hartwig et al. (2017) [299] (See Weighted MBE in the 3160 
cited article). 3161 
Two additional sensitivity analyses were applied when the IVW estimators showed plausible effect from an exposure to an outcome but not in an opposite 3162 
direction: (4) The leave-one-out analysis [300] and (5) Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) approach. The 3163 
leave-one-out removes one genetic variant out of the IVW analysis at a time to examine whether the causal effect of an exposure is driven by the variant 3164 
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removed. The MR-PRESSO detects and corrects for horizontal pleiotropic outliers in MR that uses multiple instruments [294]. When no outliers are 3165 
detected, MR-PRESSO generates causal estimates similar to those from the IVW estimator. 3166 
The causal relationship between an exposure and outcome of interest was first explored using inverse-variance weighted (IVW) linear regression, a 3167 
conventionally used method that combines the ratio estimates from each genetic variant using a formula from the meta-analysis literature (Johnson, 3168 
2013). This IVW method requires that all genetic variants are independent (i.e. uncorrelated), are valid instrumental variables, and that Instrument 3169 
Strength Independent of Direct Effect (InSIDE) assumption is met. However, when multiple variants are used, it is highly implausible that all the variants 3170 
satisfy the instrumental variable assumptions. Therefore, we further conducted sensitivity analyses (Burgess et al., 2017), which rely on a less stringent 3171 
set of assumptions than the conventional MR analysis, or the IVW.  3172 
Four sensitivity analyses were applied: (1) heterogeneity test, (2) MR-Egger regression, (3) weighted median, and (4) weighted mode estimator. The 3173 
heterogeneity test uses Cochran’s Q statistic to test for the presence of heterogeneity. The presence of heterogeneity provides evidence of horizontal 3174 
pleiotropy. MR-Egger regression (Bowden et al., 2015, 2016b) relaxes the assumption of the IVW analysis that the average pleiotropic effect is zero by 3175 
allowing a non-zero intercept. An intercept term different from zero indicates that either the InSIDE assumption is violated, or the average pleiotropic 3176 
effect differs from zero (Burgess and Thompson, 2017), also known as directional pleiotropy or horizontal pleiotropy. Weighted median (Bowden et al., 3177 
2016a) requires at least > 50% of the genetic variants to be valid instrumental variables (Burgess et al., 2017). The performance of weighted mode MR 3178 
estimator was evaluated by Hartwig et al. (2017). See Weighted MBE in the article. 3179 
Two additional sensitivity analyses were applied when the IVW estimators showed plausible effect from an exposure to an outcome but not in an opposite 3180 
direction: (4) The leave-one-out analysis (Burgess et al., 2017) and (5) Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) 3181 
approach. The leave-one-out removes one genetic variant out of the IVW analysis at a time to examine whether the causal effect of an exposure is driven 3182 
by the variant removed. The MR-PRESSO detects and corrects for horizontal pleiotropic outliers in MR that uses multiple instruments (Verbanck et al., 3183 
2018). When no outliers are detected, MR-PRESSO generates causal estimates similar to those from the IVW estimator.  3184 
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Supporting S5-5 Avoiding collider bias in Mendelian randomisation findings. 3185 
We included four exposures (i.e., regular smoking initiation, cannabis initiation, caffeine consumption, and number of standard drinks per week) in our 3186 
MR analysis. We were not intended to use the other substance use phenotypes (i.e., drinks consumed per week, age of initiation of regular smoking, 3187 
cigarettes per day, smoking cessation, and pack years of smoking) as our exposures because these GWAS were conducted in drinkers, and smokers. If 3188 
these GWAS were used as exposures in a MR analysis, the outcome GWAS would have to be conducted by stratifying the samples by smoking (e.g. 3189 
ever versus never smoking), or drinking (e.g. ever versus never drinking) statuses. We assumed only a small proportion of UKB participants who were 3190 
neither coffee nor tea drinkers. While this sample selection (i.e. stratification) reduces the sample size of the outcome GWAS, it is likely to induce 3191 
collider bias if the exposure and outcome independently influence the stratifying statuses [366]. 3192 
Supporting S5-6 Phenotypic associations.  3193 
Phenotypic associations were conducted using individual-level information in the UKB as a benchmark for the MR estimates. Our initial UKB sample 3194 
consisted of 487,409 participants. After non-white (n=48,730) and related individuals (n=77,396) were removed, our sample comprised 361,283 3195 
participants. Multiple logistic (for binary outcomes) and linear regressions were conducted in the statistical package R [367] to model the relationship 3196 
between the eight phenotypes: (1) age at starting smoking in current smokers, (2) caffeine consumed per day, (3) cannabis initiation, (4) estimated 3197 
standard drinks per week, (5) smoking initiation, (6) cigarettes per day, (7) pack years of smoking, and (8) smoking cessation. The pair of independent 3198 
and dependent variables (Table S7) were matched to the pair of exposure and outcome traits (Table S4) in the MR analysis. We had 21 pairs of 3199 
independent and dependent variables. For covariates, we included the first ten ancestral principal components (PCs) to adjust for ethnic differences, age, 3200 
Townsend deprivation index (TDI), overall health rating, sex, educational attainment. The TDI and educational attainment (definitions provided in 3201 
supporting information) were fitted as covariates because they have been previously shown to be associated with smoking initiation [368] and alcohol 3202 
use [369].  3203 
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Among the 21 phenotypic associations, all the independent variables were significantly associated with the dependent variables, except that cannabis 3204 
initiation and estimated standard drinks per week were not associated with age at starting smoking in current smokers (Table S7). Smoking initiation was 3205 
associated with caffeine consumption, Smoking initiation showed a similar direction of effect on caffeine consumption to the causal association of regular 3206 
smoking initiation with caffeine consumption; however, the effect size was much smaller in the phenotypic association than the IVW estimator. 3207 
Supporting S5-7 Definitions of some covariates used in phenotypic associations. 3208 
Covariate Explanation 
Townsend 
deprivation 
index 
UKB Data-Field 189 
A score that measures deprivation based on unemployment, non-car ownership, non-home ownership, and household 
overcrowding [370] 
Educational 
attainment 
UKB Data-Field 6138 
This variable assessed participants’ education in six categories- (1) held a college or university degree, (2) A levels 
or AS levels or equivalent, (3) O levels/ GCSEs or equivalent, (4) CSEs or equivalent, (5) NVQ or HND or HNC or 
equivalent, and (6) other professional qualifications. Z scores were generated by standardising the first five 
categories. 
 3209 
Supporting S5-8 Effect estimate conversion.  3210 
The effect estimates (i.e., β and se) from multiple logistic or linear regression, as well as two-sample MR analysis were converted for the purpose of 3211 
interpreting them on a meaningful scale. Given our caffeine consumption was measured in milligram, we converted the effect estimate from this exposure 3212 
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or predictor to represent the average change of the outcome per one cup of coffee or tea (i.e. multiplying beta by 57.5, or ½ (75+40)). The effect sizes 3213 
were converted according to the variable type of an exposure, predictor and outcome as the following table: 3214 
 3215 
   Converted effect size and 95% confidence intervals 
Exposure 
/predictor  
Outcome Original Estimate  Lower bound Upper bound 
continuous, non-caffeine  continuous β, se β β - 1.96*se β + 1.96*se 
continuous, caffeine  continuous β, se β*57.5 57.5*(β - 1.96*se) 57.5*(β + 1.96*se) 
continuous, non-caffeine binary β, se exp(β) exp(β - 1.96*se) exp(β + 1.96*se) 
continuous, caffeine binary β, se exp(β*57.5) exp(57.5*(β - 1.96*se)) exp(57.5*(β + 1.96*se)) 
binary  continuous β, se 0.693*β 0.693*(β - 1.96*se) 0.693*(β + 1.96*se) 
binary binary β, se exp(0.693*β) exp(0.693*(β - 1.96*se)) exp(0.693*(β + 1.96*se)) 
 3216 
Supporting S5-9 Look-up for 7 SNPs used as genetic instruments for regular smoking initiation in SNP database. 3217 
SNP Description  URL 
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rs951740 Mapped gene(s):  
protein tyrosine phosphatase 
receptor type F (PTPRF) 
https://www.ebi.ac.uk/gwas/search?query=rs95174
0 
rs7613360 Mapped gene(s):  ACTB 
pseudogene 13(ACTBP13), 
macrophage stimulating 1 receptor 
(MST1R) 
https://www.ebi.ac.uk/gwas/variants/rs7613360 
rs6756212 Mapped gene(s): AC092484.1 
(novel transcript), ribosomal 
protein L6 pseudogene 5 (RPL6P5) 
https://www.ebi.ac.uk/gwas/variants/rs6756212 
rs62025923 No results found for search term 
rs62025923 
https://www.ebi.ac.uk/gwas/search?query=rs62025
923 
https://www.ncbi.nlm.nih.gov/snp/?term=rs620259
23 
rs325535 No results found for search term 
rs325535 
https://www.ebi.ac.uk/gwas/search?query=rs32553
5 
rs2162965 No results found for search term 
rs2162965 
https://www.ebi.ac.uk/gwas/search?query=rs21629
65 
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rs2155646 Mapped gene: neural cell adhesion 
molecule 1 (NCAM1) 
https://www.ebi.ac.uk/gwas/variants/rs2155646  
3218 
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Chapter 6 3219 
None 3220 
Supplementary figures 3221 
 3222 
Figure S2-1 Distribution of psychological distress (PSYCH6) and somatic distress (SOMA6) 3223 
summed scores (CTT) and IRT scores (IRT) in three study waves (left to right: NU1, NU2 and NU3) 3224 
and across the three waves (pooled). The colours contrast the summed scores (orange) by classical 3225 
test theory (CTT) and IRT scores (blue) generated by IRT modelling.3226 
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 3227 
Figure S2-2 Nonparametric item response theory (IRT) model for each of the six items of psychological (PSYCH6) distress subscale of the SPHERE12 3228 
questionnaire. For each item, the blue item response step functions (IRSF) was computed to estimate the probability of having the symptom more than 3229 
sometimes. The orange IRSF was computed to estimate the probability of having the symptom most of the time. Dotted curves represented the 95% 3230 
confidence interval of the IRSFs. In nonparametric IRT, IRSFs are not constrained to be logistic. 3231 
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 3232 
Figure S2-3 Nonparametric IRT model for each of the six items of somatic (SOMA6) distress subscale of the SPHERE12 questionnaire. See Figure 3233 
S1-2 for details of IRSFs.  3234 
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 3235 
Figure S2-4 Nonparametric IRT model for six binary diagnoses of affective disorders and psychosis (AD). These diagnoses included (1) agoraphobia, 3236 
(2) depressive episodes, (3) major depressive disorder, (4) panic attack, (5) panic disorder, and (6) social anxiety. These items were included because 3237 
they showed acceptable monotonically nondecreasing in their item response step function (IRSF). Dotted curves represented the 95% confidence interval 3238 
of the IRSFs. 3239 
  3240 
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 3241 
Figure S2-5 Nonparametric IRT model for three ordinal diagnoses of substance use (SU): DSM-V diagnoses of alcohol use disorder, cannabis use 3242 
disorder, and degree of drug use. We quantified the degree of drug use from the use of 9 drugs, including amphetamines, analgesics, cocaine, ecstasy, 3243 
hallucinogens, inhalants, opioids, sedatives and stimulants. This variable was coded as 0 for using none of these 9 drugs, 1 for using any one of them, 2 3244 
for using any two of them, and 3 for using 3 of them or more. Dotted curves represented the 95% confidence interval of the IRSFs.3245 
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 3246 
Figure S2-6 Path diagram of a Cholesky ACE model with four observed variables (Measure1 to 3247 
Measure4) and three sets of latent variables - additive genetic factors (A1-A4), shared environmental 3248 
factors (red C1-C4) and unique environmental factors (blue E1-E4). Circles indicate latent variables 3249 
and rectangles indicate observed variables (Measure1 to Measure4). Hypothesized loading of each 3250 
factor is indicated by the initial of the observed and latent variable names (e.g. a1m1 for the loading 3251 
of A1 onto Measure1). 3252 
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 3253 
Figure S2-7 Path diagram of an independent pathway model with four observed variables and three 3254 
sets of latent variables - additive genetic factors (Ac, As1- As4), shared environmental factors (red 3255 
Cc, Cs1-Cs4) and unique environmental factors (blue Ec, Es1-Es4). Lower-case “c” indicates the 3256 
latent factor is common to all the observed variables whereas “s” indicates that the latent variable is 3257 
specific to an observed variable. Factor loading of a latent variable onto an observed variable is 3258 
indicated by the combination of the latent variable name and the initial of the observed variable name 3259 
(e.g. AcM1 for loading of Ac onto Measure1). 3260 
 3261 
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 3262 
Figure S2-8 Path diagram of a common pathway model with four observed variables (Measure1 to 3263 
Measure4) and three sets of latent variables - additive genetic factors (Ac, As1- As4), shared 3264 
environmental factors (red Cc, Cs1-Cs4) and unique environmental factors (blue Ec, Es1-Es4). This 3265 
model assumes that Ac, Cc and Ec are best explained by a latent factor (Latent_factor), which 3266 
influences the four observed variables with loading f1-f4. The assumption of the influences of specific 3267 
genetic factors (As1-As4), specific shared environmental factors (Cs1-Cs4) and specific shared 3268 
environmental factors (Es1-Es4) is similar to that of the independent pathway model.3269 
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 3270 
Figure S3-1 Associations between polygenic risk scores (PRS) and initiation of illicit substance (blue), alcohol (red) and cannabis (black) use disorders 3271 
in young Australian adults (both males and females). Shown on top of the plot are the PRSs that were calculated for five discovery phenotypes, including 3272 
187 
 
smoking initiation (SI), age at starting regular smoking (AI), cigarettes per day (CPD), smoking cessation (SC), and drinks per week (DPW), using LD-3273 
clumped SNPs with association p-values at eight different thresholds: 5e-08, 1e-05, 1e-03, 1e-02, 0.05, 0.1, 0.5, and 1. Individual grids represent the 3274 
association between a target phenotype and a PRS. Colors represent R2 for associations that survived multiple testing at significance threshold 5.8e-04, 3275 
with larger and darker circles indicating higher R2. Non-significant associations are shown as blanks. Shown vertically on the left of the plot are initiation 3276 
of (1) cocaine, amphetamine, inhalants, sedatives, hallucinogens, opioids, ecstasy, prescription painkillers, prescription stimulants, and cannabis, (2) 3277 
alcohol abuse, alcohol dependence, DSM5 alcohol use disorder (AUD, 4 point scale), DSM5 AUD (binary, absent+ mild versus moderate + severe), and 3278 
(3) cannabis abuse, cannabis dependence, DSM5 cannabis use disorder (CUD, 4 point scale) , and DSM5 CUD (binary, absent+ mild versus moderate + 3279 
severe). 3280 
  3281 
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 3282 
Figure S3-2 Associations between polygenic risk scores (PRS) and initiation of illicit substance (blue), alcohol (red) and cannabis (black) use 3283 
disorders in young male Australian adults. See Figure S3-1 for details. 3284 
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 3285 
Figure S3-3 Associations between polygenic risk scores (PRS) and initiation of illicit substance (blue), alcohol (red) and cannabis (black) use disorders 3286 
in young female Australian adults. See Figure S3-1 for details. 3287 
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 3288 
Figure S4-1 Associations between polygenic risk scores (PRS) and liability to licit substance use (black), substance use disorders, behavioural 3289 
and mental disorders (blue) in Australian adults (both males and females) aged between 20 and 89 years. Shown on top of the heatmap are the 3290 
PRSs that were calculated for five discovery phenotypes, including smoking initiation (SI), age at starting regular smoking (AI), cigarettes per day (CPD), 3291 
smoking cessation (SC), and drinks per week (DPW), using LD-clumped SNPs with association p values at eight different thresholds: 5 x10-8 (S1), 10-5 3292 
(S2), 10-3 (S3), 10-2 (S4), 0.05 (S5), 0.1 (S6), 0.5 (S7), and 1 (S8). Individual grids represent the association between a target phenotype and a PRS. Color 3293 
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and size of the circles represent proportion of variance of target phenotypes explained by the PRSs (R2) from the associations that remained significant 3294 
after accounting for multiple testing at significance threshold 7.14 x10-4, with larger and more yellowish circles indicating higher R2. Non-significant 3295 
associations are shown as blanks. Shown vertically on the left of the plot are 15 target phenotypes (1) smoking initiation (binary), (2) age at starting 3296 
regular smoking (continuous), (3) cigarettes smoked per day (continuous), (4) smoking cessation (binary), (5) drinkers versus non-drinkers (binary), (6) 3297 
drinks per week (continuous) and 9 binary diagnostic phenotypes: (7) DSM-IV alcohol dependence, (8) DSM-IV nicotine dependence, (9) nicotine 3298 
dependence defined by the Fagerstrom Test for Nicotine Dependence (FTND-based nicotine dependence), (10) DSM-IV conduct disorder, (11) DSM-3299 
IV antisocial personality disorder, (12) DSM-IV depressive disorder, (13) DSM-IV panic disorder, (14) DSM-IV social phobia, and (15) DSM-IV mania. 3300 
  3301 
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 3302 
Figure S4-2 Associations between polygenic risk scores (PRS) and liability to licit substance use (black), substance use disorders, behavioural 3303 
and mental disorders (blue) in male Australian adults aged between 20 and 90 years. See Figure S4-1 for details. 3304 
193 
 
 3305 
Figure S4-3 Associations between polygenic risk scores (PRS) and liability to licit substance use (black), substance use disorders, behavioural 3306 
and mental disorders (blue) in female Australian adults aged between 20 and 90 years. See Figure S4-1 for details. 3307 
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 3308 
Figure S6-1. Manhattan plot for the associations between all SNPs and item response theory theta score for psychological distress (PSYCH6_IRT). 3309 
The X axis shows genomic position (chromosomes 1–22) and the y axis showing statistical significance as -log10 (P) z statistics; the threshold for 3310 
significance accounting for multiple testing is shown by the horizontal line (P = 5e-8). 3311 
  3312 
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 3313 
Figure S6-2. Manhattan plot for the associations between all SNPs and item response theory theta score for somatic distress (SOMA6_IRT). See Figure 3314 
S6-1 for details. 3315 
  3316 
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 3317 
Figure S6-3. Manhattan plot for the associations between all SNPs and item response theory theta score for 12-item SPHERE (SPHERE12_IRT). See 3318 
Figure S6-1 for details 3319 
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Table S2-1. Number of complete MZ and DZ twin pairs whose twin members are cases (1) or controls (0) for each of the binary psychiatric diagnoses of 
affective disorders (AD) or substance use (SU). (0,0) means both twin 1 and twin 2 are controls. (0,1) means twin 1 is a control and twin 2 is a case. (1,0) means twin 
1 is a case and twin 2 is a control. (1,1) means both twins are cases. 
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 MZ twin pairs (twin1, twin2)  DZ twin pairs (twin1, twin2)  
Scale Diagnosis  (0, 0) (0, 1) (1, 0) (1, 1)  (0, 0) (0, 1) (1, 0) (1, 1)  Total twin pairs 
Total twin 
individuals 
AD major depressive disorder  258 46 39 27  328 67 60 20  845 2132 
 agoraphobia  361 6 3 0  467 4 4 0  845 2132 
 depressive episodes  252 49 40 29  324 69 61 21  845 2132 
 panic attack  283 33 35 19  362 55 49 9  845 2132 
 panic disorder  355 8 6 1  447 11 17 0  845 2132 
 social anxiety  275 39 34 22  341 55 63 16  845 2132 
SU alcohol use  41 24 32 273  29 43 35 368  845 2132 
 drug use ever  131 44 32 163  133 89 79 174  845 2132 
 cannabis use ever  117 28 22 74  138 75 59 83  596 1663 
 tobacco use ever  103 49 43 175  130 76 80 189  845 2132 
Table S2-2. Tests concerning thresholds (t) and covariances (c) for binary diagnoses in affective disorders (AD) or substance use (SU). The tests compare the fit 
between the base model and a submodel (H1t- H4c). Modelling results shown are the difference in log-likelihoods. Superscript a indicates p value between 0.001 and 
0.01. Superscript b indicates p value < 0.001. NC: not calculable. 
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 Homogeneity of thresholds  Homogeneity of covariances 
Scale Diagnosis  H1t H2t H3t H4t  H1c H2c H3c H4c 
AD major depressive disorder  2.87 0.61 1.11 4.65  0.59 0.06 3.74 27.14b 
 agoraphobia  1.72 1.09 NC NC  0.66 0 0.00 NC 
 depressive episodes  2.89 0.69 0.89 4.59  0.37 0 3.98 26.90b 
 panic attack  1.8 1.13 0.64 0.03  0.73 2.01 5.90 17.42a 
 panic disorder  8.42 0.26 2.36 0.01  0.22 0 2.45 2.83 
 social anxiety  2.95 4.73 1.29 0.01  3.83 0.05 4.24 23.20b 
 
SU alcohol use  6.44 9.24a 2.10 0.01  1.78 4.11 2.54 113.58b 
 drug use ever  6.02 2.89 2.65 0.02  2.74 0.67 20.22b 167.30b 
 cannabis use ever  5.81 1.79 1.61 0.06  5.29 0.87 16.66b 104.91b 
 tobacco use ever  0.43 1.17 2.83 0.03  1.97 1.43 3.47 128.77b 
 
Table S2-3. Tests concerning means (m), variances (v) and covariances (c) for affective disorder IRT (AD-IRT), psychological (PSYCH6) and somatic distress 
(SOMA6) subscale, and substance use IRT (SU-IRT). The tests compare the fit between the base model and a submodel (H1m- H4c). Modelling results shown are the 
difference in log-likelihoods. Superscript a indicates p value between 0.001 and 0.01. Superscript b indicates p value < 0.001. 
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 Homogeneity of means  Homogeneity of variances  Homogeneity of covariances 
Scale Phenotype Phenotype  H1m H2m H3m H4m  H1v H2v H3v H4v  H1c H2c H3c H4c 
AD AD-IRT AD-IRT  5.22 6.49 0.02 2.96  2.66 0.5 0.16 16.75b  1.07 0.58 14.19b 38.22b 
 
PSYCH6 IRT score IRT score  1.29 1.67 3.54 0  0.81 0.79 0.19 0.01  0.22 1.85 6.71a 13.46b 
 
SOMA6 IRT score IRT score  5.09 5.11 4.4 0  1.72 0.01 0.75 0.02  4.46 0.12 10.60a 15.01b 
 
SU SU-IRT SU-IRT  1.33 1.5 2.97 0.03  0.97 0.28 0.07 0.15  3.94 3.09 16.32b 111.96b 
 
Table S2-4. Model-fitting results for univariate ACE or ADE models for diagnoses in affective disorders (AD), substance use (SU), psychological (PSYCH6) 
and somatic distress (SOMA6) subscale. The univariate ADE models and their nested sub-models are shown in blue. Model-fitting statistics are (1) -2LL: twice 
negative log-likelihood, (2) DF: degrees of freedom, (3) diff DF: difference in degrees of freedom to previous submodel, (4) diffLL: difference in log-likelihood, (5) 
AIC: Akaike's information criterion, (6) p: p value, (7) CI: confidence interval, (8) A: additive genetic factors, (9) C: common environmental factors, (10) E: unique 
environmental factors. 
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 Goodness-of-fit statistics  Parameter estimates (95% CI) 
Scale Diagnosis Model  -2LL DF AIC 
diff 
DF diff LL p  A C/D E 
AD agoraphobia ACE  206.61 2069 -3931.4     0.00 ( 0.00-0.66 ) 0.00 ( 0.00-0.00 ) 1.00 ( 1.00-1.00 ) 
  AE  206.61 2070 -3933.4 1 0 0.999  0.00 ( 0.00-0.00 )  1.00 ( 1.00-1.00 ) 
  CE  206.61 2070 -3933.4 1 0 1   0.00 ( 0.00-0.00 ) 1.00 ( 1.00-1.00 ) 
  E  206.61 2071 -3935.4 2 0 1    1.00 ( 1.00-1.00 ) 
 
 AD-IRT ADE  8934.85 2068 4798.85     0.06 ( 0.00-0.37 ) 0.28 ( 0.00-0.42 ) 0.66 ( 0.58-0.75 ) 
  AE  8936.8 2069 4798.8 1 1.95 0.162  0.32 ( 0.23-0.39 )  0.68 ( 0.61-0.77 ) 
  E  8987.26 2070 4847.26 2 52.41 0    1.00 ( 1.00-1.00 ) 
 
 depressive episodes ADE  1986.5 2069 -2151.5     0.23 ( 0.00-0.55 ) 0.20 ( 0.00-0.59 ) 0.57 ( 0.41-0.75 ) 
  AE  1986.72 2070 -2153.3 1 0.23 0.635  0.41 ( 0.24-0.56 )  0.59 ( 0.44-0.76 ) 
  E  2008.43 2071 -2133.6 2 21.93 0    1.00 ( 1.00-1.00 ) 
 
 major depressive disorder ADE  1941.69 2069 -2196.3     0.26 ( 0.00-0.56 ) 0.17 ( 0.00-0.59 ) 0.57 ( 0.41-0.75 ) 
  AE  1941.86 2070 -2198.1 1 0.16 0.685  0.41 ( 0.24-0.57 )  0.59 ( 0.43-0.76 ) 
  E  1963.53 2071 -2178.5 2 21.84 0    1.00 ( 1.00-1.00 ) 
 
 panic attack ADE  1608.7 2069 -2529.3     0.00 ( 0.00-0.00 ) 0.42 ( 0.00-0.60 ) 0.58 ( 0.40-0.79 ) 
  AE  1610.19 2070 -2529.8 1 1.5 0.221  0.37 ( 0.17-0.55 )  0.63 ( 0.45-0.83 ) 
  E  1623.07 2071 -2518.9 2 14.38 0.001    1.00 ( 1.00-1.00 ) 
 
 panic disorder ADE  471.43 2069 -3666.6     0.00 ( 0.00-0.00 ) 0.32 ( 0.00-0.76 ) 0.68 ( 0.24-1.00 ) 
  AE  471.93 2070 -3668.1 1 0.49 0.483  0.23 ( 0.00-0.68 )  0.77 ( 0.32-1.00 ) 
  E  472.61 2071 -3669.4 2 1.17 0.556    1.00 ( 1.00-1.00 ) 
 
 social anxiety ADE  1817.56 2069 -2320.4     0.16 ( 0.00-0.57 ) 0.28 ( 0.00-0.62 ) 0.56 ( 0.38-0.76 ) 
  AE  1817.96 2070 -2322 1 0.4 0.528  0.42 ( 0.23-0.58 )  0.58 ( 0.42-0.77 ) 
  E  1836.87 2071 -2305.1 2 19.31 0    1.00 ( 1.00-1.00 ) 
 
Table S2-4. Model-fitting results for univariate ACE or ADE models for diagnoses in affective disorders (AD), substance use (SU), psychological (PSYCH6) 
and somatic distress (SOMA6) subscale. The univariate ADE models and their nested sub-models are shown in blue. Model-fitting statistics are (1) -2LL: twice 
negative log-likelihood, (2) DF: degrees of freedom, (3) diff DF: difference in degrees of freedom to previous submodel, (4) diffLL: difference in log-likelihood, (5) 
AIC: Akaike's information criterion, (6) p: p value, (7) CI: confidence interval, (8) A: additive genetic factors, (9) C: common environmental factors, (10) E: unique 
environmental factors. 
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 Goodness-of-fit statistics  Parameter estimates (95% CI) 
Scale Diagnosis Model  -2LL DF AIC 
diff 
DF diff LL p  A C/D E 
SU SU-IRT ACE  8660.64 2068 4524.64     0.46 ( 0.24-0.56 ) 0.03 ( 0.00-0.20 ) 0.51 ( 0.44-0.59 ) 
  AE  8660.75 2069 4522.75 1 0.12 0.731  0.49 ( 0.42-0.56 )  0.51 ( 0.44-0.58 ) 
  CE  8676.96 2069 4538.96 1 16.32 0   0.36 ( 0.30-0.41 ) 0.64 ( 0.59-0.70 ) 
  E  8788.91 2070 4648.91 2 128.28 0    1.00 ( 1.00-1.00 ) 
 
 alcohol use ACE  1655.59 2069 -2482.4     0.31 ( 0.00-0.69 ) 0.41 ( 0.07-0.69 ) 0.29 ( 0.19-0.42 ) 
  AE  1660.98 2070 -2479 1 5.39 0.02  0.75 ( 0.64-0.84 )  0.25 ( 0.16-0.36 ) 
  CE  1658.13 2070 -2481.9 1 2.54 0.111   0.64 ( 0.54-0.73 ) 0.36 ( 0.27-0.46 ) 
  E  1763.27 2071 -2378.7 2 107.68 0    1.00 ( 1.00-1.00 ) 
 
 alcohol use disorder ACE  4769.05 2067 635.05     0.36 ( 0.05-0.58 ) 0.12 ( 0.00-0.36 ) 0.52 ( 0.49-0.63 ) 
  AE  4769.96 2068 633.96 1 0.91 0.341  0.50 ( 0.40-0.59 )  0.50 ( 0.41-0.60 ) 
  CE  4774.13 2068 638.13 1 5.08 0.024   0.38 ( 0.30-0.46 ) 0.62 ( 0.54-0.70 ) 
  E  4846.92 2069 708.92 2 77.87 0    1.00 ( 1.00-1.00 ) 
 
 cannabis use disorder ACE  1985.18 2067 -2148.8     0.60 ( 0.16-0.83 ) 0.13 ( 0.00-0.49 ) 0.27 ( 0.17-0.41 ) 
  AE  1985.54 2068 -2150.5 1 0.36 0.548  0.74 ( 0.61-0.83 )  0.26 ( 0.17-0.39 ) 
  CE  1992.43 2068 -2143.6 1 7.26 0.007   0.59 ( 0.46-0.69 ) 0.41 ( 0.31-0.54 ) 
  E  2057.34 2069 -2080.7 2 72.16 0    1.00 ( 1.00-1.00 ) 
 
 drug use ever ACE  2640.27 2069 -1497.7     0.69 ( 0.40-0.85 ) 0.09 ( 0.00-0.34 ) 0.22 ( 0.15-0.31 ) 
  AE  2640.73 2070 -1499.3 1 0.46 0.5  0.79 ( 0.71-0.86 )  0.21 ( 0.14-0.29 ) 
  CE  2660.5 2070 -1479.5 1 20.22 0   0.60 ( 0.52-0.67 ) 0.40 ( 0.33-0.48 ) 
  E  2804.15 2071 -1337.9 2 163.87 0    1.00 ( 1.00-1.00 ) 
 
 tobacco use ever ACE  2618.87 2069 -1519.1     0.31 ( 0.00-0.63 ) 0.34 ( 0.07-0.59 ) 0.35 ( 0.25-0.47 ) 
  AE  2625.05 2070 -1514.9 1 6.18 0.013  0.70 ( 0.60-0.78 )  0.30 ( 0.22-0.40 ) 
  CE  2622.34 2070 -1517.7 1 3.47 0.062   0.57 ( 0.48-0.65 ) 0.43 ( 0.35-0.52 ) 
  E  2744.2 2071 -1397.8 2 125.34 0    1.00 ( 1.00-1.00 ) 
Table S2-4. Model-fitting results for univariate ACE or ADE models for diagnoses in affective disorders (AD), substance use (SU), psychological (PSYCH6) 
and somatic distress (SOMA6) subscale. The univariate ADE models and their nested sub-models are shown in blue. Model-fitting statistics are (1) -2LL: twice 
negative log-likelihood, (2) DF: degrees of freedom, (3) diff DF: difference in degrees of freedom to previous submodel, (4) diffLL: difference in log-likelihood, (5) 
AIC: Akaike's information criterion, (6) p: p value, (7) CI: confidence interval, (8) A: additive genetic factors, (9) C: common environmental factors, (10) E: unique 
environmental factors. 
 
 
Supplementary table page 6 
 Goodness-of-fit statistics  Parameter estimates (95% CI) 
Scale Diagnosis Model  -2LL DF AIC 
diff 
DF diff LL p  A C/D E 
 
 cannabis use ever ADE  2076.43 1611 -1145.6     0.74 ( 0.09-0.86 ) 0.04 ( 0.00-0.71 ) 0.22 ( 0.13-0.34 ) 
  AE  2076.44 1612 -1147.6 1 0.02 0.902  0.78 ( 0.66-0.86 )  0.22 ( 0.14-0.34 ) 
  E  2175.12 1613 -1050.9 2 98.69 0    1.00 ( 1.00-1.00 ) 
 
PSYCH6 IRT score ADE  6500.77 1499 3502.77     0.00 ( 0.00-0.31 ) 0.27 ( 0.00-0.37 ) 0.73 ( 0.63-0.85 ) 
  AE  6502.19 1500 3502.19 1 1.42 0.233  0.23 ( 0.13-0.33 )  0.77 ( 0.67-0.87 ) 
  E  6520.93 1501 3518.93 2 20.16 0    1.00 ( 1.00-1.00 ) 
 
SOMA6 IRT score ADE  6116.77 1499 3118.77     0.00 ( 0.00-0.30 ) 0.29 ( 0.00-0.38 ) 0.71 ( 0.62-0.82 ) 
  AE  6119.51 1500 3119.51 1 2.74 0.098  0.25 ( 0.15-0.35 )  0.75 ( 0.65-0.85 ) 
  E  6141.97 1501 3139.97 2 25.2 0    1.00 ( 1.00-1.00 ) 
 
Table S2-5. Model-fitting results for multivariate models of (1) psychological (PSYCH6r) and (2) somatic (SOMA6-r) distress subscales of the SPHERE12 and 
(3) affective disorders (ADr) and (4) substance use (SUr) scales. The models included the Cholesky decomposition (Cholesky ACE) and its submodels (Cholesky 
AE, Cholesky CE and Cholesky E), Independent pathway (IP), IP with 2 common A factors (IP2A), IP with 3 common A factors (IP3A), common pathway (CP), and 
eight submodels of the IP. Model-fitting statistics are (1) -2LL: twice negative log-likelihood, (2) DF: degrees of freedom, (3) diff DF: difference in degrees of freedom 
to previous submodel. Best-fitting models (in boldface type) are selected based on AIC. 
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Model Base model Compare DF diff DF -2LL diff LL AIC p 
1 Cholesky ACE  6,354  26388  13680  
2 Cholesky ACE Cholesky AE 6,364 10 26389 0.94 13661 0.9999 
3 Cholesky ACE Cholesky CE 6,364 10 26418 30.04 13690 0.0008 
4 Cholesky ACE Cholesky E 6,374 20 26536 148.11 13788 <.0001 
5 Cholesky ACE IP 6,360 6 26391 3.51 13671 0.7422 
6 Cholesky ACE IP2A 6,358 4 26390 1.75 13674 0.7818 
7 Cholesky ACE IP3A 6,356 2 26391 3.44 13679 0.1795 
8 Cholesky ACE CP 6,366 12 26397 9.34 13665 0.6737 
9 IP  6,360  26391  13671  
10 IP IP_CE_ACE 6,364 4 26402 10.93 13674 0.0274 
11 IP IP_AE_ACE 6,364 4 26393 1.56 13665 0.8151 
12 IP IP_AC_ACE 6,364 4 26514 122.94 13786 <.0001 
13 IP IP_E_ACE 6,368 8 26423 31.32 13687 0.0001 
14 IP IP_ACE_CE 6,364 4 26408 16.31 13680 0.0026 
15 IP IP_ACE_AE 6,364 4 26391 0 13663 1.0000 
16 IP IP_ACE_E 6,368 8 26420 29.08 13684 0.0003 
17 IP IP_AE_AE 6,368 8 26393 1.56 13657 0.9916 
18 IP_ACE_AE  6,364  26391  13663  
19 IP_ACE_AE IP_AE_AE 6,368 4 26393 1.56 13657 0.8151 
20 IP2A  6,358  26390  13674  
21 IP2A IP2A_CE_ACE 6,364 6 26402 12.69 13674 0.0482 
22 IP2A IP2A_AE_ACE 6,362 4 26391 1.1 13667 0.8946 
23 IP2A IP2A_AC_ACE 6,362 4 26520 130.67 13796 <.0001 
24 IP2A IP2A_E_ACE 6,368 10 26423 33.08 13687 0.0003 
25 IP2A IP2A_ACE_CE 6,362 4 26393 3.04 13669 0.5511 
26 IP2A IP2A_ACE_AE 6,362 4 26390 0 13666 1.0000 
27 IP2A IP2A_ACE_E 6,366 8 26393 3.58 13661 0.8931 
28 IP2A IP2A_AE_AE 6,366 8 26391 1.1 13659 0.9976 
29 IP2A_ACE_AE  6,362  26390  13666  
30 IP2A_ACE_AE IP2A_AE_AE 6,366 4 26391 1.1 13659 0.8946 
31 Cholesky AE  6,364  26389  13661  
Table S2-5. Model-fitting results for multivariate models of (1) psychological (PSYCH6r) and (2) somatic (SOMA6-r) distress subscales of the SPHERE12 and 
(3) affective disorders (ADr) and (4) substance use (SUr) scales. The models included the Cholesky decomposition (Cholesky ACE) and its submodels (Cholesky 
AE, Cholesky CE and Cholesky E), Independent pathway (IP), IP with 2 common A factors (IP2A), IP with 3 common A factors (IP3A), common pathway (CP), and 
eight submodels of the IP. Model-fitting statistics are (1) -2LL: twice negative log-likelihood, (2) DF: degrees of freedom, (3) diff DF: difference in degrees of freedom 
to previous submodel. Best-fitting models (in boldface type) are selected based on AIC. 
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Model Base model Compare DF diff DF -2LL diff LL AIC p 
32 Cholesky AE CP 6,366 2 26397 8.4 13665 0.0150 
33 Cholesky AE IP_AE_AE 6,368 4 26393 4.14 13657 0.3872 
34 Cholesky AE IP2A_AE_AE 6,366 2 26391 1.91 13659 0.3848 
Table S3-1. Number of SNPs with p values lower than a p value threshold in the GSCAN GWAS files on which quality control was performed (QC) and 
number of SNPs that were selected by LD-based clumping (LD, blue) according to eight significance thresholds. The SNP numbers are shown for each autosome 
(1-22) and summed (Total). The discovery sample phenotypes are SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), 
SC (smoking cessation) and DPW (drinks per day). 
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 p < 5e-08  p < 1e-05  p < 1e-03  p < 1e-02  p < 5e-02  p < 0.1  p < 0.5  p < 1 
Trait Chromosome  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD 
SI 1  898 16  2,507 56  9,637 385  29,653 1,445  83,964 4,431  141,855 7,268  548,730 22,221  1,031,901 31,511 
 2  1,062 18  2,350 77  12,770 497  38,716 1,739  102,030 4,798  166,533 7,759  597,005 22,418  1,096,596 31,710 
 3  787 11  2,432 63  11,111 413  32,428 1,391  85,107 3,965  139,860 6,465  502,468 19,331  920,128 27,345 
 4  480 8  1,279 31  6,737 252  24,226 1,099  74,822 3,492  128,761 5,847  498,374 18,148  941,095 25,912 
 5  485 10  1,687 52  6,963 298  22,884 1,102  67,678 3,316  114,412 5,551  447,450 17,327  839,031 24,823 
 6  450 12  1,764 44  8,194 281  27,756 1,157  79,125 3,420  131,576 5,592  471,630 16,525  864,068 23,436 
 7  443 10  1,582 42  6,974 291  22,366 1,117  63,462 3,243  106,713 5,309  412,380 15,879  761,980 22,564 
 8  181 7  823 22  4,772 221  19,019 1,000  59,410 3,006  100,544 4,931  380,885 14,750  707,512 21,000 
 9  25 5  725 24  4,062 186  14,584 827  45,120 2,538  77,229 4,207  299,858 12,864  557,645 18,478 
 10  652 11  1,449 33  5,101 213  16,852 959  52,736 2,851  90,862 4,685  351,798 14,367  659,810 20,472 
 11  505 11  971 34  5,947 256  19,608 974  58,134 2,797  96,946 4,659  355,736 13,917  644,268 19,722 
 12  34 4  401 18  3,465 189  14,901 819  48,160 2,584  84,966 4,357  334,258 13,678  628,572 19,789 
 13  60 3  346 23  3,757 161  12,204 637  37,300 2,054  65,015 3,377  251,847 10,445  475,016 14,957 
 14  5 1  498 15  2,571 141  10,748 597  34,267 1,887  60,091 3,099  230,514 9,317  427,053 13,312 
 15  358 6  769 22  2,575 124  9,186 503  29,171 1,596  50,830 2,694  197,740 8,375  375,590 12,248 
 16  30 4  540 21  3,132 183  11,415 712  33,790 1,945  57,023 3,196  219,586 9,705  403,863 13,935 
 17  23 3  399 13  3,121 101  11,620 480  31,230 1,541  51,999 2,606  194,845 8,458  365,677 12,489 
 18  14 4  498 20  2,921 143  9,828 574  30,505 1,701  52,152 2,858  198,609 9,101  370,903 13,055 
 19  2 1  71 6  821 75  5,826 390  21,403 1,319  38,653 2,258  160,102 7,028  306,515 10,152 
 20  67 3  336 10  1,751 80  7,250 399  21,845 1,364  37,647 2,269  152,996 7,670  289,784 11,081 
 21  2 1  40 5  1,328 52  4,210 231  13,143 790  23,159 1,367  94,073 4,470  179,287 6,502 
 22  2 1  179 7  815 40  3,366 223  12,741 786  22,380 1,352  94,814 4,370  181,222 6,523 
 Total  6,565 150  21,646 638  108,52
5 
4,582  368,64
6 
18,375  1,085,143 55,424  1,839,206 91,706  6,995,698 280,36
4 
 13,027,516 401,01
6 
 
AI 1  0 0  68 7  2,818 166  15,819 1,031  62,236 3,880  117,897 6,783  541,484 22,128  1,050,270 31,418 
 2  292 3  537 10  3,836 225  19,709 1,239  74,185 4,369  135,960 7,286  587,465 22,382  1,115,507 31,636 
 3  63 1  247 10  2,526 183  15,588 1,030  62,825 3,646  116,909 6,208  494,184 19,238  936,996 27,354 
 4  3 1  326 10  2,198 129  13,533 892  55,773 3,279  107,540 5,708  491,591 18,138  956,626 25,980 
 5  0 0  6 4  1,738 132  12,989 859  52,873 3,178  99,707 5,481  443,467 17,458  853,872 24,775 
 6  0 0  181 6  1,921 143  12,521 822  52,480 2,973  98,889 5,130  450,587 16,459  880,787 23,540 
Table S3-1. Number of SNPs with p values lower than a p value threshold in the GSCAN GWAS files on which quality control was performed (QC) and 
number of SNPs that were selected by LD-based clumping (LD, blue) according to eight significance thresholds. The SNP numbers are shown for each autosome 
(1-22) and summed (Total). The discovery sample phenotypes are SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), 
SC (smoking cessation) and DPW (drinks per day). 
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 p < 5e-08  p < 1e-05  p < 1e-03  p < 1e-02  p < 5e-02  p < 0.1  p < 0.5  p < 1 
Trait Chromosome  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD 
 7  0 0  25 6  2,064 151  11,482 846  46,972 2,922  89,346 5,028  399,541 15,803  776,785 22,554 
 8  5 1  140 6  1,432 99  9,109 672  41,057 2,601  78,212 4,463  366,426 14,616  721,727 20,960 
 9  0 0  11 5  946 101  7,709 657  34,679 2,346  65,735 4,008  294,334 12,932  571,355 18,380 
 10  0 0  43 4  870 102  8,315 687  38,073 2,544  73,469 4,445  343,299 14,222  672,512 20,440 
 11  0 0  20 3  1,237 116  10,428 718  40,624 2,590  77,857 4,416  342,300 13,834  655,648 19,710 
 12  0 0  39 5  1,496 107  9,383 697  38,687 2,556  73,221 4,293  332,207 13,892  641,757 19,805 
 13  0 0  26 3  1,277 85  7,253 499  29,547 1,838  54,725 3,230  247,726 10,360  482,755 14,908 
 14  0 0  2 0  642 72  6,314 512  26,812 1,684  50,511 2,963  224,494 9,293  434,252 13,349 
 15  1 1  14 5  775 64  5,570 426  23,412 1,574  44,040 2,663  197,850 8,600  383,523 12,310 
 16  0 0  1 1  721 85  6,088 532  25,844 1,853  49,076 3,181  212,632 9,833  409,997 14,002 
 17  20 1  57 2  927 82  6,025 461  22,674 1,534  42,427 2,647  191,982 8,735  370,824 12,502 
 18  0 0  57 3  1,211 90  5,989 431  23,213 1,588  43,524 2,788  194,387 9,131  377,969 13,036 
 19  0 0  46 1  438 44  3,459 299  16,797 1,136  32,823 1,982  155,737 6,975  310,173 10,178 
 20  0 0  11 1  479 43  4,050 355  17,555 1,279  33,468 2,290  152,207 7,593  294,245 11,059 
 21  0 0  0 0  138 23  1,818 188  9,650 775  19,370 1,351  93,359 4,542  183,504 6,483 
 22  0 0  1 0  372 28  2,571 199  10,280 739  19,663 1,302  93,653 4,418  185,085 6,517 
 Total  384 8  1,858 92  30,062 2,270  195,72
2 
14,052  806,248 50,884  1,524,369 87,646  6,850,912 280,58
2 
 13,266,169 400,89
6 
 
CPD 1  2 1  232 10  3,077 184  17,085 1,110  67,428 3,979  125,772 6,759  547,876 21,944  1,050,545 31,418 
 2  0 0  43 10  3,090 205  17,304 1,114  68,028 4,092  129,636 7,145  577,958 22,188  1,116,431 31,678 
 3  89 2  367 10  4,027 199  17,955 1,096  61,264 3,587  111,653 6,112  485,697 19,258  937,783 27,330 
 4  25 2  477 12  2,941 156  14,949 892  58,589 3,195  109,107 5,536  494,742 18,223  957,180 25,954 
 5  0 0  17 4  1,858 134  12,848 910  54,077 3,175  102,045 5,481  447,601 17,319  854,960 24,672 
 6  7 1  85 7  2,355 126  13,233 865  55,471 3,108  103,830 5,238  457,377 16,566  881,810 23,502 
 7  129 1  222 9  2,114 148  14,282 798  53,127 2,864  96,356 4,963  405,495 15,880  777,421 22,540 
 8  251 7  403 12  2,275 140  13,139 774  47,533 2,768  87,903 4,696  379,379 14,788  722,369 21,059 
 9  30 4  69 11  1,796 131  8,688 649  33,985 2,359  64,445 4,010  294,154 12,912  571,707 18,434 
 10  0 0  92 2  1,542 112  10,529 731  41,126 2,561  76,819 4,432  348,031 14,266  672,911 20,503 
 11  47 5  319 12  2,078 130  10,295 723  41,868 2,529  77,677 4,342  339,509 13,844  655,999 19,707 
 12  0 0  48 5  1,382 116  8,913 661  38,181 2,404  73,270 4,156  330,203 13,763  642,649 19,843 
Table S3-1. Number of SNPs with p values lower than a p value threshold in the GSCAN GWAS files on which quality control was performed (QC) and 
number of SNPs that were selected by LD-based clumping (LD, blue) according to eight significance thresholds. The SNP numbers are shown for each autosome 
(1-22) and summed (Total). The discovery sample phenotypes are SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), 
SC (smoking cessation) and DPW (drinks per day). 
 
 
Supplementary table page 11 
 p < 5e-08  p < 1e-05  p < 1e-03  p < 1e-02  p < 5e-02  p < 0.1  p < 0.5  p < 1 
Trait Chromosome  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD 
 13  0 0  91 5  927 86  7,096 529  30,124 1,861  56,973 3,202  251,728 10,343  483,335 14,863 
 14  0 0  33 4  1,322 74  6,631 458  26,579 1,668  50,070 2,913  222,474 9,368  434,826 13,397 
 15  1,031 36  1,171 46  2,354 136  7,395 504  25,938 1,630  47,119 2,734  201,092 8,533  384,214 12,313 
 16  47 2  188 9  1,879 100  7,639 513  27,182 1,764  49,765 3,078  215,040 9,772  410,070 14,045 
 17  0 0  11 2  859 57  4,673 387  21,239 1,457  40,395 2,519  188,638 8,519  371,174 12,476 
 18  0 0  53 5  1,172 89  6,211 498  24,804 1,679  44,936 2,845  195,940 9,097  378,367 13,019 
 19  394 21  737 33  2,150 104  6,668 433  21,807 1,331  38,430 2,247  160,876 7,102  310,344 10,198 
 20  14 2  150 6  876 67  4,664 379  18,663 1,299  34,563 2,258  151,783 7,556  294,441 11,077 
 21  0 0  2 1  493 35  2,350 167  10,279 676  19,231 1,231  91,600 4,475  183,808 6,510 
 22  0 0  0 0  303 19  2,414 187  10,367 704  20,089 1,273  93,900 4,401  185,105 6,513 
 Total  2,066 84  4,810 215  40,870 2,548  214,96
1 
14,378  837,659 50,690  1,560,084 87,170  6,881,093 280,11
7 
 13,277,449 401,05
1 
 
SC 1  0 0  29 4  2,278 151  13,591 977  59,250 3,914  112,211 6,795  511,618 22,074  990,550 31,573 
 2  0 0  22 5  2,610 201  16,161 1,150  65,613 4,075  124,818 7,068  549,857 22,480  1,056,808 31,852 
 3  0 0  61 4  1,522 132  11,207 961  51,506 3,484  99,464 6,031  455,146 19,292  890,512 27,465 
 4  0 0  378 1  1,451 99  11,292 839  52,385 3,265  100,419 5,793  468,492 18,360  910,375 26,097 
 5  0 0  19 2  1,552 143  11,294 846  48,865 3,115  93,079 5,441  416,619 17,429  813,216 24,835 
 6  0 0  55 5  1,172 115  11,622 792  49,944 2,976  94,808 5,096  431,955 16,639  837,392 23,679 
 7  0 0  2 2  1,262 125  9,551 741  41,860 2,747  79,668 4,794  374,725 15,856  736,810 22,784 
 8  0 0  18 5  1,358 112  8,479 741  39,193 2,742  75,795 4,668  350,454 14,772  686,535 21,031 
 9  49 6  340 13  1,377 96  7,158 613  30,319 2,334  59,738 3,995  276,404 12,935  540,025 18,466 
 10  0 0  0 0  1,144 106  8,407 707  36,516 2,545  69,946 4,427  320,633 14,432  635,982 20,630 
 11  6 1  78 6  1,342 90  8,813 605  34,238 2,344  66,639 4,137  318,192 13,858  621,285 19,878 
 12  0 0  10 1  758 93  7,355 654  34,240 2,500  67,226 4,346  311,368 13,881  606,311 19,878 
 13  0 0  0 0  470 62  5,289 472  25,132 1,816  49,686 3,200  233,780 10,443  457,816 15,003 
 14  0 0  130 1  792 60  5,527 405  24,180 1,584  46,376 2,811  209,990 9,379  409,609 13,508 
 15  59 3  292 6  1,414 67  5,640 419  20,947 1,508  39,247 2,600  181,998 8,572  360,453 12,373 
 16  0 0  1 1  495 73  4,833 432  21,715 1,672  42,158 2,922  196,129 9,687  387,105 14,020 
 17  0 0  2 2  598 53  4,939 383  22,937 1,495  41,048 2,616  177,202 8,654  346,068 12,547 
 18  0 0  4 0  542 56  4,441 417  20,828 1,603  40,192 2,769  183,443 9,134  358,537 13,094 
Table S3-1. Number of SNPs with p values lower than a p value threshold in the GSCAN GWAS files on which quality control was performed (QC) and 
number of SNPs that were selected by LD-based clumping (LD, blue) according to eight significance thresholds. The SNP numbers are shown for each autosome 
(1-22) and summed (Total). The discovery sample phenotypes are SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), 
SC (smoking cessation) and DPW (drinks per day). 
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 p < 5e-08  p < 1e-05  p < 1e-03  p < 1e-02  p < 5e-02  p < 0.1  p < 0.5  p < 1 
Trait Chromosome  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD 
 19  57 5  149 17  840 74  3,934 348  16,381 1,239  31,153 2,150  146,820 7,005  289,386 10,240 
 20  20 3  108 8  684 48  3,422 338  15,098 1,273  28,404 2,211  141,271 7,529  279,408 11,193 
 21  0 0  1 0  208 36  1,745 197  9,260 783  18,095 1,350  87,310 4,493  173,767 6,602 
 22  10 1  265 5  1,627 49  3,653 246  11,756 820  21,356 1,393  89,644 4,496  174,076 6,534 
 Total  201 19  1,964 88  25,496 2,041  168,35
3 
13,283  732,163 49,834  1,401,526 86,613  6,433,050 281,40
0 
 12,562,026 403,28
2 
 
DPW 1  2 1  297 19  4,481 188  18,634 1,147  65,086 3,919  119,936 6,791  534,222 21,930  1,045,907 31,459 
 2  217 9  1,111 41  6,932 315  24,214 1,351  78,440 4,247  139,223 7,180  577,570 22,381  1,107,792 31,752 
 3  528 3  946 18  4,134 193  18,768 1,009  64,841 3,461  113,984 5,950  481,918 19,173  929,662 27,327 
 4  744 21  1,437 41  4,872 259  21,466 1,164  68,285 3,584  120,599 5,914  494,305 18,280  949,852 26,037 
 5  3 2  374 15  3,201 179  15,492 955  57,168 3,213  102,507 5,403  436,366 17,343  847,271 24,792 
 6  0 0  19 6  2,559 131  16,068 864  57,512 2,984  103,991 5,150  448,522 16,490  873,169 23,456 
 7  309 2  827 16  3,513 193  14,235 919  50,971 2,959  92,583 5,038  399,787 15,874  772,182 22,559 
 8  0 0  367 13  2,831 148  13,223 834  47,612 2,876  87,285 4,767  372,220 14,745  718,035 20,987 
 9  1 1  247 9  2,240 146  11,131 696  38,853 2,364  68,459 3,928  290,281 12,754  566,063 18,341 
 10  0 0  260 4  1,587 119  10,030 711  42,603 2,584  79,402 4,425  343,282 14,287  667,947 20,577 
 11  334 6  1,019 22  3,608 152  14,578 751  46,956 2,510  81,502 4,318  336,772 13,783  651,833 19,654 
 12  32 1  346 21  2,673 153  12,603 731  43,666 2,443  77,677 4,207  328,450 13,755  637,249 19,803 
 13  0 0  77 5  1,486 103  7,801 554  29,898 1,891  56,063 3,192  244,663 10,376  478,164 14,968 
 14  69 3  163 7  1,116 83  7,103 464  28,673 1,636  52,199 2,921  223,680 9,324  432,097 13,427 
 15  0 0  130 8  2,182 82  7,122 459  24,361 1,528  43,798 2,614  194,266 8,478  380,216 12,327 
 16  305 8  629 23  2,690 149  9,392 603  30,114 1,897  53,104 3,168  213,666 9,856  410,772 14,035 
 17  2,198 3  3,201 13  6,070 96  11,559 451  28,756 1,574  48,234 2,624  192,684 8,669  372,508 12,518 
 18  0 0  196 9  1,726 87  6,413 404  23,521 1,550  43,131 2,728  190,791 9,061  374,843 13,098 
 19  104 1  138 4  772 55  4,081 372  17,087 1,243  32,851 2,146  155,420 6,969  314,998 10,171 
 20  1 1  76 3  1,093 65  5,778 406  20,989 1,352  37,056 2,367  153,692 7,623  293,686 11,047 
 21  0 0  2 1  313 27  2,151 183  9,471 750  18,533 1,309  90,283 4,483  182,071 6,530 
 22  0 0  62 4  849 51  3,016 213  11,552 748  21,060 1,331  94,228 4,460  186,676 6,522 
Table S3-1. Number of SNPs with p values lower than a p value threshold in the GSCAN GWAS files on which quality control was performed (QC) and 
number of SNPs that were selected by LD-based clumping (LD, blue) according to eight significance thresholds. The SNP numbers are shown for each autosome 
(1-22) and summed (Total). The discovery sample phenotypes are SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), 
SC (smoking cessation) and DPW (drinks per day). 
 
 
Supplementary table page 13 
 p < 5e-08  p < 1e-05  p < 1e-03  p < 1e-02  p < 5e-02  p < 0.1  p < 0.5  p < 1 
Trait Chromosome  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD  QC LD 
 Total  4,847 62  11,924 302  60,928 2,974  254,85
8 
15,241  886,415 51,313  1,593,177 87,471  6,797,068 280,09
4 
 13,192,993 401,38
7 
 
Table S3-2. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5) in females (F), males (M) or 
both sexes (F+M). PRS for SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), SC (smoking cessation) and DPW 
(drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) p< T3 with the adjustment for number of independent target phenotypes, 
(4) p< T4 with the adjustment for number of both independent target phenotypes and discovery traits, and (5) p< T5 with the adjustment by Bonferroni procedure. T3 is 
3.607512e-03 for females, 3.622416e-03 for males, and 3.633203e-03 for both sexes. T4 is 7.142857e-04 for all the sex groups. T5 is 5.681818e-05 for all the sex 
groups. 
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 SI  AI  CPD  SC  DPW 
Target phenotype Sex  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
Ever used cocaine F+M  8 6 6 1 0  8 3 0 0 0  8 0 0 0 0  8 0 0 0 0  8 6 5 3 0 
 F  8 6 5 1 0  8 1 0 0 0  8 0 0 0 0  8 4 0 0 0  8 3 0 0 0 
 M  8 6 5 1 0  8 1 0 0 0  8 0 0 0 0  8 4 0 0 0  8 3 0 0 0 
 
Ever used amphetamine F+M  8 7 6 5 4  8 5 2 0 0  8 0 0 0 0  8 0 0 0 0  8 5 1 1 0 
 F  8 6 5 5 4  8 4 1 0 0  8 0 0 0 0  8 0 0 0 0  8 5 0 0 0 
 M  8 6 5 5 4  8 4 1 0 0  8 0 0 0 0  8 0 0 0 0  8 5 0 0 0 
 
Ever used inhalants F+M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0 
 F  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0 
 
Ever used sedatives F+M  8 5 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 3 0 0 
 F  8 2 1 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 2 0 0 
 M  8 2 1 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 2 0 0 
 
Ever used hallucinogens F+M  8 6 4 3 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 1 0 0 
 F  8 6 5 5 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 3 0 0 0 
 M  8 6 5 5 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 3 0 0 0 
 
Ever used opioids F+M  8 5 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 2 0 0 0 
 F  8 6 5 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 1 0 0 
 M  8 6 5 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 1 0 0 
 
Ever used ecstasy F+M  8 7 6 6 5  8 4 0 0 0  8 0 0 0 0  8 0 0 0 0  8 7 5 5 3 
 F  8 6 6 5 5  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 7 5 5 0 
 M  8 6 6 5 5  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 7 5 5 0 
 
Table S3-2. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5) in females (F), males (M) or 
both sexes (F+M). PRS for SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), SC (smoking cessation) and DPW 
(drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) p< T3 with the adjustment for number of independent target phenotypes, 
(4) p< T4 with the adjustment for number of both independent target phenotypes and discovery traits, and (5) p< T5 with the adjustment by Bonferroni procedure. T3 is 
3.607512e-03 for females, 3.622416e-03 for males, and 3.633203e-03 for both sexes. T4 is 7.142857e-04 for all the sex groups. T5 is 5.681818e-05 for all the sex 
groups. 
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 SI  AI  CPD  SC  DPW 
Target phenotype Sex  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
Ever used prescription pain 
killers 
F+M  8 4 0 0 0  8 2 0 0 0  8 1 0 0 0  8 2 1 0 0  8 1 0 0 0 
 F  8 7 1 0 0  8 2 0 0 0  8 3 0 0 0  8 2 0 0 0  8 2 0 0 0 
 M  8 7 1 0 0  8 2 0 0 0  8 3 0 0 0  8 2 0 0 0  8 2 0 0 0 
 
Ever used prescription stimulants F+M  8 2 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 2 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 2 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Ever used cannabis F+M  8 7 6 6 1  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 1 0 0 
 F  8 7 6 1 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0 
 M  8 6 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0  8 2 0 0 0 
 
Age at onset of cannabis initiation F+M  8 0 0 0 0  8 0 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Alcohol abuse F+M  8 7 1 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 6 0 0 0  8 0 0 0 0  8 0 0 0 0  8 5 0 0 0  8 0 0 0 0 
 M  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Alcohol dependence F+M  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 3 0 0 0  8 0 0 0 0  8 0 0 0 0  8 4 0 0 0  8 1 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0 
 
DSM5 AUD (4 point scale) F+M  8 6 5 1 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 6 0 0 0 
 F  8 6 0 0 0  8 4 0 0 0  8 0 0 0 0  8 4 1 0 0  8 1 0 0 0 
 M  8 5 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 4 0 0 0 
 
Table S3-2. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5) in females (F), males (M) or 
both sexes (F+M). PRS for SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), SC (smoking cessation) and DPW 
(drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) p< T3 with the adjustment for number of independent target phenotypes, 
(4) p< T4 with the adjustment for number of both independent target phenotypes and discovery traits, and (5) p< T5 with the adjustment by Bonferroni procedure. T3 is 
3.607512e-03 for females, 3.622416e-03 for males, and 3.633203e-03 for both sexes. T4 is 7.142857e-04 for all the sex groups. T5 is 5.681818e-05 for all the sex 
groups. 
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 SI  AI  CPD  SC  DPW 
Target phenotype Sex  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
DSM5 AUD (ctrl mild vs 
moderate severe) 
F+M  8 6 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 8 0 0 0 
 F  8 1 0 0 0  8 1 0 0 0  8 0 0 0 0  8 4 0 0 0  8 1 0 0 0 
 M  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 6 0 0 0 
 
Cannabis abuse F+M  8 0 0 0 0  8 1 0 0 0  8 2 0 0 0  8 0 0 0 0  8 3 0 0 0 
 F  8 3 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 1 0 0 0  8 3 0 0 0  8 0 0 0 0  8 2 0 0 0 
 
Age at onset of cannabis abuse F+M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 2 0 0 0 
 F  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0 
 
Cannabis dependence F+M  8 5 0 0 0  8 1 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 5 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0 
 M  8 0 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Age at onset of cannabis 
dependence 
F+M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0 
 F  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0 
 
DSM5 CUD (4 point scale) F+M  8 5 0 0 0  8 4 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 6 5 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 1 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
DSM5 CUD (ctrl mild vs 
moderate severe) 
F+M  8 5 1 0 0  8 4 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 5 4 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 2 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0 
Table S3-2. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5) in females (F), males (M) or 
both sexes (F+M). PRS for SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), SC (smoking cessation) and DPW 
(drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) p< T3 with the adjustment for number of independent target phenotypes, 
(4) p< T4 with the adjustment for number of both independent target phenotypes and discovery traits, and (5) p< T5 with the adjustment by Bonferroni procedure. T3 is 
3.607512e-03 for females, 3.622416e-03 for males, and 3.633203e-03 for both sexes. T4 is 7.142857e-04 for all the sex groups. T5 is 5.681818e-05 for all the sex 
groups. 
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 SI  AI  CPD  SC  DPW 
Target phenotype Sex  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
 
Age at onset of DSM5 CUD F+M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 2 0 0 0 
 F  8 0 0 0 0  8 0 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0  8 1 0 0 0 
 
Number target phenotypes 
predicted 
F+M  22 16 8 6 3  22 12 1 0 0  22 6 0 0 0  22 2 1 0 0  22 14 6 3 1 
 F  22 17 10 5 2  22 8 1 0 0  22 2 0 0 0  22 8 1 0 0  22 13 3 1 0 
 M  22 12 7 4 2  22 9 1 0 0  22 6 0 0 0  22 4 0 0 0  22 14 3 1 0 
 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
Ever used 
cocaine 
S1 F+M  0.012 0.01 0.1764 0.09  -0.014 0.01 0.1051 0.13  -0.014 0.01 0.1078 0.13  -0.005 0.01 0.5479 0.02  0.005 0.01 0.5376 0.02 
 S1 F  0.011 0.01 0.2884 0.10  -0.014 0.01 0.1524 0.18  -0.012 0.01 0.2453 0.12  -0.013 0.01 0.2187 0.13  0.007 0.01 0.4717 0.05 
 S1 M  0.011 0.01 0.2884 0.06  -0.014 0.01 0.1524 0.12  -0.012 0.01 0.2453 0.08  -0.013 0.01 0.2187 0.10  0.007 0.01 0.4717 0.03 
 S2 F+M  0.014 0.01 0.1066 0.13  0.004 0.01 0.6417 0.01  -0.014 0.01 0.1219 0.12  -0.012 0.01 0.1804 0.09  0.008 0.01 0.3823 0.04 
 S2 F  0.011 0.01 0.2581 0.11  -0.001 0.01 0.8977 0.00  -0.010 0.01 0.3593 0.07  -0.004 0.01 0.7061 0.01  0.016 0.01 0.1085 0.22 
 S2 M  0.011 0.01 0.2581 0.07  -0.001 0.01 0.8977 0.00  -0.010 0.01 0.3593 0.05  -0.004 0.01 0.7061 0.01  0.016 0.01 0.1085 0.14 
 S3 F+M  0.025 0.01 0.0032 0.44  0.002 0.01 0.8087 0.00  -0.017 0.01 0.0518 0.19  -0.005 0.01 0.5678 0.02  0.018 0.01 0.0405 0.21 
 S3 F  0.022 0.01 0.0246 0.44  0.003 0.01 0.7393 0.01  -0.012 0.01 0.2639 0.11  -0.013 0.01 0.2008 0.15  0.017 0.01 0.1120 0.22 
 S3 M  0.022 0.01 0.0246 0.28  0.003 0.01 0.7393 0.01  -0.012 0.01 0.2639 0.07  -0.013 0.01 0.2008 0.09  0.017 0.01 0.1120 0.15 
 S4 F+M  0.026 0.01 0.0032 0.44  -0.008 0.01 0.3759 0.04  -0.016 0.01 0.0780 0.16  0.006 0.01 0.4964 0.02  0.029 0.01 0.0008 0.56 
 S4 F  0.032 0.01 0.0018 0.83  0.004 0.01 0.6961 0.01  -0.006 0.01 0.5918 0.03  -0.018 0.01 0.0951 0.25  0.018 0.01 0.0798 0.26 
 S4 M  0.032 0.01 0.0018 0.51  0.004 0.01 0.6961 0.01  -0.006 0.01 0.5918 0.02  -0.018 0.01 0.0951 0.17  0.018 0.01 0.0798 0.19 
 S5 F+M  0.029 0.01 0.0010 0.54  -0.019 0.01 0.0368 0.22  -0.006 0.01 0.4995 0.02  0.001 0.01 0.8899 0.00  0.028 0.01 0.0014 0.51 
 S5 F  0.034 0.01 0.0010 0.95  -0.011 0.01 0.2599 0.11  -0.006 0.01 0.5849 0.03  -0.029 0.01 0.0127 0.56  0.020 0.01 0.0555 0.32 
 S5 M  0.034 0.01 0.0010 0.61  -0.011 0.01 0.2599 0.06  -0.006 0.01 0.5849 0.02  -0.029 0.01 0.0127 0.42  0.020 0.01 0.0555 0.21 
 S6 F+M  0.032 0.01 0.0003 0.67  -0.017 0.01 0.0541 0.19  -0.007 0.01 0.4071 0.04  0.000 0.01 0.9667 0.00  0.033 0.01 0.0001 0.75 
 S6 F  0.037 0.01 0.0003 1.15  -0.012 0.01 0.2244 0.13  -0.011 0.01 0.3074 0.09  -0.027 0.01 0.0225 0.48  0.026 0.01 0.0120 0.55 
 S6 M  0.037 0.01 0.0003 0.75  -0.012 0.01 0.2244 0.07  -0.011 0.01 0.3074 0.06  -0.027 0.01 0.0225 0.35  0.026 0.01 0.0120 0.36 
 S7 F+M  0.027 0.01 0.0020 0.48  -0.020 0.01 0.0271 0.26  -0.002 0.01 0.8344 0.00  -0.003 0.01 0.7450 0.01  0.032 0.01 0.0001 0.71 
 S7 F  0.032 0.01 0.0015 0.87  -0.019 0.01 0.0685 0.30  -0.004 0.01 0.6857 0.01  -0.028 0.01 0.0150 0.55  0.029 0.01 0.0041 0.70 
 S7 M  0.032 0.01 0.0015 0.55  -0.019 0.01 0.0685 0.16  -0.004 0.01 0.6857 0.01  -0.028 0.01 0.0150 0.40  0.029 0.01 0.0041 0.46 
 S8 F+M  0.028 0.01 0.0017 0.50  -0.021 0.01 0.0229 0.27  -0.002 0.01 0.7922 0.00  -0.004 0.01 0.6526 0.01  0.032 0.01 0.0002 0.70 
 S8 F  0.034 0.01 0.0010 0.94  -0.021 0.01 0.0448 0.36  -0.005 0.01 0.6266 0.02  -0.029 0.01 0.0133 0.58  0.029 0.01 0.0037 0.72 
 S8 M  0.034 0.01 0.0010 0.59  -0.021 0.01 0.0448 0.20  -0.005 0.01 0.6266 0.01  -0.029 0.01 0.0133 0.41  0.029 0.01 0.0037 0.46 
 
Ever used 
amphetamine 
S1 F+M  0.012 0.01 0.1676 0.10  -0.002 0.01 0.8247 0.00  -0.001 0.01 0.8995 0.00  -0.006 0.01 0.5262 0.02  0.008 0.01 0.3802 0.04 
 S1 F  0.012 0.01 0.2981 0.10  -0.002 0.01 0.8795 0.00  -0.003 0.01 0.8198 0.00  -0.015 0.01 0.2046 0.14  0.009 0.01 0.3975 0.06 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S1 M  0.012 0.01 0.2981 0.08  -0.002 0.01 0.8795 0.00  -0.003 0.01 0.8198 0.00  -0.015 0.01 0.2046 0.13  0.009 0.01 0.3975 0.05 
 S2 F+M  0.021 0.01 0.0158 0.30  -0.000 0.01 0.9930 0.00  -0.001 0.01 0.9035 0.00  -0.007 0.01 0.4647 0.03  0.011 0.01 0.2380 0.07 
 S2 F  0.019 0.01 0.0831 0.27  -0.005 0.01 0.6563 0.02  -0.004 0.01 0.7589 0.01  -0.009 0.01 0.4316 0.05  0.016 0.01 0.1582 0.17 
 S2 M  0.019 0.01 0.0831 0.22  -0.005 0.01 0.6563 0.01  -0.004 0.01 0.7589 0.01  -0.009 0.01 0.4316 0.05  0.016 0.01 0.1582 0.14 
 S3 F+M  0.028 0.01 0.0016 0.51  -0.011 0.01 0.2070 0.08  0.001 0.01 0.8710 0.00  0.002 0.01 0.7870 0.00  0.014 0.01 0.1142 0.13 
 S3 F  0.029 0.01 0.0076 0.61  -0.004 0.01 0.7519 0.01  0.008 0.01 0.4706 0.05  -0.005 0.01 0.6931 0.01  0.019 0.01 0.0986 0.24 
 S3 M  0.029 0.01 0.0076 0.51  -0.004 0.01 0.7519 0.01  0.008 0.01 0.4706 0.04  -0.005 0.01 0.6931 0.01  0.019 0.01 0.0986 0.21 
 S4 F+M  0.034 0.01 0.0002 0.70  -0.023 0.01 0.0122 0.32  0.001 0.01 0.8721 0.00  0.007 0.01 0.4581 0.03  0.031 0.01 0.0006 0.59 
 S4 F  0.039 0.01 0.0005 1.05  -0.018 0.01 0.1170 0.22  0.012 0.01 0.2867 0.10  -0.002 0.01 0.9007 0.00  0.031 0.01 0.0067 0.64 
 S4 M  0.039 0.01 0.0005 0.82  -0.018 0.01 0.1170 0.15  0.012 0.01 0.2867 0.08  -0.002 0.01 0.9007 0.00  0.031 0.01 0.0067 0.57 
 S5 F+M  0.048 0.01 <.0001 1.40  -0.030 0.01 0.0011 0.54  0.007 0.01 0.4326 0.03  0.008 0.01 0.4000 0.04  0.021 0.01 0.0179 0.28 
 S5 F  0.050 0.01 <.0001 1.70  -0.028 0.01 0.0141 0.53  0.007 0.01 0.5445 0.03  -0.004 0.01 0.7752 0.01  0.023 0.01 0.0408 0.36 
 S5 M  0.050 0.01 <.0001 1.39  -0.028 0.01 0.0141 0.36  0.007 0.01 0.5445 0.03  -0.004 0.01 0.7752 0.01  0.023 0.01 0.0408 0.31 
 S6 F+M  0.050 0.01 <.0001 1.54  -0.028 0.01 0.0033 0.44  0.009 0.01 0.3007 0.06  0.008 0.01 0.4256 0.03  0.026 0.01 0.0039 0.42 
 S6 F  0.052 0.01 <.0001 1.79  -0.030 0.01 0.0086 0.61  0.005 0.01 0.6497 0.02  -0.005 0.01 0.6845 0.02  0.027 0.01 0.0169 0.50 
 S6 M  0.052 0.01 <.0001 1.49  -0.030 0.01 0.0086 0.41  0.005 0.01 0.6497 0.02  -0.005 0.01 0.6845 0.01  0.027 0.01 0.0169 0.42 
 S7 F+M  0.041 0.01 <.0001 1.05  -0.023 0.01 0.0175 0.30  0.013 0.01 0.1442 0.11  0.004 0.01 0.6826 0.01  0.020 0.01 0.0250 0.25 
 S7 F  0.047 0.01 <.0001 1.51  -0.033 0.01 0.0040 0.74  0.013 0.01 0.2626 0.11  -0.011 0.01 0.4119 0.06  0.025 0.01 0.0256 0.43 
 S7 M  0.047 0.01 <.0001 1.22  -0.033 0.01 0.0040 0.52  0.013 0.01 0.2626 0.10  -0.011 0.01 0.4119 0.06  0.025 0.01 0.0256 0.36 
 S8 F+M  0.042 0.01 <.0001 1.07  -0.025 0.01 0.0079 0.37  0.014 0.01 0.1346 0.12  0.003 0.01 0.7848 0.00  0.019 0.01 0.0297 0.24 
 S8 F  0.048 0.01 <.0001 1.57  -0.037 0.01 0.0011 0.95  0.012 0.01 0.2880 0.10  -0.012 0.01 0.3704 0.08  0.024 0.01 0.0299 0.40 
 S8 M  0.048 0.01 <.0001 1.27  -0.037 0.01 0.0011 0.66  0.012 0.01 0.2880 0.09  -0.012 0.01 0.3704 0.07  0.024 0.01 0.0299 0.33 
 
Ever used 
inhalants 
S1 F+M  0.007 0.00 0.1254 0.11  0.001 0.00 0.8193 0.00  -0.007 0.00 0.1619 0.09  0.006 0.00 0.2380 0.07  -0.002 0.00 0.6173 0.01 
 S1 F  0.005 0.01 0.2989 0.10  0.002 0.01 0.6353 0.02  -0.003 0.01 0.5602 0.03  -0.000 0.01 0.9313 0.00  0.003 0.01 0.6349 0.02 
 S1 M  0.005 0.01 0.2989 0.04  0.002 0.01 0.6353 0.01  -0.003 0.01 0.5602 0.02  -0.000 0.01 0.9313 0.00  0.003 0.01 0.6349 0.01 
 S2 F+M  0.006 0.00 0.1899 0.08  0.007 0.00 0.1247 0.11  -0.004 0.00 0.3663 0.04  0.002 0.00 0.6338 0.01  0.005 0.00 0.3216 0.05 
 S2 F  0.002 0.01 0.6779 0.02  0.008 0.01 0.1446 0.19  -0.002 0.01 0.6622 0.02  0.004 0.01 0.4937 0.04  0.011 0.01 0.0444 0.35 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S2 M  0.002 0.01 0.6779 0.01  0.008 0.01 0.1446 0.09  -0.002 0.01 0.6622 0.01  0.004 0.01 0.4937 0.02  0.011 0.01 0.0444 0.16 
 S3 F+M  0.006 0.00 0.1664 0.09  -0.003 0.00 0.5505 0.02  -0.005 0.00 0.3542 0.04  -0.002 0.00 0.6385 0.01  0.002 0.00 0.6454 0.01 
 S3 F  0.006 0.01 0.2841 0.10  -0.002 0.01 0.6858 0.01  -0.002 0.01 0.7594 0.01  -0.006 0.01 0.2925 0.10  0.009 0.01 0.1013 0.23 
 S3 M  0.006 0.01 0.2841 0.05  -0.002 0.01 0.6858 0.01  -0.002 0.01 0.7594 0.00  -0.006 0.01 0.2925 0.05  0.009 0.01 0.1013 0.12 
 S4 F+M  0.008 0.00 0.0992 0.13  -0.000 0.00 0.9678 0.00  -0.003 0.00 0.5980 0.01  0.002 0.01 0.6901 0.01  0.008 0.00 0.0858 0.14 
 S4 F  0.010 0.01 0.0704 0.28  -0.007 0.01 0.2092 0.14  0.001 0.01 0.8958 0.00  -0.006 0.01 0.3320 0.08  0.006 0.01 0.2492 0.11 
 S4 M  0.010 0.01 0.0704 0.13  -0.007 0.01 0.2092 0.06  0.001 0.01 0.8958 0.00  -0.006 0.01 0.3320 0.04  0.006 0.01 0.2492 0.06 
 S5 F+M  0.008 0.00 0.1146 0.12  -0.006 0.00 0.2037 0.08  0.001 0.00 0.9058 0.00  0.002 0.01 0.6793 0.01  0.009 0.00 0.0663 0.16 
 S5 F  0.005 0.01 0.3365 0.08  -0.007 0.01 0.1715 0.16  0.002 0.01 0.7203 0.01  -0.003 0.01 0.5959 0.03  0.006 0.01 0.2289 0.12 
 S5 M  0.005 0.01 0.3365 0.04  -0.007 0.01 0.1715 0.06  0.002 0.01 0.7203 0.01  -0.003 0.01 0.5959 0.01  0.006 0.01 0.2289 0.06 
 S6 F+M  0.007 0.00 0.1499 0.10  -0.005 0.00 0.3273 0.05  0.002 0.00 0.6281 0.01  0.001 0.01 0.8288 0.00  0.010 0.00 0.0353 0.21 
 S6 F  0.005 0.01 0.3322 0.08  -0.007 0.01 0.2133 0.14  0.004 0.01 0.5182 0.04  -0.002 0.01 0.8043 0.01  0.005 0.01 0.3730 0.07 
 S6 M  0.005 0.01 0.3322 0.04  -0.007 0.01 0.2133 0.05  0.004 0.01 0.5182 0.02  -0.002 0.01 0.8043 0.00  0.005 0.01 0.3730 0.03 
 S7 F+M  0.006 0.00 0.2197 0.07  0.000 0.01 0.9595 0.00  0.004 0.00 0.3640 0.04  0.001 0.01 0.8912 0.00  0.007 0.00 0.1592 0.09 
 S7 F  0.009 0.01 0.0843 0.26  -0.006 0.01 0.2577 0.11  0.005 0.01 0.3454 0.08  -0.004 0.01 0.5507 0.03  0.001 0.01 0.9113 0.00 
 S7 M  0.009 0.01 0.0843 0.12  -0.006 0.01 0.2577 0.05  0.005 0.01 0.3454 0.04  -0.004 0.01 0.5507 0.02  0.001 0.01 0.9113 0.00 
 S8 F+M  0.006 0.00 0.2035 0.08  0.000 0.01 0.9512 0.00  0.004 0.00 0.3998 0.03  0.001 0.01 0.8465 0.00  0.006 0.00 0.1854 0.08 
 S8 F  0.010 0.01 0.0692 0.28  -0.007 0.01 0.2236 0.13  0.005 0.01 0.3242 0.09  -0.004 0.01 0.5520 0.03  0.000 0.01 0.9535 0.00 
 S8 M  0.010 0.01 0.0692 0.13  -0.007 0.01 0.2236 0.05  0.005 0.01 0.3242 0.04  -0.004 0.01 0.5520 0.02  0.000 0.01 0.9535 0.00 
 
Ever used 
sedatives 
S1 F+M  0.021 0.01 0.0056 0.37  0.008 0.01 0.3054 0.05  0.001 0.01 0.9406 0.00  0.001 0.01 0.9149 0.00  0.005 0.01 0.5096 0.02 
 S1 F  0.032 0.01 0.0008 0.92  0.014 0.01 0.1442 0.17  0.009 0.01 0.3476 0.07  -0.005 0.01 0.6092 0.02  0.000 0.01 0.9782 0.00 
 S1 M  0.032 0.01 0.0008 0.78  0.014 0.01 0.1442 0.16  0.009 0.01 0.3476 0.07  -0.005 0.01 0.6092 0.02  0.000 0.01 0.9782 0.00 
 S2 F+M  0.019 0.01 0.0095 0.32  0.007 0.01 0.3476 0.04  0.001 0.01 0.9220 0.00  -0.004 0.01 0.6254 0.01  0.008 0.01 0.2867 0.05 
 S2 F  0.024 0.01 0.0125 0.51  0.007 0.01 0.4687 0.04  0.009 0.01 0.3654 0.07  -0.001 0.01 0.8879 0.00  0.013 0.01 0.1785 0.14 
 S2 M  0.024 0.01 0.0125 0.45  0.007 0.01 0.4687 0.04  0.009 0.01 0.3654 0.06  -0.001 0.01 0.8879 0.00  0.013 0.01 0.1785 0.12 
 S3 F+M  0.016 0.01 0.0398 0.20  -0.010 0.01 0.1879 0.08  0.001 0.01 0.9418 0.00  0.003 0.01 0.6718 0.01  0.009 0.01 0.2377 0.07 
 S3 F  0.015 0.01 0.1037 0.21  -0.003 0.01 0.7612 0.01  0.008 0.01 0.4392 0.05  0.008 0.01 0.4056 0.06  0.018 0.01 0.0607 0.28 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S3 M  0.015 0.01 0.1037 0.19  -0.003 0.01 0.7612 0.01  0.008 0.01 0.4392 0.04  0.008 0.01 0.4056 0.05  0.018 0.01 0.0607 0.27 
 S4 F+M  0.014 0.01 0.0635 0.17  -0.012 0.01 0.1429 0.10  -0.002 0.01 0.8160 0.00  0.006 0.01 0.4394 0.03  0.023 0.01 0.0026 0.44 
 S4 F  0.018 0.01 0.0639 0.28  -0.010 0.01 0.2932 0.09  0.005 0.01 0.5754 0.03  -0.006 0.01 0.5483 0.03  0.032 0.01 0.0011 0.85 
 S4 M  0.018 0.01 0.0639 0.23  -0.010 0.01 0.2932 0.07  0.005 0.01 0.5754 0.02  -0.006 0.01 0.5483 0.03  0.032 0.01 0.0011 0.82 
 S5 F+M  0.018 0.01 0.0217 0.25  -0.016 0.01 0.0480 0.19  0.000 0.01 0.9918 0.00  0.003 0.01 0.7646 0.00  0.025 0.01 0.0012 0.50 
 S5 F  0.017 0.01 0.0873 0.24  -0.016 0.01 0.1017 0.22  -0.002 0.01 0.8416 0.00  -0.013 0.01 0.2143 0.13  0.030 0.01 0.0022 0.75 
 S5 M  0.017 0.01 0.0873 0.21  -0.016 0.01 0.1017 0.16  -0.002 0.01 0.8416 0.00  -0.013 0.01 0.2143 0.13  0.030 0.01 0.0022 0.68 
 S6 F+M  0.017 0.01 0.0323 0.22  -0.012 0.01 0.1455 0.10  0.000 0.01 0.9620 0.00  0.004 0.01 0.6248 0.01  0.024 0.01 0.0018 0.47 
 S6 F  0.013 0.01 0.1843 0.14  -0.014 0.01 0.1442 0.17  -0.005 0.01 0.5825 0.03  -0.012 0.01 0.2793 0.10  0.026 0.01 0.0071 0.58 
 S6 M  0.013 0.01 0.1843 0.13  -0.014 0.01 0.1442 0.12  -0.005 0.01 0.5825 0.02  -0.012 0.01 0.2793 0.10  0.026 0.01 0.0071 0.52 
 S7 F+M  0.014 0.01 0.0764 0.15  -0.008 0.01 0.3031 0.05  0.003 0.01 0.6615 0.01  -0.003 0.01 0.7557 0.00  0.021 0.01 0.0058 0.36 
 S7 F  0.016 0.01 0.1033 0.21  -0.014 0.01 0.1586 0.17  -0.003 0.01 0.7408 0.01  -0.021 0.01 0.0535 0.31  0.026 0.01 0.0061 0.60 
 S7 M  0.016 0.01 0.1033 0.18  -0.014 0.01 0.1586 0.12  -0.003 0.01 0.7408 0.01  -0.021 0.01 0.0535 0.30  0.026 0.01 0.0061 0.53 
 S8 F+M  0.014 0.01 0.0795 0.15  -0.010 0.01 0.2358 0.07  0.003 0.01 0.6770 0.01  -0.003 0.01 0.6912 0.01  0.020 0.01 0.0075 0.34 
 S8 F  0.016 0.01 0.1039 0.21  -0.017 0.01 0.0931 0.24  -0.004 0.01 0.7178 0.01  -0.021 0.01 0.0578 0.30  0.025 0.01 0.0096 0.53 
 S8 M  0.016 0.01 0.1039 0.18  -0.017 0.01 0.0931 0.17  -0.004 0.01 0.7178 0.01  -0.021 0.01 0.0578 0.29  0.025 0.01 0.0096 0.46 
 
Ever used 
hallucinogens 
S1 F+M  -0.001 0.01 0.9383 0.00  -0.002 0.01 0.7513 0.01  -0.004 0.01 0.6165 0.01  -0.000 0.01 0.9570 0.00  0.012 0.01 0.1410 0.11 
 S1 F  -0.004 0.01 0.6592 0.02  0.002 0.01 0.8391 0.00  -0.002 0.01 0.8414 0.00  -0.003 0.01 0.7693 0.01  0.001 0.01 0.9438 0.00 
 S1 M  -0.004 0.01 0.6592 0.01  0.002 0.01 0.8391 0.00  -0.002 0.01 0.8414 0.00  -0.003 0.01 0.7693 0.01  0.001 0.01 0.9438 0.00 
 S2 F+M  0.010 0.01 0.2121 0.08  0.011 0.01 0.1658 0.10  -0.003 0.01 0.6744 0.01  -0.008 0.01 0.3125 0.05  0.012 0.01 0.1310 0.12 
 S2 F  0.012 0.01 0.1659 0.18  0.003 0.01 0.7300 0.01  -0.002 0.01 0.8105 0.01  -0.001 0.01 0.9439 0.00  0.009 0.01 0.3245 0.09 
 S2 M  0.012 0.01 0.1659 0.10  0.003 0.01 0.7300 0.01  -0.002 0.01 0.8105 0.00  -0.001 0.01 0.9439 0.00  0.009 0.01 0.3245 0.05 
 S3 F+M  0.019 0.01 0.0196 0.28  -0.014 0.01 0.0762 0.16  -0.012 0.01 0.1552 0.10  -0.007 0.01 0.4095 0.04  0.015 0.01 0.0633 0.18 
 S3 F  0.025 0.01 0.0049 0.70  -0.007 0.01 0.4541 0.05  -0.004 0.01 0.6711 0.02  -0.013 0.01 0.1667 0.18  0.006 0.01 0.5321 0.04 
 S3 M  0.025 0.01 0.0049 0.40  -0.007 0.01 0.4541 0.03  -0.004 0.01 0.6711 0.01  -0.013 0.01 0.1667 0.10  0.006 0.01 0.5321 0.02 
 S4 F+M  0.022 0.01 0.0066 0.38  -0.011 0.01 0.1706 0.10  -0.004 0.01 0.6148 0.01  0.000 0.01 0.9786 0.00  0.022 0.01 0.0056 0.39 
 S4 F  0.033 0.01 0.0003 1.17  -0.005 0.01 0.5660 0.03  0.002 0.01 0.8002 0.01  -0.010 0.01 0.3064 0.10  0.012 0.01 0.1885 0.15 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S4 M  0.033 0.01 0.0003 0.63  -0.005 0.01 0.5660 0.01  0.002 0.01 0.8002 0.00  -0.010 0.01 0.3064 0.06  0.012 0.01 0.1885 0.10 
 S5 F+M  0.027 0.01 0.0007 0.58  -0.014 0.01 0.0884 0.15  0.005 0.01 0.5021 0.02  0.001 0.01 0.9334 0.00  0.021 0.01 0.0081 0.36 
 S5 F  0.033 0.01 0.0003 1.16  -0.009 0.01 0.3096 0.09  0.007 0.01 0.4856 0.05  -0.015 0.01 0.1587 0.19  0.016 0.01 0.0961 0.25 
 S5 M  0.033 0.01 0.0003 0.66  -0.009 0.01 0.3096 0.04  0.007 0.01 0.4856 0.03  -0.015 0.01 0.1587 0.12  0.016 0.01 0.0961 0.15 
 S6 F+M  0.029 0.01 0.0003 0.67  -0.017 0.01 0.0473 0.21  0.011 0.01 0.1793 0.10  0.001 0.01 0.8905 0.00  0.024 0.01 0.0022 0.48 
 S6 F  0.032 0.01 0.0006 1.06  -0.012 0.01 0.1943 0.15  0.006 0.01 0.5273 0.04  -0.015 0.01 0.1598 0.19  0.020 0.01 0.0334 0.41 
 S6 M  0.032 0.01 0.0006 0.61  -0.012 0.01 0.1943 0.07  0.006 0.01 0.5273 0.02  -0.015 0.01 0.1598 0.12  0.020 0.01 0.0334 0.24 
 S7 F+M  0.030 0.01 0.0002 0.70  -0.015 0.01 0.0807 0.16  0.016 0.01 0.0534 0.20  -0.000 0.01 0.9901 0.00  0.022 0.01 0.0057 0.39 
 S7 F  0.031 0.01 0.0007 1.03  -0.013 0.01 0.1561 0.19  0.010 0.01 0.2767 0.11  -0.016 0.01 0.1363 0.21  0.021 0.01 0.0178 0.50 
 S7 M  0.031 0.01 0.0007 0.58  -0.013 0.01 0.1561 0.09  0.010 0.01 0.2767 0.06  -0.016 0.01 0.1363 0.14  0.021 0.01 0.0178 0.29 
 S8 F+M  0.030 0.01 0.0002 0.72  -0.016 0.01 0.0546 0.20  0.015 0.01 0.0660 0.18  -0.001 0.01 0.9478 0.00  0.023 0.01 0.0040 0.42 
 S8 F  0.032 0.01 0.0004 1.10  -0.016 0.01 0.0919 0.26  0.009 0.01 0.3281 0.09  -0.016 0.01 0.1245 0.23  0.022 0.01 0.0151 0.52 
 S8 M  0.032 0.01 0.0004 0.62  -0.016 0.01 0.0919 0.13  0.009 0.01 0.3281 0.05  -0.016 0.01 0.1245 0.14  0.022 0.01 0.0151 0.29 
 
Ever used 
opioids 
S1 F+M  0.005 0.00 0.3244 0.04  0.005 0.00 0.3112 0.05  -0.001 0.01 0.9173 0.00  -0.003 0.00 0.5800 0.01  0.003 0.01 0.5631 0.02 
 S1 F  0.006 0.01 0.3389 0.08  0.003 0.01 0.5871 0.02  -0.005 0.01 0.4545 0.05  -0.003 0.01 0.6620 0.02  0.006 0.01 0.3220 0.08 
 S1 M  0.006 0.01 0.3389 0.06  0.003 0.01 0.5871 0.02  -0.005 0.01 0.4545 0.04  -0.003 0.01 0.6620 0.01  0.006 0.01 0.3220 0.06 
 S2 F+M  0.006 0.00 0.2330 0.07  0.004 0.00 0.4063 0.03  0.002 0.01 0.6421 0.01  -0.004 0.01 0.3806 0.04  0.004 0.01 0.3901 0.03 
 S2 F  0.012 0.01 0.0605 0.29  -0.001 0.01 0.8783 0.00  -0.003 0.01 0.6312 0.02  -0.005 0.01 0.4661 0.04  0.012 0.01 0.0720 0.26 
 S2 M  0.012 0.01 0.0605 0.24  -0.001 0.01 0.8783 0.00  -0.003 0.01 0.6312 0.02  -0.005 0.01 0.4661 0.04  0.012 0.01 0.0720 0.21 
 S3 F+M  0.006 0.00 0.2142 0.07  -0.004 0.01 0.3886 0.03  0.001 0.01 0.7970 0.00  0.003 0.01 0.6021 0.01  0.000 0.01 0.9889 0.00 
 S3 F  0.015 0.01 0.0178 0.46  -0.005 0.01 0.4744 0.04  -0.002 0.01 0.8053 0.01  0.003 0.01 0.6264 0.02  0.011 0.01 0.1042 0.21 
 S3 M  0.015 0.01 0.0178 0.38  -0.005 0.01 0.4744 0.04  -0.002 0.01 0.8053 0.00  0.003 0.01 0.6264 0.02  0.011 0.01 0.1042 0.19 
 S4 F+M  0.013 0.01 0.0140 0.28  -0.008 0.01 0.1144 0.12  0.000 0.01 0.9304 0.00  0.001 0.01 0.9146 0.00  0.012 0.01 0.0165 0.26 
 S4 F  0.022 0.01 0.0008 0.90  -0.003 0.01 0.6006 0.02  -0.004 0.01 0.5787 0.03  -0.006 0.01 0.3999 0.06  0.020 0.01 0.0023 0.75 
 S4 M  0.022 0.01 0.0008 0.71  -0.003 0.01 0.6006 0.02  -0.004 0.01 0.5787 0.02  -0.006 0.01 0.3999 0.05  0.020 0.01 0.0023 0.68 
 S5 F+M  0.014 0.01 0.0054 0.36  -0.006 0.01 0.2374 0.07  0.001 0.01 0.8650 0.00  -0.001 0.01 0.8650 0.00  0.009 0.01 0.0782 0.14 
 S5 F  0.022 0.01 0.0008 0.91  -0.002 0.01 0.8001 0.01  0.001 0.01 0.9186 0.00  -0.007 0.01 0.3392 0.08  0.018 0.01 0.0062 0.61 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S5 M  0.022 0.01 0.0008 0.75  -0.002 0.01 0.8001 0.00  0.001 0.01 0.9186 0.00  -0.007 0.01 0.3392 0.07  0.018 0.01 0.0062 0.52 
 S6 F+M  0.012 0.01 0.0150 0.27  -0.006 0.01 0.2465 0.06  -0.001 0.01 0.7921 0.00  -0.002 0.01 0.7672 0.00  0.010 0.01 0.0553 0.17 
 S6 F  0.019 0.01 0.0031 0.71  -0.003 0.01 0.6179 0.02  -0.004 0.01 0.4991 0.04  -0.009 0.01 0.2227 0.13  0.018 0.01 0.0058 0.62 
 S6 M  0.019 0.01 0.0031 0.60  -0.003 0.01 0.6179 0.01  -0.004 0.01 0.4991 0.03  -0.009 0.01 0.2227 0.12  0.018 0.01 0.0058 0.53 
 S7 F+M  0.015 0.01 0.0041 0.38  -0.006 0.01 0.3032 0.05  -0.000 0.01 0.9279 0.00  -0.001 0.01 0.9075 0.00  0.010 0.00 0.0447 0.18 
 S7 F  0.020 0.01 0.0020 0.77  -0.005 0.01 0.4927 0.04  -0.003 0.01 0.6161 0.02  -0.009 0.01 0.2158 0.13  0.016 0.01 0.0109 0.52 
 S7 M  0.020 0.01 0.0020 0.63  -0.005 0.01 0.4927 0.03  -0.003 0.01 0.6161 0.02  -0.009 0.01 0.2158 0.12  0.016 0.01 0.0109 0.44 
 S8 F+M  0.014 0.01 0.0048 0.36  -0.006 0.01 0.2879 0.05  -0.000 0.01 0.9413 0.00  -0.001 0.01 0.8305 0.00  0.010 0.01 0.0554 0.17 
 S8 F  0.020 0.01 0.0022 0.76  -0.006 0.01 0.3892 0.06  -0.003 0.01 0.6159 0.02  -0.009 0.01 0.2042 0.14  0.015 0.01 0.0155 0.47 
 S8 M  0.020 0.01 0.0022 0.62  -0.006 0.01 0.3892 0.04  -0.003 0.01 0.6159 0.02  -0.009 0.01 0.2042 0.13  0.015 0.01 0.0155 0.39 
 
Ever used 
ecstasy 
S1 F+M  0.007 0.01 0.4974 0.02  0.000 0.01 0.9849 0.00  -0.009 0.01 0.3809 0.04  0.013 0.01 0.1953 0.09  0.008 0.01 0.4247 0.03 
 S1 F  0.004 0.01 0.7750 0.01  0.005 0.01 0.6765 0.02  -0.014 0.01 0.2736 0.11  0.012 0.01 0.3504 0.08  0.010 0.01 0.4212 0.06 
 S1 M  0.004 0.01 0.7750 0.01  0.005 0.01 0.6765 0.01  -0.014 0.01 0.2736 0.09  0.012 0.01 0.3504 0.07  0.010 0.01 0.4212 0.04 
 S2 F+M  0.021 0.01 0.0335 0.23  0.010 0.01 0.3066 0.05  -0.005 0.01 0.6191 0.01  0.004 0.01 0.7268 0.01  0.022 0.01 0.0338 0.23 
 S2 F  0.016 0.01 0.1876 0.16  -0.002 0.01 0.8718 0.00  -0.008 0.01 0.5221 0.04  0.014 0.01 0.2831 0.10  0.031 0.01 0.0152 0.51 
 S2 M  0.016 0.01 0.1876 0.13  -0.002 0.01 0.8718 0.00  -0.008 0.01 0.5221 0.03  0.014 0.01 0.2831 0.09  0.031 0.01 0.0152 0.40 
 S3 F+M  0.037 0.01 0.0002 0.71  -0.004 0.01 0.6847 0.01  -0.009 0.01 0.3587 0.04  -0.002 0.01 0.8142 0.00  0.020 0.01 0.0463 0.20 
 S3 F  0.037 0.01 0.0027 0.78  0.005 0.01 0.6807 0.01  -0.015 0.01 0.2620 0.11  -0.011 0.01 0.3996 0.06  0.031 0.01 0.0160 0.51 
 S3 M  0.037 0.01 0.0027 0.63  0.005 0.01 0.6807 0.01  -0.015 0.01 0.2620 0.09  -0.011 0.01 0.3996 0.05  0.031 0.01 0.0160 0.45 
 S4 F+M  0.048 0.01 <.0001 1.12  -0.017 0.01 0.1081 0.13  -0.010 0.01 0.3543 0.04  0.005 0.01 0.6327 0.01  0.043 0.01 <.0001 0.90 
 S4 F  0.054 0.01 <.0001 1.57  -0.009 0.01 0.5010 0.04  -0.000 0.01 0.9890 0.00  -0.006 0.01 0.6467 0.02  0.048 0.01 0.0002 1.22 
 S4 M  0.054 0.01 <.0001 1.20  -0.009 0.01 0.5010 0.03  -0.000 0.01 0.9890 0.00  -0.006 0.01 0.6467 0.02  0.048 0.01 0.0002 1.08 
 S5 F+M  0.054 0.01 <.0001 1.40  -0.026 0.01 0.0144 0.31  0.001 0.01 0.8941 0.00  -0.002 0.01 0.8648 0.00  0.043 0.01 <.0001 0.87 
 S5 F  0.057 0.01 <.0001 1.76  -0.017 0.01 0.1807 0.16  -0.003 0.01 0.8406 0.00  -0.020 0.01 0.1615 0.18  0.049 0.01 0.0001 1.27 
 S5 M  0.057 0.01 <.0001 1.41  -0.017 0.01 0.1807 0.11  -0.003 0.01 0.8406 0.00  -0.020 0.01 0.1615 0.17  0.049 0.01 0.0001 1.06 
 S6 F+M  0.059 0.01 <.0001 1.66  -0.026 0.01 0.0150 0.31  0.003 0.01 0.7348 0.01  -0.002 0.01 0.8699 0.00  0.042 0.01 <.0001 0.90 
 S6 F  0.064 0.01 <.0001 2.21  -0.021 0.01 0.0958 0.25  -0.001 0.01 0.9278 0.00  -0.015 0.01 0.2904 0.10  0.050 0.01 <.0001 1.37 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S6 M  0.064 0.01 <.0001 1.80  -0.021 0.01 0.0958 0.16  -0.001 0.01 0.9278 0.00  -0.015 0.01 0.2904 0.09  0.050 0.01 <.0001 1.13 
 S7 F+M  0.052 0.01 <.0001 1.34  -0.026 0.01 0.0148 0.31  0.012 0.01 0.2555 0.07  -0.005 0.01 0.6465 0.01  0.038 0.01 0.0001 0.74 
 S7 F  0.062 0.01 <.0001 2.08  -0.032 0.01 0.0144 0.54  0.008 0.01 0.5302 0.04  -0.017 0.01 0.2355 0.13  0.049 0.01 <.0001 1.36 
 S7 M  0.062 0.01 <.0001 1.65  -0.032 0.01 0.0144 0.37  0.008 0.01 0.5302 0.03  -0.017 0.01 0.2355 0.12  0.049 0.01 <.0001 1.12 
 S8 F+M  0.052 0.01 <.0001 1.32  -0.028 0.01 0.0093 0.36  0.011 0.01 0.2747 0.06  -0.007 0.01 0.5573 0.02  0.039 0.01 <.0001 0.76 
 S8 F  0.062 0.01 <.0001 2.08  -0.034 0.01 0.0082 0.63  0.007 0.01 0.5747 0.03  -0.018 0.01 0.2145 0.15  0.049 0.01 <.0001 1.37 
 S8 M  0.062 0.01 <.0001 1.65  -0.034 0.01 0.0082 0.43  0.007 0.01 0.5747 0.02  -0.018 0.01 0.2145 0.13  0.049 0.01 <.0001 1.09 
 
Ever used 
prescription 
pain killers 
S1 F+M  0.018 0.01 0.0317 0.23  -0.002 0.01 0.8297 0.00  0.012 0.01 0.1741 0.09  -0.002 0.01 0.7750 0.00  -0.011 0.01 0.1953 0.08 
 S1 F  0.019 0.01 0.0812 0.26  -0.009 0.01 0.4276 0.05  0.010 0.01 0.4029 0.06  -0.003 0.01 0.8280 0.00  -0.022 0.01 0.0496 0.33 
 S1 M  0.019 0.01 0.0812 0.25  -0.009 0.01 0.4276 0.06  0.010 0.01 0.4029 0.06  -0.003 0.01 0.8280 0.00  -0.022 0.01 0.0496 0.30 
 S2 F+M  0.022 0.01 0.0085 0.34  0.003 0.01 0.7482 0.01  0.014 0.01 0.0991 0.13  0.001 0.01 0.9481 0.00  -0.001 0.01 0.9172 0.00 
 S2 F  0.022 0.01 0.0459 0.34  -0.004 0.01 0.7238 0.01  0.011 0.01 0.3477 0.07  0.000 0.01 0.9993 0.00  -0.015 0.01 0.1784 0.15 
 S2 M  0.022 0.01 0.0459 0.34  -0.004 0.01 0.7238 0.01  0.011 0.01 0.3477 0.08  0.000 0.01 0.9993 0.00  -0.015 0.01 0.1784 0.15 
 S3 F+M  0.021 0.01 0.0118 0.31  -0.003 0.01 0.7364 0.01  0.017 0.01 0.0467 0.20  0.026 0.01 0.0030 0.44  -0.018 0.01 0.0364 0.22 
 S3 F  0.034 0.01 0.0021 0.79  -0.004 0.01 0.6912 0.01  0.029 0.01 0.0131 0.52  0.029 0.01 0.0105 0.57  -0.029 0.01 0.0114 0.54 
 S3 M  0.034 0.01 0.0021 0.80  -0.004 0.01 0.6912 0.01  0.029 0.01 0.0131 0.55  0.029 0.01 0.0105 0.56  -0.029 0.01 0.0114 0.59 
 S4 F+M  0.019 0.01 0.0321 0.23  -0.016 0.01 0.0737 0.16  0.015 0.01 0.0833 0.15  0.022 0.01 0.0156 0.29  -0.007 0.01 0.4373 0.03 
 S4 F  0.031 0.01 0.0056 0.64  -0.020 0.01 0.0757 0.27  0.024 0.01 0.0393 0.38  0.028 0.01 0.0200 0.47  -0.018 0.01 0.1151 0.21 
 S4 M  0.031 0.01 0.0056 0.61  -0.020 0.01 0.0757 0.23  0.024 0.01 0.0393 0.35  0.028 0.01 0.0200 0.49  -0.018 0.01 0.1151 0.23 
 S5 F+M  0.016 0.01 0.0627 0.17  -0.019 0.01 0.0326 0.23  0.014 0.01 0.1094 0.13  0.014 0.01 0.1285 0.12  -0.006 0.01 0.5142 0.02 
 S5 F  0.029 0.01 0.0120 0.54  -0.023 0.01 0.0411 0.35  0.023 0.01 0.0450 0.35  0.021 0.01 0.1017 0.23  -0.018 0.01 0.1277 0.20 
 S5 M  0.029 0.01 0.0120 0.54  -0.023 0.01 0.0411 0.29  0.023 0.01 0.0450 0.35  0.021 0.01 0.1017 0.27  -0.018 0.01 0.1277 0.20 
 S6 F+M  0.015 0.01 0.0909 0.14  -0.023 0.01 0.0112 0.32  0.010 0.01 0.2452 0.07  0.012 0.01 0.1954 0.09  -0.004 0.01 0.6245 0.01 
 S6 F  0.025 0.01 0.0292 0.40  -0.030 0.01 0.0075 0.61  0.017 0.01 0.1443 0.19  0.021 0.01 0.1047 0.23  -0.013 0.01 0.2671 0.10 
 S6 M  0.025 0.01 0.0292 0.41  -0.030 0.01 0.0075 0.50  0.017 0.01 0.1443 0.19  0.021 0.01 0.1047 0.26  -0.013 0.01 0.2671 0.11 
 S7 F+M  0.017 0.01 0.0560 0.18  -0.016 0.01 0.0750 0.16  0.007 0.01 0.3939 0.04  0.010 0.01 0.2924 0.06  -0.001 0.01 0.8879 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S7 F  0.023 0.01 0.0453 0.34  -0.022 0.01 0.0624 0.30  0.012 0.01 0.3136 0.09  0.018 0.01 0.1553 0.18  -0.011 0.01 0.3086 0.09 
 S7 M  0.023 0.01 0.0453 0.33  -0.022 0.01 0.0624 0.26  0.012 0.01 0.3136 0.09  0.018 0.01 0.1553 0.20  -0.011 0.01 0.3086 0.09 
 S8 F+M  0.017 0.01 0.0533 0.18  -0.015 0.01 0.1034 0.14  0.007 0.01 0.4422 0.03  0.009 0.01 0.3563 0.05  -0.001 0.01 0.9471 0.00 
 S8 F  0.023 0.01 0.0434 0.34  -0.021 0.01 0.0652 0.30  0.011 0.01 0.3232 0.08  0.017 0.01 0.1779 0.16  -0.011 0.01 0.3394 0.08 
 S8 M  0.023 0.01 0.0434 0.34  -0.021 0.01 0.0652 0.25  0.011 0.01 0.3232 0.09  0.017 0.01 0.1779 0.18  -0.011 0.01 0.3394 0.08 
 
Ever used 
prescription 
stimulants 
S1 F+M  0.009 0.01 0.2385 0.07  -0.001 0.01 0.8601 0.00  0.007 0.01 0.3772 0.04  0.005 0.01 0.4759 0.02  -0.007 0.01 0.3823 0.04 
 S1 F  0.003 0.01 0.7300 0.01  -0.005 0.01 0.5590 0.03  0.001 0.01 0.8983 0.00  -0.001 0.01 0.9135 0.00  0.003 0.01 0.7104 0.01 
 S1 M  0.003 0.01 0.7300 0.01  -0.005 0.01 0.5590 0.02  0.001 0.01 0.8983 0.00  -0.001 0.01 0.9135 0.00  0.003 0.01 0.7104 0.01 
 S2 F+M  0.010 0.01 0.1612 0.09  0.008 0.01 0.2520 0.06  0.006 0.01 0.3963 0.03  0.002 0.01 0.7466 0.01  -0.001 0.01 0.8928 0.00 
 S2 F  0.010 0.01 0.2844 0.09  0.002 0.01 0.8475 0.00  0.000 0.01 0.9804 0.00  0.004 0.01 0.6273 0.02  0.005 0.01 0.5622 0.03 
 S2 M  0.010 0.01 0.2844 0.07  0.002 0.01 0.8475 0.00  0.000 0.01 0.9804 0.00  0.004 0.01 0.6273 0.01  0.005 0.01 0.5622 0.02 
 S3 F+M  0.010 0.01 0.1651 0.09  -0.005 0.01 0.4663 0.02  0.006 0.01 0.4323 0.03  0.007 0.01 0.3908 0.04  -0.008 0.01 0.2864 0.05 
 S3 F  0.013 0.01 0.1606 0.16  -0.000 0.01 0.9731 0.00  0.009 0.01 0.3452 0.07  0.010 0.01 0.2758 0.10  -0.007 0.01 0.4675 0.04 
 S3 M  0.013 0.01 0.1606 0.12  -0.000 0.01 0.9731 0.00  0.009 0.01 0.3452 0.06  0.010 0.01 0.2758 0.07  -0.007 0.01 0.4675 0.03 
 S4 F+M  0.014 0.01 0.0616 0.17  -0.011 0.01 0.1420 0.10  -0.000 0.01 0.9533 0.00  -0.002 0.01 0.8417 0.00  0.000 0.01 0.9609 0.00 
 S4 F  0.019 0.01 0.0337 0.37  -0.015 0.01 0.1056 0.22  0.006 0.01 0.5012 0.04  -0.004 0.01 0.7109 0.01  -0.004 0.01 0.6862 0.01 
 S4 M  0.019 0.01 0.0337 0.25  -0.015 0.01 0.1056 0.13  0.006 0.01 0.5012 0.03  -0.004 0.01 0.7109 0.01  -0.004 0.01 0.6862 0.01 
 S5 F+M  0.018 0.01 0.0180 0.27  -0.016 0.01 0.0424 0.20  0.007 0.01 0.3696 0.04  -0.006 0.01 0.4448 0.03  0.007 0.01 0.3561 0.04 
 S5 F  0.018 0.01 0.0499 0.32  -0.015 0.01 0.1048 0.22  0.006 0.01 0.5270 0.03  -0.016 0.01 0.1106 0.21  -0.003 0.01 0.7775 0.01 
 S5 M  0.018 0.01 0.0499 0.23  -0.015 0.01 0.1048 0.13  0.006 0.01 0.5270 0.02  -0.016 0.01 0.1106 0.18  -0.003 0.01 0.7775 0.00 
 S6 F+M  0.015 0.01 0.0404 0.20  -0.016 0.01 0.0360 0.21  0.006 0.01 0.4135 0.03  -0.003 0.01 0.7152 0.01  0.009 0.01 0.2404 0.07 
 S6 F  0.016 0.01 0.0868 0.24  -0.018 0.01 0.0485 0.32  0.001 0.01 0.9383 0.00  -0.012 0.01 0.2371 0.12  0.002 0.01 0.8193 0.00 
 S6 M  0.016 0.01 0.0868 0.18  -0.018 0.01 0.0485 0.19  0.001 0.01 0.9383 0.00  -0.012 0.01 0.2371 0.10  0.002 0.01 0.8193 0.00 
 S7 F+M  0.014 0.01 0.0715 0.15  -0.013 0.01 0.1015 0.13  0.005 0.01 0.4977 0.02  -0.006 0.01 0.4535 0.03  0.012 0.01 0.0904 0.14 
 S7 F  0.012 0.01 0.2032 0.13  -0.015 0.01 0.1000 0.23  -0.003 0.01 0.7130 0.01  -0.014 0.01 0.1797 0.16  0.005 0.01 0.6051 0.02 
 S7 M  0.012 0.01 0.2032 0.09  -0.015 0.01 0.1000 0.14  -0.003 0.01 0.7130 0.01  -0.014 0.01 0.1797 0.12  0.005 0.01 0.6051 0.02 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S8 F+M  0.014 0.01 0.0737 0.15  -0.012 0.01 0.1229 0.12  0.006 0.01 0.4375 0.03  -0.006 0.01 0.4687 0.03  0.013 0.01 0.0897 0.14 
 S8 F  0.012 0.01 0.1936 0.14  -0.015 0.01 0.1039 0.22  -0.003 0.01 0.7639 0.01  -0.014 0.01 0.1788 0.16  0.004 0.01 0.6317 0.02 
 S8 M  0.012 0.01 0.1936 0.10  -0.015 0.01 0.1039 0.14  -0.003 0.01 0.7639 0.01  -0.014 0.01 0.1788 0.12  0.004 0.01 0.6317 0.01 
 
Ever used 
cannabis 
S1 F+M  0.015 0.01 0.2084 0.09  0.001 0.01 0.9153 0.00  -0.002 0.01 0.8994 0.00  -0.007 0.01 0.5563 0.02  -0.010 0.01 0.4332 0.04 
 S1 F  0.018 0.02 0.2394 0.00  -0.005 0.02 0.7595 0.00  -0.004 0.02 0.8222 0.00  -0.014 0.02 0.3812 0.00  -0.006 0.02 0.6804 0.00 
 S1 M  0.012 0.02 0.5124 0.00  0.008 0.02 0.6384 0.00  0.003 0.02 0.8788 0.00  0.003 0.02 0.8566 0.00  -0.018 0.02 0.3424 0.00 
 S2 F+M  0.030 0.01 0.0098 0.39  0.012 0.01 0.3147 0.06  0.000 0.01 0.9673 0.00  -0.006 0.01 0.6447 0.01  -0.001 0.01 0.9203 0.00 
 S2 F  0.037 0.02 0.0142 0.00  -0.006 0.02 0.7111 0.00  -0.003 0.02 0.8638 0.00  -0.004 0.02 0.7931 0.00  0.002 0.02 0.8888 0.00 
 S2 M  0.025 0.02 0.1672 0.00  0.031 0.02 0.0927 0.00  0.001 0.02 0.9412 0.00  -0.005 0.02 0.7850 0.00  -0.008 0.02 0.6874 0.00 
 S3 F+M  0.048 0.01 <.0001 0.97  -0.002 0.01 0.8350 0.00  -0.005 0.01 0.6820 0.01  -0.002 0.01 0.8746 0.00  0.003 0.01 0.8040 0.00 
 S3 F  0.056 0.02 0.0002 0.00  -0.014 0.02 0.3567 0.00  -0.016 0.02 0.3101 0.00  -0.007 0.02 0.6380 0.00  0.008 0.02 0.5977 0.00 
 S3 M  0.038 0.02 0.0356 0.00  0.014 0.02 0.4324 0.00  0.004 0.02 0.8190 0.00  0.020 0.02 0.2935 0.00  -0.002 0.02 0.9273 0.00 
 S4 F+M  0.045 0.01 0.0002 0.78  -0.004 0.01 0.7432 0.01  -0.011 0.01 0.3574 0.05  0.005 0.01 0.6925 0.01  0.029 0.01 0.0149 0.35 
 S4 F  0.047 0.02 0.0025 0.00  -0.008 0.02 0.6172 0.00  -0.013 0.02 0.4029 0.00  0.006 0.02 0.7190 0.00  0.026 0.02 0.1155 0.00 
 S4 M  0.043 0.02 0.0226 0.00  0.009 0.02 0.6311 0.00  -0.015 0.02 0.4295 0.00  0.007 0.02 0.7346 0.00  0.035 0.02 0.0526 0.00 
 S5 F+M  0.046 0.01 0.0001 0.86  -0.007 0.01 0.5625 0.02  -0.019 0.01 0.1251 0.14  -0.004 0.01 0.7908 0.00  0.038 0.01 0.0017 0.58 
 S5 F  0.053 0.02 0.0009 0.00  -0.016 0.02 0.3140 0.00  -0.021 0.02 0.1870 0.00  -0.010 0.02 0.5687 0.00  0.030 0.02 0.0625 0.00 
 S5 M  0.039 0.02 0.0355 0.00  0.009 0.02 0.6440 0.00  -0.024 0.02 0.1905 0.00  0.002 0.02 0.9183 0.00  0.048 0.02 0.0090 0.00 
 S6 F+M  0.044 0.01 0.0003 0.77  -0.001 0.01 0.9246 0.00  -0.017 0.01 0.1676 0.11  -0.005 0.01 0.6890 0.01  0.034 0.01 0.0052 0.46 
 S6 F  0.050 0.02 0.0016 0.00  -0.007 0.02 0.6498 0.00  -0.020 0.02 0.2025 0.00  -0.013 0.02 0.4774 0.00  0.028 0.02 0.0798 0.00 
 S6 M  0.037 0.02 0.0483 0.00  0.010 0.02 0.6128 0.00  -0.024 0.02 0.2053 0.00  -0.001 0.02 0.9529 0.00  0.041 0.02 0.0262 0.00 
 S7 F+M  0.047 0.01 0.0001 0.88  0.012 0.01 0.3445 0.05  -0.023 0.01 0.0607 0.21  -0.003 0.01 0.8235 0.00  0.033 0.01 0.0046 0.46 
 S7 F  0.049 0.02 0.0016 0.00  0.006 0.02 0.7128 0.00  -0.022 0.02 0.1782 0.00  -0.011 0.02 0.5465 0.00  0.031 0.02 0.0484 0.00 
 S7 M  0.046 0.02 0.0152 0.00  0.018 0.02 0.3886 0.00  -0.035 0.02 0.0596 0.00  0.003 0.02 0.8950 0.00  0.034 0.02 0.0541 0.00 
 S8 F+M  0.046 0.01 0.0001 0.85  0.011 0.01 0.4009 0.04  -0.023 0.01 0.0585 0.21  -0.006 0.01 0.6751 0.01  0.033 0.01 0.0057 0.44 
 S8 F  0.050 0.02 0.0015 0.00  0.004 0.02 0.7940 0.00  -0.020 0.02 0.2046 0.00  -0.014 0.02 0.4480 0.00  0.030 0.02 0.0525 0.00 
 S8 M  0.045 0.02 0.0181 0.00  0.017 0.02 0.4083 0.00  -0.037 0.02 0.0452 0.00  -0.000 0.02 0.9962 0.00  0.034 0.02 0.0561 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 
Age at onset 
of cannabis 
initiation 
S1 F+M  0.038 0.13 0.7634 0.02  0.010 0.12 0.9363 0.00  -0.174 0.12 0.1640 0.29  0.055 0.12 0.6443 0.03  -0.044 0.12 0.7152 0.02 
 S1 F  0.006 0.21 0.9759 0.00  0.052 0.21 0.8059 0.00  -0.102 0.21 0.6214 0.00  0.351 0.21 0.0963 0.00  0.203 0.20 0.3224 0.00 
 S1 M  0.094 0.16 0.5555 0.00  -0.018 0.15 0.9047 0.00  -0.209 0.16 0.1827 0.00  -0.088 0.15 0.5454 0.00  -0.204 0.15 0.1741 0.00 
 S2 F+M  -0.190 0.13 0.1398 0.38  0.244 0.12 0.0509 0.59  -0.150 0.12 0.2250 0.22  0.040 0.13 0.7482 0.02  0.032 0.13 0.7965 0.01 
 S2 F  -0.169 0.21 0.4245 0.00  0.338 0.20 0.0937 0.00  -0.095 0.20 0.6434 0.00  0.331 0.22 0.1266 0.00  0.248 0.21 0.2413 0.00 
 S2 M  -0.157 0.17 0.3420 0.00  0.142 0.16 0.3818 0.00  -0.175 0.15 0.2586 0.00  -0.119 0.15 0.4380 0.00  -0.104 0.16 0.5050 0.00 
 S3 F+M  -0.126 0.13 0.3354 0.16  -0.034 0.13 0.7847 0.01  -0.264 0.12 0.0318 0.68  -0.083 0.13 0.5210 0.07  0.170 0.12 0.1567 0.29 
 S3 F  -0.029 0.21 0.8899 0.00  0.125 0.21 0.5470 0.00  -0.255 0.20 0.1972 0.00  0.151 0.22 0.4913 0.00  0.270 0.20 0.1844 0.00 
 S3 M  -0.102 0.17 0.5463 0.00  -0.221 0.16 0.1653 0.00  -0.289 0.16 0.0649 0.00  -0.208 0.16 0.1996 0.00  0.105 0.15 0.4760 0.00 
 S4 F+M  -0.161 0.14 0.2525 0.25  0.011 0.13 0.9366 0.00  -0.254 0.13 0.0468 0.64  -0.043 0.13 0.7379 0.02  0.129 0.12 0.2985 0.17 
 S4 F  -0.032 0.22 0.8855 0.00  -0.017 0.22 0.9398 0.00  -0.325 0.20 0.1117 0.00  0.015 0.21 0.9436 0.00  0.245 0.21 0.2477 0.00 
 S4 M  -0.221 0.18 0.2259 0.00  -0.004 0.17 0.9828 0.00  -0.177 0.17 0.2896 0.00  -0.059 0.16 0.7168 0.00  0.059 0.15 0.6976 0.00 
 S5 F+M  -0.217 0.13 0.1079 0.46  0.064 0.14 0.6457 0.04  -0.100 0.13 0.4354 0.10  -0.053 0.14 0.6954 0.02  -0.038 0.12 0.7590 0.01 
 S5 F  -0.217 0.22 0.3274 0.00  -0.039 0.22 0.8632 0.00  -0.109 0.21 0.5996 0.00  0.090 0.23 0.6947 0.00  0.147 0.21 0.4823 0.00 
 S5 M  -0.208 0.17 0.2269 0.00  0.103 0.18 0.5640 0.00  -0.118 0.16 0.4679 0.00  -0.107 0.17 0.5270 0.00  -0.089 0.16 0.5678 0.00 
 S6 F+M  -0.189 0.14 0.1632 0.35  0.115 0.14 0.4190 0.12  -0.092 0.13 0.4665 0.08  -0.147 0.14 0.2945 0.18  0.028 0.12 0.8216 0.01 
 S6 F  -0.200 0.22 0.3582 0.00  0.072 0.23 0.7513 0.00  -0.040 0.20 0.8447 0.00  -0.006 0.23 0.9794 0.00  0.209 0.21 0.3159 0.00 
 S6 M  -0.168 0.18 0.3387 0.00  0.147 0.19 0.4295 0.00  -0.161 0.16 0.3167 0.00  -0.197 0.18 0.2633 0.00  -0.035 0.15 0.8189 0.00 
 S7 F+M  -0.105 0.14 0.4407 0.11  -0.004 0.15 0.9766 0.00  -0.107 0.13 0.4003 0.11  -0.144 0.14 0.3094 0.18  0.021 0.12 0.8621 0.00 
 S7 F  -0.069 0.22 0.7523 0.00  -0.152 0.23 0.5180 0.00  -0.068 0.21 0.7421 0.00  0.118 0.24 0.6215 0.00  0.180 0.20 0.3606 0.00 
 S7 M  -0.095 0.18 0.5895 0.00  0.116 0.19 0.5348 0.00  -0.170 0.16 0.2946 0.00  -0.274 0.18 0.1213 0.00  -0.034 0.15 0.8260 0.00 
 S8 F+M  -0.108 0.14 0.4308 0.11  0.027 0.15 0.8509 0.01  -0.104 0.13 0.4078 0.11  -0.128 0.14 0.3715 0.14  0.032 0.12 0.7922 0.01 
 S8 F  -0.060 0.22 0.7858 0.00  -0.109 0.24 0.6470 0.00  -0.084 0.21 0.6853 0.00  0.140 0.24 0.5605 0.00  0.172 0.20 0.3838 0.00 
 S8 M  -0.109 0.18 0.5399 0.00  0.137 0.19 0.4616 0.00  -0.150 0.16 0.3505 0.00  -0.263 0.18 0.1397 0.00  -0.008 0.15 0.9589 0.00 
 
Alcohol abuse S1 F+M  0.006 0.01 0.5574 0.02  -0.004 0.01 0.6884 0.01  -0.011 0.01 0.2799 0.05  -0.008 0.01 0.4482 0.03  0.003 0.01 0.8073 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S1 F  0.005 0.01 0.6644 0.00  0.004 0.01 0.7467 0.00  -0.010 0.01 0.4275 0.00  -0.005 0.01 0.7074 0.00  0.006 0.01 0.6486 0.00 
 S1 M  0.012 0.02 0.4575 0.00  -0.016 0.02 0.3177 0.00  -0.014 0.02 0.3869 0.00  -0.015 0.02 0.3359 0.00  -0.000 0.02 0.9839 0.00 
 S2 F+M  0.022 0.01 0.0302 0.22  0.010 0.01 0.3164 0.05  -0.013 0.01 0.2206 0.07  -0.011 0.01 0.2905 0.05  0.006 0.01 0.5553 0.02 
 S2 F  0.021 0.01 0.0882 0.00  0.008 0.01 0.5282 0.00  -0.013 0.01 0.3233 0.00  -0.006 0.01 0.6578 0.00  0.002 0.01 0.8586 0.00 
 S2 M  0.026 0.02 0.0999 0.00  0.008 0.02 0.6499 0.00  -0.016 0.02 0.3248 0.00  -0.022 0.02 0.1740 0.00  0.016 0.02 0.3328 0.00 
 S3 F+M  0.030 0.01 0.0034 0.41  -0.010 0.01 0.3060 0.05  -0.012 0.01 0.2658 0.06  -0.015 0.01 0.1551 0.10  0.005 0.01 0.6528 0.01 
 S3 F  0.025 0.01 0.0440 0.00  -0.001 0.01 0.9457 0.00  -0.003 0.01 0.7971 0.00  -0.020 0.01 0.1323 0.00  0.013 0.01 0.3238 0.00 
 S3 M  0.040 0.02 0.0141 0.00  -0.021 0.02 0.2060 0.00  -0.027 0.02 0.1009 0.00  -0.008 0.02 0.6370 0.00  -0.002 0.02 0.8834 0.00 
 S4 F+M  0.026 0.01 0.0128 0.29  -0.014 0.01 0.1904 0.08  -0.000 0.01 0.9696 0.00  -0.009 0.01 0.3987 0.03  0.015 0.01 0.1326 0.11 
 S4 F  0.029 0.01 0.0256 0.00  -0.011 0.01 0.3840 0.00  0.012 0.01 0.3455 0.00  -0.028 0.01 0.0405 0.00  0.016 0.01 0.2180 0.00 
 S4 M  0.024 0.02 0.1546 0.00  -0.014 0.02 0.4434 0.00  -0.026 0.02 0.1172 0.00  0.014 0.02 0.4166 0.00  0.015 0.02 0.3621 0.00 
 S5 F+M  0.029 0.01 0.0056 0.36  -0.011 0.01 0.3185 0.05  -0.010 0.01 0.3373 0.04  -0.021 0.01 0.0641 0.17  0.015 0.01 0.1397 0.10 
 S5 F  0.031 0.01 0.0166 0.00  -0.014 0.01 0.2638 0.00  -0.004 0.01 0.7854 0.00  -0.042 0.01 0.0038 0.00  0.015 0.01 0.2533 0.00 
 S5 M  0.027 0.02 0.1006 0.00  -0.001 0.02 0.9449 0.00  -0.028 0.02 0.0974 0.00  0.001 0.02 0.9724 0.00  0.015 0.02 0.3579 0.00 
 S6 F+M  0.028 0.01 0.0063 0.35  -0.008 0.01 0.4420 0.03  -0.009 0.01 0.3938 0.03  -0.018 0.01 0.1221 0.12  0.014 0.01 0.1656 0.09 
 S6 F  0.030 0.01 0.0202 0.00  -0.020 0.01 0.1283 0.00  -0.003 0.01 0.7949 0.00  -0.036 0.01 0.0124 0.00  0.016 0.01 0.2124 0.00 
 S6 M  0.027 0.02 0.1058 0.00  0.013 0.02 0.4806 0.00  -0.028 0.02 0.0950 0.00  0.001 0.02 0.9705 0.00  0.010 0.02 0.5488 0.00 
 S7 F+M  0.028 0.01 0.0060 0.36  -0.002 0.01 0.8447 0.00  -0.012 0.01 0.2651 0.06  -0.021 0.01 0.0685 0.17  0.012 0.01 0.2486 0.06 
 S7 F  0.037 0.01 0.0037 0.00  -0.012 0.01 0.3652 0.00  -0.004 0.01 0.7814 0.00  -0.040 0.01 0.0060 0.00  0.016 0.01 0.2073 0.00 
 S7 M  0.018 0.02 0.2868 0.00  0.014 0.02 0.4457 0.00  -0.032 0.02 0.0531 0.00  -0.001 0.02 0.9648 0.00  0.004 0.02 0.8064 0.00 
 S8 F+M  0.028 0.01 0.0066 0.35  -0.004 0.01 0.7227 0.01  -0.011 0.01 0.3003 0.05  -0.021 0.01 0.0706 0.16  0.013 0.01 0.1932 0.08 
 S8 F  0.036 0.01 0.0055 0.00  -0.015 0.01 0.2435 0.00  -0.003 0.01 0.8082 0.00  -0.038 0.01 0.0081 0.00  0.019 0.01 0.1334 0.00 
 S8 M  0.019 0.02 0.2564 0.00  0.015 0.02 0.4118 0.00  -0.031 0.02 0.0642 0.00  -0.002 0.02 0.8939 0.00  0.003 0.02 0.8527 0.00 
 
Alcohol 
dependence 
S1 F+M  0.003 0.01 0.7635 0.00  0.003 0.01 0.7776 0.00  -0.012 0.01 0.2320 0.07  0.004 0.01 0.6418 0.01  0.016 0.01 0.0980 0.13 
 S1 F  0.011 0.01 0.3337 0.00  0.012 0.01 0.3164 0.00  -0.009 0.01 0.4433 0.00  0.011 0.01 0.3774 0.00  0.024 0.01 0.0414 0.00 
 S1 M  -0.005 0.02 0.7462 0.00  -0.010 0.02 0.5136 0.00  -0.016 0.02 0.3062 0.00  -0.007 0.02 0.6524 0.00  0.004 0.02 0.7892 0.00 
 S2 F+M  0.006 0.01 0.5385 0.02  0.003 0.01 0.7199 0.01  -0.010 0.01 0.2974 0.05  -0.011 0.01 0.2581 0.06  0.019 0.01 0.0576 0.17 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S2 F  0.024 0.01 0.0366 0.00  0.003 0.01 0.7763 0.00  -0.012 0.01 0.3338 0.00  0.002 0.01 0.8871 0.00  0.021 0.01 0.0762 0.00 
 S2 M  -0.015 0.02 0.3340 0.00  0.003 0.02 0.8747 0.00  -0.012 0.02 0.4631 0.00  -0.033 0.02 0.0394 0.00  0.017 0.02 0.3134 0.00 
 S3 F+M  0.019 0.01 0.0465 0.19  0.000 0.01 0.9760 0.00  -0.011 0.01 0.2582 0.06  -0.003 0.01 0.7975 0.00  0.011 0.01 0.2456 0.06 
 S3 F  0.024 0.01 0.0394 0.00  -0.006 0.01 0.6404 0.00  -0.008 0.01 0.5171 0.00  -0.001 0.01 0.9338 0.00  0.013 0.01 0.3003 0.00 
 S3 M  0.017 0.02 0.2962 0.00  0.004 0.02 0.7863 0.00  -0.021 0.02 0.2001 0.00  -0.006 0.02 0.7373 0.00  0.012 0.02 0.4335 0.00 
 S4 F+M  0.019 0.01 0.0577 0.17  -0.012 0.01 0.2159 0.07  -0.006 0.01 0.5658 0.02  -0.009 0.01 0.4001 0.03  0.010 0.01 0.2868 0.05 
 S4 F  0.026 0.01 0.0263 0.00  -0.013 0.01 0.2667 0.00  0.002 0.01 0.8606 0.00  -0.019 0.01 0.1407 0.00  0.007 0.01 0.5623 0.00 
 S4 M  0.010 0.02 0.5456 0.00  -0.013 0.02 0.4562 0.00  -0.023 0.02 0.1609 0.00  0.002 0.02 0.9002 0.00  0.017 0.02 0.2748 0.00 
 S5 F+M  0.018 0.01 0.0684 0.16  -0.017 0.01 0.0982 0.13  -0.010 0.01 0.2919 0.05  -0.018 0.01 0.0881 0.14  0.012 0.01 0.2350 0.07 
 S5 F  0.020 0.01 0.1026 0.00  -0.022 0.01 0.0658 0.00  -0.017 0.01 0.1577 0.00  -0.034 0.01 0.0109 0.00  0.003 0.01 0.7791 0.00 
 S5 M  0.019 0.02 0.2325 0.00  -0.010 0.02 0.5735 0.00  -0.004 0.02 0.7839 0.00  -0.004 0.02 0.8146 0.00  0.026 0.02 0.1061 0.00 
 S6 F+M  0.020 0.01 0.0447 0.19  -0.015 0.01 0.1523 0.10  -0.008 0.01 0.4174 0.03  -0.014 0.01 0.1934 0.08  0.011 0.01 0.2690 0.06 
 S6 F  0.023 0.01 0.0515 0.00  -0.023 0.01 0.0530 0.00  -0.015 0.01 0.2002 0.00  -0.031 0.01 0.0208 0.00  0.002 0.01 0.8453 0.00 
 S6 M  0.018 0.02 0.2830 0.00  -0.004 0.02 0.8341 0.00  -0.003 0.02 0.8442 0.00  0.002 0.02 0.9009 0.00  0.025 0.02 0.1159 0.00 
 S7 F+M  0.012 0.01 0.2336 0.07  -0.007 0.01 0.4787 0.02  -0.010 0.01 0.3058 0.05  -0.016 0.01 0.1377 0.11  0.008 0.01 0.3776 0.04 
 S7 F  0.016 0.01 0.1886 0.00  -0.016 0.01 0.2000 0.00  -0.018 0.01 0.1291 0.00  -0.030 0.01 0.0241 0.00  0.001 0.01 0.9351 0.00 
 S7 M  0.009 0.02 0.5639 0.00  0.003 0.02 0.8739 0.00  -0.005 0.02 0.7827 0.00  -0.004 0.02 0.8078 0.00  0.022 0.02 0.1635 0.00 
 S8 F+M  0.013 0.01 0.1995 0.08  -0.008 0.01 0.4522 0.03  -0.009 0.01 0.3854 0.04  -0.017 0.01 0.1165 0.13  0.008 0.01 0.3782 0.04 
 S8 F  0.015 0.01 0.2158 0.00  -0.016 0.01 0.1875 0.00  -0.018 0.01 0.1432 0.00  -0.032 0.01 0.0193 0.00  0.002 0.01 0.8764 0.00 
 S8 M  0.012 0.02 0.4484 0.00  0.003 0.02 0.8820 0.00  -0.002 0.02 0.9012 0.00  -0.005 0.02 0.7719 0.00  0.021 0.02 0.1842 0.00 
 
DSM5 AUD 
(4 point scale) 
S1 F+M  0.025 0.02 0.2906 0.05  0.002 0.02 0.9374 0.00  -0.030 0.02 0.2098 0.07  0.000 0.02 0.9854 0.00  0.044 0.02 0.0688 0.16 
 S1 F  0.020 0.03 0.4941 0.00  0.021 0.03 0.4813 0.00  -0.018 0.03 0.5559 0.00  0.012 0.03 0.6829 0.00  0.057 0.03 0.0547 0.00 
 S1 M  0.048 0.04 0.2136 0.00  -0.028 0.04 0.4557 0.00  -0.052 0.04 0.1742 0.00  -0.023 0.04 0.5362 0.00  0.027 0.04 0.5012 0.00 
 S2 F+M  0.043 0.02 0.0681 0.16  0.000 0.02 0.9880 0.00  -0.024 0.02 0.3111 0.05  -0.028 0.02 0.2460 0.06  0.045 0.02 0.0643 0.16 
 S2 F  0.051 0.03 0.0764 0.00  0.001 0.03 0.9753 0.00  -0.020 0.03 0.5034 0.00  0.001 0.03 0.9651 0.00  0.037 0.03 0.2095 0.00 
 S2 M  0.044 0.04 0.2474 0.00  -0.012 0.04 0.7615 0.00  -0.039 0.04 0.3087 0.00  -0.074 0.04 0.0547 0.00  0.068 0.04 0.0876 0.00 
 S3 F+M  0.069 0.02 0.0035 0.41  -0.030 0.02 0.2033 0.08  -0.017 0.02 0.4814 0.02  -0.023 0.02 0.3345 0.04  0.048 0.02 0.0480 0.19 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S3 F  0.058 0.03 0.0449 0.00  -0.013 0.03 0.6607 0.00  0.001 0.03 0.9737 0.00  -0.009 0.03 0.7576 0.00  0.049 0.03 0.1088 0.00 
 S3 M  0.100 0.04 0.0085 0.00  -0.058 0.04 0.1327 0.00  -0.051 0.04 0.1882 0.00  -0.041 0.04 0.3060 0.00  0.059 0.04 0.1231 0.00 
 S4 F+M  0.065 0.02 0.0076 0.34  -0.048 0.02 0.0537 0.18  0.008 0.02 0.7330 0.01  -0.019 0.03 0.4519 0.03  0.062 0.02 0.0094 0.32 
 S4 F  0.067 0.03 0.0237 0.00  -0.054 0.03 0.0713 0.00  0.034 0.03 0.2448 0.00  -0.054 0.03 0.0884 0.00  0.061 0.03 0.0417 0.00 
 S4 M  0.071 0.04 0.0765 0.00  -0.037 0.04 0.3764 0.00  -0.040 0.04 0.3166 0.00  0.017 0.04 0.6711 0.00  0.071 0.04 0.0585 0.00 
 S5 F+M  0.077 0.02 0.0014 0.49  -0.054 0.02 0.0316 0.22  -0.017 0.02 0.4872 0.02  -0.049 0.03 0.0644 0.17  0.056 0.02 0.0208 0.25 
 S5 F  0.067 0.03 0.0247 0.00  -0.069 0.03 0.0203 0.00  -0.016 0.03 0.5998 0.00  -0.101 0.03 0.0025 0.00  0.041 0.03 0.1755 0.00 
 S5 M  0.101 0.04 0.0097 0.00  -0.027 0.04 0.5367 0.00  -0.025 0.04 0.5274 0.00  -0.001 0.04 0.9799 0.00  0.085 0.04 0.0273 0.00 
 S6 F+M  0.085 0.02 0.0005 0.58  -0.052 0.03 0.0375 0.21  -0.009 0.02 0.7030 0.01  -0.032 0.03 0.2359 0.07  0.054 0.02 0.0226 0.25 
 S6 F  0.078 0.03 0.0092 0.00  -0.081 0.03 0.0063 0.00  -0.009 0.03 0.7621 0.00  -0.080 0.03 0.0185 0.00  0.042 0.03 0.1611 0.00 
 S6 M  0.099 0.04 0.0111 0.00  -0.008 0.04 0.8490 0.00  -0.023 0.04 0.5522 0.00  0.010 0.04 0.8160 0.00  0.078 0.04 0.0397 0.00 
 S7 F+M  0.074 0.02 0.0021 0.45  -0.036 0.03 0.1532 0.10  -0.009 0.02 0.7251 0.01  -0.042 0.03 0.1239 0.12  0.051 0.02 0.0291 0.22 
 S7 F  0.073 0.03 0.0141 0.00  -0.071 0.03 0.0192 0.00  -0.002 0.03 0.9419 0.00  -0.087 0.03 0.0102 0.00  0.037 0.03 0.2113 0.00 
 S7 M  0.086 0.04 0.0280 0.00  0.014 0.04 0.7529 0.00  -0.031 0.04 0.4330 0.00  -0.002 0.04 0.9539 0.00  0.078 0.04 0.0394 0.00 
 S8 F+M  0.076 0.02 0.0017 0.47  -0.037 0.03 0.1497 0.10  -0.004 0.02 0.8595 0.00  -0.043 0.03 0.1130 0.13  0.052 0.02 0.0268 0.23 
 S8 F  0.072 0.03 0.0158 0.00  -0.072 0.03 0.0170 0.00  -0.000 0.03 0.9951 0.00  -0.087 0.03 0.0097 0.00  0.041 0.03 0.1657 0.00 
 S8 M  0.090 0.04 0.0223 0.00  0.015 0.04 0.7264 0.00  -0.023 0.04 0.5496 0.00  -0.004 0.04 0.9161 0.00  0.075 0.04 0.0492 0.00 
 
DSM5 AUD 
(ctrl mild vs 
moderate 
severe) 
S1 F+M  0.010 0.01 0.3088 0.05  0.000 0.01 0.9762 0.00  -0.013 0.01 0.1888 0.08  0.006 0.01 0.5587 0.02  0.021 0.01 0.0303 0.22 
 S1 F  0.012 0.01 0.3026 0.00  0.005 0.01 0.6632 0.00  -0.007 0.01 0.5936 0.00  0.014 0.01 0.2626 0.00  0.028 0.01 0.0163 0.00 
 S1 M  0.010 0.02 0.5160 0.00  -0.008 0.02 0.6130 0.00  -0.022 0.02 0.1628 0.00  -0.008 0.02 0.6062 0.00  0.011 0.02 0.5058 0.00 
 S2 F+M  0.011 0.01 0.2488 0.06  -0.002 0.01 0.8571 0.00  -0.011 0.01 0.2509 0.06  -0.006 0.01 0.5221 0.02  0.020 0.01 0.0384 0.20 
 S2 F  0.021 0.01 0.0713 0.00  -0.003 0.01 0.7716 0.00  -0.007 0.01 0.5878 0.00  0.010 0.01 0.4143 0.00  0.021 0.01 0.0765 0.00 
 S2 M  0.001 0.02 0.9665 0.00  -0.002 0.02 0.8875 0.00  -0.019 0.02 0.2184 0.00  -0.031 0.02 0.0537 0.00  0.021 0.02 0.2023 0.00 
 S3 F+M  0.021 0.01 0.0273 0.23  -0.005 0.01 0.6219 0.01  -0.008 0.01 0.4087 0.03  -0.008 0.01 0.4128 0.03  0.026 0.01 0.0089 0.32 
 S3 F  0.019 0.01 0.1040 0.00  0.000 0.01 0.9878 0.00  -0.000 0.01 0.9866 0.00  -0.001 0.01 0.9372 0.00  0.022 0.01 0.0720 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S3 M  0.030 0.02 0.0615 0.00  -0.015 0.02 0.3556 0.00  -0.022 0.02 0.1797 0.00  -0.018 0.02 0.2632 0.00  0.033 0.02 0.0398 0.00 
 S4 F+M  0.020 0.01 0.0445 0.19  -0.014 0.01 0.1481 0.10  -0.003 0.01 0.7726 0.00  -0.003 0.01 0.7567 0.00  0.025 0.01 0.0085 0.32 
 S4 F  0.022 0.01 0.0673 0.00  -0.014 0.01 0.2428 0.00  0.009 0.01 0.4303 0.00  -0.018 0.01 0.1581 0.00  0.021 0.01 0.0848 0.00 
 S4 M  0.020 0.02 0.2266 0.00  -0.017 0.02 0.3152 0.00  -0.024 0.02 0.1462 0.00  0.013 0.02 0.4351 0.00  0.033 0.02 0.0327 0.00 
 S5 F+M  0.025 0.01 0.0122 0.29  -0.015 0.01 0.1501 0.10  -0.010 0.01 0.3282 0.04  -0.013 0.01 0.2256 0.07  0.024 0.01 0.0137 0.28 
 S5 F  0.019 0.01 0.1065 0.00  -0.023 0.01 0.0547 0.00  -0.010 0.01 0.3881 0.00  -0.037 0.01 0.0066 0.00  0.017 0.01 0.1532 0.00 
 S5 M  0.035 0.02 0.0290 0.00  -0.002 0.02 0.9101 0.00  -0.011 0.02 0.5098 0.00  0.011 0.02 0.5186 0.00  0.035 0.02 0.0262 0.00 
 S6 F+M  0.028 0.01 0.0051 0.37  -0.015 0.01 0.1369 0.10  -0.008 0.01 0.3878 0.04  -0.005 0.01 0.6498 0.01  0.025 0.01 0.0091 0.31 
 S6 F  0.024 0.01 0.0458 0.00  -0.028 0.01 0.0208 0.00  -0.007 0.01 0.5476 0.00  -0.029 0.01 0.0340 0.00  0.018 0.01 0.1312 0.00 
 S6 M  0.035 0.02 0.0326 0.00  0.003 0.02 0.8736 0.00  -0.014 0.02 0.3769 0.00  0.019 0.02 0.2633 0.00  0.037 0.02 0.0201 0.00 
 S7 F+M  0.023 0.01 0.0176 0.26  -0.011 0.01 0.3029 0.05  -0.003 0.01 0.7578 0.00  -0.009 0.01 0.3959 0.04  0.021 0.01 0.0244 0.23 
 S7 F  0.021 0.01 0.0772 0.00  -0.021 0.01 0.0812 0.00  -0.001 0.01 0.9082 0.00  -0.030 0.01 0.0270 0.00  0.015 0.01 0.2044 0.00 
 S7 M  0.030 0.02 0.0702 0.00  0.004 0.02 0.8242 0.00  -0.009 0.02 0.5808 0.00  0.011 0.02 0.5151 0.00  0.032 0.02 0.0405 0.00 
 S8 F+M  0.025 0.01 0.0124 0.29  -0.010 0.01 0.3166 0.05  -0.001 0.01 0.9011 0.00  -0.009 0.01 0.3890 0.04  0.022 0.01 0.0215 0.24 
 S8 F  0.021 0.01 0.0764 0.00  -0.022 0.01 0.0788 0.00  -0.001 0.01 0.9584 0.00  -0.030 0.01 0.0268 0.00  0.017 0.01 0.1572 0.00 
 S8 M  0.032 0.02 0.0501 0.00  0.005 0.02 0.7838 0.00  -0.006 0.02 0.7251 0.00  0.011 0.02 0.5171 0.00  0.031 0.02 0.0478 0.00 
 
Cannabis 
abuse 
S1 F+M  -0.002 0.01 0.7909 0.00  -0.009 0.01 0.2141 0.08  0.017 0.01 0.0152 0.29  0.003 0.01 0.6402 0.01  -0.007 0.01 0.3647 0.04 
 S1 F  -0.004 0.01 0.6531 0.00  -0.002 0.01 0.7887 0.00  0.010 0.01 0.2263 0.00  0.007 0.01 0.4086 0.00  -0.011 0.01 0.1566 0.00 
 S1 M  0.003 0.01 0.8003 0.00  -0.013 0.01 0.2848 0.00  0.025 0.01 0.0437 0.00  -0.006 0.01 0.5941 0.00  -0.003 0.01 0.7904 0.00 
 S2 F+M  0.013 0.01 0.0702 0.16  0.006 0.01 0.3640 0.04  0.018 0.01 0.0128 0.30  -0.002 0.01 0.7340 0.01  -0.000 0.01 0.9912 0.00 
 S2 F  0.015 0.01 0.0588 0.00  -0.008 0.01 0.3230 0.00  0.007 0.01 0.3974 0.00  0.011 0.01 0.1810 0.00  -0.003 0.01 0.6871 0.00 
 S2 M  0.012 0.01 0.3327 0.00  0.024 0.01 0.0613 0.00  0.030 0.01 0.0137 0.00  -0.024 0.01 0.0561 0.00  0.002 0.01 0.8915 0.00 
 S3 F+M  0.007 0.01 0.2923 0.06  0.001 0.01 0.8471 0.00  0.010 0.01 0.1449 0.11  -0.005 0.01 0.4564 0.03  0.004 0.01 0.5405 0.02 
 S3 F  0.014 0.01 0.0781 0.00  0.005 0.01 0.5224 0.00  0.000 0.01 0.9624 0.00  -0.006 0.01 0.4666 0.00  0.003 0.01 0.7140 0.00 
 S3 M  0.004 0.01 0.7199 0.00  -0.002 0.01 0.8836 0.00  0.029 0.01 0.0203 0.00  -0.005 0.01 0.7264 0.00  0.007 0.01 0.5743 0.00 
 S4 F+M  0.013 0.01 0.0685 0.17  -0.010 0.01 0.1607 0.10  0.008 0.01 0.2482 0.07  0.000 0.01 0.9696 0.00  0.010 0.01 0.1593 0.10 
 S4 F  0.017 0.01 0.0376 0.00  0.002 0.01 0.7866 0.00  -0.002 0.01 0.8209 0.00  -0.002 0.01 0.8223 0.00  0.004 0.01 0.5849 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S4 M  0.010 0.01 0.4445 0.00  -0.025 0.01 0.0696 0.00  0.024 0.01 0.0583 0.00  0.006 0.01 0.6389 0.00  0.020 0.01 0.0998 0.00 
 S5 F+M  0.010 0.01 0.1476 0.11  -0.016 0.01 0.0309 0.24  0.005 0.01 0.4586 0.03  -0.003 0.01 0.7098 0.01  0.012 0.01 0.1024 0.13 
 S5 F  0.013 0.01 0.0979 0.00  -0.004 0.01 0.6247 0.00  -0.007 0.01 0.3976 0.00  -0.005 0.01 0.6000 0.00  0.005 0.01 0.5765 0.00 
 S5 M  0.006 0.01 0.6328 0.00  -0.029 0.01 0.0367 0.00  0.021 0.01 0.0982 0.00  0.003 0.01 0.8203 0.00  0.026 0.01 0.0380 0.00 
 S6 F+M  0.012 0.01 0.0857 0.15  -0.013 0.01 0.0788 0.16  0.003 0.01 0.6435 0.01  -0.005 0.01 0.5297 0.02  0.016 0.01 0.0263 0.24 
 S6 F  0.015 0.01 0.0718 0.00  -0.002 0.01 0.8092 0.00  -0.008 0.01 0.3179 0.00  -0.006 0.01 0.4877 0.00  0.009 0.01 0.2644 0.00 
 S6 M  0.009 0.01 0.4840 0.00  -0.026 0.01 0.0657 0.00  0.019 0.01 0.1327 0.00  -0.000 0.01 0.9966 0.00  0.029 0.01 0.0188 0.00 
 S7 F+M  0.012 0.01 0.0886 0.15  -0.013 0.01 0.1002 0.14  0.001 0.01 0.9444 0.00  -0.011 0.01 0.1821 0.10  0.015 0.01 0.0296 0.23 
 S7 F  0.016 0.01 0.0437 0.00  -0.002 0.01 0.7628 0.00  -0.009 0.01 0.2964 0.00  -0.013 0.01 0.1559 0.00  0.012 0.01 0.1150 0.00 
 S7 M  0.007 0.01 0.5716 0.00  -0.025 0.01 0.0861 0.00  0.011 0.01 0.3801 0.00  -0.005 0.01 0.6971 0.00  0.021 0.01 0.0874 0.00 
 S8 F+M  0.012 0.01 0.0883 0.15  -0.013 0.01 0.0872 0.15  0.000 0.01 0.9915 0.00  -0.011 0.01 0.1720 0.10  0.015 0.01 0.0323 0.23 
 S8 F  0.016 0.01 0.0398 0.00  -0.003 0.01 0.7255 0.00  -0.008 0.01 0.3056 0.00  -0.012 0.01 0.1905 0.00  0.012 0.01 0.1217 0.00 
 S8 M  0.006 0.01 0.6257 0.00  -0.025 0.01 0.0787 0.00  0.010 0.01 0.4342 0.00  -0.007 0.01 0.5858 0.00  0.021 0.01 0.0939 0.00 
 
Age at onset 
of cannabis 
abuse 
S1 F+M  -0.407 0.21 0.0538 1.69  -0.077 0.20 0.7015 0.06  -0.066 0.22 0.7636 0.04  0.014 0.21 0.9440 0.00  0.142 0.19 0.4465 0.20 
 S1 F  -0.710 0.38 0.0646 0.00  -0.254 0.35 0.4654 0.00  0.554 0.39 0.1564 0.00  0.352 0.41 0.3941 0.00  0.169 0.32 0.5961 0.00 
 S1 M  -0.257 0.26 0.3240 0.00  0.089 0.26 0.7348 0.00  -0.417 0.27 0.1311 0.00  -0.170 0.25 0.4924 0.00  0.084 0.25 0.7350 0.00 
 S2 F+M  -0.312 0.21 0.1412 1.01  0.013 0.20 0.9452 0.00  0.021 0.21 0.9198 0.00  0.028 0.22 0.9004 0.01  0.170 0.21 0.4102 0.29 
 S2 F  -0.424 0.38 0.2683 0.00  0.325 0.32 0.3116 0.00  0.561 0.37 0.1357 0.00  0.318 0.45 0.4850 0.00  0.168 0.36 0.6457 0.00 
 S2 M  -0.273 0.27 0.3176 0.00  -0.199 0.26 0.4464 0.00  -0.272 0.27 0.3141 0.00  -0.134 0.27 0.6176 0.00  0.172 0.27 0.5225 0.00 
 S3 F+M  -0.155 0.22 0.4844 0.24  -0.044 0.21 0.8293 0.02  -0.089 0.21 0.6757 0.08  -0.038 0.22 0.8634 0.01  0.415 0.20 0.0440 1.69 
 S3 F  -0.003 0.41 0.9943 0.00  0.638 0.36 0.0784 0.00  0.547 0.38 0.1516 0.00  0.678 0.44 0.1227 0.00  0.434 0.35 0.2192 0.00 
 S3 M  -0.166 0.28 0.5555 0.00  -0.389 0.26 0.1300 0.00  -0.493 0.26 0.0635 0.00  -0.364 0.27 0.1832 0.00  0.472 0.26 0.0746 0.00 
 S4 F+M  -0.194 0.24 0.4277 0.36  0.113 0.23 0.6209 0.12  -0.007 0.22 0.9749 0.00  0.222 0.21 0.2966 0.43  0.583 0.21 0.0051 3.37 
 S4 F  -0.314 0.44 0.4731 0.00  0.648 0.40 0.1098 0.00  0.239 0.42 0.5691 0.00  0.484 0.39 0.2219 0.00  0.635 0.35 0.0711 0.00 
 S4 M  -0.139 0.32 0.6650 0.00  -0.222 0.29 0.4455 0.00  -0.240 0.27 0.3827 0.00  0.061 0.28 0.8271 0.00  0.585 0.26 0.0280 0.00 
 S5 F+M  -0.103 0.23 0.6501 0.10  0.224 0.25 0.3657 0.46  0.147 0.22 0.5063 0.21  0.247 0.22 0.2668 0.51  0.267 0.20 0.1897 0.69 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S5 F  -0.332 0.42 0.4295 0.00  0.963 0.43 0.0263 0.00  0.198 0.40 0.6237 0.00  0.768 0.40 0.0590 0.00  0.055 0.34 0.8706 0.00 
 S5 M  -0.011 0.28 0.9681 0.00  -0.223 0.31 0.4701 0.00  -0.012 0.28 0.9667 0.00  -0.066 0.29 0.8238 0.00  0.453 0.27 0.0958 0.00 
 S6 F+M  0.044 0.24 0.8533 0.02  0.179 0.24 0.4652 0.29  0.192 0.22 0.3796 0.36  0.308 0.23 0.1871 0.78  0.249 0.20 0.2253 0.62 
 S6 F  -0.405 0.42 0.3389 0.00  0.715 0.39 0.0683 0.00  0.260 0.39 0.5027 0.00  0.806 0.41 0.0529 0.00  0.039 0.33 0.9057 0.00 
 S6 M  0.205 0.30 0.4960 0.00  -0.238 0.32 0.4594 0.00  0.058 0.28 0.8364 0.00  -0.025 0.32 0.9357 0.00  0.455 0.27 0.0968 0.00 
 S7 F+M  0.153 0.24 0.5259 0.23  0.058 0.24 0.8103 0.03  0.124 0.22 0.5718 0.15  0.277 0.24 0.2480 0.64  0.136 0.20 0.4933 0.19 
 S7 F  -0.191 0.44 0.6626 0.00  0.440 0.41 0.2813 0.00  0.100 0.40 0.8010 0.00  0.777 0.40 0.0532 0.00  -0.132 0.33 0.6873 0.00 
 S7 M  0.274 0.30 0.3624 0.00  -0.139 0.31 0.6523 0.00  0.012 0.28 0.9648 0.00  -0.148 0.33 0.6521 0.00  0.404 0.26 0.1263 0.00 
 S8 F+M  0.153 0.24 0.5262 0.23  0.087 0.24 0.7196 0.07  0.119 0.22 0.5872 0.14  0.309 0.24 0.1989 0.79  0.127 0.20 0.5274 0.16 
 S8 F  -0.153 0.43 0.7238 0.00  0.419 0.41 0.3038 0.00  0.051 0.40 0.8979 0.00  0.843 0.40 0.0362 0.00  -0.150 0.33 0.6492 0.00 
 S8 M  0.272 0.30 0.3680 0.00  -0.095 0.30 0.7556 0.00  0.051 0.28 0.8557 0.00  -0.125 0.33 0.7039 0.00  0.408 0.27 0.1295 0.00 
 
Cannabis 
dependence 
S1 F+M  0.002 0.01 0.7197 0.01  -0.006 0.01 0.2566 0.06  0.011 0.01 0.0440 0.20  0.003 0.01 0.6180 0.01  -0.006 0.01 0.2834 0.06 
 S1 F  0.002 0.01 0.7764 0.00  -0.002 0.01 0.6764 0.00  0.007 0.01 0.2529 0.00  0.005 0.01 0.4556 0.00  -0.012 0.01 0.0471 0.00 
 S1 M  0.007 0.01 0.4511 0.00  -0.009 0.01 0.3756 0.00  0.015 0.01 0.1331 0.00  -0.000 0.01 0.9823 0.00  0.001 0.01 0.8844 0.00 
 S2 F+M  0.005 0.01 0.3880 0.04  0.008 0.01 0.1220 0.12  0.010 0.01 0.0637 0.17  -0.000 0.01 0.9524 0.00  -0.008 0.01 0.1716 0.09 
 S2 F  0.009 0.01 0.1163 0.00  -0.002 0.01 0.7556 0.00  0.002 0.01 0.6920 0.00  0.006 0.01 0.2983 0.00  -0.006 0.01 0.2816 0.00 
 S2 M  0.004 0.01 0.7014 0.00  0.020 0.01 0.0405 0.00  0.018 0.01 0.0685 0.00  -0.010 0.01 0.3207 0.00  -0.010 0.01 0.3278 0.00 
 S3 F+M  0.005 0.01 0.3533 0.04  -0.005 0.01 0.3863 0.04  0.003 0.01 0.6007 0.01  -0.004 0.01 0.4377 0.03  -0.004 0.01 0.4325 0.03 
 S3 F  0.011 0.01 0.0534 0.00  -0.003 0.01 0.6553 0.00  -0.002 0.01 0.7907 0.00  -0.005 0.01 0.3886 0.00  0.000 0.01 0.9971 0.00 
 S3 M  0.002 0.01 0.8688 0.00  -0.010 0.01 0.3287 0.00  0.010 0.01 0.3362 0.00  -0.002 0.01 0.8502 0.00  -0.008 0.01 0.4110 0.00 
 S4 F+M  0.011 0.01 0.0470 0.20  -0.012 0.01 0.0325 0.23  -0.001 0.01 0.8101 0.00  -0.001 0.01 0.8074 0.00  0.006 0.01 0.2739 0.06 
 S4 F  0.014 0.01 0.0159 0.00  -0.004 0.01 0.4907 0.00  -0.004 0.01 0.4736 0.00  -0.001 0.01 0.9288 0.00  0.005 0.01 0.4143 0.00 
 S4 M  0.012 0.01 0.2403 0.00  -0.024 0.01 0.0265 0.00  0.004 0.01 0.6643 0.00  -0.000 0.01 0.9933 0.00  0.008 0.01 0.3870 0.00 
 S5 F+M  0.013 0.01 0.0162 0.29  -0.009 0.01 0.1013 0.13  0.000 0.01 0.9924 0.00  0.001 0.01 0.9098 0.00  -0.001 0.01 0.7975 0.00 
 S5 F  0.016 0.01 0.0067 0.00  -0.005 0.01 0.3980 0.00  -0.006 0.01 0.3333 0.00  -0.001 0.01 0.8323 0.00  -0.002 0.01 0.7454 0.00 
 S5 M  0.013 0.01 0.1750 0.00  -0.017 0.01 0.1177 0.00  0.007 0.01 0.4661 0.00  0.003 0.01 0.7456 0.00  0.001 0.01 0.9568 0.00 
 S6 F+M  0.014 0.01 0.0123 0.31  -0.008 0.01 0.1784 0.09  -0.001 0.01 0.9002 0.00  0.001 0.01 0.8276 0.00  0.000 0.01 0.9821 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S6 F  0.017 0.01 0.0047 0.00  -0.003 0.01 0.6004 0.00  -0.009 0.01 0.1383 0.00  -0.003 0.01 0.6385 0.00  -0.000 0.01 0.9489 0.00 
 S6 M  0.013 0.01 0.1767 0.00  -0.016 0.01 0.1446 0.00  0.009 0.01 0.3762 0.00  0.006 0.01 0.5500 0.00  0.001 0.01 0.8869 0.00 
 S7 F+M  0.012 0.01 0.0274 0.24  -0.008 0.01 0.1599 0.10  -0.003 0.01 0.5964 0.01  -0.005 0.01 0.4342 0.03  0.001 0.01 0.8941 0.00 
 S7 F  0.017 0.01 0.0056 0.00  -0.003 0.01 0.6162 0.00  -0.011 0.01 0.0747 0.00  -0.010 0.01 0.1432 0.00  -0.001 0.01 0.9302 0.00 
 S7 M  0.011 0.01 0.2610 0.00  -0.018 0.01 0.1175 0.00  0.007 0.01 0.4614 0.00  0.002 0.01 0.8760 0.00  0.003 0.01 0.7866 0.00 
 S8 F+M  0.012 0.01 0.0319 0.23  -0.008 0.01 0.1597 0.10  -0.003 0.01 0.5792 0.02  -0.005 0.01 0.4596 0.03  0.001 0.01 0.8620 0.00 
 S8 F  0.016 0.01 0.0075 0.00  -0.004 0.01 0.5364 0.00  -0.011 0.01 0.0752 0.00  -0.010 0.01 0.1657 0.00  -0.000 0.01 0.9900 0.00 
 S8 M  0.011 0.01 0.2665 0.00  -0.016 0.01 0.1477 0.00  0.007 0.01 0.4931 0.00  0.001 0.01 0.8935 0.00  0.002 0.01 0.8256 0.00 
 
Age at onset 
of cannabis 
dependence 
S1 F+M  -0.145 0.26 0.5743 0.25  -0.205 0.25 0.4130 0.49  0.285 0.28 0.3052 0.89  -0.558 0.26 0.0325 3.63  -0.034 0.21 0.8697 0.01 
 S1 F  0.450 0.47 0.3422 0.00  -0.449 0.43 0.3073 0.00  0.754 0.45 0.1001 0.00  -1.119 0.52 0.0358 0.00  0.541 0.32 0.0954 0.00 
 S1 M  -0.293 0.31 0.3555 0.00  0.224 0.32 0.4829 0.00  0.048 0.35 0.8920 0.00  -0.445 0.30 0.1421 0.00  -0.351 0.28 0.2123 0.00 
 S2 F+M  -0.366 0.27 0.1846 1.59  0.167 0.25 0.5002 0.32  0.276 0.27 0.3046 0.83  -0.367 0.28 0.1857 1.51  0.013 0.25 0.9595 0.00 
 S2 F  0.161 0.45 0.7198 0.00  0.508 0.38 0.1837 0.00  0.650 0.42 0.1298 0.00  -0.347 0.53 0.5157 0.00  0.506 0.43 0.2500 0.00 
 S2 M  -0.609 0.37 0.1029 0.00  -0.073 0.33 0.8243 0.00  0.051 0.35 0.8839 0.00  -0.445 0.33 0.1750 0.00  -0.199 0.32 0.5369 0.00 
 S3 F+M  -0.187 0.27 0.4935 0.40  -0.149 0.26 0.5645 0.25  0.171 0.27 0.5301 0.32  -0.329 0.26 0.2153 1.19  0.239 0.25 0.3359 0.64 
 S3 F  0.153 0.46 0.7436 0.00  0.160 0.37 0.6682 0.00  0.429 0.47 0.3658 0.00  0.184 0.51 0.7183 0.00  0.215 0.43 0.6223 0.00 
 S3 M  -0.410 0.36 0.2555 0.00  -0.466 0.36 0.2007 0.00  -0.226 0.34 0.5039 0.00  -0.775 0.32 0.0167 0.00  0.268 0.32 0.4042 0.00 
 S4 F+M  -0.182 0.30 0.5431 0.36  0.005 0.28 0.9851 0.00  -0.196 0.31 0.5220 0.43  0.130 0.26 0.6125 0.17  0.343 0.27 0.2114 1.34 
 S4 F  0.322 0.50 0.5231 0.00  0.112 0.43 0.7943 0.00  -0.087 0.51 0.8662 0.00  -0.058 0.45 0.8987 0.00  0.325 0.42 0.4384 0.00 
 S4 M  -0.481 0.40 0.2371 0.00  -0.096 0.40 0.8105 0.00  -0.452 0.38 0.2355 0.00  -0.011 0.34 0.9755 0.00  0.322 0.38 0.3931 0.00 
 S5 F+M  -0.111 0.28 0.6939 0.14  0.145 0.31 0.6359 0.22  -0.223 0.30 0.4587 0.56  0.308 0.27 0.2594 0.91  0.095 0.28 0.7322 0.10 
 S5 F  -0.161 0.46 0.7296 0.00  0.347 0.45 0.4475 0.00  0.046 0.50 0.9263 0.00  0.273 0.46 0.5550 0.00  -0.108 0.42 0.7984 0.00 
 S5 M  -0.219 0.38 0.5674 0.00  -0.026 0.44 0.9534 0.00  -0.494 0.38 0.1992 0.00  0.066 0.37 0.8609 0.00  0.103 0.40 0.7996 0.00 
 S6 F+M  -0.031 0.30 0.9185 0.01  0.260 0.32 0.4194 0.71  -0.178 0.31 0.5684 0.35  0.402 0.28 0.1528 1.52  0.087 0.28 0.7568 0.09 
 S6 F  -0.298 0.47 0.5322 0.00  0.237 0.47 0.6179 0.00  0.093 0.51 0.8572 0.00  0.334 0.49 0.4964 0.00  -0.009 0.41 0.9833 0.00 
 S6 M  0.119 0.41 0.7738 0.00  0.243 0.47 0.6095 0.00  -0.470 0.41 0.2548 0.00  0.182 0.39 0.6428 0.00  -0.021 0.42 0.9605 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S7 F+M  0.332 0.29 0.2558 1.23  0.147 0.32 0.6504 0.22  -0.154 0.29 0.6003 0.26  0.344 0.29 0.2406 1.13  0.063 0.26 0.8086 0.05 
 S7 F  0.093 0.48 0.8469 0.00  0.338 0.51 0.5126 0.00  -0.193 0.49 0.6979 0.00  0.497 0.50 0.3233 0.00  -0.215 0.38 0.5732 0.00 
 S7 M  0.401 0.39 0.3115 0.00  0.132 0.45 0.7712 0.00  -0.304 0.38 0.4205 0.00  -0.052 0.40 0.8973 0.00  0.266 0.38 0.4873 0.00 
 S8 F+M  0.369 0.29 0.2095 1.51  0.157 0.32 0.6275 0.26  -0.153 0.29 0.6027 0.26  0.367 0.29 0.2091 1.28  0.069 0.26 0.7940 0.05 
 S8 F  0.169 0.49 0.7298 0.00  0.330 0.52 0.5269 0.00  -0.239 0.50 0.6373 0.00  0.577 0.50 0.2513 0.00  -0.223 0.38 0.5616 0.00 
 S8 M  0.396 0.40 0.3209 0.00  0.156 0.45 0.7297 0.00  -0.261 0.37 0.4816 0.00  -0.029 0.40 0.9428 0.00  0.287 0.38 0.4564 0.00 
 
DSM5 CUD 
(4 point scale) 
S1 F+M  -0.002 0.02 0.8849 0.00  -0.029 0.02 0.0825 0.15  0.040 0.02 0.0191 0.28  0.014 0.02 0.3917 0.04  -0.013 0.02 0.4406 0.03 
 S1 F  0.003 0.02 0.8754 0.00  -0.011 0.02 0.5286 0.00  0.017 0.02 0.3562 0.00  0.023 0.02 0.2226 0.00  -0.029 0.02 0.1166 0.00 
 S1 M  0.002 0.03 0.9581 0.00  -0.044 0.03 0.1303 0.00  0.061 0.03 0.0404 0.00  -0.003 0.03 0.9047 0.00  0.003 0.03 0.9298 0.00 
 S2 F+M  0.022 0.02 0.1768 0.09  0.021 0.02 0.2049 0.08  0.041 0.02 0.0145 0.30  -0.001 0.02 0.9707 0.00  -0.007 0.02 0.6968 0.01 
 S2 F  0.032 0.02 0.0769 0.00  -0.006 0.02 0.7399 0.00  0.008 0.02 0.6556 0.00  0.032 0.02 0.0856 0.00  -0.009 0.02 0.6042 0.00 
 S2 M  0.019 0.03 0.5121 0.00  0.049 0.03 0.1059 0.00  0.074 0.03 0.0115 0.00  -0.050 0.03 0.0914 0.00  -0.006 0.03 0.8364 0.00 
 S3 F+M  0.022 0.02 0.1932 0.09  -0.005 0.02 0.7578 0.00  0.019 0.02 0.2709 0.06  -0.010 0.02 0.5414 0.02  -0.002 0.02 0.9264 0.00 
 S3 F  0.042 0.02 0.0195 0.00  0.001 0.02 0.9466 0.00  -0.005 0.02 0.8090 0.00  -0.002 0.02 0.9106 0.00  0.005 0.02 0.8023 0.00 
 S3 M  0.008 0.03 0.7983 0.00  -0.014 0.03 0.6408 0.00  0.054 0.03 0.0730 0.00  -0.015 0.03 0.6331 0.00  -0.007 0.03 0.8227 0.00 
 S4 F+M  0.039 0.02 0.0217 0.27  -0.029 0.02 0.0936 0.14  0.011 0.02 0.5150 0.02  0.005 0.02 0.7814 0.00  0.029 0.02 0.0874 0.15 
 S4 F  0.054 0.02 0.0034 0.00  -0.007 0.02 0.6882 0.00  -0.012 0.02 0.5278 0.00  0.012 0.02 0.5436 0.00  0.015 0.02 0.4355 0.00 
 S4 M  0.027 0.03 0.3875 0.00  -0.061 0.03 0.0588 0.00  0.049 0.03 0.1129 0.00  0.005 0.03 0.8781 0.00  0.047 0.03 0.1085 0.00 
 S5 F+M  0.040 0.02 0.0179 0.29  -0.039 0.02 0.0268 0.25  0.012 0.02 0.4848 0.02  0.010 0.02 0.5995 0.01  0.019 0.02 0.2495 0.07 
 S5 F  0.056 0.02 0.0026 0.00  -0.022 0.02 0.2223 0.00  -0.021 0.02 0.2481 0.00  0.009 0.02 0.6588 0.00  0.004 0.02 0.8184 0.00 
 S5 M  0.023 0.03 0.4538 0.00  -0.067 0.03 0.0457 0.00  0.052 0.03 0.0845 0.00  0.014 0.03 0.6519 0.00  0.040 0.03 0.1735 0.00 
 S6 F+M  0.046 0.02 0.0070 0.37  -0.037 0.02 0.0353 0.23  0.009 0.02 0.5929 0.01  0.009 0.02 0.6210 0.01  0.025 0.02 0.1410 0.11 
 S6 F  0.059 0.02 0.0014 0.00  -0.022 0.02 0.2360 0.00  -0.026 0.02 0.1691 0.00  0.006 0.02 0.7769 0.00  0.012 0.02 0.5042 0.00 
 S6 M  0.031 0.03 0.3016 0.00  -0.063 0.03 0.0597 0.00  0.052 0.03 0.0874 0.00  0.017 0.03 0.6037 0.00  0.039 0.03 0.1821 0.00 
 S7 F+M  0.041 0.02 0.0158 0.30  -0.039 0.02 0.0277 0.26  0.001 0.02 0.9710 0.00  -0.009 0.02 0.6509 0.01  0.022 0.02 0.1778 0.09 
 S7 F  0.059 0.02 0.0014 0.00  -0.030 0.02 0.1154 0.00  -0.031 0.02 0.0940 0.00  -0.016 0.02 0.4515 0.00  0.013 0.02 0.4656 0.00 
 S7 M  0.022 0.03 0.4774 0.00  -0.056 0.03 0.1001 0.00  0.042 0.03 0.1687 0.00  0.004 0.03 0.8975 0.00  0.029 0.03 0.3129 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S8 F+M  0.041 0.02 0.0167 0.29  -0.039 0.02 0.0298 0.25  -0.000 0.02 0.9898 0.00  -0.008 0.02 0.6719 0.01  0.023 0.02 0.1701 0.09 
 S8 F  0.058 0.02 0.0015 0.00  -0.030 0.02 0.1070 0.00  -0.031 0.02 0.0999 0.00  -0.015 0.02 0.4791 0.00  0.014 0.02 0.4363 0.00 
 S8 M  0.021 0.03 0.5012 0.00  -0.053 0.03 0.1206 0.00  0.039 0.03 0.1967 0.00  0.003 0.03 0.9229 0.00  0.029 0.03 0.3347 0.00 
 
DSM5 CUD 
(ctrl mild vs 
moderate 
severe) 
S1 F+M  -0.002 0.01 0.7235 0.01  -0.011 0.01 0.0817 0.15  0.012 0.01 0.0634 0.17  0.004 0.01 0.5500 0.02  -0.000 0.01 0.9567 0.00 
 S1 F  -0.000 0.01 0.9469 0.00  -0.005 0.01 0.4286 0.00  0.005 0.01 0.4472 0.00  0.007 0.01 0.3063 0.00  -0.006 0.01 0.3538 0.00 
 S1 M  0.000 0.01 0.9873 0.00  -0.015 0.01 0.1729 0.00  0.018 0.01 0.1121 0.00  -0.002 0.01 0.8390 0.00  0.006 0.01 0.6146 0.00 
 S2 F+M  0.005 0.01 0.3882 0.04  0.007 0.01 0.2747 0.06  0.012 0.01 0.0488 0.19  -0.002 0.01 0.7154 0.01  -0.002 0.01 0.7514 0.01 
 S2 F  0.008 0.01 0.2259 0.00  -0.002 0.01 0.7690 0.00  0.001 0.01 0.9105 0.00  0.008 0.01 0.2049 0.00  -0.002 0.01 0.7272 0.00 
 S2 M  0.006 0.01 0.5948 0.00  0.018 0.01 0.1239 0.00  0.024 0.01 0.0310 0.00  -0.020 0.01 0.0852 0.00  -0.002 0.01 0.8642 0.00 
 S3 F+M  0.006 0.01 0.2980 0.05  -0.003 0.01 0.5895 0.01  0.004 0.01 0.5414 0.02  -0.004 0.01 0.5713 0.02  -0.001 0.01 0.8625 0.00 
 S3 F  0.012 0.01 0.0535 0.00  0.001 0.01 0.8966 0.00  -0.004 0.01 0.5319 0.00  -0.002 0.01 0.8121 0.00  0.004 0.01 0.5463 0.00 
 S3 M  0.003 0.01 0.7833 0.00  -0.008 0.01 0.4914 0.00  0.015 0.01 0.1796 0.00  -0.005 0.01 0.6441 0.00  -0.006 0.01 0.6070 0.00 
 S4 F+M  0.014 0.01 0.0293 0.24  -0.012 0.01 0.0582 0.18  0.003 0.01 0.6677 0.01  -0.000 0.01 0.9628 0.00  0.008 0.01 0.1729 0.09 
 S4 F  0.017 0.01 0.0106 0.00  -0.005 0.01 0.4381 0.00  -0.005 0.01 0.4250 0.00  0.004 0.01 0.5956 0.00  0.007 0.01 0.3065 0.00 
 S4 M  0.014 0.01 0.2414 0.00  -0.023 0.01 0.0653 0.00  0.015 0.01 0.1888 0.00  -0.003 0.01 0.7805 0.00  0.010 0.01 0.3676 0.00 
 S5 F+M  0.015 0.01 0.0139 0.31  -0.015 0.01 0.0184 0.28  0.005 0.01 0.4686 0.03  0.001 0.01 0.8444 0.00  0.003 0.01 0.6125 0.01 
 S5 F  0.019 0.01 0.0035 0.00  -0.010 0.01 0.1137 0.00  -0.008 0.01 0.2390 0.00  0.002 0.01 0.7723 0.00  0.001 0.01 0.9095 0.00 
 S5 M  0.013 0.01 0.2574 0.00  -0.026 0.01 0.0440 0.00  0.020 0.01 0.0801 0.00  0.001 0.01 0.9151 0.00  0.006 0.01 0.5810 0.00 
 S6 F+M  0.018 0.01 0.0034 0.43  -0.016 0.01 0.0175 0.29  0.005 0.01 0.4664 0.03  0.000 0.01 0.9877 0.00  0.006 0.01 0.3712 0.04 
 S6 F  0.022 0.01 0.0011 0.00  -0.010 0.01 0.1313 0.00  -0.009 0.01 0.1822 0.00  -0.001 0.01 0.8826 0.00  0.003 0.01 0.6406 0.00 
 S6 M  0.017 0.01 0.1430 0.00  -0.026 0.01 0.0408 0.00  0.022 0.01 0.0596 0.00  0.002 0.01 0.8678 0.00  0.008 0.01 0.4875 0.00 
 S7 F+M  0.015 0.01 0.0150 0.30  -0.016 0.01 0.0143 0.31  0.001 0.01 0.8602 0.00  -0.006 0.01 0.4179 0.04  0.003 0.01 0.5693 0.02 
 S7 F  0.020 0.01 0.0019 0.00  -0.012 0.01 0.0686 0.00  -0.012 0.01 0.0698 0.00  -0.009 0.01 0.2513 0.00  0.002 0.01 0.8168 0.00 
 S7 M  0.011 0.01 0.3340 0.00  -0.024 0.01 0.0692 0.00  0.019 0.01 0.0986 0.00  -0.001 0.01 0.9167 0.00  0.004 0.01 0.6925 0.00 
 S8 F+M  0.015 0.01 0.0192 0.28  -0.016 0.01 0.0191 0.29  0.001 0.01 0.8909 0.00  -0.005 0.01 0.4459 0.03  0.004 0.01 0.5571 0.02 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S8 F  0.020 0.01 0.0026 0.00  -0.013 0.01 0.0620 0.00  -0.012 0.01 0.0708 0.00  -0.008 0.01 0.2698 0.00  0.002 0.01 0.7719 0.00 
 S8 M  0.010 0.01 0.3663 0.00  -0.021 0.01 0.1024 0.00  0.018 0.01 0.1108 0.00  -0.001 0.01 0.9158 0.00  0.004 0.01 0.7464 0.00 
 
Age at onset 
of DSM5 
CUD 
S1 F+M  -0.301 0.19 0.1078 0.98  0.047 0.18 0.7988 0.02  -0.041 0.20 0.8367 0.02  -0.046 0.18 0.7975 0.02  0.115 0.16 0.4816 0.14 
 S1 F  -0.349 0.32 0.2792 0.00  0.006 0.31 0.9837 0.00  0.676 0.32 0.0385 0.00  0.325 0.33 0.3197 0.00  0.502 0.28 0.0723 0.00 
 S1 M  -0.294 0.23 0.1938 0.00  0.141 0.24 0.5517 0.00  -0.404 0.25 0.1032 0.00  -0.179 0.21 0.4014 0.00  -0.049 0.20 0.8107 0.00 
 S2 F+M  -0.356 0.20 0.0721 1.41  0.135 0.19 0.4753 0.19  0.032 0.19 0.8674 0.01  -0.006 0.20 0.9759 0.00  0.241 0.18 0.1861 0.61 
 S2 F  -0.337 0.33 0.3085 0.00  0.295 0.28 0.2902 0.00  0.665 0.31 0.0345 0.00  0.268 0.37 0.4689 0.00  0.577 0.31 0.0632 0.00 
 S2 M  -0.304 0.25 0.2309 0.00  -0.032 0.26 0.9027 0.00  -0.311 0.24 0.2013 0.00  -0.071 0.23 0.7588 0.00  0.095 0.23 0.6761 0.00 
 S3 F+M  -0.320 0.19 0.0992 1.11  -0.122 0.19 0.5133 0.16  -0.233 0.18 0.2077 0.56  -0.107 0.19 0.5814 0.12  0.387 0.18 0.0315 1.57 
 S3 F  -0.295 0.31 0.3458 0.00  0.211 0.30 0.4866 0.00  0.149 0.29 0.6090 0.00  0.353 0.36 0.3233 0.00  0.477 0.29 0.1060 0.00 
 S3 M  -0.229 0.25 0.3651 0.00  -0.327 0.24 0.1680 0.00  -0.534 0.24 0.0245 0.00  -0.384 0.24 0.1105 0.00  0.336 0.23 0.1453 0.00 
 S4 F+M  -0.244 0.21 0.2373 0.61  -0.057 0.20 0.7810 0.03  -0.167 0.18 0.3648 0.29  0.082 0.19 0.6629 0.06  0.516 0.19 0.0059 2.83 
 S4 F  -0.283 0.32 0.3845 0.00  0.091 0.33 0.7839 0.00  0.064 0.29 0.8256 0.00  0.239 0.33 0.4662 0.00  0.472 0.30 0.1229 0.00 
 S4 M  -0.203 0.27 0.4595 0.00  -0.208 0.28 0.4507 0.00  -0.341 0.25 0.1692 0.00  0.029 0.24 0.9043 0.00  0.516 0.24 0.0306 0.00 
 S5 F+M  -0.176 0.19 0.3640 0.32  -0.020 0.22 0.9277 0.00  0.021 0.19 0.9128 0.00  0.109 0.20 0.5791 0.11  0.103 0.18 0.5638 0.11 
 S5 F  -0.188 0.31 0.5503 0.00  0.026 0.34 0.9404 0.00  0.307 0.31 0.3304 0.00  0.460 0.33 0.1673 0.00  -0.192 0.28 0.4998 0.00 
 S5 M  -0.153 0.25 0.5371 0.00  -0.119 0.29 0.6850 0.00  -0.228 0.24 0.3534 0.00  -0.160 0.26 0.5374 0.00  0.356 0.23 0.1283 0.00 
 S6 F+M  -0.117 0.20 0.5584 0.14  -0.026 0.22 0.9066 0.01  0.113 0.19 0.5541 0.13  0.151 0.21 0.4660 0.20  0.072 0.18 0.6887 0.06 
 S6 F  -0.234 0.31 0.4530 0.00  0.045 0.32 0.8862 0.00  0.360 0.31 0.2419 0.00  0.517 0.33 0.1243 0.00  -0.161 0.28 0.5688 0.00 
 S6 M  -0.032 0.26 0.9038 0.00  -0.071 0.31 0.8179 0.00  -0.125 0.25 0.6197 0.00  -0.135 0.28 0.6272 0.00  0.337 0.24 0.1597 0.00 
 S7 F+M  0.057 0.20 0.7767 0.03  -0.103 0.22 0.6431 0.10  0.064 0.19 0.7404 0.04  0.115 0.21 0.5840 0.12  -0.047 0.17 0.7868 0.02 
 S7 F  -0.066 0.32 0.8365 0.00  -0.119 0.34 0.7280 0.00  0.360 0.31 0.2542 0.00  0.460 0.33 0.1691 0.00  -0.328 0.27 0.2286 0.00 
 S7 M  0.080 0.26 0.7636 0.00  -0.004 0.29 0.9896 0.00  -0.203 0.25 0.4140 0.00  -0.198 0.28 0.4839 0.00  0.266 0.23 0.2424 0.00 
 S8 F+M  0.060 0.20 0.7663 0.04  -0.054 0.22 0.8069 0.03  0.079 0.19 0.6799 0.06  0.134 0.21 0.5267 0.16  -0.054 0.17 0.7562 0.03 
 S8 F  -0.046 0.32 0.8849 0.00  -0.055 0.35 0.8747 0.00  0.347 0.31 0.2691 0.00  0.498 0.33 0.1398 0.00  -0.350 0.27 0.2020 0.00 
Table S3-3. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to initiation of illicit 
substance, alcohol-related disorders, and cannabis-related disorders for females (F), males (M), and both sexes (F+M). PRS was calculated for five discovery 
phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking cessation (SC) and drinks per week (DPW) 
at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 (S8). Associations that survive multiple testing 
are presented in bold-face blue. The corrected significance threshold is 7.14e-4. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R²  Beta SE p R² 
 S8 M  0.081 0.27 0.7613 0.00  0.034 0.29 0.9044 0.00  -0.151 0.25 0.5400 0.00  -0.187 0.28 0.5093 0.00  0.266 0.23 0.2476 0.00 
 
Table S3-4. Phenotypic correlation between illicit substance use or substance use disorders and polygenic risk scores (PRS) for licit substance use in females, 
males or both sexes (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes 
per day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08, 1e-05 , 1e-03, 1e-02, 5e-02, 1e-01, 5e-01, and 1. 
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 Females  Males  F+M 
Target phenotype PT  SI AI CPD SC DPW  SI AI CPD SC DPW  SI AI CPD SC DPW 
Ever used cocaine p < 5e-08  0.04 -0.04 -0.05 -0.03 0.04  0.06 -0.03 -0.02 -0.00 -0.01  0.04 -0.03 -0.04 -0.02 0.02 
 p < 1e-05  0.02 -0.01 -0.03 -0.01 0.04  0.05 0.01 -0.03 -0.06 -0.00  0.03 0.00 -0.03 -0.03 0.02 
 p < 1e-03  0.06 -0.02 -0.04 -0.04 0.04  0.09 -0.02 -0.03 0.00 0.05  0.07 -0.02 -0.05 -0.02 0.04 
 p < 0.01  0.08 0.00 -0.01 -0.05 0.04  0.05 -0.08 -0.07 0.04 0.11  0.06 -0.03 -0.04 -0.01 0.07 
 p < 0.05  0.09 -0.05 -0.01 -0.07 0.04  0.07 -0.07 -0.01 0.04 0.11  0.07 -0.05 -0.02 -0.03 0.07 
 p < 0.1  0.09 -0.04 -0.02 -0.07 0.05  0.07 -0.06 -0.00 0.03 0.11  0.08 -0.05 -0.02 -0.03 0.08 
 p < 0.5  0.09 -0.06 -0.01 -0.07 0.07  0.04 -0.07 0.00 0.02 0.11  0.06 -0.06 -0.01 -0.04 0.08 
 p < 1  0.09 -0.06 -0.02 -0.07 0.07  0.04 -0.06 0.00 0.01 0.10  0.06 -0.06 -0.02 -0.04 0.08 
 
Ever used 
amphetamine 
p < 5e-08  0.03 -0.01 -0.02 -0.03 0.05  0.06 -0.01 -0.00 0.03 -0.00  0.04 -0.01 -0.01 -0.01 0.03 
 p < 1e-05  0.03 -0.02 -0.02 -0.02 0.05  0.09 -0.02 0.01 -0.00 0.01  0.06 -0.02 -0.01 -0.01 0.03 
 p < 1e-03  0.06 -0.02 0.01 -0.04 0.06  0.09 -0.07 -0.01 -0.01 0.03  0.07 -0.04 -0.00 -0.02 0.05 
 p < 0.01  0.08 -0.04 0.02 -0.00 0.07  0.08 -0.10 -0.03 0.02 0.08  0.08 -0.06 -0.00 0.00 0.07 
 p < 0.05  0.12 -0.07 0.01 -0.01 0.05  0.13 -0.09 0.02 0.02 0.05  0.12 -0.07 0.01 0.00 0.05 
 p < 0.1  0.12 -0.07 0.00 -0.01 0.05  0.12 -0.07 0.03 0.02 0.06  0.12 -0.07 0.01 0.00 0.06 
 p < 0.5  0.11 -0.07 0.02 -0.02 0.06  0.08 -0.04 0.03 0.02 0.05  0.09 -0.06 0.02 -0.01 0.05 
 p < 1  0.11 -0.08 0.02 -0.02 0.05  0.08 -0.04 0.03 0.01 0.04  0.09 -0.06 0.02 -0.01 0.05 
 
Ever used inhalants p < 5e-08  0.02 0.01 -0.01 0.01 0.00  0.05 -0.00 -0.04 0.05 -0.02  0.03 0.01 -0.03 0.03 -0.01 
 p < 1e-05  0.00 0.03 -0.01 0.03 0.04  0.05 0.03 -0.01 0.00 0.00  0.03 0.03 -0.01 0.02 0.02 
 p < 1e-03  0.02 -0.01 -0.01 -0.02 0.02  0.03 -0.02 -0.02 -0.02 -0.01  0.02 -0.01 -0.02 -0.01 0.01 
 p < 0.01  0.04 -0.04 0.01 -0.01 0.02  0.01 0.01 -0.03 0.03 0.05  0.02 -0.01 -0.01 0.00 0.03 
 p < 0.05  0.02 -0.04 0.02 -0.01 0.02  0.04 -0.02 0.01 0.01 0.05  0.03 -0.03 0.01 -0.00 0.03 
 p < 0.1  0.03 -0.03 0.02 -0.00 0.01  0.03 -0.01 0.01 0.00 0.07  0.03 -0.02 0.01 -0.01 0.04 
 p < 0.5  0.05 -0.03 0.03 -0.02 -0.01  0.01 0.02 0.02 0.01 0.06  0.03 -0.00 0.02 -0.01 0.02 
 p < 1  0.05 -0.03 0.03 -0.02 -0.01  0.01 0.03 0.01 0.01 0.06  0.03 -0.00 0.02 -0.01 0.02 
 
Ever used sedatives p < 5e-08  0.10 0.04 0.02 0.00 0.02  0.04 -0.01 -0.02 0.01 0.03  0.07 0.02 0.00 0.01 0.03 
 p < 1e-05  0.06 0.02 0.02 0.01 0.04  0.04 -0.00 -0.02 -0.02 0.00  0.05 0.01 0.00 -0.00 0.02 
 p < 1e-03  0.04 -0.01 0.02 0.01 0.04  0.05 -0.07 -0.02 -0.04 -0.00  0.04 -0.03 0.00 -0.01 0.02 
 p < 0.01  0.05 -0.04 0.01 -0.01 0.08  0.02 -0.06 -0.04 0.01 0.04  0.03 -0.04 -0.01 -0.00 0.06 
Table S3-4. Phenotypic correlation between illicit substance use or substance use disorders and polygenic risk scores (PRS) for licit substance use in females, 
males or both sexes (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes 
per day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08, 1e-05 , 1e-03, 1e-02, 5e-02, 1e-01, 5e-01, and 1. 
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 Females  Males  F+M 
Target phenotype PT  SI AI CPD SC DPW  SI AI CPD SC DPW  SI AI CPD SC DPW 
 p < 0.05  0.04 -0.05 0.01 -0.03 0.07  0.04 -0.06 0.01 0.01 0.05  0.04 -0.05 0.01 -0.01 0.06 
 p < 0.1  0.03 -0.04 -0.00 -0.03 0.06  0.05 -0.04 0.02 0.02 0.06  0.03 -0.04 0.01 -0.01 0.06 
 p < 0.5  0.04 -0.05 -0.01 -0.05 0.07  0.01 -0.02 0.03 0.01 0.04  0.02 -0.03 0.01 -0.03 0.05 
 p < 1  0.04 -0.05 -0.01 -0.05 0.06  0.01 -0.02 0.03 0.00 0.04  0.03 -0.04 0.01 -0.03 0.05 
 
Ever used 
hallucinogens 
p < 5e-08  -0.02 0.01 -0.01 0.02 0.01  0.03 -0.04 0.00 0.02 0.08  0.00 -0.01 -0.01 0.02 0.05 
 p < 1e-05  0.02 0.01 -0.01 0.02 0.03  0.03 0.02 0.01 -0.04 0.06  0.02 0.02 -0.00 -0.01 0.04 
 p < 1e-03  0.06 -0.02 -0.01 -0.04 0.02  0.03 -0.08 -0.03 -0.01 0.08  0.04 -0.05 -0.03 -0.02 0.05 
 p < 0.01  0.08 -0.02 0.02 -0.03 0.03  0.01 -0.08 -0.03 0.00 0.09  0.03 -0.04 -0.01 -0.02 0.05 
 p < 0.05  0.10 -0.04 0.02 -0.05 0.03  0.04 -0.07 0.01 0.02 0.07  0.07 -0.05 0.01 -0.02 0.05 
 p < 0.1  0.09 -0.04 0.02 -0.05 0.04  0.05 -0.06 0.04 0.03 0.08  0.07 -0.05 0.02 -0.02 0.06 
 p < 0.5  0.09 -0.05 0.03 -0.05 0.05  0.05 -0.05 0.05 0.02 0.06  0.06 -0.05 0.03 -0.02 0.05 
 p < 1  0.09 -0.06 0.02 -0.05 0.05  0.05 -0.05 0.05 0.02 0.06  0.06 -0.05 0.03 -0.03 0.06 
 
Ever used opioids p < 5e-08  0.03 0.02 -0.02 -0.01 0.05  0.03 0.03 0.02 -0.00 -0.01  0.03 0.02 -0.00 -0.01 0.02 
 p < 1e-05  0.06 0.00 -0.02 -0.02 0.05  -0.00 0.03 0.04 -0.02 -0.01  0.03 0.01 0.01 -0.02 0.02 
 p < 1e-03  0.06 -0.02 -0.01 0.01 0.04  -0.02 -0.02 0.01 -0.01 -0.03  0.02 -0.02 -0.00 0.00 0.01 
 p < 0.01  0.09 -0.01 -0.02 -0.01 0.07  -0.01 -0.08 0.01 0.01 0.02  0.04 -0.04 -0.00 -0.00 0.05 
 p < 0.05  0.09 -0.00 0.01 -0.02 0.06  0.01 -0.05 0.01 0.00 -0.01  0.06 -0.02 0.01 -0.01 0.03 
 p < 0.1  0.08 -0.01 -0.02 -0.02 0.06  0.01 -0.04 0.02 0.01 0.00  0.05 -0.02 -0.00 -0.01 0.03 
 p < 0.5  0.08 -0.01 -0.02 -0.02 0.06  0.02 -0.03 0.01 0.02 0.00  0.05 -0.02 -0.00 -0.01 0.03 
 p < 1  0.08 -0.02 -0.01 -0.02 0.05  0.02 -0.02 0.01 0.01 0.00  0.05 -0.02 -0.00 -0.01 0.03 
 
Ever used ecstasy p < 5e-08  0.00 0.01 -0.04 0.03 0.03  0.05 -0.02 -0.00 0.05 0.01  0.02 -0.00 -0.02 0.04 0.02 
 p < 1e-05  0.03 -0.01 -0.03 0.03 0.06  0.07 0.03 -0.00 -0.01 0.04  0.05 0.01 -0.02 0.01 0.05 
 p < 1e-03  0.08 0.01 -0.03 -0.03 0.06  0.10 -0.05 -0.01 -0.02 0.04  0.08 -0.02 -0.03 -0.02 0.05 
 p < 0.01  0.12 -0.01 0.00 -0.01 0.09  0.09 -0.08 -0.06 0.01 0.10  0.10 -0.04 -0.03 -0.01 0.09 
 p < 0.05  0.13 -0.04 -0.01 -0.04 0.09  0.11 -0.07 0.00 0.00 0.09  0.12 -0.05 -0.01 -0.03 0.09 
 p < 0.1  0.14 -0.05 -0.01 -0.03 0.09  0.11 -0.05 0.01 -0.00 0.08  0.12 -0.05 -0.01 -0.03 0.08 
 p < 0.5  0.13 -0.07 0.01 -0.03 0.09  0.07 -0.03 0.01 -0.02 0.08  0.10 -0.05 0.00 -0.04 0.08 
 p < 1  0.13 -0.08 0.00 -0.03 0.09  0.07 -0.03 0.01 -0.03 0.08  0.10 -0.06 -0.00 -0.04 0.08 
Table S3-4. Phenotypic correlation between illicit substance use or substance use disorders and polygenic risk scores (PRS) for licit substance use in females, 
males or both sexes (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes 
per day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08, 1e-05 , 1e-03, 1e-02, 5e-02, 1e-01, 5e-01, and 1. 
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 Females  Males  F+M 
Target phenotype PT  SI AI CPD SC DPW  SI AI CPD SC DPW  SI AI CPD SC DPW 
 
Ever used prescription 
pain killers 
p < 5e-08  0.04 -0.01 0.02 -0.01 -0.05  0.06 0.02 0.04 -0.00 0.00  0.05 0.00 0.03 -0.01 -0.02 
 p < 1e-05  0.06 0.01 0.03 -0.00 -0.04  0.07 0.02 0.05 0.03 0.05  0.07 0.01 0.04 0.01 -0.00 
 p < 1e-03  0.08 -0.02 0.08 0.07 -0.08  0.03 -0.01 0.01 0.06 0.01  0.06 -0.01 0.05 0.06 -0.04 
 p < 0.01  0.07 -0.05 0.06 0.07 -0.06  0.01 -0.03 0.01 0.06 0.02  0.05 -0.04 0.04 0.06 -0.02 
 p < 0.05  0.06 -0.06 0.06 0.06 -0.05  0.01 -0.03 0.03 0.02 0.01  0.04 -0.05 0.05 0.04 -0.02 
 p < 0.1  0.05 -0.07 0.04 0.05 -0.04  0.01 -0.02 0.02 0.01 0.01  0.04 -0.05 0.03 0.04 -0.02 
 p < 0.5  0.06 -0.05 0.04 0.05 -0.03  0.02 -0.01 0.03 -0.00 0.03  0.04 -0.03 0.04 0.03 -0.01 
 p < 1  0.06 -0.05 0.04 0.05 -0.03  0.02 -0.00 0.03 -0.01 0.03  0.04 -0.03 0.04 0.03 -0.00 
 
Ever used prescription 
stimulants 
p < 5e-08  0.00 -0.01 0.00 0.00 0.03  0.05 0.00 0.04 0.03 -0.04  0.02 -0.00 0.02 0.02 -0.00 
 p < 1e-05  0.02 0.02 -0.00 0.02 0.03  0.03 0.04 0.04 0.01 -0.01  0.02 0.03 0.01 0.01 0.01 
 p < 1e-03  0.02 -0.00 0.02 0.02 -0.02  0.03 -0.05 0.01 -0.01 -0.00  0.02 -0.02 0.01 0.01 -0.01 
 p < 0.01  0.04 -0.05 0.02 -0.01 -0.01  0.02 -0.04 -0.02 -0.02 0.03  0.03 -0.04 -0.00 -0.02 0.01 
 p < 0.05  0.04 -0.05 0.02 -0.04 -0.01  0.05 -0.04 0.03 -0.00 0.05  0.04 -0.04 0.02 -0.03 0.02 
 p < 0.1  0.03 -0.06 0.00 -0.04 -0.01  0.04 -0.04 0.04 -0.00 0.05  0.04 -0.05 0.01 -0.03 0.02 
 p < 0.5  0.03 -0.05 0.00 -0.03 0.01  0.04 -0.02 0.05 -0.02 0.07  0.03 -0.03 0.02 -0.03 0.03 
 p < 1  0.03 -0.05 0.00 -0.03 0.01  0.03 -0.02 0.05 -0.02 0.07  0.03 -0.03 0.02 -0.03 0.03 
 
Alcohol abuse p < 5e-08  0.02 -0.00 -0.02 -0.02 0.03  0.03 -0.03 -0.02 -0.04 -0.01  0.02 -0.01 -0.03 -0.03 0.01 
 p < 1e-05  0.05 0.02 -0.03 -0.01 0.01  0.05 0.03 -0.02 -0.05 0.04  0.05 0.02 -0.03 -0.03 0.02 
 p < 1e-03  0.05 -0.01 -0.00 -0.04 0.03  0.07 -0.04 -0.07 -0.03 -0.00  0.06 -0.02 -0.04 -0.03 0.01 
 p < 0.01  0.05 -0.03 0.04 -0.07 0.03  0.04 -0.04 -0.06 0.01 0.04  0.04 -0.03 -0.01 -0.04 0.03 
 p < 0.05  0.06 -0.03 0.00 -0.08 0.02  0.06 0.00 -0.06 -0.02 0.03  0.06 -0.01 -0.03 -0.06 0.03 
 p < 0.1  0.06 -0.04 -0.00 -0.07 0.03  0.07 0.03 -0.05 -0.01 0.02  0.06 -0.01 -0.03 -0.06 0.03 
 p < 0.5  0.08 -0.02 -0.00 -0.08 0.02  0.05 0.02 -0.07 -0.02 0.01  0.06 -0.00 -0.04 -0.06 0.02 
 p < 1  0.07 -0.03 -0.00 -0.07 0.03  0.04 0.03 -0.06 -0.03 0.01  0.05 -0.00 -0.04 -0.06 0.02 
 
Alcohol dependence p < 5e-08  0.04 0.02 -0.03 0.02 0.06  -0.01 -0.01 -0.03 -0.02 -0.01  0.01 0.01 -0.03 0.00 0.03 
 p < 1e-05  0.06 0.00 -0.03 0.01 0.05  -0.04 0.01 -0.03 -0.06 0.05  0.02 0.01 -0.03 -0.02 0.04 
Table S3-4. Phenotypic correlation between illicit substance use or substance use disorders and polygenic risk scores (PRS) for licit substance use in females, 
males or both sexes (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes 
per day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08, 1e-05 , 1e-03, 1e-02, 5e-02, 1e-01, 5e-01, and 1. 
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 Females  Males  F+M 
Target phenotype PT  SI AI CPD SC DPW  SI AI CPD SC DPW  SI AI CPD SC DPW 
 p < 1e-03  0.06 -0.02 -0.01 0.01 0.03  0.03 0.01 -0.05 -0.03 0.02  0.04 -0.01 -0.04 -0.00 0.03 
 p < 0.01  0.07 -0.03 0.01 -0.03 0.02  0.02 -0.04 -0.05 -0.02 0.03  0.04 -0.03 -0.02 -0.03 0.02 
 p < 0.05  0.05 -0.05 -0.03 -0.06 0.00  0.04 -0.02 -0.03 -0.03 0.05  0.04 -0.03 -0.04 -0.06 0.02 
 p < 0.1  0.06 -0.05 -0.02 -0.06 0.00  0.05 -0.01 -0.02 -0.01 0.05  0.05 -0.03 -0.03 -0.05 0.02 
 p < 0.5  0.03 -0.03 -0.03 -0.06 -0.00  0.02 -0.00 -0.01 -0.02 0.06  0.02 -0.02 -0.03 -0.05 0.02 
 p < 1  0.03 -0.04 -0.03 -0.06 0.00  0.03 -0.00 -0.01 -0.02 0.05  0.02 -0.02 -0.03 -0.06 0.02 
 
Cannabis abuse p < 5e-08  -0.01 -0.02 0.03 0.05 0.01  0.02 -0.04 0.07 -0.02 0.03  0.01 -0.02 0.05 0.01 0.02 
 p < 1e-05  0.06 -0.03 0.02 0.05 0.02  0.03 0.04 0.09 -0.07 0.02  0.04 0.01 0.05 -0.01 0.02 
 p < 1e-03  0.05 0.03 -0.01 -0.01 0.02  0.02 -0.02 0.07 -0.03 0.04  0.03 0.00 0.02 -0.02 0.03 
 p < 0.01  0.06 0.02 -0.01 0.00 -0.00  0.03 -0.08 0.06 0.00 0.06  0.04 -0.02 0.01 -0.00 0.02 
 p < 0.05  0.06 -0.01 -0.03 -0.00 0.00  0.03 -0.08 0.06 -0.01 0.06  0.04 -0.04 0.01 -0.02 0.03 
 p < 0.1  0.07 -0.00 -0.03 -0.01 0.01  0.04 -0.06 0.06 -0.02 0.08  0.05 -0.03 0.01 -0.02 0.04 
 p < 0.5  0.07 -0.00 -0.02 -0.03 0.02  0.04 -0.05 0.04 -0.02 0.07  0.05 -0.03 0.00 -0.04 0.05 
 p < 1  0.07 -0.01 -0.02 -0.03 0.02  0.03 -0.06 0.04 -0.03 0.07  0.05 -0.03 -0.00 -0.04 0.05 
 
Cannabis dependence p < 5e-08  0.00 -0.01 0.03 0.02 -0.03  0.03 -0.03 0.05 0.01 0.03  0.02 -0.02 0.03 0.01 0.00 
 p < 1e-05  0.05 -0.01 0.01 0.03 -0.02  0.00 0.06 0.06 -0.03 -0.01  0.02 0.02 0.03 0.00 -0.02 
 p < 1e-03  0.05 -0.01 -0.01 -0.01 0.01  -0.01 -0.04 0.02 -0.03 -0.01  0.02 -0.02 -0.00 -0.02 -0.00 
 p < 0.01  0.07 -0.01 -0.02 0.01 0.01  0.02 -0.10 0.01 -0.01 0.03  0.04 -0.05 -0.01 -0.01 0.02 
 p < 0.05  0.08 -0.02 -0.02 0.02 -0.01  0.05 -0.07 0.02 -0.01 0.00  0.06 -0.04 -0.00 -0.00 -0.01 
 p < 0.1  0.08 -0.01 -0.03 0.01 -0.01  0.06 -0.06 0.04 0.00 0.01  0.07 -0.03 -0.00 -0.00 0.00 
 p < 0.5  0.08 -0.00 -0.03 -0.02 -0.01  0.05 -0.07 0.02 -0.01 0.03  0.06 -0.04 -0.01 -0.02 0.01 
 p < 1  0.08 -0.01 -0.03 -0.02 -0.01  0.05 -0.07 0.02 -0.01 0.03  0.06 -0.04 -0.01 -0.02 0.01 
 
DSM5 AUD (4 point 
scale) 
p < 5e-08  0.04 0.00 -0.02 0.00 0.05  0.04 -0.02 -0.03 -0.03 0.01  0.04 -0.00 -0.03 -0.01 0.04 
 p < 1e-05  0.06 -0.01 -0.02 0.01 0.03  0.05 0.00 -0.02 -0.06 0.07  0.05 -0.00 -0.03 -0.02 0.05 
 p < 1e-03  0.07 -0.04 0.01 -0.01 0.04  0.09 -0.05 -0.04 -0.05 0.04  0.07 -0.04 -0.02 -0.02 0.04 
 p < 0.01  0.07 -0.05 0.04 -0.05 0.05  0.07 -0.05 -0.04 -0.01 0.06  0.06 -0.04 0.00 -0.04 0.05 
 p < 0.05  0.07 -0.07 0.01 -0.08 0.03  0.10 -0.03 -0.03 -0.03 0.07  0.08 -0.04 -0.02 -0.07 0.04 
 p < 0.1  0.08 -0.08 0.01 -0.07 0.03  0.11 -0.01 -0.02 -0.02 0.07  0.09 -0.04 -0.01 -0.06 0.05 
Table S3-4. Phenotypic correlation between illicit substance use or substance use disorders and polygenic risk scores (PRS) for licit substance use in females, 
males or both sexes (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes 
per day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08, 1e-05 , 1e-03, 1e-02, 5e-02, 1e-01, 5e-01, and 1. 
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 Females  Males  F+M 
Target phenotype PT  SI AI CPD SC DPW  SI AI CPD SC DPW  SI AI CPD SC DPW 
 p < 0.5  0.07 -0.06 0.01 -0.07 0.03  0.09 0.01 -0.02 -0.02 0.08  0.07 -0.03 -0.01 -0.07 0.04 
 p < 1  0.07 -0.07 0.01 -0.08 0.03  0.09 0.01 -0.02 -0.03 0.07  0.07 -0.03 -0.01 -0.07 0.05 
 
DSM5 AUD (ctrl mild 
vs moderate severe) 
p < 5e-08  0.04 0.00 -0.02 0.02 0.07  0.02 0.00 -0.04 -0.03 0.01  0.03 0.01 -0.03 0.00 0.05 
 p < 1e-05  0.06 -0.01 -0.02 0.03 0.06  -0.00 0.01 -0.03 -0.06 0.06  0.03 0.00 -0.03 -0.01 0.06 
 p < 1e-03  0.04 -0.00 -0.00 -0.00 0.06  0.06 -0.03 -0.05 -0.06 0.06  0.04 -0.02 -0.03 -0.02 0.06 
 p < 0.01  0.04 -0.04 0.03 -0.04 0.05  0.04 -0.06 -0.06 0.00 0.07  0.03 -0.04 -0.01 -0.03 0.05 
 p < 0.05  0.04 -0.05 -0.01 -0.06 0.03  0.08 -0.02 -0.03 0.00 0.07  0.05 -0.03 -0.03 -0.04 0.05 
 p < 0.1  0.05 -0.06 -0.00 -0.05 0.04  0.09 -0.01 -0.03 0.02 0.08  0.06 -0.03 -0.02 -0.03 0.06 
 p < 0.5  0.04 -0.05 0.01 -0.06 0.03  0.07 -0.01 -0.02 0.00 0.08  0.05 -0.03 -0.01 -0.04 0.05 
 p < 1  0.04 -0.05 0.01 -0.06 0.04  0.07 -0.01 -0.02 0.00 0.08  0.05 -0.03 -0.01 -0.05 0.05 
 
DSM5 CUD (4 point 
scale) 
p < 5e-08  0.01 -0.02 0.03 0.06 -0.00  0.03 -0.05 0.07 0.01 0.03  0.02 -0.03 0.05 0.03 0.02 
 p < 1e-05  0.06 -0.00 0.02 0.07 0.01  0.03 0.03 0.09 -0.05 0.01  0.04 0.02 0.05 0.01 0.01 
 p < 1e-03  0.06 0.02 -0.02 0.00 0.02  0.00 -0.04 0.06 -0.05 0.03  0.03 -0.01 0.01 -0.02 0.03 
 p < 0.01  0.08 0.02 -0.03 0.02 0.02  0.01 -0.10 0.04 -0.01 0.08  0.04 -0.03 0.00 -0.00 0.04 
 p < 0.05  0.09 -0.03 -0.05 0.02 0.01  0.03 -0.09 0.06 -0.01 0.06  0.05 -0.05 -0.01 -0.00 0.03 
 p < 0.1  0.09 -0.02 -0.05 0.03 0.02  0.04 -0.08 0.06 -0.01 0.07  0.06 -0.05 -0.00 -0.01 0.04 
 p < 0.5  0.10 -0.03 -0.04 -0.00 0.02  0.03 -0.07 0.04 -0.02 0.07  0.06 -0.05 -0.01 -0.02 0.04 
 p < 1  0.10 -0.04 -0.04 -0.00 0.02  0.03 -0.08 0.04 -0.02 0.07  0.06 -0.05 -0.01 -0.03 0.04 
 
DSM5 CUD (ctrl mild 
vs moderate severe) 
p < 5e-08  -0.00 -0.02 0.02 0.03 0.00  0.02 -0.05 0.06 -0.00 0.05  0.00 -0.03 0.04 0.01 0.03 
 p < 1e-05  0.04 -0.01 0.01 0.04 0.00  0.01 0.04 0.08 -0.06 0.01  0.02 0.02 0.04 -0.01 0.01 
 p < 1e-03  0.05 0.01 -0.02 0.01 0.02  0.00 -0.04 0.04 -0.04 -0.00  0.02 -0.02 0.00 -0.01 0.01 
 p < 0.01  0.08 -0.02 -0.02 0.02 0.02  0.03 -0.09 0.04 -0.02 0.04  0.04 -0.05 0.00 -0.00 0.03 
 p < 0.05  0.10 -0.04 -0.03 0.02 -0.01  0.04 -0.09 0.06 -0.01 0.03  0.06 -0.06 0.01 -0.00 0.01 
 p < 0.1  0.10 -0.04 -0.03 0.01 0.00  0.06 -0.08 0.07 -0.01 0.04  0.07 -0.06 0.01 -0.01 0.02 
 p < 0.5  0.10 -0.05 -0.03 -0.01 -0.00  0.04 -0.08 0.05 -0.01 0.04  0.06 -0.06 0.00 -0.02 0.02 
 p < 1  0.10 -0.05 -0.04 -0.01 -0.00  0.04 -0.08 0.05 -0.01 0.04  0.06 -0.06 0.00 -0.03 0.02 
Table S3-4. Phenotypic correlation between illicit substance use or substance use disorders and polygenic risk scores (PRS) for licit substance use in females, 
males or both sexes (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes 
per day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08, 1e-05 , 1e-03, 1e-02, 5e-02, 1e-01, 5e-01, and 1. 
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 Females  Males  F+M 
Target phenotype PT  SI AI CPD SC DPW  SI AI CPD SC DPW  SI AI CPD SC DPW 
 
Ever used cannabis p < 5e-08  0.03 -0.02 0.01 -0.01 -0.01  0.04 0.03 -0.00 0.00 -0.03  0.04 0.01 -0.00 -0.01 -0.01 
 p < 1e-05  0.08 -0.02 0.02 0.01 0.01  0.05 0.07 -0.01 0.00 -0.00  0.07 0.02 -0.00 0.01 -0.00 
 p < 1e-03  0.11 -0.04 -0.02 -0.02 0.02  0.06 0.01 -0.02 -0.00 0.02  0.09 -0.02 -0.03 -0.01 0.02 
 p < 0.01  0.09 -0.03 -0.01 0.00 0.03  0.07 0.01 -0.06 -0.02 0.08  0.07 -0.01 -0.03 -0.01 0.05 
 p < 0.05  0.10 -0.05 -0.03 -0.03 0.04  0.08 0.03 -0.06 -0.04 0.10  0.08 -0.01 -0.05 -0.04 0.07 
 p < 0.1  0.09 -0.03 -0.04 -0.03 0.03  0.08 0.02 -0.05 -0.04 0.09  0.08 -0.00 -0.05 -0.04 0.06 
 p < 0.5  0.09 -0.01 -0.04 -0.02 0.04  0.09 0.02 -0.06 -0.03 0.10  0.08 0.00 -0.06 -0.03 0.06 
 p < 1  0.09 -0.01 -0.04 -0.02 0.03  0.08 0.02 -0.07 -0.04 0.09  0.08 0.00 -0.07 -0.04 0.06 
 
Age at onset of 
cannabis initiation 
p < 5e-08  -0.01 -0.01 -0.01 0.06 0.04  0.02 -0.02 -0.05 0.02 -0.06  0.01 -0.01 -0.03 0.04 -0.01 
 p < 1e-05  -0.06 0.04 -0.02 0.07 0.04  -0.08 0.03 -0.03 -0.00 -0.02  -0.07 0.04 -0.03 0.02 0.01 
 p < 1e-03  -0.05 0.06 -0.05 0.07 0.11  -0.05 -0.07 -0.06 -0.07 0.08  -0.06 -0.01 -0.06 -0.01 0.09 
 p < 0.01  -0.04 -0.02 -0.09 0.02 0.03  -0.06 -0.00 -0.03 -0.00 0.09  -0.06 -0.01 -0.06 -0.00 0.06 
 p < 0.05  -0.05 -0.01 -0.04 0.02 -0.02  -0.08 -0.01 -0.00 -0.02 0.05  -0.08 -0.00 -0.03 -0.01 0.02 
 p < 0.1  -0.06 0.01 -0.01 -0.00 0.00  -0.06 0.03 -0.03 -0.03 0.07  -0.07 0.02 -0.02 -0.03 0.04 
 p < 0.5  -0.03 -0.01 -0.02 0.02 0.00  -0.06 -0.00 -0.04 -0.04 0.08  -0.06 -0.00 -0.04 -0.03 0.04 
 p < 1  -0.02 0.00 -0.02 0.03 0.00  -0.05 0.00 -0.03 -0.04 0.08  -0.05 0.01 -0.03 -0.02 0.05 
 
Age at onset of 
cannabis abuse 
p < 5e-08  -0.09 -0.24 0.11 0.01 0.09  -0.13 0.04 -0.09 -0.01 0.02  -0.12 -0.07 -0.01 0.00 0.04 
 p < 1e-05  -0.07 -0.01 0.11 0.08 0.02  -0.17 -0.01 -0.05 -0.00 0.08  -0.13 0.01 0.01 0.02 0.06 
 p < 1e-03  -0.06 0.19 0.13 0.17 0.13  -0.10 -0.10 -0.10 -0.09 0.16  -0.08 0.01 -0.01 0.01 0.15 
 p < 0.01  -0.11 0.13 0.04 0.06 0.15  -0.09 -0.03 -0.03 0.01 0.25  -0.10 0.03 0.00 0.03 0.21 
 p < 0.05  -0.09 0.20 0.07 0.09 -0.03  -0.08 -0.05 0.05 -0.05 0.22  -0.09 0.05 0.06 0.01 0.12 
 p < 0.1  -0.12 0.15 0.07 0.11 -0.03  -0.03 -0.05 0.03 -0.04 0.20  -0.07 0.03 0.05 0.02 0.10 
 p < 0.5  -0.06 0.12 -0.00 0.11 -0.08  -0.03 -0.07 0.02 -0.06 0.21  -0.05 0.01 0.01 0.01 0.08 
 p < 1  -0.05 0.13 -0.03 0.14 -0.10  -0.02 -0.06 0.04 -0.06 0.20  -0.04 0.02 0.01 0.02 0.08 
 
Age at onset of 
cannabis dependence 
p < 5e-08  0.23 -0.30 0.15 -0.26 0.37  -0.11 0.14 -0.01 -0.06 -0.17  0.03 -0.03 0.05 -0.14 0.03 
Table S3-4. Phenotypic correlation between illicit substance use or substance use disorders and polygenic risk scores (PRS) for licit substance use in females, 
males or both sexes (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes 
per day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08, 1e-05 , 1e-03, 1e-02, 5e-02, 1e-01, 5e-01, and 1. 
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 Females  Males  F+M 
Target phenotype PT  SI AI CPD SC DPW  SI AI CPD SC DPW  SI AI CPD SC DPW 
 p < 1e-05  0.15 -0.00 0.15 0.00 0.15  -0.23 0.02 0.01 -0.03 -0.05  -0.07 0.03 0.06 -0.02 0.03 
 p < 1e-03  0.09 0.13 0.17 0.02 0.15  -0.20 -0.09 -0.04 -0.02 0.13  -0.10 -0.00 0.03 -0.01 0.13 
 p < 0.01  0.06 0.04 -0.02 -0.07 0.10  -0.17 -0.05 -0.15 0.12 0.17  -0.09 -0.03 -0.10 0.04 0.14 
 p < 0.05  -0.05 0.09 -0.01 0.01 0.00  -0.09 -0.02 -0.12 0.07 0.15  -0.09 0.03 -0.07 0.05 0.08 
 p < 0.1  -0.14 0.06 0.00 0.04 0.06  -0.06 0.03 -0.19 0.11 0.09  -0.10 0.04 -0.11 0.07 0.07 
 p < 0.5  -0.00 0.11 -0.05 0.06 -0.02  -0.00 0.01 -0.19 0.01 0.18  -0.02 0.05 -0.12 0.04 0.09 
 p < 1  0.02 0.07 -0.06 0.08 -0.02  0.02 0.01 -0.17 0.01 0.17  0.00 0.04 -0.12 0.04 0.09 
 
Age at onset of DSM5 
CUD 
p < 5e-08  -0.01 -0.14 0.14 0.02 0.22  -0.14 0.04 -0.10 0.03 -0.03  -0.09 -0.03 -0.00 0.03 0.07 
 p < 1e-05  -0.05 0.02 0.13 0.05 0.16  -0.17 0.02 -0.07 0.03 0.08  -0.12 0.02 0.01 0.03 0.12 
 p < 1e-03  -0.08 0.12 0.09 0.12 0.18  -0.12 -0.07 -0.14 -0.06 0.13  -0.10 0.01 -0.04 0.01 0.16 
 p < 0.01  -0.05 -0.01 0.02 0.02 0.15  -0.09 -0.02 -0.12 0.02 0.23  -0.09 -0.02 -0.05 0.02 0.19 
 p < 0.05  -0.07 0.02 0.10 0.08 -0.07  -0.12 -0.01 -0.06 -0.06 0.19  -0.11 0.01 0.02 -0.00 0.08 
 p < 0.1  -0.08 -0.01 0.11 0.08 -0.05  -0.08 0.01 -0.07 -0.06 0.16  -0.09 0.00 0.01 0.00 0.06 
 p < 0.5  -0.02 -0.01 0.11 0.09 -0.10  -0.05 -0.01 -0.12 -0.09 0.15  -0.05 -0.01 -0.02 -0.01 0.04 
 p < 1  -0.01 -0.00 0.10 0.11 -0.11  -0.05 -0.01 -0.10 -0.09 0.14  -0.04 -0.00 -0.01 -0.00 0.03 
 
Table S4-1. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5). Modelling in these associations 
contained a sex*PRS interaction term. PRS for SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), SC (smoking 
cessation) and DPW (drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) p< T3 with the adjustment for number of 
independent target phenotypes, (4) p< T4 with the adjustment for number of both independent target phenotypes and discovery traits, and (5) p< T5 with the adjustment 
by Bonferroni procedure. T3, T4 and T5 are 3.657103e-03, 7.142857e-04, and 8.333333e-05 respectively. 
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 SI  AI  CPD  SC  DPW 
Target phenotype  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
Smoking initiation  8 7 6 6 6  8 4 0 0 0  8 5 0 0 0  8 0 0 0 0  8 4 1 0 0 
 
Age at starting regular 
smoking 
 8 0 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Cigarettes per day  8 1 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Smoking cessation  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0 
 
Drinking initiation  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Drinks per week  8 8 8 8 8  8 8 7 1 1  8 0 0 0 0  8 7 0 0 0  8 8 8 7 7 
 
DSM-IV alcohol dependence  8 1 0 0 0  8 4 3 0 0  8 0 0 0 0  8 2 0 0 0  8 5 0 0 0 
 
DSM-IV nicotine dependence  8 7 5 5 2  8 0 0 0 0  8 5 3 1 0  8 4 1 0 0  8 4 1 0 0 
 
FTND-based nicotine 
dependence 
 8 8 7 5 5  8 6 4 0 0  8 7 1 0 0  8 4 3 1 0  8 0 0 0 0 
 
DSM-IV antisocial 
personality disorder 
 8 4 0 0 0  8 6 5 0 0  8 6 0 0 0  8 3 0 0 0  8 0 0 0 0 
 
DSM-IV major depressive 
disorder 
 8 0 0 0 0  8 0 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
DSM-IV conduct disorder  8 6 5 5 2  8 6 1 0 0  8 6 5 1 0  8 0 0 0 0  8 1 0 0 0 
 
Mania screen  8 4 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 6 3 0 0 
 
DSM-IV panic disorder  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
Table S4-1. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5). Modelling in these associations 
contained a sex*PRS interaction term. PRS for SI (smoking initiation), AI (age of initiation of regular smoking), CPD (number of cigarettes per day), SC (smoking 
cessation) and DPW (drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) p< T3 with the adjustment for number of 
independent target phenotypes, (4) p< T4 with the adjustment for number of both independent target phenotypes and discovery traits, and (5) p< T5 with the adjustment 
by Bonferroni procedure. T3, T4 and T5 are 3.657103e-03, 7.142857e-04, and 8.333333e-05 respectively. 
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 SI  AI  CPD  SC  DPW 
Target phenotype  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
 
DSM-IV social anxiety 
disorder 
 8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Numb_target_pheno_predic  15 10 5 5 5  15 8 5 1 1  15 6 3 2 0  15 6 2 1 0  15 6 4 1 1 
 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
Smoking 
initiation 
S1 PRS  0.014 0.02 0.43969 0.08  0.003 0.02 0.87911 0.00  0.002 0.02 0.89326 0.00  0.017 0.02 0.36152 0.12  -0.007 0.02 0.69761 0.02 
 S1 sexPRS  0.007 0.01 0.49253 0.06  -0.008 0.01 0.48107 0.07  -0.001 0.01 0.89741 0.00  -0.009 0.01 0.41462 0.09  0.006 0.01 0.60640 0.04 
 S2 PRS  0.049 0.02 0.00685 0.99  0.010 0.02 0.57063 0.04  -0.002 0.02 0.93254 0.00  0.027 0.02 0.14007 0.31  0.005 0.02 0.78524 0.01 
 S2 sexPRS  0.003 0.01 0.78101 0.01  -0.014 0.01 0.20571 0.21  0.003 0.01 0.79660 0.01  -0.014 0.01 0.20715 0.22  0.005 0.01 0.62397 0.03 
 S3 PRS  0.088 0.02 <.00001 3.15  -0.007 0.02 0.71469 0.02  0.015 0.02 0.39889 0.10  0.014 0.02 0.44406 0.08  0.028 0.02 0.13292 0.32 
 S3 sexPRS  -0.006 0.01 0.54910 0.05  -0.012 0.01 0.27495 0.16  -0.005 0.01 0.67667 0.02  -0.003 0.01 0.77762 0.01  -0.005 0.01 0.63666 0.03 
 S4 PRS  0.094 0.02 <.00001 3.63  -0.034 0.02 0.05849 0.48  0.043 0.02 0.02089 0.74  0.017 0.02 0.35770 0.12  0.034 0.02 0.07124 0.47 
 S4 sexPRS  -0.007 0.01 0.50585 0.06  0.005 0.01 0.65655 0.03  -0.018 0.01 0.10955 0.35  -0.004 0.01 0.68848 0.02  -0.006 0.01 0.57701 0.04 
 S5 PRS  0.109 0.02 <.00001 4.85  -0.049 0.02 0.00681 1.01  0.039 0.02 0.03327 0.62  0.019 0.02 0.29246 0.16  0.042 0.02 0.02351 0.73 
 S5 sexPRS  -0.012 0.01 0.25290 0.17  0.011 0.01 0.33098 0.13  -0.016 0.01 0.13196 0.30  -0.012 0.01 0.27146 0.16  -0.013 0.01 0.23754 0.19 
 S6 PRS  0.112 0.02 <.00001 5.09  -0.050 0.02 0.00627 1.05  0.041 0.02 0.02486 0.68  0.017 0.02 0.35710 0.13  0.056 0.02 0.00290 1.26 
 S6 sexPRS  -0.013 0.01 0.21892 0.20  0.010 0.01 0.36786 0.11  -0.019 0.01 0.08712 0.39  -0.007 0.01 0.49446 0.06  -0.020 0.01 0.07272 0.44 
 S7 PRS  0.104 0.02 <.00001 4.43  -0.044 0.02 0.01567 0.82  0.045 0.02 0.01308 0.85  0.021 0.02 0.25218 0.19  0.048 0.02 0.01166 0.92 
 S7 sexPRS  -0.012 0.01 0.26287 0.16  0.004 0.01 0.69749 0.02  -0.021 0.01 0.05160 0.51  -0.007 0.01 0.49792 0.06  -0.015 0.01 0.17390 0.26 
 S8 PRS  0.103 0.02 <.00001 4.37  -0.043 0.02 0.01995 0.76  0.047 0.02 0.01038 0.91  0.019 0.02 0.29149 0.16  0.044 0.02 0.01875 0.80 
 S8 sexPRS  -0.012 0.01 0.25377 0.17  0.003 0.01 0.78016 0.01  -0.022 0.01 0.04248 0.56  -0.007 0.01 0.51094 0.06  -0.014 0.01 0.20142 0.23 
 
Age at 
starting 
regular 
smoking 
S1 PRS  0.292 0.25 0.24079 0.64  0.165 0.26 0.51971 0.20  -0.115 0.26 0.65401 0.10  0.344 0.25 0.17048 0.89  -0.038 0.25 0.87837 0.01 
 S1 sexPRS  -0.223 0.15 0.13575 1.04  0.012 0.15 0.93994 0.00  0.056 0.15 0.71231 0.07  -0.172 0.15 0.25309 0.62  -0.006 0.15 0.96955 0.00 
 S2 PRS  -0.059 0.26 0.81942 0.03  0.137 0.25 0.59240 0.14  -0.030 0.26 0.90633 0.01  0.475 0.26 0.06541 1.69  -0.204 0.26 0.42561 0.32 
 S2 sexPRS  -0.063 0.15 0.68145 0.08  0.005 0.15 0.97588 0.00  -0.016 0.15 0.91513 0.01  -0.226 0.15 0.14098 1.07  0.019 0.15 0.90052 0.01 
 S3 PRS  -0.036 0.26 0.89117 0.01  -0.022 0.26 0.93233 0.00  0.029 0.25 0.90733 0.01  0.245 0.26 0.35486 0.45  0.159 0.26 0.53640 0.19 
 S3 sexPRS  -0.065 0.16 0.67861 0.09  0.032 0.15 0.83491 0.02  0.005 0.15 0.97316 0.00  -0.111 0.16 0.48236 0.25  -0.211 0.15 0.16501 0.92 
 S4 PRS  -0.008 0.26 0.97550 0.00  0.535 0.25 0.03252 2.15  -0.286 0.26 0.26320 0.61  0.144 0.26 0.57663 0.16  -0.128 0.26 0.61994 0.12 
 S4 sexPRS  -0.108 0.16 0.48884 0.24  -0.238 0.15 0.10867 1.17  0.187 0.15 0.22397 0.72  -0.075 0.15 0.62737 0.12  0.011 0.15 0.94297 0.00 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S5 PRS  -0.318 0.26 0.22244 0.75  0.339 0.26 0.18701 0.86  -0.178 0.26 0.49492 0.24  -0.037 0.25 0.88458 0.01  -0.332 0.27 0.21078 0.82 
 S5 sexPRS  0.066 0.16 0.67357 0.09  -0.097 0.15 0.52357 0.20  0.158 0.16 0.30947 0.51  -0.038 0.15 0.80009 0.03  0.114 0.16 0.46721 0.27 
 S6 PRS  -0.178 0.26 0.49306 0.24  0.168 0.26 0.51462 0.21  -0.101 0.26 0.69682 0.08  -0.026 0.26 0.91839 0.01  -0.079 0.26 0.76321 0.05 
 S6 sexPRS  0.007 0.16 0.96574 0.00  0.015 0.15 0.92112 0.00  0.090 0.15 0.55696 0.17  -0.035 0.15 0.81964 0.03  -0.056 0.15 0.71868 0.06 
 S7 PRS  -0.149 0.26 0.56762 0.16  0.170 0.25 0.50598 0.22  0.015 0.26 0.95244 0.00  -0.036 0.26 0.88967 0.01  -0.047 0.27 0.86364 0.02 
 S7 sexPRS  -0.016 0.16 0.91771 0.01  -0.016 0.15 0.91758 0.01  0.009 0.15 0.95104 0.00  -0.010 0.15 0.94826 0.00  -0.032 0.16 0.84269 0.02 
 S8 PRS  -0.149 0.26 0.56733 0.17  0.128 0.25 0.61559 0.12  0.038 0.26 0.88470 0.01  -0.041 0.26 0.87265 0.01  -0.025 0.27 0.92589 0.00 
 S8 sexPRS  -0.012 0.16 0.93772 0.00  -0.003 0.15 0.98307 0.00  0.002 0.15 0.99158 0.00  -0.005 0.15 0.97485 0.00  -0.042 0.16 0.79209 0.04 
 
Cigarettes per 
day 
S1 PRS  0.170 0.08 0.02629 2.50  -0.227 0.08 0.00385 4.43  0.037 0.08 0.63596 0.12  0.042 0.08 0.58548 0.15  0.073 0.08 0.33592 0.47 
 S1 sexPRS  -0.080 0.05 0.08059 1.53  0.139 0.05 0.00299 4.60  0.029 0.05 0.53444 0.20  -0.008 0.05 0.86364 0.01  -0.042 0.04 0.34083 0.44 
 S2 PRS  0.114 0.08 0.14263 1.13  -0.080 0.08 0.31076 0.54  0.056 0.08 0.47470 0.27  0.042 0.08 0.59654 0.15  0.121 0.08 0.12050 1.29 
 S2 sexPRS  -0.023 0.05 0.61659 0.13  0.039 0.05 0.40482 0.36  0.023 0.05 0.61806 0.13  -0.005 0.05 0.91407 0.01  -0.062 0.05 0.17969 0.92 
 S3 PRS  0.015 0.08 0.84597 0.02  0.061 0.08 0.43915 0.32  0.121 0.08 0.11912 1.26  -0.001 0.08 0.99055 0.00  0.039 0.08 0.61199 0.14 
 S3 sexPRS  0.059 0.05 0.21278 0.83  -0.065 0.05 0.16776 0.99  -0.004 0.05 0.93535 0.00  0.027 0.05 0.56909 0.18  -0.023 0.05 0.62200 0.12 
 S4 PRS  0.037 0.08 0.63788 0.12  -0.034 0.08 0.65434 0.10  0.129 0.08 0.09822 1.43  -0.099 0.08 0.21359 0.86  0.087 0.08 0.27445 0.65 
 S4 sexPRS  0.035 0.05 0.45827 0.29  -0.019 0.05 0.66934 0.09  0.002 0.05 0.96855 0.00  0.086 0.05 0.06658 1.81  -0.048 0.05 0.30627 0.54 
 S5 PRS  0.078 0.08 0.32155 0.52  -0.017 0.08 0.82699 0.03  0.126 0.08 0.11302 1.36  -0.114 0.08 0.14468 1.16  0.103 0.08 0.20611 0.92 
 S5 sexPRS  0.025 0.05 0.58953 0.15  -0.035 0.05 0.45411 0.29  0.016 0.05 0.73332 0.06  0.101 0.05 0.02936 2.51  -0.057 0.05 0.23342 0.78 
 S6 PRS  0.089 0.08 0.26114 0.68  -0.000 0.08 0.99660 0.00  0.112 0.08 0.15615 1.08  -0.094 0.08 0.24035 0.79  0.115 0.08 0.15813 1.13 
 S6 sexPRS  0.009 0.05 0.85450 0.02  -0.049 0.05 0.29465 0.58  0.023 0.05 0.61665 0.13  0.093 0.05 0.04911 2.12  -0.071 0.05 0.13848 1.19 
 S7 PRS  0.060 0.08 0.44431 0.31  -0.054 0.08 0.49066 0.26  0.107 0.08 0.17524 0.99  -0.090 0.08 0.26068 0.72  0.140 0.08 0.09668 1.67 
 S7 sexPRS  0.022 0.05 0.63366 0.12  -0.017 0.05 0.71714 0.07  0.015 0.05 0.74883 0.05  0.081 0.05 0.08369 1.62  -0.089 0.05 0.06999 1.87 
 S8 PRS  0.072 0.08 0.36405 0.44  -0.050 0.08 0.52683 0.22  0.102 0.08 0.19902 0.90  -0.088 0.08 0.26837 0.70  0.136 0.08 0.10388 1.58 
 S8 sexPRS  0.016 0.05 0.73415 0.06  -0.017 0.05 0.70930 0.07  0.018 0.05 0.70400 0.08  0.079 0.05 0.08996 1.55  -0.086 0.05 0.07684 1.77 
 
Smoking 
cessation 
S1 PRS  0.008 0.03 0.74262 0.03  -0.048 0.03 0.06608 0.93  0.037 0.03 0.14863 0.56  0.049 0.03 0.05816 0.98  0.011 0.03 0.65826 0.05 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S1 sexPRS  0.003 0.02 0.86657 0.01  0.030 0.02 0.06696 1.01  -0.009 0.02 0.56368 0.10  -0.021 0.02 0.19526 0.49  -0.011 0.02 0.47043 0.15 
 S2 PRS  0.004 0.03 0.87815 0.01  -0.007 0.03 0.79555 0.02  0.040 0.03 0.10942 0.67  0.043 0.03 0.09933 0.77  0.019 0.03 0.44738 0.16 
 S2 sexPRS  0.015 0.02 0.35258 0.24  0.005 0.02 0.74439 0.03  -0.012 0.02 0.46251 0.15  -0.026 0.02 0.11175 0.77  -0.013 0.02 0.43093 0.18 
 S3 PRS  0.008 0.03 0.76910 0.02  0.009 0.03 0.71789 0.03  0.033 0.03 0.18918 0.45  0.057 0.03 0.02841 1.34  0.014 0.03 0.57710 0.08 
 S3 sexPRS  0.014 0.02 0.39669 0.21  -0.006 0.02 0.69153 0.04  -0.008 0.02 0.62510 0.07  -0.027 0.02 0.08979 0.86  -0.013 0.02 0.40240 0.20 
 S4 PRS  0.044 0.03 0.09055 0.79  -0.001 0.02 0.95626 0.00  0.039 0.03 0.12433 0.64  0.020 0.03 0.43205 0.17  -0.012 0.03 0.64848 0.06 
 S4 sexPRS  -0.003 0.02 0.84570 0.01  -0.006 0.02 0.67767 0.05  -0.010 0.02 0.52843 0.12  -0.004 0.02 0.79267 0.02  0.012 0.02 0.45664 0.16 
 S5 PRS  0.033 0.03 0.21090 0.43  -0.002 0.03 0.94786 0.00  0.009 0.03 0.71977 0.03  0.015 0.03 0.56181 0.09  -0.011 0.03 0.67792 0.05 
 S5 sexPRS  0.001 0.02 0.96630 0.00  -0.010 0.02 0.54380 0.10  0.004 0.02 0.77725 0.02  0.002 0.02 0.90212 0.00  0.012 0.02 0.44106 0.18 
 S6 PRS  0.020 0.03 0.44389 0.16  0.008 0.03 0.75656 0.03  0.005 0.03 0.84756 0.01  0.016 0.03 0.53764 0.11  0.004 0.03 0.86956 0.01 
 S6 sexPRS  0.006 0.02 0.73144 0.04  -0.015 0.02 0.35071 0.25  0.005 0.02 0.72928 0.03  -0.001 0.02 0.95269 0.00  0.000 0.02 0.99511 0.00 
 S7 PRS  0.009 0.03 0.71890 0.04  -0.001 0.03 0.95441 0.00  0.002 0.03 0.94832 0.00  0.010 0.03 0.69713 0.04  0.002 0.03 0.93385 0.00 
 S7 sexPRS  0.009 0.02 0.58337 0.09  -0.008 0.02 0.60413 0.08  0.003 0.02 0.82951 0.01  -0.000 0.02 0.98193 0.00  0.001 0.02 0.96963 0.00 
 S8 PRS  0.011 0.03 0.66494 0.05  -0.002 0.03 0.94097 0.00  0.002 0.03 0.94767 0.00  0.012 0.03 0.64333 0.06  0.004 0.03 0.89247 0.01 
 S8 sexPRS  0.007 0.02 0.66495 0.05  -0.008 0.02 0.62909 0.07  0.004 0.02 0.78097 0.02  -0.001 0.02 0.94949 0.00  -0.000 0.02 0.98869 0.00 
 
Drinking 
initiation 
S1 PRS  0.022 0.02 0.13818 0.32  -0.009 0.02 0.57203 0.05  0.023 0.02 0.13514 0.33  -0.000 0.02 0.98252 0.00  0.001 0.01 0.94133 0.00 
 S1 sexPRS  -0.013 0.01 0.14890 0.30  -0.003 0.01 0.74921 0.02  -0.013 0.01 0.14932 0.31  -0.003 0.01 0.74926 0.02  0.005 0.01 0.61471 0.04 
 S2 PRS  0.025 0.02 0.10132 0.39  0.014 0.02 0.37133 0.12  0.029 0.02 0.05775 0.53  0.005 0.02 0.72471 0.02  0.004 0.02 0.76833 0.01 
 S2 sexPRS  -0.017 0.01 0.06517 0.49  -0.007 0.01 0.44218 0.09  -0.017 0.01 0.06090 0.52  -0.006 0.01 0.54928 0.05  0.006 0.01 0.54410 0.05 
 S3 PRS  0.034 0.02 0.02386 0.75  0.003 0.02 0.85638 0.00  0.020 0.02 0.18630 0.26  0.019 0.02 0.21506 0.23  0.000 0.02 0.98005 0.00 
 S3 sexPRS  -0.017 0.01 0.05712 0.52  0.002 0.01 0.83336 0.01  -0.016 0.01 0.07352 0.47  -0.016 0.01 0.08518 0.44  0.013 0.01 0.13968 0.32 
 S4 PRS  0.028 0.02 0.06404 0.50  0.003 0.02 0.81604 0.01  0.015 0.02 0.33317 0.14  0.020 0.02 0.17641 0.27  0.011 0.02 0.49379 0.07 
 S4 sexPRS  -0.012 0.01 0.18913 0.25  0.004 0.01 0.64750 0.03  -0.015 0.01 0.11422 0.37  -0.019 0.01 0.03583 0.64  0.007 0.01 0.44686 0.09 
 S5 PRS  0.013 0.02 0.39618 0.10  -0.001 0.02 0.97213 0.00  0.003 0.02 0.84763 0.01  0.013 0.01 0.37086 0.12  0.011 0.02 0.46573 0.08 
 S5 sexPRS  -0.001 0.01 0.92183 0.00  0.006 0.01 0.48110 0.07  -0.010 0.01 0.27892 0.17  -0.013 0.01 0.13167 0.32  0.007 0.01 0.42056 0.10 
 S6 PRS  0.015 0.02 0.31309 0.15  -0.003 0.02 0.86924 0.00  0.008 0.02 0.59220 0.04  0.013 0.01 0.39695 0.11  0.022 0.02 0.15618 0.30 
 S6 sexPRS  -0.001 0.01 0.87915 0.00  0.006 0.01 0.52054 0.06  -0.013 0.01 0.14273 0.31  -0.013 0.01 0.15007 0.29  0.002 0.01 0.86041 0.00 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S7 PRS  0.012 0.02 0.42961 0.09  -0.003 0.02 0.85970 0.00  0.013 0.02 0.37037 0.12  0.011 0.01 0.46425 0.08  0.025 0.02 0.10846 0.40 
 S7 sexPRS  -0.000 0.01 0.99868 0.00  0.003 0.01 0.76821 0.01  -0.017 0.01 0.06135 0.50  -0.013 0.01 0.12358 0.33  -0.001 0.01 0.93065 0.00 
 S8 PRS  0.011 0.02 0.45221 0.08  -0.002 0.02 0.88505 0.00  0.015 0.02 0.33364 0.14  0.011 0.01 0.45096 0.08  0.025 0.02 0.11328 0.38 
 S8 sexPRS  -0.000 0.01 0.98807 0.00  0.002 0.01 0.84869 0.01  -0.018 0.01 0.05088 0.55  -0.014 0.01 0.12163 0.33  -0.001 0.01 0.89990 0.00 
 
Drinks per 
week 
S1 PRS  2.419 0.57 0.00003 3.21  -1.739 0.59 0.00317 1.63  1.047 0.59 0.07450 0.60  -1.357 0.59 0.02188 1.01  1.782 0.57 0.00187 1.78 
 S1 sexPRS  -1.260 0.35 0.00036 2.40  0.830 0.36 0.02189 1.03  -0.472 0.36 0.18863 0.34  0.718 0.36 0.04895 0.78  -0.690 0.35 0.04951 0.73 
 S2 PRS  2.840 0.58 <.00001 4.39  -2.714 0.58 <.00001 3.91  0.884 0.58 0.12992 0.42  -1.170 0.59 0.04858 0.75  2.463 0.58 0.00002 3.39 
 S2 sexPRS  -1.361 0.35 0.00013 2.77  1.307 0.36 0.00029 2.48  -0.400 0.36 0.26459 0.24  0.497 0.36 0.17175 0.37  -0.936 0.36 0.00882 1.33 
 S3 PRS  2.360 0.58 0.00005 3.01  -1.280 0.58 0.02807 0.89  0.438 0.58 0.44985 0.10  -1.197 0.59 0.04299 0.78  3.382 0.58 <.00001 6.26 
 S3 sexPRS  -0.976 0.36 0.00605 1.42  0.539 0.36 0.13347 0.43  -0.126 0.36 0.72421 0.02  0.591 0.36 0.10061 0.53  -1.396 0.35 0.00008 2.94 
 S4 PRS  2.593 0.58 <.00001 3.67  -1.756 0.57 0.00215 1.69  0.826 0.58 0.15507 0.37  -1.222 0.58 0.03556 0.83  3.048 0.59 <.00001 5.07 
 S4 sexPRS  -1.093 0.35 0.00202 1.78  0.790 0.35 0.02571 0.94  -0.350 0.36 0.32791 0.18  0.654 0.35 0.06387 0.66  -1.153 0.36 0.00138 2.01 
 S5 PRS  2.811 0.58 <.00001 4.27  -1.826 0.58 0.00178 1.82  -0.493 0.57 0.38758 0.13  -0.929 0.57 0.10286 0.49  2.734 0.59 <.00001 4.07 
 S5 sexPRS  -1.182 0.36 0.00094 2.07  0.817 0.36 0.02277 1.00  0.364 0.35 0.30251 0.20  0.557 0.35 0.10726 0.48  -1.005 0.36 0.00500 1.53 
 S6 PRS  2.403 0.58 0.00004 3.11  -1.770 0.58 0.00245 1.73  -0.538 0.57 0.34653 0.16  -1.168 0.57 0.04114 0.77  2.760 0.59 <.00001 4.10 
 S6 sexPRS  -0.960 0.36 0.00740 1.36  0.774 0.36 0.03104 0.91  0.388 0.35 0.27064 0.23  0.662 0.35 0.05538 0.68  -1.030 0.36 0.00399 1.59 
 S7 PRS  2.402 0.58 0.00003 3.12  -1.937 0.59 0.00095 2.07  -1.045 0.57 0.06720 0.60  -1.413 0.57 0.01276 1.13  2.558 0.59 0.00002 3.51 
 S7 sexPRS  -1.020 0.36 0.00418 1.54  0.901 0.36 0.01220 1.24  0.639 0.35 0.06894 0.62  0.784 0.34 0.02174 0.96  -0.966 0.36 0.00747 1.40 
 S8 PRS  2.488 0.57 0.00002 3.35  -1.976 0.59 0.00074 2.16  -1.081 0.57 0.05875 0.64  -1.420 0.57 0.01220 1.15  2.706 0.59 <.00001 3.93 
 S8 sexPRS  -1.068 0.36 0.00265 1.69  0.930 0.36 0.00956 1.32  0.650 0.35 0.06447 0.64  0.778 0.34 0.02257 0.95  -1.054 0.36 0.00351 1.67 
 
DSM-IV 
alcohol 
dependence 
S1 PRS  -0.007 0.02 0.65923 0.03  0.014 0.02 0.34355 0.11  -0.009 0.02 0.56722 0.04  -0.009 0.02 0.55151 0.05  0.021 0.02 0.16938 0.24 
 S1 sexPRS  0.016 0.01 0.08969 0.37  -0.011 0.01 0.22614 0.19  0.007 0.01 0.44717 0.07  0.002 0.01 0.85396 0.00  0.001 0.01 0.95223 0.00 
 S2 PRS  -0.016 0.02 0.29971 0.14  0.007 0.02 0.66042 0.02  -0.015 0.02 0.33038 0.12  -0.005 0.02 0.74023 0.01  0.023 0.01 0.12281 0.30 
 S2 sexPRS  0.022 0.01 0.01535 0.75  -0.004 0.01 0.64421 0.03  0.013 0.01 0.18230 0.23  -0.002 0.01 0.83555 0.01  0.002 0.01 0.79880 0.01 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S3 PRS  0.008 0.02 0.57656 0.04  -0.022 0.02 0.14999 0.27  -0.017 0.02 0.26870 0.16  -0.021 0.02 0.17997 0.24  0.033 0.02 0.02975 0.61 
 S3 sexPRS  0.011 0.01 0.24893 0.17  0.008 0.01 0.42294 0.08  0.013 0.01 0.15630 0.26  0.010 0.01 0.30385 0.14  -0.002 0.01 0.84042 0.01 
 S4 PRS  0.024 0.02 0.10395 0.34  -0.021 0.02 0.16186 0.26  -0.011 0.02 0.47384 0.07  -0.016 0.02 0.28829 0.15  0.029 0.02 0.05403 0.47 
 S4 sexPRS  -0.000 0.01 0.99584 0.00  0.008 0.01 0.40569 0.09  0.008 0.01 0.37752 0.10  0.007 0.01 0.46072 0.07  -0.001 0.01 0.91876 0.00 
 S5 PRS  0.032 0.02 0.03394 0.58  -0.041 0.02 0.00741 0.94  -0.010 0.02 0.50489 0.06  -0.027 0.01 0.06690 0.45  0.040 0.02 0.00898 0.87 
 S5 sexPRS  -0.004 0.01 0.63879 0.03  0.017 0.01 0.07092 0.42  0.008 0.01 0.38488 0.10  0.016 0.01 0.07766 0.40  -0.007 0.01 0.44394 0.07 
 S6 PRS  0.027 0.02 0.07638 0.41  -0.050 0.02 0.00110 1.41  -0.006 0.02 0.68708 0.02  -0.025 0.01 0.09296 0.38  0.034 0.02 0.02599 0.63 
 S6 sexPRS  -0.001 0.01 0.87447 0.00  0.023 0.01 0.01314 0.81  0.005 0.01 0.59467 0.04  0.014 0.01 0.12224 0.31  -0.005 0.01 0.63133 0.03 
 S7 PRS  0.024 0.02 0.11549 0.32  -0.049 0.02 0.00145 1.35  -0.009 0.02 0.54468 0.05  -0.036 0.01 0.01675 0.77  0.038 0.02 0.01458 0.77 
 S7 sexPRS  -0.001 0.01 0.94803 0.00  0.022 0.01 0.02035 0.71  0.007 0.01 0.43513 0.08  0.020 0.01 0.02409 0.65  -0.006 0.01 0.51652 0.05 
 S8 PRS  0.024 0.02 0.10790 0.34  -0.049 0.02 0.00146 1.35  -0.004 0.02 0.76661 0.01  -0.037 0.01 0.01225 0.84  0.041 0.02 0.00724 0.93 
 S8 sexPRS  -0.001 0.01 0.92388 0.00  0.021 0.01 0.02219 0.69  0.005 0.01 0.61118 0.03  0.021 0.01 0.01866 0.71  -0.008 0.01 0.38223 0.10 
 
DSM-IV 
nicotine 
dependence 
S1 PRS  0.029 0.02 0.10419 0.36  0.005 0.02 0.79538 0.01  0.018 0.02 0.32815 0.13  0.038 0.02 0.03707 0.60  0.010 0.02 0.55738 0.05 
 S1 sexPRS  0.002 0.01 0.86158 0.00  -0.009 0.01 0.38545 0.10  -0.001 0.01 0.91628 0.00  -0.016 0.01 0.14344 0.29  -0.010 0.01 0.36531 0.11 
 S2 PRS  0.037 0.02 0.03552 0.60  -0.006 0.02 0.71665 0.02  0.018 0.02 0.32932 0.13  0.036 0.02 0.04484 0.55  0.017 0.02 0.32440 0.13 
 S2 sexPRS  0.008 0.01 0.48534 0.07  -0.002 0.01 0.83046 0.01  0.001 0.01 0.91966 0.00  -0.017 0.01 0.11762 0.34  -0.015 0.01 0.15526 0.27 
 S3 PRS  0.045 0.02 0.01191 0.86  -0.017 0.02 0.33409 0.13  0.014 0.02 0.42873 0.09  0.056 0.02 0.00184 1.34  0.016 0.02 0.35633 0.11 
 S3 sexPRS  0.009 0.01 0.38648 0.10  -0.002 0.01 0.84566 0.01  0.006 0.01 0.61898 0.03  -0.024 0.01 0.03081 0.64  -0.015 0.01 0.16106 0.26 
 S4 PRS  0.068 0.02 0.00011 1.99  -0.026 0.02 0.14385 0.29  0.036 0.02 0.04011 0.57  0.043 0.02 0.01437 0.84  0.025 0.02 0.16241 0.26 
 S4 sexPRS  -0.003 0.01 0.80344 0.01  -0.000 0.01 0.97966 0.00  -0.004 0.01 0.68448 0.02  -0.018 0.01 0.10205 0.36  -0.012 0.01 0.26262 0.17 
 S5 PRS  0.070 0.02 0.00008 2.12  -0.011 0.02 0.54712 0.05  0.054 0.02 0.00232 1.25  0.023 0.02 0.19781 0.23  0.044 0.02 0.01261 0.84 
 S5 sexPRS  -0.001 0.01 0.89600 0.00  -0.015 0.01 0.17476 0.25  -0.014 0.01 0.21178 0.21  -0.002 0.01 0.84104 0.01  -0.024 0.01 0.03127 0.62 
 S6 PRS  0.075 0.02 0.00003 2.39  -0.022 0.02 0.22808 0.20  0.048 0.02 0.00643 1.00  0.027 0.02 0.12812 0.33  0.053 0.02 0.00321 1.16 
 S6 sexPRS  -0.003 0.01 0.77672 0.01  -0.011 0.01 0.32560 0.13  -0.008 0.01 0.46022 0.07  -0.004 0.01 0.73825 0.02  -0.028 0.01 0.01168 0.85 
 S7 PRS  0.067 0.02 0.00013 1.98  -0.032 0.02 0.07861 0.43  0.056 0.02 0.00152 1.36  0.018 0.02 0.30859 0.15  0.050 0.02 0.00558 1.04 
 S7 sexPRS  0.000 0.01 0.98468 0.00  -0.005 0.01 0.63007 0.03  -0.015 0.01 0.16877 0.25  0.000 0.01 0.97084 0.00  -0.024 0.01 0.02989 0.64 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S8 PRS  0.068 0.02 0.00012 2.00  -0.029 0.02 0.10466 0.36  0.060 0.02 0.00068 1.56  0.018 0.02 0.31632 0.14  0.049 0.02 0.00680 0.99 
 S8 sexPRS  -0.000 0.01 0.96544 0.00  -0.007 0.01 0.53665 0.05  -0.017 0.01 0.12254 0.32  0.000 0.01 0.96514 0.00  -0.024 0.01 0.03429 0.61 
 
FTND-based 
nicotine 
dependence 
S1 PRS  0.040 0.02 0.01361 0.82  -0.015 0.02 0.36542 0.11  0.029 0.02 0.08548 0.41  0.054 0.02 0.00118 1.44  -0.002 0.02 0.92368 0.00 
 S1 sexPRS  -0.009 0.01 0.37315 0.11  0.004 0.01 0.67674 0.02  -0.001 0.01 0.95520 0.00  -0.020 0.01 0.05187 0.52  0.001 0.01 0.91523 0.00 
 S2 PRS  0.053 0.02 0.00129 1.41  -0.029 0.02 0.08107 0.40  0.034 0.02 0.04320 0.56  0.059 0.02 0.00044 1.70  0.009 0.02 0.59909 0.04 
 S2 sexPRS  -0.006 0.01 0.55456 0.05  0.011 0.01 0.30011 0.14  -0.002 0.01 0.86182 0.00  -0.027 0.01 0.00926 0.93  -0.003 0.01 0.75520 0.01 
 S3 PRS  0.053 0.02 0.00122 1.42  -0.039 0.02 0.01940 0.74  0.036 0.02 0.02754 0.66  0.055 0.02 0.00103 1.49  -0.013 0.02 0.41728 0.09 
 S3 sexPRS  0.000 0.01 0.96289 0.00  0.014 0.01 0.15966 0.27  -0.002 0.01 0.81109 0.01  -0.020 0.01 0.05212 0.52  0.009 0.01 0.37138 0.11 
 S4 PRS  0.068 0.02 0.00003 2.35  -0.046 0.02 0.00504 1.07  0.041 0.02 0.01173 0.86  0.040 0.02 0.01407 0.84  -0.003 0.02 0.84042 0.01 
 S4 sexPRS  -0.005 0.01 0.60739 0.03  0.013 0.01 0.20802 0.21  -0.001 0.01 0.94445 0.00  -0.008 0.01 0.40501 0.09  0.007 0.01 0.50824 0.06 
 S5 PRS  0.077 0.02 <.00001 2.99  -0.050 0.02 0.00233 1.27  0.050 0.02 0.00213 1.26  0.024 0.02 0.14383 0.30  0.010 0.02 0.55407 0.05 
 S5 sexPRS  -0.010 0.01 0.31188 0.14  0.011 0.01 0.26740 0.17  -0.004 0.01 0.69216 0.02  0.004 0.01 0.70090 0.02  -0.000 0.01 0.96831 0.00 
 S6 PRS  0.084 0.02 <.00001 3.57  -0.050 0.02 0.00275 1.24  0.039 0.02 0.01692 0.77  0.024 0.02 0.14402 0.30  0.010 0.02 0.55014 0.05 
 S6 sexPRS  -0.015 0.01 0.14955 0.28  0.009 0.01 0.38882 0.10  0.005 0.01 0.63986 0.03  0.004 0.01 0.65557 0.03  0.001 0.01 0.95644 0.00 
 S7 PRS  0.077 0.02 <.00001 2.99  -0.053 0.02 0.00144 1.40  0.039 0.02 0.01643 0.78  0.022 0.02 0.17960 0.26  0.014 0.02 0.38787 0.10 
 S7 sexPRS  -0.010 0.01 0.33506 0.12  0.010 0.01 0.33713 0.13  0.001 0.01 0.94836 0.00  0.002 0.01 0.82264 0.01  -0.002 0.01 0.85447 0.00 
 S8 PRS  0.078 0.02 <.00001 3.10  -0.053 0.02 0.00135 1.42  0.043 0.02 0.00793 0.95  0.022 0.02 0.17792 0.26  0.014 0.02 0.40943 0.09 
 S8 sexPRS  -0.011 0.01 0.28726 0.15  0.011 0.01 0.29014 0.15  -0.001 0.01 0.89461 0.00  0.002 0.01 0.84147 0.01  -0.002 0.01 0.87994 0.00 
 
DSM-IV 
conduct 
disorder 
S1 PRS  0.001 0.01 0.91085 0.00  -0.013 0.01 0.05780 0.53  0.011 0.01 0.09754 0.41  0.004 0.01 0.60459 0.04  -0.017 0.01 0.00836 1.02 
 S1 sexPRS  0.003 0.00 0.52801 0.06  0.006 0.00 0.13250 0.33  -0.006 0.00 0.14826 0.31  -0.003 0.00 0.52788 0.06  0.010 0.00 0.01862 0.80 
 S2 PRS  0.011 0.01 0.08766 0.43  0.004 0.01 0.55982 0.05  0.010 0.01 0.14303 0.32  0.005 0.01 0.42622 0.10  -0.012 0.01 0.06378 0.50 
 S2 sexPRS  -0.003 0.00 0.39656 0.11  -0.004 0.00 0.32487 0.14  -0.005 0.00 0.24525 0.20  -0.004 0.00 0.30863 0.16  0.007 0.00 0.07610 0.45 
 S3 PRS  0.013 0.01 0.04490 0.59  -0.015 0.01 0.02884 0.71  0.020 0.01 0.00224 1.37  -0.001 0.01 0.85267 0.01  -0.012 0.01 0.07113 0.48 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S3 sexPRS  -0.005 0.00 0.25442 0.19  0.007 0.00 0.10623 0.39  -0.011 0.00 0.01056 0.96  -0.000 0.00 0.95790 0.00  0.006 0.00 0.15930 0.29 
 S4 PRS  0.022 0.01 0.00071 1.67  -0.020 0.01 0.00325 1.30  0.019 0.01 0.00471 1.18  0.003 0.01 0.62698 0.04  -0.007 0.01 0.28398 0.17 
 S4 sexPRS  -0.009 0.00 0.02196 0.76  0.008 0.00 0.06761 0.50  -0.010 0.00 0.01571 0.86  -0.001 0.00 0.74626 0.02  0.004 0.00 0.36382 0.12 
 S5 PRS  0.025 0.01 0.00020 2.06  -0.014 0.01 0.04399 0.61  0.021 0.01 0.00166 1.47  0.006 0.01 0.36048 0.13  -0.001 0.01 0.83593 0.01 
 S5 sexPRS  -0.010 0.00 0.01326 0.90  0.004 0.00 0.36934 0.12  -0.011 0.00 0.00741 1.06  -0.002 0.00 0.64598 0.03  0.000 0.00 0.95353 0.00 
 S6 PRS  0.023 0.01 0.00054 1.77  -0.016 0.01 0.02129 0.80  0.021 0.01 0.00146 1.51  0.010 0.01 0.13153 0.35  -0.001 0.01 0.82426 0.01 
 S6 sexPRS  -0.010 0.00 0.02068 0.79  0.005 0.00 0.23308 0.21  -0.011 0.00 0.00777 1.05  -0.004 0.00 0.27304 0.18  0.000 0.00 0.97770 0.00 
 S7 PRS  0.027 0.01 0.00005 2.42  -0.016 0.01 0.02004 0.82  0.023 0.01 0.00057 1.77  0.006 0.01 0.33579 0.14  -0.002 0.01 0.78815 0.01 
 S7 sexPRS  -0.012 0.00 0.00407 1.21  0.005 0.00 0.27058 0.18  -0.011 0.00 0.00482 1.18  -0.002 0.00 0.53255 0.06  0.000 0.00 0.98364 0.00 
 S8 PRS  0.027 0.01 0.00005 2.45  -0.015 0.01 0.02205 0.80  0.022 0.01 0.00074 1.71  0.006 0.01 0.33593 0.14  -0.000 0.01 0.95989 0.00 
 S8 sexPRS  -0.012 0.00 0.00404 1.22  0.004 0.00 0.29952 0.16  -0.011 0.00 0.00553 1.15  -0.002 0.00 0.52988 0.06  -0.001 0.00 0.90204 0.00 
 
DSM-IV 
antisocial 
personality 
disorder 
S1 PRS  0.005 0.01 0.31935 0.14  -0.009 0.01 0.08088 0.44  0.005 0.01 0.32430 0.14  -0.007 0.01 0.19770 0.24  -0.008 0.01 0.12620 0.34 
 S1 sexPRS  -0.001 0.00 0.68680 0.02  0.005 0.00 0.13369 0.32  -0.002 0.00 0.53688 0.06  0.004 0.00 0.27093 0.18  0.005 0.00 0.17869 0.26 
 S2 PRS  0.009 0.01 0.08933 0.42  -0.004 0.01 0.45059 0.08  0.006 0.01 0.30310 0.15  -0.007 0.01 0.20429 0.24  -0.003 0.01 0.60479 0.04 
 S2 sexPRS  -0.003 0.00 0.36327 0.12  0.002 0.00 0.58623 0.04  -0.002 0.00 0.61719 0.04  0.004 0.00 0.29110 0.16  0.002 0.00 0.49872 0.06 
 S3 PRS  0.011 0.01 0.05093 0.55  -0.014 0.01 0.01167 0.93  0.015 0.01 0.00779 1.02  0.004 0.01 0.46149 0.08  -0.004 0.01 0.41437 0.10 
 S3 sexPRS  -0.004 0.00 0.24055 0.20  0.006 0.00 0.07743 0.46  -0.007 0.00 0.04504 0.58  -0.001 0.00 0.66436 0.03  0.003 0.00 0.41321 0.10 
 S4 PRS  0.008 0.01 0.14240 0.31  -0.017 0.01 0.00158 1.47  0.015 0.01 0.00528 1.12  0.013 0.01 0.01567 0.86  -0.002 0.01 0.76116 0.01 
 S4 sexPRS  -0.002 0.00 0.50849 0.06  0.007 0.00 0.03911 0.62  -0.007 0.00 0.02616 0.71  -0.006 0.00 0.08295 0.44  0.001 0.00 0.73415 0.02 
 S5 PRS  0.012 0.01 0.03173 0.67  -0.018 0.01 0.00113 1.55  0.015 0.01 0.00751 1.03  0.011 0.01 0.03094 0.68  0.002 0.01 0.69473 0.02 
 S5 sexPRS  -0.004 0.00 0.18053 0.26  0.007 0.00 0.03557 0.65  -0.007 0.00 0.03160 0.67  -0.005 0.00 0.15263 0.29  -0.001 0.00 0.81864 0.01 
 S6 PRS  0.011 0.01 0.04451 0.58  -0.016 0.01 0.00329 1.27  0.011 0.01 0.03850 0.62  0.011 0.01 0.04619 0.58  0.005 0.01 0.34578 0.13 
 S6 sexPRS  -0.004 0.00 0.23582 0.20  0.006 0.00 0.05739 0.53  -0.005 0.00 0.10715 0.38  -0.004 0.00 0.17691 0.26  -0.002 0.00 0.52821 0.06 
 S7 PRS  0.014 0.01 0.01066 0.94  -0.017 0.01 0.00199 1.41  0.013 0.01 0.01784 0.81  0.009 0.01 0.07942 0.45  0.010 0.01 0.08032 0.45 
 S7 sexPRS  -0.005 0.00 0.11433 0.36  0.007 0.00 0.05148 0.56  -0.007 0.00 0.04797 0.57  -0.003 0.00 0.28544 0.17  -0.005 0.00 0.15947 0.29 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S8 PRS  0.015 0.01 0.00606 1.09  -0.017 0.01 0.00180 1.44  0.013 0.01 0.01702 0.83  0.009 0.01 0.09995 0.40  0.010 0.01 0.08698 0.43 
 S8 sexPRS  -0.006 0.00 0.08193 0.44  0.007 0.00 0.04730 0.58  -0.007 0.00 0.04389 0.59  -0.003 0.00 0.32200 0.14  -0.005 0.00 0.17840 0.26 
 
DSM-IV 
major 
depressive 
disorder 
S1 PRS  -0.004 0.02 0.83915 0.01  0.007 0.02 0.68379 0.02  0.020 0.02 0.24901 0.19  -0.029 0.02 0.10041 0.39  -0.018 0.02 0.29796 0.15 
 S1 sexPRS  0.008 0.01 0.43815 0.09  0.001 0.01 0.91408 0.00  -0.005 0.01 0.66984 0.03  0.021 0.01 0.05273 0.54  0.010 0.01 0.34616 0.12 
 S2 PRS  -0.009 0.02 0.60891 0.04  0.016 0.02 0.35126 0.12  0.025 0.02 0.15109 0.30  -0.028 0.02 0.11291 0.36  0.004 0.02 0.79665 0.01 
 S2 sexPRS  0.007 0.01 0.49794 0.07  -0.002 0.01 0.84083 0.01  -0.007 0.01 0.49563 0.07  0.018 0.01 0.08729 0.42  -0.004 0.01 0.70517 0.02 
 S3 PRS  0.006 0.02 0.74828 0.01  -0.024 0.02 0.17251 0.27  0.021 0.02 0.23565 0.20  -0.031 0.02 0.07813 0.45  0.011 0.02 0.52475 0.06 
 S3 sexPRS  0.003 0.01 0.80679 0.01  0.014 0.01 0.17779 0.26  -0.006 0.01 0.59178 0.04  0.019 0.01 0.08311 0.43  -0.004 0.01 0.68384 0.02 
 S4 PRS  0.012 0.02 0.50068 0.06  -0.021 0.02 0.22150 0.22  0.029 0.02 0.08901 0.41  0.003 0.02 0.88396 0.00  0.019 0.02 0.28167 0.16 
 S4 sexPRS  0.001 0.01 0.88935 0.00  0.009 0.01 0.39586 0.10  -0.013 0.01 0.22723 0.21  -0.004 0.01 0.72648 0.02  -0.013 0.01 0.21236 0.22 
 S5 PRS  0.005 0.02 0.76799 0.01  -0.028 0.02 0.10789 0.38  0.041 0.02 0.01772 0.81  -0.004 0.02 0.82216 0.01  0.020 0.02 0.25840 0.18 
 S5 sexPRS  0.006 0.01 0.60000 0.04  0.014 0.01 0.20413 0.23  -0.016 0.01 0.13356 0.32  0.004 0.01 0.66626 0.03  -0.010 0.01 0.34978 0.12 
 S6 PRS  -0.003 0.02 0.87358 0.00  -0.027 0.02 0.12617 0.34  0.033 0.02 0.05272 0.54  -0.003 0.02 0.87507 0.00  0.020 0.02 0.24470 0.19 
 S6 sexPRS  0.010 0.01 0.32856 0.14  0.013 0.01 0.20922 0.23  -0.013 0.01 0.22576 0.21  0.005 0.01 0.63089 0.03  -0.008 0.01 0.43913 0.08 
 S7 PRS  -0.004 0.02 0.80775 0.01  -0.023 0.02 0.18941 0.25  0.031 0.02 0.07187 0.47  -0.005 0.02 0.76737 0.01  0.019 0.02 0.27327 0.17 
 S7 sexPRS  0.013 0.01 0.21749 0.22  0.010 0.01 0.35749 0.12  -0.012 0.01 0.25875 0.18  0.006 0.01 0.53956 0.05  -0.006 0.01 0.57152 0.05 
 S8 PRS  -0.003 0.02 0.86304 0.00  -0.017 0.02 0.33987 0.13  0.034 0.02 0.04936 0.56  -0.007 0.02 0.69575 0.02  0.021 0.02 0.23969 0.20 
 S8 sexPRS  0.012 0.01 0.24847 0.19  0.007 0.01 0.51411 0.06  -0.014 0.01 0.18964 0.25  0.007 0.01 0.50011 0.07  -0.007 0.01 0.54049 0.05 
 
DSM-IV 
panic 
disorder 
S1 PRS  -0.013 0.01 0.09118 0.42  -0.007 0.01 0.39481 0.11  0.008 0.01 0.32881 0.14  -0.004 0.01 0.63342 0.03  -0.006 0.01 0.46838 0.08 
 S1 sexPRS  0.011 0.00 0.02992 0.70  0.006 0.00 0.23232 0.21  -0.004 0.00 0.37561 0.12  0.003 0.00 0.56034 0.05  0.006 0.00 0.23559 0.21 
 S2 PRS  -0.005 0.01 0.53468 0.06  0.013 0.01 0.09561 0.41  0.004 0.01 0.62871 0.03  -0.001 0.01 0.94460 0.00  -0.003 0.01 0.70388 0.02 
 S2 sexPRS  0.007 0.00 0.17696 0.27  -0.008 0.00 0.10728 0.38  -0.002 0.00 0.70560 0.02  0.001 0.00 0.82497 0.01  0.003 0.00 0.59415 0.04 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
 
 
Supplementary table page 56 
 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S3 PRS  -0.008 0.01 0.28828 0.16  -0.000 0.01 0.98213 0.00  0.002 0.01 0.78170 0.01  0.009 0.01 0.27520 0.18  0.002 0.01 0.76982 0.01 
 S3 sexPRS  0.009 0.00 0.07177 0.47  -0.001 0.00 0.85954 0.00  0.001 0.00 0.82645 0.01  -0.004 0.00 0.41739 0.10  -0.000 0.00 0.99369 0.00 
 S4 PRS  -0.002 0.01 0.80587 0.01  -0.007 0.01 0.38105 0.12  0.009 0.01 0.27331 0.18  0.009 0.01 0.24452 0.20  0.005 0.01 0.51678 0.06 
 S4 sexPRS  0.005 0.00 0.33087 0.14  0.004 0.00 0.43606 0.09  -0.002 0.00 0.64567 0.03  -0.003 0.00 0.56315 0.05  -0.004 0.00 0.41128 0.10 
 S5 PRS  -0.001 0.01 0.85628 0.00  -0.000 0.01 0.98555 0.00  0.002 0.01 0.80493 0.01  0.004 0.01 0.61751 0.04  0.004 0.01 0.65046 0.03 
 S5 sexPRS  0.004 0.00 0.38541 0.11  -0.001 0.00 0.81780 0.01  0.003 0.00 0.60333 0.04  0.002 0.00 0.72321 0.02  -0.001 0.00 0.81911 0.01 
 S6 PRS  -0.002 0.01 0.82368 0.01  -0.004 0.01 0.60752 0.04  0.002 0.01 0.84624 0.01  0.001 0.01 0.86434 0.00  0.002 0.01 0.78610 0.01 
 S6 sexPRS  0.005 0.00 0.33245 0.14  0.001 0.00 0.84175 0.01  0.002 0.00 0.67086 0.03  0.003 0.00 0.49561 0.07  -0.000 0.00 0.94475 0.00 
 S7 PRS  -0.005 0.01 0.54731 0.05  -0.007 0.01 0.38167 0.12  -0.002 0.01 0.75362 0.01  -0.001 0.01 0.92759 0.00  -0.001 0.01 0.86352 0.00 
 S7 sexPRS  0.007 0.00 0.13394 0.33  0.002 0.00 0.74378 0.02  0.004 0.00 0.36425 0.12  0.004 0.00 0.38710 0.11  0.002 0.00 0.72033 0.02 
 S8 PRS  -0.005 0.01 0.54152 0.05  -0.008 0.01 0.31903 0.15  -0.003 0.01 0.70217 0.02  -0.002 0.01 0.81628 0.01  -0.000 0.01 0.97750 0.00 
 S8 sexPRS  0.007 0.00 0.13359 0.33  0.002 0.00 0.62102 0.04  0.005 0.00 0.33740 0.14  0.005 0.00 0.30576 0.15  0.001 0.00 0.85070 0.01 
 
DSM-IV 
social anxiety 
disorder 
S1 PRS  -0.014 0.01 0.33970 0.13  -0.015 0.01 0.29501 0.16  0.007 0.02 0.65796 0.03  -0.010 0.02 0.52370 0.06  -0.007 0.01 0.63897 0.03 
 S1 sexPRS  0.017 0.01 0.06904 0.49  0.010 0.01 0.28930 0.16  -0.003 0.01 0.72293 0.02  0.004 0.01 0.65002 0.03  0.003 0.01 0.70395 0.02 
 S2 PRS  -0.018 0.01 0.21756 0.22  0.011 0.01 0.48120 0.07  0.002 0.01 0.88550 0.00  -0.012 0.02 0.42557 0.10  -0.008 0.01 0.58780 0.04 
 S2 sexPRS  0.017 0.01 0.06591 0.49  -0.004 0.01 0.67626 0.03  -0.001 0.01 0.95082 0.00  0.005 0.01 0.62025 0.04  0.004 0.01 0.62636 0.03 
 S3 PRS  -0.018 0.01 0.21939 0.22  0.013 0.02 0.38104 0.11  -0.005 0.01 0.71574 0.02  -0.019 0.01 0.21270 0.23  0.005 0.01 0.74688 0.02 
 S3 sexPRS  0.020 0.01 0.03205 0.67  -0.008 0.01 0.38285 0.11  0.005 0.01 0.55391 0.05  0.015 0.01 0.10373 0.39  -0.002 0.01 0.83035 0.01 
 S4 PRS  -0.019 0.01 0.18814 0.25  0.024 0.01 0.11480 0.37  0.008 0.01 0.58377 0.04  -0.016 0.01 0.27570 0.18  0.008 0.01 0.59121 0.04 
 S4 sexPRS  0.019 0.01 0.03367 0.65  -0.016 0.01 0.08213 0.45  -0.001 0.01 0.90311 0.00  0.012 0.01 0.19510 0.25  -0.006 0.01 0.51988 0.06 
 S5 PRS  -0.022 0.01 0.13357 0.33  0.009 0.01 0.55946 0.05  0.012 0.01 0.42180 0.10  -0.020 0.01 0.16944 0.28  0.002 0.01 0.91180 0.00 
 S5 sexPRS  0.021 0.01 0.02358 0.75  -0.007 0.01 0.41688 0.10  -0.001 0.01 0.92819 0.00  0.015 0.01 0.09990 0.40  -0.001 0.01 0.94642 0.00 
 S6 PRS  -0.023 0.01 0.12538 0.35  0.008 0.01 0.59182 0.04  0.010 0.01 0.51261 0.06  -0.023 0.01 0.11750 0.37  -0.002 0.01 0.89445 0.00 
 S6 sexPRS  0.020 0.01 0.02871 0.70  -0.006 0.01 0.52095 0.06  -0.000 0.01 0.97368 0.00  0.015 0.01 0.08435 0.44  0.003 0.01 0.75225 0.01 
 S7 PRS  -0.016 0.01 0.28645 0.17  0.007 0.01 0.64677 0.03  0.007 0.01 0.63780 0.03  -0.020 0.01 0.17527 0.28  -0.004 0.02 0.80595 0.01 
 S7 sexPRS  0.017 0.01 0.05357 0.55  -0.008 0.01 0.38642 0.11  0.001 0.01 0.88392 0.00  0.014 0.01 0.10576 0.39  0.001 0.01 0.90008 0.00 
Table S4-2. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores (PRS in Predictor column) and the interaction between 
sex and PRS (sexPRS in Predictor column) on target phenotypes related to lifetime use of licit substance, substance use disorders, and psychiatric disorders. 
PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per day (CPD), smoking 
cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 5e-01 (S7), and 1 
(S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Effect  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S8 PRS  -0.015 0.01 0.29318 0.16  0.009 0.01 0.53667 0.06  0.007 0.01 0.61251 0.04  -0.019 0.01 0.19027 0.26  -0.004 0.02 0.77551 0.01 
 S8 sexPRS  0.018 0.01 0.04885 0.57  -0.009 0.01 0.33233 0.14  0.001 0.01 0.89316 0.00  0.013 0.01 0.12861 0.34  0.002 0.01 0.85378 0.01 
 
Mania screen S1 PRS  -0.003 0.00 0.51252 0.08  -0.004 0.00 0.39567 0.13  0.005 0.00 0.26271 0.24  0.002 0.00 0.68155 0.03  0.005 0.00 0.25376 0.23 
 S1 sexPRS  0.002 0.00 0.51353 0.08  0.003 0.00 0.27916 0.22  -0.002 0.00 0.40393 0.13  -0.003 0.00 0.35903 0.16  -0.003 0.00 0.34233 0.16 
 S2 PRS  0.001 0.00 0.90721 0.00  -0.001 0.00 0.86701 0.01  0.001 0.00 0.77240 0.02  -0.001 0.00 0.90805 0.00  0.007 0.00 0.08174 0.55 
 S2 sexPRS  -0.000 0.00 0.92806 0.00  -0.000 0.00 0.92712 0.00  -0.000 0.00 0.97592 0.00  -0.001 0.00 0.63364 0.04  -0.004 0.00 0.10648 0.48 
 S3 PRS  0.003 0.00 0.43324 0.11  -0.001 0.00 0.88969 0.00  -0.002 0.00 0.59767 0.05  -0.003 0.00 0.53901 0.07  0.015 0.00 0.00079 2.11 
 S3 sexPRS  -0.001 0.00 0.68646 0.03  0.000 0.00 0.88486 0.00  0.001 0.00 0.59626 0.05  0.001 0.00 0.83704 0.01  -0.009 0.00 0.00132 1.93 
 S4 PRS  0.006 0.00 0.13896 0.41  0.000 0.00 0.98442 0.00  0.001 0.00 0.86712 0.01  -0.001 0.00 0.78884 0.01  0.009 0.00 0.03622 0.82 
 S4 sexPRS  -0.003 0.00 0.28950 0.21  -0.001 0.00 0.81488 0.01  0.001 0.00 0.73676 0.02  -0.000 0.00 0.95216 0.00  -0.006 0.00 0.01715 1.07 
 S5 PRS  0.009 0.00 0.03656 0.83  0.000 0.00 0.95688 0.00  -0.000 0.00 0.96119 0.00  0.000 0.00 0.91630 0.00  0.009 0.00 0.03037 0.86 
 S5 sexPRS  -0.005 0.00 0.07388 0.60  -0.000 0.00 0.88019 0.00  0.001 0.00 0.63437 0.04  -0.000 0.00 0.85516 0.01  -0.006 0.00 0.02830 0.90 
 S6 PRS  0.010 0.00 0.01946 1.03  -0.002 0.00 0.65739 0.04  0.001 0.00 0.87520 0.00  0.001 0.00 0.77351 0.02  0.009 0.00 0.03416 0.83 
 S6 sexPRS  -0.006 0.00 0.03454 0.84  0.001 0.00 0.70734 0.03  0.001 0.00 0.84867 0.01  -0.001 0.00 0.76829 0.02  -0.005 0.00 0.04519 0.75 
 S7 PRS  0.010 0.00 0.02386 0.96  -0.002 0.00 0.67496 0.03  0.001 0.00 0.85260 0.01  -0.000 0.00 0.96118 0.00  0.014 0.00 0.00135 1.95 
 S7 sexPRS  -0.006 0.00 0.03742 0.81  -0.000 0.00 0.98277 0.00  0.000 0.00 0.95091 0.00  -0.000 0.00 0.94231 0.00  -0.009 0.00 0.00169 1.89 
 S8 PRS  0.011 0.00 0.01250 1.17  -0.001 0.00 0.75633 0.02  0.000 0.00 0.91579 0.00  -0.000 0.00 0.98777 0.00  0.015 0.00 0.00108 2.03 
 S8 sexPRS  -0.006 0.00 0.01971 1.02  -0.000 0.00 0.92365 0.00  0.000 0.00 0.90158 0.00  -0.000 0.00 0.90145 0.00  -0.009 0.00 0.00145 1.95 
 
Table S4-3. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5). Modelling in these associations 
stratified the target sample by sex into females (F), males (M) and both sexes together (F+M). PRS for SI (smoking initiation), AI (age of initiation of regular smoking), 
CPD (number of cigarettes per day), SC (smoking cessation) and DPW (drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) 
p< T3 with the adjustment for number of independent target phenotypes, (4) p< T4 with the adjustment for number of both independent target phenotypes and discovery 
traits, and (5) p< T5 with the adjustment by Bonferroni procedure. T3, T4 and T5 are 3.657103e-03, 7.142857e-04, and 8.333333e-05 respectively. 
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 SI  AI  CPD  SC  DPW 
Target phenotype Sex  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
Smoking initiation F+M  8 8 8 8 8  8 6 6 6 6  8 2 0 0 0  8 0 0 0 0  8 7 6 5 0 
 F  8 8 8 8 7  8 7 6 5 2  8 0 0 0 0  8 0 0 0 0  8 7 0 0 0 
 M  8 8 7 7 7  8 6 5 4 4  8 5 0 0 0  8 0 0 0 0  8 5 3 1 0 
 
Age at starting regular 
smoking 
F+M  8 6 0 0 0  8 4 0 0 0  8 0 0 0 0  8 0 0 0 0  8 3 0 0 0 
 F  8 1 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 2 0 0 0 
 M  8 1 0 0 0  8 1 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0 
 
Cigarettes per day F+M  8 7 7 6 3  8 5 3 0 0  8 8 8 8 6  8 1 0 0 0  8 0 0 0 0 
 F  8 7 6 6 2  8 6 4 1 0  8 8 8 6 5  8 3 0 0 0  8 0 0 0 0 
 M  8 4 0 0 0  8 1 0 0 0  8 7 6 3 0  8 0 0 0 0  8 0 0 0 0 
 
Smoking cessation F+M  8 7 5 2 1  8 0 0 0 0  8 4 0 0 0  8 2 0 0 0  8 0 0 0 0 
 F  8 7 1 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 3 1 1 0  8 0 0 0 0  8 4 0 0 0  8 2 0 0 0  8 0 0 0 0 
 
Drinking initiation F+M  8 4 0 0 0  8 2 0 0 0  8 4 0 0 0  8 0 0 0 0  8 7 6 6 6 
 F  8 0 0 0 0  8 1 0 0 0  8 6 2 0 0  8 6 0 0 0  8 7 6 6 1 
 M  8 3 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 6 3 3 0 
 
Drinks per week F+M  8 8 7 7 7  8 8 3 1 0  8 0 0 0 0  8 1 0 0 0  8 8 8 8 7 
 F  8 6 0 0 0  8 2 0 0 0  8 0 0 0 0  8 0 0 0 0  8 8 8 7 7 
 M  8 8 8 7 3  8 7 1 1 0  8 0 0 0 0  8 0 0 0 0  8 8 7 7 6 
 
DSM-IV alcohol 
dependence 
F+M  8 8 8 8 6  8 5 3 0 0  8 0 0 0 0  8 0 0 0 0  8 8 8 8 8 
 F  8 8 8 8 6  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 8 8 8 8 
 M  8 6 3 0 0  8 4 3 0 0  8 0 0 0 0  8 0 0 0 0  8 8 6 6 2 
 
Table S4-3. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5). Modelling in these associations 
stratified the target sample by sex into females (F), males (M) and both sexes together (F+M). PRS for SI (smoking initiation), AI (age of initiation of regular smoking), 
CPD (number of cigarettes per day), SC (smoking cessation) and DPW (drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) 
p< T3 with the adjustment for number of independent target phenotypes, (4) p< T4 with the adjustment for number of both independent target phenotypes and discovery 
traits, and (5) p< T5 with the adjustment by Bonferroni procedure. T3, T4 and T5 are 3.657103e-03, 7.142857e-04, and 8.333333e-05 respectively. 
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 SI  AI  CPD  SC  DPW 
Target phenotype Sex  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
DSM-IV nicotine 
dependence 
F+M  8 8 8 8 8  8 6 6 5 5  8 8 7 6 5  8 7 2 0 0  8 2 0 0 0 
 F  8 8 8 8 8  8 7 5 4 4  8 8 6 3 1  8 4 0 0 0  8 0 0 0 0 
 M  8 8 8 8 7  8 6 3 2 0  8 8 5 5 4  8 5 2 1 0  8 4 3 0 0 
 
FTND-based nicotine 
dependence 
F+M  8 8 8 8 8  8 7 6 5 5  8 8 8 8 8  8 8 8 7 6  8 2 0 0 0 
 F  8 8 7 7 7  8 5 5 4 3  8 8 8 8 8  8 5 4 2 1  8 0 0 0 0 
 M  8 8 8 8 7  8 7 6 5 5  8 8 8 8 7  8 8 6 4 3  8 0 0 0 0 
 
DSM-IV conduct disorder F+M  8 8 5 5 3  8 6 5 5 1  8 4 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 6 0 0 0  8 5 1 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 6 5 3 0  8 6 1 0 0  8 6 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
DSM-IV antisocial 
personality disorder 
F+M  8 7 2 1 0  8 6 5 5 1  8 3 0 0 0  8 5 0 0 0  8 0 0 0 0 
 F  8 8 0 0 0  8 5 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 4 0 0 0  8 6 5 0 0  8 3 0 0 0  8 2 0 0 0  8 0 0 0 0 
 
DSM-IV major depressive 
disorder 
F+M  8 5 0 0 0  8 1 0 0 0  8 7 1 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 4 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 8 2 1 0  8 0 0 0 0  8 0 0 0 0 
 
DSM-IV panic disorder F+M  8 7 0 0 0  8 0 0 0 0  8 2 0 0 0  8 4 0 0 0  8 0 0 0 0 
 F  8 7 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 0 0 0 0  8 0 0 0 0  8 1 0 0 0  8 2 0 0 0  8 0 0 0 0 
 
DSM-IV social anxiety 
disorder 
F+M  8 6 0 0 0  8 0 0 0 0  8 1 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 8 3 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
Table S4-3. Number of phenotype-PRS associations with observed p values lower than various significance thresholds (T1- T5). Modelling in these associations 
stratified the target sample by sex into females (F), males (M) and both sexes together (F+M). PRS for SI (smoking initiation), AI (age of initiation of regular smoking), 
CPD (number of cigarettes per day), SC (smoking cessation) and DPW (drinks per week). The significance threshold was (1) p < 1 (T1), (2) nominal p< 0.05 (T2), (3) 
p< T3 with the adjustment for number of independent target phenotypes, (4) p< T4 with the adjustment for number of both independent target phenotypes and discovery 
traits, and (5) p< T5 with the adjustment by Bonferroni procedure. T3, T4 and T5 are 3.657103e-03, 7.142857e-04, and 8.333333e-05 respectively. 
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 SI  AI  CPD  SC  DPW 
Target phenotype Sex  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5  T1 T2 T3 T4 T5 
 M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 
Mania screen F+M  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 F  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0 
 M  8 4 0 0 0  8 0 0 0 0  8 0 0 0 0  8 0 0 0 0  8 4 3 0 0 
 
Number target phenotypes 
predicted 
F+M  15 14 9 9 8  15 11 8 6 5  15 11 4 3 3  15 7 2 1 1  15 7 4 4 3 
 F  15 13 7 5 5  15 10 5 4 3  15 4 4 3 3  15 4 1 1 1  15 5 3 3 3 
 M  15 12 7 6 4  15 9 7 4 2  15 9 4 4 2  15 6 2 2 1  15 6 6 4 2 
 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
Smoking 
initiation 
S1 F+M  0.026 0.01 0.00004 0.27  -0.009 0.01 0.13554 0.04  0.000 0.01 0.96961 0.00  0.003 0.01 0.66828 0.00  0.002 0.01 0.77602 0.00 
 S1 F  0.030 0.01 0.00021 0.38  -0.016 0.01 0.05160 0.11  -0.001 0.01 0.88210 0.00  0.000 0.01 0.95702 0.00  0.010 0.01 0.22940 0.04 
 S1 M  0.023 0.01 0.01045 0.21  -0.004 0.01 0.66816 0.01  0.001 0.01 0.94865 0.00  0.009 0.01 0.31827 0.03  -0.004 0.01 0.62939 0.01 
 S2 F+M  0.054 0.01 <.00001 1.19  -0.012 0.01 0.06671 0.05  0.003 0.01 0.64634 0.00  0.005 0.01 0.39236 0.01  0.013 0.01 0.03080 0.08 
 S2 F  0.057 0.01 <.00001 1.35  -0.020 0.01 0.01383 0.17  0.002 0.01 0.76841 0.00  0.002 0.01 0.84031 0.00  0.019 0.01 0.01734 0.16 
 S2 M  0.053 0.01 <.00001 1.17  0.000 0.01 0.98119 0.00  0.002 0.01 0.84502 0.00  0.011 0.01 0.21030 0.05  0.006 0.01 0.51117 0.01 
 S3 F+M  0.078 0.01 <.00001 2.45  -0.026 0.01 0.00003 0.27  0.008 0.01 0.18642 0.03  0.009 0.01 0.14374 0.04  0.020 0.01 0.00169 0.16 
 S3 F  0.078 0.01 <.00001 2.50  -0.029 0.01 0.00039 0.34  0.005 0.01 0.56391 0.01  0.011 0.01 0.17921 0.05  0.020 0.01 0.01393 0.16 
 S3 M  0.079 0.01 <.00001 2.57  -0.021 0.01 0.01778 0.18  0.009 0.01 0.32536 0.03  0.007 0.01 0.47581 0.02  0.016 0.01 0.08163 0.10 
 S4 F+M  0.082 0.01 <.00001 2.81  -0.027 0.01 0.00002 0.29  0.015 0.01 0.01790 0.09  0.010 0.01 0.12765 0.04  0.024 0.01 0.00014 0.24 
 S4 F  0.082 0.01 <.00001 2.79  -0.025 0.01 0.00239 0.25  0.007 0.01 0.39451 0.02  0.011 0.01 0.19929 0.05  0.023 0.01 0.00398 0.23 
 S4 M  0.083 0.01 <.00001 2.87  -0.028 0.01 0.00163 0.32  0.025 0.01 0.00617 0.25  0.011 0.01 0.23775 0.05  0.022 0.01 0.01561 0.20 
 S5 F+M  0.089 0.01 <.00001 3.27  -0.033 0.01 <.00001 0.44  0.013 0.01 0.03794 0.07  0.001 0.01 0.92750 0.00  0.021 0.01 0.00056 0.19 
 S5 F  0.085 0.01 <.00001 2.97  -0.029 0.01 0.00049 0.34  0.006 0.01 0.49831 0.01  -0.004 0.01 0.63333 0.01  0.017 0.01 0.03186 0.12 
 S5 M  0.094 0.01 <.00001 3.60  -0.041 0.01 <.00001 0.71  0.022 0.01 0.01133 0.21  0.010 0.01 0.31892 0.04  0.026 0.01 0.00463 0.27 
 S6 F+M  0.091 0.01 <.00001 3.35  -0.035 0.01 <.00001 0.50  0.012 0.01 0.06466 0.06  0.005 0.01 0.44759 0.01  0.024 0.01 0.00011 0.23 
 S6 F  0.085 0.01 <.00001 2.94  -0.032 0.01 0.00011 0.42  0.002 0.01 0.77864 0.00  0.002 0.01 0.84531 0.00  0.017 0.01 0.03379 0.12 
 S6 M  0.095 0.01 <.00001 3.69  -0.043 0.01 <.00001 0.79  0.024 0.01 0.00763 0.23  0.012 0.01 0.22976 0.06  0.033 0.01 0.00025 0.46 
 S7 F+M  0.085 0.01 <.00001 2.96  -0.038 0.01 <.00001 0.59  0.012 0.01 0.05905 0.06  0.010 0.01 0.17958 0.04  0.023 0.01 0.00017 0.22 
 S7 F  0.080 0.01 <.00001 2.64  -0.038 0.01 <.00001 0.60  0.002 0.01 0.81969 0.00  0.006 0.01 0.53091 0.01  0.019 0.01 0.01727 0.15 
 S7 M  0.090 0.01 <.00001 3.29  -0.043 0.01 <.00001 0.77  0.025 0.01 0.00529 0.26  0.016 0.01 0.11324 0.11  0.029 0.01 0.00145 0.35 
 S8 F+M  0.084 0.01 <.00001 2.88  -0.038 0.01 <.00001 0.60  0.012 0.01 0.05726 0.06  0.008 0.01 0.24763 0.03  0.022 0.01 0.00051 0.19 
 S8 F  0.079 0.01 <.00001 2.54  -0.038 0.01 <.00001 0.62  0.002 0.01 0.85354 0.00  0.005 0.01 0.61759 0.01  0.018 0.01 0.02654 0.13 
 S8 M  0.089 0.01 <.00001 3.23  -0.042 0.01 <.00001 0.75  0.026 0.01 0.00376 0.29  0.015 0.01 0.13239 0.10  0.027 0.01 0.00319 0.30 
 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
Age at 
starting 
regular 
smoking 
S1 F+M  -0.061 0.08 0.43783 0.03  0.183 0.08 0.02102 0.25  -0.025 0.08 0.75089 0.00  0.071 0.08 0.35818 0.04  -0.048 0.08 0.54487 0.02 
 S1 F  -0.150 0.10 0.14991 0.17  0.209 0.11 0.04722 0.32  -0.008 0.10 0.93543 0.00  -0.009 0.10 0.92785 0.00  -0.035 0.10 0.73317 0.01 
 S1 M  0.056 0.12 0.62724 0.02  0.172 0.12 0.14540 0.22  -0.082 0.12 0.49566 0.05  0.163 0.12 0.15831 0.20  -0.002 0.12 0.98573 0.00 
 S2 F+M  -0.159 0.08 0.04729 0.19  0.144 0.08 0.06838 0.15  -0.056 0.08 0.47693 0.02  0.113 0.08 0.14643 0.10  -0.173 0.08 0.02907 0.23 
 S2 F  -0.184 0.11 0.08064 0.25  0.163 0.11 0.12165 0.19  -0.067 0.10 0.51577 0.03  0.036 0.10 0.72862 0.01  -0.150 0.10 0.15088 0.17 
 S2 M  -0.151 0.12 0.20526 0.17  0.158 0.12 0.17891 0.18  -0.054 0.12 0.64645 0.02  0.234 0.12 0.04970 0.41  -0.153 0.12 0.20265 0.18 
 S3 F+M  -0.139 0.08 0.08321 0.14  0.029 0.08 0.71135 0.01  0.038 0.08 0.63161 0.01  0.068 0.08 0.40873 0.03  -0.181 0.08 0.02158 0.25 
 S3 F  -0.158 0.11 0.13575 0.19  0.042 0.10 0.68907 0.01  0.049 0.10 0.63627 0.02  0.069 0.11 0.52342 0.04  -0.255 0.10 0.01249 0.49 
 S3 M  -0.102 0.12 0.39988 0.08  0.001 0.12 0.99404 0.00  0.021 0.12 0.85353 0.00  0.107 0.12 0.39188 0.09  -0.045 0.12 0.70963 0.02 
 S4 F+M  -0.177 0.08 0.02805 0.24  0.153 0.08 0.04864 0.18  0.009 0.08 0.90482 0.00  0.025 0.08 0.75729 0.00  -0.111 0.08 0.15602 0.09 
 S4 F  -0.214 0.11 0.04677 0.34  0.064 0.10 0.52818 0.03  0.104 0.11 0.32649 0.08  0.048 0.11 0.65495 0.02  -0.113 0.10 0.26361 0.09 
 S4 M  -0.136 0.12 0.25357 0.14  0.282 0.12 0.01604 0.60  -0.100 0.12 0.39615 0.07  0.013 0.12 0.91776 0.00  -0.127 0.12 0.29360 0.12 
 S5 F+M  -0.214 0.08 0.00823 0.34  0.184 0.08 0.02314 0.25  0.074 0.08 0.35368 0.04  -0.097 0.08 0.24228 0.07  -0.148 0.08 0.06155 0.16 
 S5 F  -0.176 0.11 0.09991 0.23  0.153 0.11 0.14857 0.17  0.165 0.11 0.11683 0.20  -0.049 0.11 0.65746 0.02  -0.113 0.10 0.26817 0.10 
 S5 M  -0.272 0.12 0.02450 0.55  0.206 0.12 0.09320 0.32  -0.023 0.12 0.84852 0.00  -0.132 0.12 0.27524 0.14  -0.229 0.12 0.06371 0.39 
 S6 F+M  -0.168 0.08 0.03705 0.21  0.192 0.08 0.01791 0.28  0.044 0.08 0.57931 0.01  -0.082 0.08 0.33010 0.05  -0.170 0.08 0.03031 0.21 
 S6 F  -0.149 0.11 0.16362 0.16  0.215 0.11 0.04273 0.35  0.099 0.10 0.33698 0.07  -0.026 0.11 0.81807 0.01  -0.203 0.10 0.04391 0.30 
 S6 M  -0.201 0.12 0.09410 0.30  0.161 0.12 0.19108 0.20  -0.006 0.12 0.95819 0.00  -0.132 0.12 0.28856 0.14  -0.139 0.12 0.25860 0.14 
 S7 F+M  -0.175 0.08 0.03012 0.23  0.145 0.08 0.07743 0.16  0.030 0.08 0.70348 0.01  -0.051 0.08 0.54096 0.02  -0.099 0.08 0.21406 0.07 
 S7 F  -0.163 0.11 0.12436 0.20  0.156 0.11 0.14981 0.18  0.057 0.10 0.58284 0.02  0.019 0.11 0.86471 0.00  -0.133 0.10 0.18980 0.13 
 S7 M  -0.196 0.12 0.10481 0.28  0.128 0.12 0.29644 0.12  0.007 0.12 0.95522 0.00  -0.129 0.12 0.29826 0.13  -0.075 0.13 0.55441 0.04 
 S8 F+M  -0.169 0.08 0.03644 0.21  0.123 0.08 0.13301 0.11  0.040 0.08 0.61561 0.01  -0.049 0.08 0.56146 0.02  -0.094 0.08 0.23758 0.06 
 S8 F  -0.153 0.11 0.14974 0.17  0.141 0.11 0.19189 0.15  0.064 0.10 0.53964 0.03  0.025 0.11 0.82296 0.00  -0.131 0.10 0.19555 0.13 
 S8 M  -0.194 0.12 0.10890 0.28  0.102 0.12 0.40516 0.08  0.017 0.12 0.89115 0.00  -0.127 0.12 0.30374 0.13  -0.063 0.13 0.61666 0.03 
 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
Cigarettes per 
day 
S1 F+M  0.043 0.02 0.07710 0.16  -0.006 0.02 0.81879 0.00  0.084 0.02 0.00068 0.60  0.029 0.02 0.22519 0.07  0.005 0.02 0.85094 0.00 
 S1 F  0.023 0.03 0.45801 0.05  0.045 0.03 0.15712 0.17  0.095 0.03 0.00215 0.77  0.020 0.03 0.52098 0.03  -0.020 0.03 0.51922 0.03 
 S1 M  0.079 0.04 0.03750 0.54  -0.095 0.04 0.01440 0.77  0.061 0.04 0.12161 0.32  0.039 0.04 0.29504 0.13  0.028 0.04 0.46987 0.07 
 S2 F+M  0.077 0.02 0.00189 0.52  -0.018 0.02 0.47827 0.03  0.093 0.02 0.00017 0.74  0.034 0.02 0.16785 0.10  0.022 0.02 0.37654 0.04 
 S2 F  0.081 0.03 0.01025 0.57  0.000 0.03 0.98824 0.00  0.103 0.03 0.00092 0.91  0.025 0.03 0.42388 0.05  -0.010 0.03 0.74578 0.01 
 S2 M  0.082 0.04 0.03583 0.57  -0.043 0.04 0.27056 0.15  0.077 0.04 0.04724 0.51  0.042 0.04 0.28063 0.15  0.056 0.04 0.14795 0.28 
 S3 F+M  0.110 0.02 0.00001 1.03  -0.042 0.02 0.08442 0.16  0.115 0.02 <.00001 1.14  0.043 0.03 0.09489 0.16  0.003 0.02 0.90087 0.00 
 S3 F  0.140 0.03 <.00001 1.69  -0.079 0.03 0.01098 0.54  0.113 0.03 0.00031 1.09  0.047 0.03 0.14569 0.19  -0.016 0.03 0.60217 0.02 
 S3 M  0.053 0.04 0.18468 0.24  0.005 0.04 0.89007 0.00  0.116 0.04 0.00245 1.15  0.021 0.04 0.60086 0.04  0.019 0.04 0.62607 0.03 
 S4 F+M  0.092 0.02 0.00024 0.73  -0.065 0.02 0.00759 0.37  0.132 0.02 <.00001 1.49  0.039 0.03 0.12732 0.14  0.009 0.02 0.69762 0.01 
 S4 F  0.113 0.03 0.00038 1.11  -0.084 0.03 0.00620 0.61  0.133 0.03 0.00003 1.51  0.068 0.03 0.03420 0.41  -0.019 0.03 0.52670 0.03 
 S4 M  0.053 0.04 0.17197 0.24  -0.047 0.04 0.22531 0.19  0.134 0.04 0.00052 1.53  -0.017 0.04 0.67031 0.03  0.040 0.04 0.31775 0.14 
 S5 F+M  0.119 0.03 <.00001 1.20  -0.073 0.03 0.00372 0.46  0.151 0.02 <.00001 1.97  0.046 0.03 0.07917 0.19  0.010 0.02 0.67073 0.01 
 S5 F  0.139 0.03 0.00001 1.65  -0.100 0.03 0.00152 0.86  0.147 0.03 <.00001 1.87  0.079 0.03 0.01726 0.56  -0.013 0.03 0.66083 0.02 
 S5 M  0.085 0.04 0.03066 0.62  -0.043 0.04 0.27933 0.16  0.151 0.04 0.00013 1.95  -0.016 0.04 0.68281 0.02  0.043 0.04 0.29277 0.16 
 S6 F+M  0.103 0.02 0.00004 0.90  -0.079 0.03 0.00185 0.54  0.150 0.02 <.00001 1.93  0.054 0.03 0.04239 0.26  -0.000 0.02 0.99802 0.00 
 S6 F  0.115 0.03 0.00030 1.13  -0.113 0.03 0.00039 1.11  0.145 0.03 <.00001 1.81  0.083 0.03 0.01258 0.63  -0.029 0.03 0.33690 0.07 
 S6 M  0.083 0.04 0.03497 0.59  -0.039 0.04 0.33847 0.13  0.146 0.04 0.00022 1.84  -0.005 0.04 0.90957 0.00  0.039 0.04 0.33248 0.13 
 S7 F+M  0.096 0.03 0.00013 0.79  -0.081 0.03 0.00153 0.57  0.131 0.02 <.00001 1.48  0.040 0.03 0.13369 0.15  -0.006 0.02 0.81478 0.00 
 S7 F  0.112 0.03 0.00040 1.08  -0.102 0.03 0.00161 0.91  0.126 0.03 0.00006 1.38  0.065 0.03 0.05090 0.38  -0.040 0.03 0.19005 0.14 
 S7 M  0.069 0.04 0.07786 0.41  -0.064 0.04 0.11651 0.35  0.132 0.04 0.00088 1.51  -0.009 0.04 0.83405 0.01  0.041 0.04 0.32849 0.14 
 S8 F+M  0.097 0.03 0.00011 0.81  -0.077 0.03 0.00245 0.52  0.130 0.02 <.00001 1.47  0.039 0.03 0.14580 0.14  -0.005 0.02 0.83268 0.00 
 S8 F  0.111 0.03 0.00050 1.05  -0.100 0.03 0.00197 0.88  0.127 0.03 0.00005 1.40  0.063 0.03 0.05979 0.36  -0.038 0.03 0.21594 0.12 
 S8 M  0.074 0.04 0.05937 0.47  -0.059 0.04 0.14577 0.30  0.130 0.04 0.00114 1.46  -0.009 0.04 0.83527 0.01  0.040 0.04 0.33558 0.14 
 
Smoking 
cessation 
S1 F+M  0.012 0.01 0.13754 0.06  -0.003 0.01 0.74252 0.00  0.023 0.01 0.00631 0.22  0.017 0.01 0.04243 0.12  -0.006 0.01 0.47528 0.02 
 S1 F  0.011 0.01 0.33059 0.05  0.011 0.01 0.35155 0.05  0.017 0.01 0.16313 0.11  0.008 0.01 0.52711 0.02  -0.013 0.01 0.27221 0.07 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S1 M  0.013 0.01 0.27197 0.07  -0.020 0.01 0.08479 0.17  0.028 0.01 0.01700 0.32  0.026 0.01 0.02539 0.28  0.002 0.01 0.85166 0.00 
 S2 F+M  0.026 0.01 0.00173 0.28  0.001 0.01 0.88218 0.00  0.023 0.01 0.00621 0.22  0.004 0.01 0.65683 0.01  0.000 0.01 0.95997 0.00 
 S2 F  0.032 0.01 0.00539 0.43  0.004 0.01 0.73787 0.01  0.015 0.01 0.20737 0.09  -0.009 0.01 0.46311 0.03  -0.007 0.01 0.56946 0.02 
 S2 M  0.019 0.01 0.09462 0.15  -0.004 0.01 0.71112 0.01  0.028 0.01 0.01371 0.33  0.016 0.01 0.17525 0.11  0.010 0.01 0.38100 0.05 
 S3 F+M  0.028 0.01 0.00084 0.33  -0.000 0.01 0.96785 0.00  0.021 0.01 0.01026 0.19  0.015 0.01 0.07699 0.10  -0.006 0.01 0.48071 0.01 
 S3 F  0.033 0.01 0.00627 0.44  -0.004 0.01 0.72371 0.01  0.018 0.01 0.13854 0.13  0.000 0.01 0.99988 0.00  -0.015 0.01 0.21796 0.09 
 S3 M  0.022 0.01 0.06789 0.19  0.002 0.01 0.86441 0.00  0.023 0.01 0.04039 0.22  0.028 0.01 0.02128 0.31  0.002 0.01 0.86508 0.00 
 S4 F+M  0.039 0.01 <.00001 0.63  -0.011 0.01 0.18258 0.05  0.024 0.01 0.00464 0.24  0.014 0.01 0.11386 0.08  0.006 0.01 0.44662 0.02 
 S4 F  0.037 0.01 0.00256 0.56  -0.017 0.01 0.14555 0.12  0.019 0.01 0.11594 0.15  0.008 0.01 0.49739 0.03  0.011 0.01 0.35528 0.05 
 S4 M  0.040 0.01 0.00056 0.68  -0.009 0.01 0.42348 0.04  0.029 0.01 0.01214 0.35  0.015 0.01 0.21366 0.09  -0.002 0.01 0.89713 0.00 
 S5 F+M  0.034 0.01 0.00010 0.46  -0.016 0.01 0.05709 0.11  0.016 0.01 0.06023 0.10  0.018 0.01 0.04775 0.13  0.008 0.01 0.33607 0.03 
 S5 F  0.034 0.01 0.00595 0.46  -0.024 0.01 0.04248 0.24  0.018 0.01 0.13970 0.13  0.016 0.01 0.21339 0.10  0.014 0.01 0.23020 0.08 
 S5 M  0.032 0.01 0.00660 0.42  -0.011 0.01 0.34588 0.05  0.014 0.01 0.22480 0.08  0.016 0.01 0.18550 0.11  -0.000 0.01 0.98112 0.00 
 S6 F+M  0.029 0.01 0.00097 0.33  -0.014 0.01 0.09223 0.09  0.013 0.01 0.11967 0.07  0.014 0.01 0.11117 0.09  0.004 0.01 0.60335 0.01 
 S6 F  0.030 0.01 0.01547 0.36  -0.025 0.01 0.03632 0.26  0.016 0.01 0.19018 0.10  0.012 0.01 0.35852 0.06  0.006 0.01 0.62677 0.01 
 S6 M  0.025 0.01 0.03293 0.26  -0.007 0.01 0.58295 0.02  0.011 0.01 0.35334 0.05  0.015 0.01 0.22359 0.09  0.002 0.01 0.85260 0.00 
 S7 F+M  0.023 0.01 0.00785 0.21  -0.014 0.01 0.11193 0.08  0.007 0.01 0.42467 0.02  0.009 0.01 0.29990 0.04  0.003 0.01 0.71436 0.00 
 S7 F  0.026 0.01 0.03082 0.28  -0.023 0.01 0.06238 0.22  0.008 0.01 0.49075 0.03  0.007 0.01 0.58083 0.02  0.004 0.01 0.74221 0.01 
 S7 M  0.018 0.01 0.13157 0.13  -0.007 0.01 0.53947 0.02  0.006 0.01 0.61071 0.01  0.010 0.01 0.41453 0.04  0.001 0.01 0.93854 0.00 
 S8 F+M  0.022 0.01 0.01070 0.19  -0.013 0.01 0.12391 0.08  0.008 0.01 0.32746 0.03  0.010 0.01 0.25591 0.04  0.003 0.01 0.70796 0.00 
 S8 F  0.024 0.01 0.04597 0.24  -0.022 0.01 0.06864 0.21  0.010 0.01 0.40151 0.04  0.007 0.01 0.56486 0.02  0.004 0.01 0.73572 0.01 
 S8 M  0.018 0.01 0.13477 0.13  -0.007 0.01 0.54154 0.02  0.007 0.01 0.53492 0.02  0.011 0.01 0.35633 0.05  0.002 0.01 0.89747 0.00 
 
Drinking 
initiation 
S1 F+M  0.002 0.00 0.71817 0.00  -0.013 0.00 0.00707 0.11  0.002 0.00 0.68884 0.00  -0.005 0.00 0.30665 0.02  0.008 0.00 0.08922 0.04 
 S1 F  -0.004 0.01 0.51542 0.01  -0.014 0.01 0.03863 0.13  -0.005 0.01 0.49172 0.01  -0.008 0.01 0.25125 0.04  0.010 0.01 0.14197 0.06 
 S1 M  0.010 0.01 0.13000 0.06  -0.011 0.01 0.10291 0.08  0.009 0.01 0.18305 0.05  -0.002 0.01 0.72548 0.00  0.006 0.01 0.39526 0.02 
 S2 F+M  -0.002 0.00 0.74151 0.00  0.003 0.00 0.60566 0.00  0.002 0.00 0.70182 0.00  -0.003 0.00 0.49633 0.01  0.013 0.00 0.00728 0.11 
 S2 F  -0.010 0.01 0.15161 0.06  -0.000 0.01 0.95941 0.00  -0.006 0.01 0.35186 0.03  -0.006 0.01 0.36186 0.02  0.016 0.01 0.01878 0.17 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S2 M  0.006 0.01 0.39690 0.02  0.008 0.01 0.24545 0.04  0.011 0.01 0.09985 0.08  -0.001 0.01 0.92833 0.00  0.010 0.01 0.12455 0.07 
 S3 F+M  0.007 0.00 0.15414 0.03  0.006 0.00 0.23219 0.02  -0.006 0.00 0.24603 0.02  -0.006 0.00 0.23581 0.02  0.022 0.00 <.00001 0.30 
 S3 F  -0.001 0.01 0.84883 0.00  0.007 0.01 0.33271 0.03  -0.014 0.01 0.04589 0.12  -0.014 0.01 0.04588 0.12  0.028 0.01 0.00004 0.49 
 S3 M  0.015 0.01 0.02591 0.14  0.004 0.01 0.57913 0.01  0.002 0.01 0.72343 0.00  0.002 0.01 0.72478 0.00  0.015 0.01 0.02827 0.14 
 S4 F+M  0.009 0.00 0.05985 0.05  0.010 0.00 0.04018 0.06  -0.008 0.00 0.10336 0.04  -0.009 0.01 0.06576 0.06  0.022 0.00 <.00001 0.30 
 S4 F  0.004 0.01 0.60265 0.01  0.012 0.01 0.06862 0.10  -0.016 0.01 0.02147 0.16  -0.020 0.01 0.00471 0.26  0.025 0.01 0.00018 0.41 
 S4 M  0.015 0.01 0.02356 0.14  0.007 0.01 0.28730 0.03  -0.002 0.01 0.71261 0.00  0.002 0.01 0.72318 0.00  0.018 0.01 0.00767 0.21 
 S5 F+M  0.011 0.00 0.01981 0.08  0.010 0.00 0.05220 0.06  -0.012 0.00 0.01107 0.10  -0.008 0.01 0.14496 0.04  0.023 0.00 <.00001 0.34 
 S5 F  0.011 0.01 0.11467 0.07  0.013 0.01 0.05743 0.11  -0.018 0.01 0.00929 0.20  -0.016 0.01 0.02612 0.17  0.026 0.01 0.00010 0.43 
 S5 M  0.011 0.01 0.09758 0.08  0.004 0.01 0.55886 0.01  -0.010 0.01 0.15122 0.06  0.001 0.01 0.87068 0.00  0.019 0.01 0.00514 0.23 
 S6 F+M  0.013 0.00 0.00746 0.11  0.007 0.00 0.17417 0.03  -0.013 0.00 0.00954 0.10  -0.007 0.01 0.16117 0.04  0.024 0.00 <.00001 0.38 
 S6 F  0.012 0.01 0.06995 0.10  0.010 0.01 0.14730 0.06  -0.020 0.01 0.00397 0.25  -0.016 0.01 0.03001 0.17  0.025 0.01 0.00015 0.40 
 S6 M  0.013 0.01 0.04568 0.11  0.001 0.01 0.89115 0.00  -0.008 0.01 0.23022 0.04  0.000 0.01 0.95952 0.00  0.024 0.01 0.00037 0.37 
 S7 F+M  0.012 0.00 0.01534 0.09  0.002 0.01 0.75941 0.00  -0.013 0.00 0.00864 0.11  -0.010 0.01 0.05017 0.07  0.024 0.00 <.00001 0.36 
 S7 F  0.012 0.01 0.08670 0.09  0.004 0.01 0.57965 0.01  -0.022 0.01 0.00146 0.31  -0.019 0.01 0.00863 0.24  0.024 0.01 0.00039 0.35 
 S7 M  0.011 0.01 0.09840 0.08  -0.003 0.01 0.67876 0.01  -0.007 0.01 0.31180 0.03  -0.002 0.01 0.75638 0.00  0.026 0.01 0.00021 0.41 
 S8 F+M  0.011 0.00 0.02334 0.08  0.001 0.01 0.91490 0.00  -0.013 0.00 0.00807 0.11  -0.010 0.01 0.05528 0.07  0.023 0.00 <.00001 0.33 
 S8 F  0.011 0.01 0.11228 0.07  0.002 0.01 0.73337 0.00  -0.022 0.01 0.00125 0.32  -0.019 0.01 0.00918 0.24  0.023 0.01 0.00065 0.32 
 S8 M  0.010 0.01 0.12305 0.07  -0.003 0.01 0.65552 0.01  -0.006 0.01 0.34589 0.03  -0.002 0.01 0.79317 0.00  0.025 0.01 0.00033 0.38 
 
Drinks per 
week 
S1 F+M  0.488 0.19 0.01100 0.13  -0.464 0.19 0.01704 0.12  0.319 0.19 0.10085 0.06  -0.256 0.19 0.18760 0.04  0.721 0.19 0.00016 0.29 
 S1 F  -0.124 0.15 0.41003 0.01  -0.120 0.15 0.42944 0.01  0.033 0.15 0.82628 0.00  0.056 0.15 0.71490 0.00  0.497 0.15 0.00086 0.14 
 S1 M  1.171 0.36 0.00130 0.75  -0.896 0.37 0.01590 0.43  0.594 0.37 0.11021 0.19  -0.650 0.37 0.07998 0.23  0.909 0.37 0.01305 0.46 
 S2 F+M  0.756 0.19 0.00008 0.31  -0.719 0.19 0.00020 0.27  0.270 0.19 0.16435 0.04  -0.404 0.19 0.03694 0.09  1.028 0.19 <.00001 0.59 
 S2 F  0.117 0.15 0.43986 0.01  -0.103 0.15 0.49991 0.01  0.016 0.15 0.91551 0.00  -0.272 0.15 0.07207 0.04  0.642 0.15 0.00002 0.23 
 S2 M  1.469 0.36 0.00005 1.17  -1.387 0.37 0.00015 1.02  0.503 0.37 0.17255 0.14  -0.654 0.37 0.07992 0.23  1.393 0.37 0.00016 1.08 
 S3 F+M  0.853 0.19 <.00001 0.39  -0.454 0.19 0.01764 0.11  0.245 0.19 0.20174 0.03  -0.282 0.20 0.15363 0.04  1.235 0.19 <.00001 0.84 
 S3 F  0.369 0.15 0.01351 0.07  -0.247 0.15 0.10226 0.03  0.101 0.15 0.50250 0.01  -0.168 0.15 0.27215 0.02  0.668 0.15 <.00001 0.24 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S3 M  1.337 0.37 0.00029 0.96  -0.633 0.37 0.08466 0.22  0.363 0.36 0.31850 0.07  -0.460 0.38 0.22835 0.12  1.854 0.36 <.00001 1.88 
 S4 F+M  0.915 0.19 <.00001 0.46  -0.553 0.19 0.00387 0.17  0.290 0.19 0.13421 0.05  -0.211 0.20 0.29478 0.02  1.268 0.19 <.00001 0.88 
 S4 F  0.368 0.15 0.01442 0.07  -0.235 0.15 0.12300 0.03  0.033 0.15 0.83062 0.00  -0.168 0.16 0.28246 0.02  0.855 0.15 <.00001 0.40 
 S4 M  1.455 0.36 0.00007 1.16  -0.843 0.36 0.01974 0.39  0.582 0.37 0.11368 0.18  -0.436 0.38 0.25550 0.11  1.770 0.37 <.00001 1.71 
 S5 F+M  1.009 0.19 <.00001 0.55  -0.571 0.19 0.00341 0.18  0.061 0.19 0.75227 0.00  -0.074 0.21 0.72096 0.00  1.179 0.19 <.00001 0.76 
 S5 F  0.397 0.15 0.00952 0.09  -0.298 0.15 0.05233 0.05  0.097 0.15 0.52566 0.01  -0.059 0.16 0.71000 0.00  0.802 0.15 <.00001 0.35 
 S5 M  1.589 0.36 0.00001 1.36  -0.871 0.37 0.01983 0.41  -0.026 0.36 0.94182 0.00  -0.240 0.38 0.53190 0.03  1.653 0.37 <.00001 1.49 
 S6 F+M  0.935 0.19 <.00001 0.47  -0.583 0.20 0.00297 0.19  0.055 0.19 0.77752 0.00  -0.147 0.21 0.47932 0.01  1.160 0.19 <.00001 0.73 
 S6 F  0.444 0.15 0.00372 0.11  -0.346 0.15 0.02504 0.07  0.104 0.15 0.49537 0.01  -0.072 0.16 0.65189 0.00  0.760 0.15 <.00001 0.31 
 S6 M  1.394 0.37 0.00015 1.05  -0.842 0.38 0.02498 0.39  -0.049 0.36 0.89245 0.00  -0.382 0.39 0.32605 0.08  1.673 0.37 <.00001 1.51 
 S7 F+M  0.846 0.19 0.00001 0.39  -0.554 0.20 0.00530 0.17  -0.069 0.20 0.72332 0.00  -0.202 0.21 0.33249 0.02  1.055 0.19 <.00001 0.60 
 S7 F  0.342 0.15 0.02580 0.06  -0.314 0.16 0.04471 0.05  0.100 0.15 0.51738 0.01  -0.059 0.16 0.71164 0.00  0.685 0.15 <.00001 0.25 
 S7 M  1.356 0.36 0.00020 0.99  -0.846 0.38 0.02610 0.40  -0.313 0.37 0.39333 0.05  -0.527 0.39 0.17544 0.16  1.537 0.38 0.00004 1.27 
 S8 F+M  0.860 0.19 <.00001 0.40  -0.548 0.20 0.00588 0.17  -0.087 0.20 0.65590 0.00  -0.219 0.21 0.29442 0.03  1.066 0.19 <.00001 0.61 
 S8 F  0.327 0.15 0.03278 0.06  -0.299 0.16 0.05613 0.05  0.094 0.15 0.54151 0.00  -0.075 0.16 0.64076 0.00  0.657 0.15 0.00001 0.23 
 S8 M  1.398 0.36 0.00012 1.06  -0.856 0.38 0.02451 0.41  -0.335 0.37 0.36173 0.06  -0.537 0.39 0.16676 0.16  1.603 0.38 0.00002 1.38 
 
DSM-IV 
alcohol 
dependence 
S1 F+M  0.018 0.01 0.00043 0.17  -0.003 0.00 0.55218 0.00  0.002 0.01 0.65362 0.00  -0.006 0.00 0.19433 0.02  0.022 0.01 0.00002 0.26 
 S1 F  0.024 0.01 0.00006 0.32  -0.007 0.01 0.20562 0.03  0.003 0.01 0.56236 0.01  -0.006 0.01 0.33193 0.02  0.025 0.01 0.00004 0.34 
 S1 M  0.008 0.01 0.30071 0.04  0.002 0.01 0.82559 0.00  -0.003 0.01 0.75244 0.00  -0.007 0.01 0.39208 0.03  0.018 0.01 0.02918 0.17 
 S2 F+M  0.019 0.00 0.00015 0.20  0.000 0.01 0.99246 0.00  0.004 0.01 0.38057 0.01  -0.008 0.01 0.10440 0.04  0.027 0.00 <.00001 0.40 
 S2 F  0.028 0.01 <.00001 0.45  -0.002 0.01 0.79602 0.00  0.008 0.01 0.17090 0.04  -0.010 0.01 0.10547 0.05  0.030 0.01 <.00001 0.50 
 S2 M  0.008 0.01 0.33015 0.03  0.002 0.01 0.77649 0.00  -0.003 0.01 0.68595 0.01  -0.006 0.01 0.44885 0.02  0.023 0.01 0.00419 0.29 
 S3 F+M  0.025 0.00 <.00001 0.35  -0.010 0.00 0.03614 0.06  0.004 0.01 0.47743 0.01  -0.006 0.01 0.26443 0.02  0.030 0.01 <.00001 0.51 
 S3 F  0.029 0.01 <.00001 0.48  -0.009 0.01 0.15046 0.04  0.008 0.01 0.16650 0.04  -0.004 0.01 0.50130 0.01  0.030 0.01 <.00001 0.51 
 S3 M  0.018 0.01 0.02290 0.18  -0.014 0.01 0.07939 0.11  -0.003 0.01 0.72768 0.00  -0.009 0.01 0.27928 0.04  0.031 0.01 0.00016 0.52 
 S4 F+M  0.024 0.00 <.00001 0.33  -0.009 0.01 0.06104 0.05  0.002 0.00 0.72080 0.00  -0.006 0.01 0.28204 0.02  0.028 0.00 <.00001 0.43 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
 
 
Supplementary table page 67 
 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S4 F  0.024 0.01 0.00004 0.33  -0.008 0.01 0.17459 0.04  0.003 0.01 0.57329 0.01  -0.005 0.01 0.37043 0.02  0.029 0.01 <.00001 0.47 
 S4 M  0.024 0.01 0.00272 0.32  -0.012 0.01 0.14300 0.08  -0.001 0.01 0.89819 0.00  -0.004 0.01 0.59937 0.01  0.029 0.01 0.00035 0.46 
 S5 F+M  0.025 0.00 <.00001 0.36  -0.015 0.01 0.00334 0.12  0.002 0.01 0.64348 0.00  -0.003 0.01 0.60686 0.00  0.029 0.00 <.00001 0.45 
 S5 F  0.024 0.01 0.00007 0.31  -0.010 0.01 0.09607 0.06  0.003 0.01 0.59016 0.01  0.002 0.01 0.73496 0.00  0.027 0.01 <.00001 0.42 
 S5 M  0.027 0.01 0.00072 0.42  -0.023 0.01 0.00603 0.28  0.000 0.01 0.96543 0.00  -0.007 0.01 0.39203 0.03  0.033 0.01 0.00004 0.59 
 S6 F+M  0.025 0.00 <.00001 0.34  -0.014 0.01 0.00537 0.11  0.002 0.01 0.76494 0.00  -0.004 0.01 0.50793 0.01  0.027 0.00 <.00001 0.40 
 S6 F  0.024 0.01 0.00006 0.32  -0.007 0.01 0.22028 0.03  0.001 0.01 0.91047 0.00  0.000 0.01 0.96973 0.00  0.027 0.01 <.00001 0.41 
 S6 M  0.025 0.01 0.00181 0.35  -0.025 0.01 0.00247 0.35  0.001 0.01 0.86472 0.00  -0.006 0.01 0.44913 0.02  0.030 0.01 0.00024 0.48 
 S7 F+M  0.023 0.00 <.00001 0.30  -0.015 0.01 0.00277 0.13  0.002 0.01 0.69849 0.00  -0.004 0.01 0.42429 0.01  0.028 0.01 <.00001 0.43 
 S7 F  0.022 0.01 0.00014 0.29  -0.010 0.01 0.10751 0.05  0.002 0.01 0.73193 0.00  0.003 0.01 0.61745 0.01  0.028 0.01 <.00001 0.41 
 S7 M  0.022 0.01 0.00536 0.28  -0.025 0.01 0.00255 0.35  0.000 0.01 0.95633 0.00  -0.012 0.01 0.16811 0.08  0.032 0.01 0.00008 0.55 
 S8 F+M  0.023 0.00 <.00001 0.30  -0.016 0.01 0.00207 0.14  0.003 0.01 0.58523 0.00  -0.005 0.01 0.38854 0.01  0.029 0.01 <.00001 0.45 
 S8 F  0.022 0.01 0.00015 0.28  -0.010 0.01 0.08334 0.06  0.002 0.01 0.79795 0.00  0.003 0.01 0.58031 0.01  0.027 0.01 <.00001 0.39 
 S8 M  0.023 0.01 0.00468 0.29  -0.025 0.01 0.00241 0.36  0.003 0.01 0.72759 0.00  -0.013 0.01 0.13713 0.10  0.034 0.01 0.00004 0.61 
 
DSM-IV 
nicotine 
dependence 
S1 F+M  0.032 0.01 <.00001 0.43  -0.010 0.01 0.11018 0.04  0.016 0.01 0.01089 0.11  0.013 0.01 0.03791 0.07  -0.005 0.01 0.45254 0.01 
 S1 F  0.033 0.01 0.00004 0.47  -0.019 0.01 0.02186 0.15  0.017 0.01 0.03507 0.12  0.004 0.01 0.59619 0.01  -0.007 0.01 0.38900 0.02 
 S1 M  0.031 0.01 0.00051 0.40  -0.007 0.01 0.40447 0.02  0.018 0.01 0.04329 0.14  0.021 0.01 0.01832 0.18  0.000 0.01 0.99755 0.00 
 S2 F+M  0.049 0.01 <.00001 1.04  -0.010 0.01 0.10446 0.04  0.019 0.01 0.00193 0.16  0.010 0.01 0.11715 0.04  -0.006 0.01 0.32305 0.02 
 S2 F  0.054 0.01 <.00001 1.24  -0.013 0.01 0.12697 0.07  0.022 0.01 0.00795 0.20  0.002 0.01 0.84089 0.00  -0.013 0.01 0.12326 0.07 
 S2 M  0.047 0.01 <.00001 0.95  -0.009 0.01 0.28559 0.04  0.020 0.01 0.02235 0.18  0.017 0.01 0.05381 0.12  0.004 0.01 0.65732 0.01 
 S3 F+M  0.059 0.01 <.00001 1.50  -0.021 0.01 0.00074 0.18  0.023 0.01 0.00027 0.22  0.020 0.01 0.00183 0.17  -0.007 0.01 0.26045 0.02 
 S3 F  0.067 0.01 <.00001 1.90  -0.021 0.01 0.00983 0.18  0.027 0.01 0.00090 0.32  0.006 0.01 0.44423 0.02  -0.014 0.01 0.08508 0.08 
 S3 M  0.052 0.01 <.00001 1.17  -0.019 0.01 0.02971 0.15  0.021 0.01 0.01766 0.18  0.031 0.01 0.00062 0.41  0.003 0.01 0.74417 0.00 
 S4 F+M  0.064 0.01 <.00001 1.76  -0.026 0.01 0.00001 0.30  0.030 0.01 <.00001 0.38  0.016 0.01 0.01134 0.12  0.006 0.01 0.31799 0.02 
 S4 F  0.066 0.01 <.00001 1.89  -0.027 0.01 0.00075 0.32  0.030 0.01 0.00021 0.39  0.007 0.01 0.43661 0.02  0.000 0.01 0.96862 0.00 
 S4 M  0.063 0.01 <.00001 1.70  -0.026 0.01 0.00385 0.28  0.034 0.01 0.00011 0.50  0.027 0.01 0.00347 0.32  0.014 0.01 0.12133 0.08 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S5 F+M  0.068 0.01 <.00001 1.99  -0.034 0.01 <.00001 0.48  0.033 0.01 <.00001 0.47  0.019 0.01 0.00388 0.17  0.008 0.01 0.17062 0.03 
 S5 F  0.069 0.01 <.00001 2.05  -0.042 0.01 <.00001 0.76  0.029 0.01 0.00045 0.35  0.017 0.01 0.04365 0.14  -0.003 0.01 0.74061 0.00 
 S5 M  0.067 0.01 <.00001 1.93  -0.023 0.01 0.00935 0.23  0.043 0.01 <.00001 0.78  0.020 0.01 0.03458 0.18  0.022 0.01 0.01164 0.21 
 S6 F+M  0.070 0.01 <.00001 2.10  -0.038 0.01 <.00001 0.62  0.036 0.01 <.00001 0.56  0.021 0.01 0.00170 0.21  0.010 0.01 0.09280 0.05 
 S6 F  0.069 0.01 <.00001 2.06  -0.045 0.01 <.00001 0.87  0.034 0.01 0.00003 0.50  0.019 0.01 0.03158 0.16  -0.003 0.01 0.72909 0.00 
 S6 M  0.070 0.01 <.00001 2.13  -0.030 0.01 0.00093 0.39  0.042 0.01 <.00001 0.77  0.023 0.01 0.01570 0.24  0.026 0.01 0.00312 0.28 
 S7 F+M  0.068 0.01 <.00001 1.99  -0.040 0.01 <.00001 0.68  0.033 0.01 <.00001 0.48  0.018 0.01 0.00712 0.16  0.013 0.01 0.03277 0.07 
 S7 F  0.070 0.01 <.00001 2.11  -0.044 0.01 <.00001 0.85  0.028 0.01 0.00080 0.33  0.019 0.01 0.02970 0.17  0.002 0.01 0.81191 0.00 
 S7 M  0.066 0.01 <.00001 1.89  -0.034 0.01 0.00018 0.50  0.042 0.01 <.00001 0.78  0.017 0.01 0.07255 0.14  0.027 0.01 0.00277 0.29 
 S8 F+M  0.067 0.01 <.00001 1.96  -0.039 0.01 <.00001 0.67  0.034 0.01 <.00001 0.52  0.018 0.01 0.00777 0.16  0.013 0.01 0.03607 0.07 
 S8 F  0.069 0.01 <.00001 2.05  -0.045 0.01 <.00001 0.88  0.028 0.01 0.00072 0.34  0.019 0.01 0.03268 0.16  0.002 0.01 0.81098 0.00 
 S8 M  0.066 0.01 <.00001 1.88  -0.033 0.01 0.00026 0.48  0.045 0.01 <.00001 0.88  0.017 0.01 0.07738 0.13  0.026 0.01 0.00334 0.28 
 
FTND-based 
nicotine 
dependence 
S1 F+M  0.027 0.01 <.00001 0.36  -0.008 0.01 0.13978 0.04  0.028 0.01 <.00001 0.38  0.024 0.01 0.00004 0.27  0.000 0.01 0.99101 0.00 
 S1 F  0.021 0.01 0.00373 0.23  -0.010 0.01 0.19663 0.05  0.030 0.01 0.00004 0.45  0.014 0.01 0.05759 0.10  0.002 0.01 0.83606 0.00 
 S1 M  0.030 0.01 0.00028 0.47  -0.012 0.01 0.14799 0.07  0.029 0.01 0.00054 0.43  0.035 0.01 0.00003 0.60  -0.003 0.01 0.75873 0.00 
 S2 F+M  0.044 0.01 <.00001 0.97  -0.013 0.01 0.02645 0.08  0.031 0.01 <.00001 0.47  0.018 0.01 0.00184 0.16  0.004 0.01 0.50546 0.01 
 S2 F  0.040 0.01 <.00001 0.83  -0.009 0.01 0.25205 0.04  0.033 0.01 <.00001 0.53  0.006 0.01 0.45526 0.02  0.001 0.01 0.84719 0.00 
 S2 M  0.045 0.01 <.00001 1.02  -0.018 0.01 0.03030 0.16  0.033 0.01 0.00008 0.55  0.031 0.01 0.00020 0.48  0.004 0.01 0.60091 0.01 
 S3 F+M  0.054 0.01 <.00001 1.45  -0.017 0.01 0.00293 0.14  0.033 0.01 <.00001 0.53  0.024 0.01 0.00003 0.30  0.000 0.01 0.93972 0.00 
 S3 F  0.055 0.01 <.00001 1.50  -0.009 0.01 0.24309 0.04  0.034 0.01 <.00001 0.56  0.014 0.01 0.06084 0.10  0.004 0.01 0.63481 0.01 
 S3 M  0.051 0.01 <.00001 1.32  -0.027 0.01 0.00142 0.35  0.035 0.01 0.00002 0.62  0.038 0.01 0.00001 0.71  -0.005 0.01 0.53714 0.01 
 S4 F+M  0.060 0.01 <.00001 1.84  -0.027 0.01 <.00001 0.36  0.040 0.01 <.00001 0.81  0.027 0.01 <.00001 0.39  0.007 0.01 0.22868 0.02 
 S4 F  0.059 0.01 <.00001 1.77  -0.021 0.01 0.00326 0.23  0.042 0.01 <.00001 0.90  0.021 0.01 0.00597 0.23  0.008 0.01 0.25984 0.03 
 S4 M  0.061 0.01 <.00001 1.87  -0.034 0.01 0.00006 0.57  0.039 0.01 <.00001 0.78  0.035 0.01 0.00005 0.65  0.003 0.01 0.73534 0.00 
 S5 F+M  0.061 0.01 <.00001 1.90  -0.033 0.01 <.00001 0.55  0.044 0.01 <.00001 0.98  0.029 0.01 <.00001 0.46  0.009 0.01 0.11001 0.04 
 S5 F  0.056 0.01 <.00001 1.58  -0.029 0.01 0.00011 0.41  0.046 0.01 <.00001 1.07  0.029 0.01 0.00017 0.47  0.007 0.01 0.31395 0.03 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S5 M  0.066 0.01 <.00001 2.19  -0.038 0.01 <.00001 0.71  0.045 0.01 <.00001 1.04  0.028 0.01 0.00180 0.41  0.010 0.01 0.24925 0.05 
 S6 F+M  0.062 0.01 <.00001 1.94  -0.036 0.01 <.00001 0.66  0.046 0.01 <.00001 1.07  0.030 0.01 <.00001 0.49  0.011 0.01 0.06104 0.06 
 S6 F  0.054 0.01 <.00001 1.48  -0.034 0.01 <.00001 0.59  0.051 0.01 <.00001 1.30  0.032 0.01 0.00006 0.55  0.010 0.01 0.19645 0.04 
 S6 M  0.069 0.01 <.00001 2.38  -0.039 0.01 <.00001 0.78  0.043 0.01 <.00001 0.93  0.028 0.01 0.00145 0.43  0.010 0.01 0.22451 0.05 
 S7 F+M  0.062 0.01 <.00001 1.95  -0.038 0.01 <.00001 0.72  0.040 0.01 <.00001 0.81  0.025 0.01 0.00008 0.34  0.012 0.01 0.04442 0.06 
 S7 F  0.057 0.01 <.00001 1.65  -0.036 0.01 <.00001 0.65  0.042 0.01 <.00001 0.92  0.026 0.01 0.00108 0.37  0.010 0.01 0.17434 0.05 
 S7 M  0.065 0.01 <.00001 2.18  -0.041 0.01 <.00001 0.84  0.040 0.01 <.00001 0.81  0.024 0.01 0.00732 0.32  0.011 0.01 0.17761 0.06 
 S8 F+M  0.062 0.01 <.00001 1.95  -0.037 0.01 <.00001 0.68  0.041 0.01 <.00001 0.86  0.025 0.01 0.00010 0.34  0.011 0.01 0.04677 0.06 
 S8 F  0.056 0.01 <.00001 1.62  -0.034 0.01 <.00001 0.58  0.042 0.01 <.00001 0.92  0.026 0.01 0.00135 0.36  0.010 0.01 0.17678 0.05 
 S8 M  0.066 0.01 <.00001 2.22  -0.040 0.01 <.00001 0.83  0.042 0.01 <.00001 0.90  0.024 0.01 0.00725 0.32  0.011 0.01 0.18882 0.06 
 
DSM-IV 
conduct 
disorder 
S1 F+M  0.005 0.00 0.02898 0.07  -0.003 0.00 0.14325 0.03  0.002 0.00 0.37017 0.01  -0.001 0.00 0.80221 0.00  -0.003 0.00 0.20667 0.03 
 S1 F  0.006 0.00 0.00451 0.13  -0.000 0.00 0.93572 0.00  -0.001 0.00 0.51380 0.01  -0.002 0.00 0.43279 0.01  0.001 0.00 0.55181 0.01 
 S1 M  0.003 0.00 0.50967 0.02  -0.007 0.00 0.07643 0.16  0.006 0.00 0.14313 0.11  0.001 0.00 0.84914 0.00  -0.008 0.00 0.05136 0.19 
 S2 F+M  0.006 0.00 0.00525 0.12  -0.002 0.00 0.28024 0.02  0.002 0.00 0.25792 0.02  -0.001 0.00 0.59957 0.00  -0.001 0.00 0.58732 0.00 
 S2 F  0.005 0.00 0.01770 0.09  -0.004 0.00 0.06414 0.06  -0.000 0.00 0.91085 0.00  -0.003 0.00 0.18867 0.03  0.002 0.00 0.31804 0.02 
 S2 M  0.007 0.00 0.07003 0.16  -0.001 0.00 0.85648 0.00  0.005 0.00 0.16167 0.10  0.001 0.00 0.84255 0.00  -0.005 0.00 0.19768 0.08 
 S3 F+M  0.006 0.00 0.00415 0.13  -0.004 0.00 0.04107 0.06  0.004 0.00 0.04899 0.06  -0.002 0.00 0.47147 0.01  -0.003 0.00 0.14431 0.03 
 S3 F  0.005 0.00 0.03093 0.07  -0.001 0.00 0.81974 0.00  -0.000 0.00 0.85751 0.00  -0.001 0.00 0.72636 0.00  -0.001 0.00 0.72908 0.00 
 S3 M  0.008 0.00 0.04538 0.20  -0.008 0.00 0.03368 0.23  0.010 0.00 0.01275 0.31  -0.002 0.00 0.53327 0.02  -0.006 0.00 0.13340 0.11 
 S4 F+M  0.008 0.00 0.00018 0.22  -0.008 0.00 0.00017 0.22  0.004 0.00 0.09431 0.04  0.001 0.00 0.58891 0.01  -0.001 0.00 0.51131 0.01 
 S4 F  0.004 0.00 0.04716 0.06  -0.004 0.00 0.04977 0.06  -0.000 0.00 0.97892 0.00  0.001 0.00 0.62557 0.00  -0.000 0.00 0.98607 0.00 
 S4 M  0.012 0.00 0.00119 0.52  -0.013 0.00 0.00129 0.53  0.009 0.00 0.02479 0.25  0.001 0.00 0.80582 0.00  -0.003 0.00 0.48257 0.02 
 S5 F+M  0.009 0.00 0.00002 0.28  -0.008 0.00 0.00037 0.20  0.004 0.00 0.05900 0.06  0.003 0.00 0.15994 0.04  -0.001 0.00 0.63803 0.00 
 S5 F  0.005 0.00 0.01815 0.09  -0.006 0.00 0.01377 0.10  -0.000 0.00 0.97824 0.00  0.003 0.00 0.17529 0.03  -0.001 0.00 0.65555 0.00 
 S5 M  0.014 0.00 0.00036 0.64  -0.010 0.00 0.00853 0.36  0.010 0.00 0.01107 0.33  0.003 0.00 0.49874 0.03  -0.001 0.00 0.88312 0.00 
 S6 F+M  0.008 0.00 0.00009 0.24  -0.008 0.00 0.00032 0.21  0.004 0.00 0.04067 0.07  0.003 0.00 0.16633 0.04  -0.001 0.00 0.54417 0.01 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S6 F  0.005 0.00 0.03567 0.07  -0.005 0.00 0.01983 0.09  0.001 0.00 0.82177 0.00  0.002 0.00 0.40818 0.01  -0.001 0.00 0.53206 0.01 
 S6 M  0.013 0.00 0.00097 0.55  -0.011 0.00 0.00600 0.40  0.010 0.00 0.01001 0.34  0.004 0.00 0.27786 0.07  -0.001 0.00 0.85046 0.00 
 S7 F+M  0.009 0.00 0.00005 0.26  -0.009 0.00 0.00009 0.25  0.005 0.00 0.01655 0.09  0.002 0.00 0.27980 0.02  -0.002 0.00 0.43710 0.01 
 S7 F  0.004 0.00 0.06332 0.06  -0.006 0.00 0.00512 0.13  0.001 0.00 0.58825 0.00  0.002 0.00 0.30920 0.02  -0.002 0.00 0.46742 0.01 
 S7 M  0.014 0.00 0.00020 0.70  -0.011 0.00 0.00445 0.44  0.011 0.00 0.00539 0.40  0.002 0.00 0.55221 0.02  -0.001 0.00 0.74694 0.01 
 S8 F+M  0.009 0.00 0.00003 0.27  -0.009 0.00 0.00007 0.26  0.005 0.00 0.02145 0.09  0.002 0.00 0.28555 0.02  -0.001 0.00 0.60272 0.00 
 S8 F  0.004 0.00 0.05347 0.06  -0.007 0.00 0.00338 0.15  0.001 0.00 0.60395 0.00  0.002 0.00 0.32747 0.02  -0.001 0.00 0.55565 0.01 
 S8 M  0.015 0.00 0.00017 0.72  -0.011 0.00 0.00422 0.44  0.011 0.00 0.00664 0.39  0.002 0.00 0.54648 0.02  -0.000 0.00 0.92530 0.00 
 
DSM-IV 
antisocial 
personality 
disorder 
S1 F+M  0.003 0.00 0.05078 0.05  -0.002 0.00 0.30521 0.01  0.002 0.00 0.19952 0.02  -0.001 0.00 0.43661 0.01  -0.001 0.00 0.42508 0.01 
 S1 F  0.003 0.00 0.02264 0.05  0.001 0.00 0.70393 0.00  0.001 0.00 0.42945 0.01  0.000 0.00 0.80213 0.00  0.001 0.00 0.70435 0.00 
 S1 M  0.004 0.00 0.28032 0.06  -0.004 0.00 0.17715 0.10  0.003 0.00 0.31650 0.06  -0.003 0.00 0.30530 0.06  -0.004 0.00 0.24583 0.07 
 S2 F+M  0.005 0.00 0.00771 0.10  -0.001 0.00 0.44954 0.01  0.003 0.00 0.07565 0.04  -0.001 0.00 0.39203 0.01  0.001 0.00 0.69642 0.00 
 S2 F  0.004 0.00 0.00981 0.07  -0.001 0.00 0.67049 0.00  0.002 0.00 0.13894 0.02  0.000 0.00 0.97637 0.00  0.002 0.00 0.28224 0.01 
 S2 M  0.006 0.00 0.08134 0.16  -0.002 0.00 0.46236 0.03  0.004 0.00 0.22950 0.08  -0.004 0.00 0.29571 0.06  -0.001 0.00 0.84380 0.00 
 S3 F+M  0.005 0.00 0.00758 0.10  -0.005 0.00 0.00691 0.10  0.004 0.00 0.01577 0.08  0.002 0.00 0.30450 0.02  -0.000 0.00 0.90000 0.00 
 S3 F  0.003 0.00 0.03254 0.05  -0.002 0.00 0.14776 0.02  0.001 0.00 0.43002 0.01  0.001 0.00 0.40810 0.01  0.001 0.00 0.59620 0.00 
 S3 M  0.006 0.00 0.05909 0.19  -0.008 0.00 0.01781 0.30  0.008 0.00 0.02060 0.29  0.002 0.00 0.47083 0.03  -0.002 0.00 0.59960 0.01 
 S4 F+M  0.005 0.00 0.00779 0.10  -0.007 0.00 0.00013 0.21  0.004 0.00 0.03077 0.07  0.004 0.00 0.01591 0.09  0.000 0.00 0.95270 0.00 
 S4 F  0.004 0.00 0.00942 0.07  -0.004 0.00 0.01354 0.06  0.000 0.00 0.79115 0.00  0.001 0.00 0.37712 0.01  0.000 0.00 0.89981 0.00 
 S4 M  0.005 0.00 0.10275 0.14  -0.010 0.00 0.00185 0.54  0.008 0.00 0.02173 0.28  0.007 0.00 0.03293 0.26  -0.001 0.00 0.88066 0.00 
 S5 F+M  0.005 0.00 0.00519 0.11  -0.007 0.00 0.00007 0.23  0.003 0.00 0.04446 0.06  0.004 0.00 0.01364 0.09  0.001 0.00 0.57714 0.00 
 S5 F  0.003 0.00 0.04239 0.04  -0.004 0.00 0.01239 0.07  0.000 0.00 0.82645 0.00  0.002 0.00 0.15849 0.02  0.000 0.00 0.88514 0.00 
 S5 M  0.007 0.00 0.03941 0.23  -0.011 0.00 0.00109 0.60  0.007 0.00 0.02954 0.26  0.007 0.00 0.04672 0.23  0.001 0.00 0.67850 0.01 
 S6 F+M  0.005 0.00 0.00489 0.11  -0.006 0.00 0.00034 0.19  0.003 0.00 0.08656 0.04  0.004 0.00 0.02870 0.08  0.002 0.00 0.27244 0.02 
 S6 F  0.003 0.00 0.02697 0.05  -0.004 0.00 0.01678 0.06  0.001 0.00 0.64435 0.00  0.002 0.00 0.21880 0.02  0.000 0.00 0.73398 0.00 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S6 M  0.007 0.00 0.04373 0.22  -0.010 0.00 0.00365 0.48  0.006 0.00 0.08564 0.16  0.006 0.00 0.07272 0.19  0.003 0.00 0.35641 0.05 
 S7 F+M  0.006 0.00 0.00079 0.16  -0.007 0.00 0.00009 0.23  0.003 0.00 0.12018 0.04  0.004 0.00 0.02358 0.08  0.002 0.00 0.18621 0.02 
 S7 F  0.003 0.00 0.01581 0.06  -0.004 0.00 0.00694 0.08  -0.000 0.00 0.89638 0.00  0.002 0.00 0.09748 0.03  -0.000 0.00 0.85843 0.00 
 S7 M  0.008 0.00 0.01135 0.35  -0.011 0.00 0.00174 0.57  0.006 0.00 0.06689 0.19  0.006 0.00 0.09643 0.17  0.005 0.00 0.14130 0.12 
 S8 F+M  0.006 0.00 0.00050 0.17  -0.007 0.00 0.00010 0.23  0.003 0.00 0.13401 0.03  0.004 0.00 0.03119 0.07  0.002 0.00 0.16498 0.03 
 S8 F  0.003 0.00 0.01655 0.06  -0.004 0.00 0.00835 0.07  -0.000 0.00 0.83647 0.00  0.002 0.00 0.10875 0.03  -0.000 0.00 0.97039 0.00 
 S8 M  0.009 0.00 0.00726 0.39  -0.011 0.00 0.00163 0.58  0.006 0.00 0.06819 0.19  0.005 0.00 0.11779 0.15  0.005 0.00 0.14256 0.12 
 
DSM-IV 
major 
depressive 
disorder 
S1 F+M  0.009 0.01 0.10310 0.04  0.009 0.01 0.11668 0.04  0.013 0.01 0.02005 0.08  0.003 0.01 0.55008 0.01  -0.003 0.01 0.64580 0.00 
 S1 F  0.013 0.01 0.09203 0.08  0.009 0.01 0.25457 0.04  0.011 0.01 0.15252 0.06  0.012 0.01 0.11584 0.07  0.004 0.01 0.58688 0.01 
 S1 M  0.005 0.01 0.55035 0.01  0.007 0.01 0.35870 0.02  0.017 0.01 0.02796 0.14  -0.007 0.01 0.35961 0.02  -0.010 0.01 0.17394 0.05 
 S2 F+M  0.002 0.01 0.69179 0.00  0.013 0.01 0.02220 0.08  0.014 0.01 0.01443 0.09  0.001 0.01 0.91561 0.00  -0.002 0.01 0.76142 0.00 
 S2 F  0.005 0.01 0.48914 0.01  0.012 0.01 0.12337 0.07  0.010 0.01 0.17887 0.05  0.009 0.01 0.25834 0.04  -0.001 0.01 0.85602 0.00 
 S2 M  -0.001 0.01 0.89736 0.00  0.013 0.01 0.09179 0.08  0.019 0.01 0.01222 0.18  -0.008 0.01 0.30547 0.03  -0.001 0.01 0.84865 0.00 
 S3 F+M  0.010 0.01 0.08863 0.04  -0.002 0.01 0.78339 0.00  0.012 0.01 0.03636 0.07  -0.002 0.01 0.70417 0.00  0.004 0.01 0.44005 0.01 
 S3 F  0.011 0.01 0.14964 0.06  0.005 0.01 0.53070 0.01  0.010 0.01 0.22360 0.04  0.006 0.01 0.46856 0.02  0.002 0.01 0.74974 0.00 
 S3 M  0.009 0.01 0.26160 0.04  -0.010 0.01 0.19834 0.05  0.017 0.01 0.03130 0.13  -0.010 0.01 0.18576 0.05  0.006 0.01 0.47103 0.01 
 S4 F+M  0.014 0.01 0.01372 0.09  -0.007 0.01 0.19525 0.03  0.010 0.01 0.08500 0.04  -0.003 0.01 0.58640 0.00  -0.002 0.01 0.74893 0.00 
 S4 F  0.014 0.01 0.07163 0.10  -0.004 0.01 0.62067 0.01  0.003 0.01 0.74150 0.00  -0.007 0.01 0.40690 0.02  -0.007 0.01 0.34226 0.03 
 S4 M  0.013 0.01 0.08752 0.08  -0.012 0.01 0.13530 0.06  0.018 0.01 0.01586 0.16  0.001 0.01 0.88957 0.00  0.004 0.01 0.56950 0.01 
 S5 F+M  0.014 0.01 0.01480 0.09  -0.007 0.01 0.21369 0.02  0.016 0.01 0.00346 0.13  0.003 0.01 0.60310 0.00  0.004 0.01 0.44839 0.01 
 S5 F  0.016 0.01 0.03398 0.13  -0.002 0.01 0.81274 0.00  0.008 0.01 0.32955 0.03  0.003 0.01 0.71578 0.00  -0.000 0.01 0.97631 0.00 
 S5 M  0.010 0.01 0.18191 0.05  -0.013 0.01 0.08917 0.09  0.027 0.01 0.00048 0.35  0.003 0.01 0.66647 0.01  0.009 0.01 0.26110 0.04 
 S6 F+M  0.013 0.01 0.01869 0.08  -0.006 0.01 0.29495 0.02  0.014 0.01 0.01533 0.09  0.005 0.01 0.40134 0.01  0.008 0.01 0.18245 0.03 
 S6 F  0.018 0.01 0.02231 0.15  -0.001 0.01 0.86336 0.00  0.006 0.01 0.45002 0.02  0.004 0.01 0.58261 0.01  0.004 0.01 0.61064 0.01 
 S6 M  0.008 0.01 0.31494 0.03  -0.012 0.01 0.13602 0.07  0.023 0.01 0.00352 0.25  0.005 0.01 0.52431 0.01  0.011 0.01 0.17076 0.05 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S7 F+M  0.016 0.01 0.00463 0.12  -0.008 0.01 0.17798 0.03  0.013 0.01 0.02603 0.08  0.005 0.01 0.42882 0.01  0.010 0.01 0.08189 0.05 
 S7 F  0.021 0.01 0.00565 0.22  -0.005 0.01 0.49596 0.01  0.005 0.01 0.53223 0.01  0.005 0.01 0.54593 0.01  0.008 0.01 0.32957 0.03 
 S7 M  0.009 0.01 0.26421 0.04  -0.011 0.01 0.16244 0.06  0.021 0.01 0.00709 0.21  0.004 0.01 0.64081 0.01  0.012 0.01 0.11247 0.07 
 S8 F+M  0.016 0.01 0.00480 0.12  -0.006 0.01 0.30453 0.02  0.013 0.01 0.02717 0.08  0.004 0.01 0.49589 0.01  0.010 0.01 0.06373 0.05 
 S8 F  0.021 0.01 0.00681 0.21  -0.005 0.01 0.52977 0.01  0.004 0.01 0.61612 0.01  0.004 0.01 0.57435 0.01  0.008 0.01 0.30113 0.03 
 S8 M  0.009 0.01 0.23435 0.04  -0.008 0.01 0.33992 0.03  0.022 0.01 0.00468 0.23  0.003 0.01 0.73679 0.00  0.013 0.01 0.08955 0.08 
 
DSM-IV 
panic 
disorder 
S1 F+M  0.003 0.00 0.23253 0.02  0.002 0.00 0.36353 0.01  0.001 0.00 0.66509 0.00  0.001 0.00 0.80411 0.00  0.003 0.00 0.21020 0.02 
 S1 F  0.008 0.00 0.03769 0.14  0.005 0.00 0.19666 0.05  -0.001 0.00 0.81492 0.00  0.002 0.00 0.54021 0.01  0.006 0.00 0.08449 0.10 
 S1 M  -0.003 0.00 0.37904 0.02  -0.001 0.00 0.75492 0.00  0.003 0.00 0.29865 0.03  -0.001 0.00 0.74042 0.00  -0.001 0.00 0.78542 0.00 
 S2 F+M  0.005 0.00 0.03415 0.06  0.001 0.00 0.66206 0.00  0.001 0.00 0.68913 0.00  0.001 0.00 0.64930 0.00  0.001 0.00 0.69215 0.00 
 S2 F  0.008 0.00 0.02999 0.15  -0.002 0.00 0.56231 0.01  0.000 0.00 0.98416 0.00  0.002 0.00 0.63649 0.01  0.002 0.00 0.52118 0.01 
 S2 M  0.001 0.00 0.63940 0.01  0.005 0.00 0.09521 0.07  0.002 0.00 0.56011 0.01  0.001 0.00 0.85728 0.00  -0.001 0.00 0.76206 0.00 
 S3 F+M  0.005 0.00 0.03801 0.06  -0.002 0.00 0.54091 0.01  0.004 0.00 0.12099 0.03  0.003 0.00 0.30712 0.02  0.002 0.00 0.36302 0.01 
 S3 F  0.009 0.00 0.01490 0.19  -0.002 0.00 0.58181 0.01  0.004 0.00 0.26971 0.04  0.000 0.00 0.94897 0.00  0.002 0.00 0.53449 0.01 
 S3 M  0.000 0.00 0.94549 0.00  -0.000 0.00 0.90504 0.00  0.003 0.00 0.27444 0.03  0.005 0.00 0.10204 0.07  0.002 0.00 0.55879 0.01 
 S4 F+M  0.005 0.00 0.03107 0.07  -0.001 0.00 0.66378 0.00  0.005 0.00 0.03538 0.06  0.005 0.00 0.05365 0.06  -0.001 0.00 0.67109 0.00 
 S4 F  0.008 0.00 0.03938 0.14  0.000 0.00 0.99524 0.00  0.003 0.00 0.35173 0.03  0.002 0.00 0.50142 0.02  -0.003 0.00 0.44727 0.02 
 S4 M  0.002 0.00 0.42890 0.01  -0.002 0.00 0.51195 0.01  0.007 0.00 0.03072 0.11  0.007 0.00 0.02648 0.13  0.001 0.00 0.74813 0.00 
 S5 F+M  0.005 0.00 0.03929 0.06  -0.002 0.00 0.45716 0.01  0.006 0.00 0.01848 0.08  0.006 0.00 0.01000 0.10  0.002 0.00 0.44998 0.01 
 S5 F  0.007 0.00 0.05573 0.12  -0.003 0.00 0.38097 0.03  0.006 0.00 0.09259 0.09  0.006 0.00 0.10830 0.09  0.001 0.00 0.70255 0.00 
 S5 M  0.002 0.00 0.46093 0.01  -0.000 0.00 0.99720 0.00  0.005 0.00 0.11602 0.06  0.007 0.00 0.03935 0.11  0.002 0.00 0.45017 0.01 
 S6 F+M  0.006 0.00 0.02562 0.07  -0.003 0.00 0.30583 0.02  0.005 0.00 0.05746 0.05  0.006 0.00 0.01223 0.10  0.002 0.00 0.51029 0.01 
 S6 F  0.008 0.00 0.03780 0.14  -0.003 0.00 0.41981 0.02  0.005 0.00 0.17694 0.06  0.007 0.00 0.07751 0.11  0.002 0.00 0.67133 0.01 
 S6 M  0.003 0.00 0.41713 0.02  -0.002 0.00 0.57820 0.01  0.004 0.00 0.20507 0.04  0.005 0.00 0.08973 0.08  0.002 0.00 0.58529 0.01 
 S7 F+M  0.006 0.00 0.00857 0.10  -0.005 0.00 0.07580 0.05  0.004 0.00 0.08416 0.04  0.006 0.00 0.02585 0.08  0.001 0.00 0.58802 0.00 
 S7 F  0.010 0.00 0.00746 0.23  -0.005 0.00 0.19761 0.06  0.005 0.00 0.14351 0.07  0.006 0.00 0.09293 0.10  0.002 0.00 0.53211 0.01 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S7 M  0.002 0.00 0.50069 0.01  -0.004 0.00 0.22700 0.04  0.002 0.00 0.44933 0.01  0.004 0.00 0.19445 0.05  0.000 0.00 0.89487 0.00 
 S8 F+M  0.006 0.00 0.00916 0.10  -0.004 0.00 0.09747 0.04  0.004 0.00 0.09486 0.04  0.006 0.00 0.02418 0.08  0.001 0.00 0.62785 0.00 
 S8 F  0.010 0.00 0.00812 0.22  -0.004 0.00 0.26369 0.04  0.005 0.00 0.14554 0.07  0.007 0.00 0.07176 0.11  0.002 0.00 0.62599 0.01 
 S8 M  0.002 0.00 0.50433 0.01  -0.004 0.00 0.21358 0.04  0.002 0.00 0.50296 0.01  0.004 0.00 0.24055 0.04  0.001 0.00 0.83340 0.00 
 
DSM-IV 
social anxiety 
disorder 
S1 F+M  0.011 0.00 0.01710 0.09  -0.001 0.00 0.89228 0.00  0.002 0.00 0.73759 0.00  -0.003 0.00 0.51364 0.01  -0.002 0.00 0.73594 0.00 
 S1 F  0.019 0.01 0.00327 0.25  0.003 0.01 0.66321 0.01  -0.000 0.01 0.98909 0.00  -0.001 0.01 0.82725 0.00  0.001 0.01 0.89127 0.00 
 S1 M  0.003 0.01 0.67071 0.01  -0.005 0.01 0.42819 0.02  0.004 0.01 0.53059 0.01  -0.004 0.01 0.53398 0.01  -0.004 0.01 0.57116 0.01 
 S2 F+M  0.007 0.00 0.11421 0.04  0.005 0.00 0.33593 0.01  0.001 0.00 0.78883 0.00  -0.005 0.00 0.30352 0.02  -0.001 0.00 0.80165 0.00 
 S2 F  0.015 0.01 0.02491 0.15  0.002 0.01 0.75329 0.00  0.001 0.01 0.91035 0.00  -0.002 0.01 0.73685 0.00  0.002 0.01 0.79798 0.00 
 S2 M  -0.001 0.01 0.90451 0.00  0.007 0.01 0.29587 0.03  0.003 0.01 0.69606 0.00  -0.006 0.01 0.33403 0.03  -0.004 0.01 0.52535 0.01 
 S3 F+M  0.012 0.00 0.01245 0.09  0.001 0.00 0.87812 0.00  0.003 0.00 0.53970 0.01  0.004 0.00 0.36632 0.01  0.002 0.00 0.70918 0.00 
 S3 F  0.021 0.01 0.00167 0.29  -0.003 0.01 0.65529 0.01  0.006 0.01 0.37097 0.02  0.012 0.01 0.06452 0.10  0.000 0.01 0.94469 0.00 
 S3 M  0.001 0.01 0.83031 0.00  0.005 0.01 0.48058 0.01  0.001 0.01 0.83905 0.00  -0.004 0.01 0.59492 0.01  0.002 0.01 0.73000 0.00 
 S4 F+M  0.010 0.00 0.03170 0.07  -0.001 0.00 0.82820 0.00  0.006 0.00 0.17776 0.03  0.002 0.00 0.69101 0.00  -0.001 0.00 0.82039 0.00 
 S4 F  0.019 0.01 0.00381 0.25  -0.009 0.01 0.18650 0.05  0.006 0.01 0.37490 0.02  0.008 0.01 0.22961 0.05  -0.004 0.01 0.56555 0.01 
 S4 M  -0.000 0.01 0.94450 0.00  0.007 0.01 0.27556 0.04  0.008 0.01 0.22668 0.04  -0.004 0.01 0.50487 0.01  0.002 0.01 0.77807 0.00 
 S5 F+M  0.010 0.00 0.04484 0.06  -0.003 0.00 0.57191 0.01  0.011 0.00 0.02618 0.08  0.003 0.00 0.61101 0.00  0.001 0.00 0.88315 0.00 
 S5 F  0.019 0.01 0.00454 0.24  -0.007 0.01 0.33015 0.03  0.010 0.01 0.12710 0.07  0.010 0.01 0.12870 0.08  -0.000 0.01 0.99576 0.00 
 S5 M  -0.002 0.01 0.73475 0.00  0.001 0.01 0.91951 0.00  0.012 0.01 0.07043 0.10  -0.006 0.01 0.38166 0.02  0.001 0.01 0.86829 0.00 
 S6 F+M  0.008 0.00 0.09374 0.04  -0.001 0.00 0.82700 0.00  0.009 0.00 0.05385 0.06  0.001 0.00 0.87083 0.00  0.002 0.00 0.60345 0.00 
 S6 F  0.017 0.01 0.01081 0.19  -0.004 0.01 0.53146 0.01  0.009 0.01 0.19040 0.05  0.009 0.01 0.17690 0.06  0.003 0.01 0.62256 0.01 
 S6 M  -0.003 0.01 0.60615 0.01  0.002 0.01 0.78901 0.00  0.010 0.01 0.11789 0.07  -0.008 0.01 0.23063 0.05  0.001 0.01 0.89256 0.00 
 S7 F+M  0.011 0.00 0.01797 0.09  -0.005 0.00 0.26910 0.02  0.009 0.00 0.06201 0.05  0.002 0.00 0.63776 0.00  -0.002 0.00 0.69096 0.00 
 S7 F  0.019 0.01 0.00417 0.24  -0.009 0.01 0.17059 0.06  0.010 0.01 0.15438 0.06  0.010 0.01 0.12973 0.08  -0.002 0.01 0.78022 0.00 
 S7 M  0.001 0.01 0.86890 0.00  -0.001 0.01 0.84143 0.00  0.009 0.01 0.18122 0.05  -0.006 0.01 0.35850 0.03  -0.002 0.01 0.71924 0.00 
 S8 F+M  0.012 0.00 0.01143 0.10  -0.004 0.00 0.36081 0.01  0.009 0.00 0.05173 0.06  0.002 0.00 0.73700 0.00  -0.002 0.00 0.72863 0.00 
Table S4-4. Effect estimates (Beta, SE, two-sided p value, and R² as percentage) of polygenic risk scores on target phenotypes related to lifetime use of licit 
substance, substance use disorders, and psychiatric disorders. Modelling in these associations stratified the target sample by sex into females (F), males (M) and 
both sexes together (F+M). PRS was calculated for five discovery phenotypes smoking initiation (SI), age of initiation of regular smoking (AI), number of cigarettes per 
day (CPD), smoking cessation (SC) and drinks per week (DPW) at eight p value thresholds (PT): 5e-08 (S1), 1e-05 (S2), 1e-03 (S3), 1e-02 (S4), 5e-02 (S5), 1e-01 (S6), 
5e-01 (S7), and 1 (S8). Associations that survive multiple testing are presented in bold-face blue. The corrected significance threshold is 7.142857e-04. 
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 SI  AI  CPD  SC  DPW 
Target 
phenotype PT Sex  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R²  Beta SE p-value R² 
 S8 F  0.020 0.01 0.00267 0.27  -0.009 0.01 0.19304 0.05  0.010 0.01 0.14049 0.07  0.009 0.01 0.17828 0.06  -0.001 0.01 0.82477 0.00 
 S8 M  0.002 0.01 0.80047 0.00  -0.000 0.01 0.99842 0.00  0.009 0.01 0.16656 0.06  -0.006 0.01 0.35344 0.03  -0.002 0.01 0.72247 0.00 
 
Mania screen S1 F+M  -0.000 0.00 0.91319 0.00  0.001 0.00 0.56380 0.01  0.001 0.00 0.29092 0.02  -0.002 0.00 0.13222 0.04  0.001 0.00 0.44826 0.01 
 S1 F  0.001 0.00 0.71875 0.00  0.002 0.00 0.28019 0.04  0.000 0.00 0.88202 0.00  -0.003 0.00 0.12167 0.09  0.000 0.00 0.96650 0.00 
 S1 M  -0.001 0.00 0.52663 0.01  -0.001 0.00 0.70251 0.01  0.003 0.00 0.19344 0.06  -0.001 0.00 0.70034 0.01  0.002 0.00 0.27004 0.04 
 S2 F+M  0.000 0.00 0.92064 0.00  -0.001 0.00 0.41171 0.01  0.001 0.00 0.40140 0.01  -0.003 0.00 0.06460 0.06  0.001 0.00 0.50705 0.01 
 S2 F  -0.000 0.00 0.98809 0.00  -0.001 0.00 0.49902 0.02  0.001 0.00 0.61487 0.01  -0.003 0.00 0.12664 0.08  -0.001 0.00 0.61296 0.01 
 S2 M  0.000 0.00 0.91627 0.00  -0.001 0.00 0.63576 0.01  0.001 0.00 0.58913 0.01  -0.002 0.00 0.35243 0.03  0.003 0.00 0.10600 0.09 
 S3 F+M  0.002 0.00 0.19539 0.03  -0.000 0.00 0.99738 0.00  -0.000 0.00 0.93804 0.00  -0.002 0.00 0.18006 0.03  0.001 0.00 0.32777 0.02 
 S3 F  0.001 0.00 0.48921 0.02  0.000 0.00 0.95368 0.00  0.000 0.00 0.82207 0.00  -0.002 0.00 0.36628 0.03  -0.003 0.00 0.15823 0.07 
 S3 M  0.002 0.00 0.21001 0.06  -0.000 0.00 0.90868 0.00  -0.001 0.00 0.61216 0.01  -0.002 0.00 0.31475 0.04  0.006 0.00 0.00146 0.36 
 S4 F+M  0.002 0.00 0.12662 0.04  -0.001 0.00 0.51281 0.01  0.002 0.00 0.11676 0.04  -0.001 0.00 0.30491 0.02  -0.001 0.00 0.57855 0.01 
 S4 F  0.001 0.00 0.72458 0.00  -0.001 0.00 0.47981 0.02  0.002 0.00 0.20604 0.06  -0.002 0.00 0.39763 0.03  -0.004 0.00 0.05656 0.13 
 S4 M  0.004 0.00 0.05070 0.13  -0.000 0.00 0.81874 0.00  0.002 0.00 0.40327 0.03  -0.001 0.00 0.51835 0.02  0.003 0.00 0.13921 0.08 
 S5 F+M  0.002 0.00 0.20539 0.03  -0.000 0.00 0.77781 0.00  0.002 0.00 0.19635 0.03  -0.000 0.00 0.83201 0.00  0.000 0.00 0.79025 0.00 
 S5 F  -0.001 0.00 0.74928 0.00  -0.001 0.00 0.64227 0.01  0.002 0.00 0.24592 0.05  -0.001 0.00 0.65033 0.01  -0.002 0.00 0.21029 0.06 
 S5 M  0.004 0.00 0.02110 0.19  0.000 0.00 0.95359 0.00  0.001 0.00 0.57014 0.01  0.000 0.00 0.93994 0.00  0.004 0.00 0.05413 0.13 
 S6 F+M  0.001 0.00 0.29121 0.02  -0.000 0.00 0.78113 0.00  0.001 0.00 0.27937 0.02  0.000 0.00 0.97868 0.00  0.001 0.00 0.48798 0.01 
 S6 F  -0.001 0.00 0.47072 0.02  -0.000 0.00 0.87107 0.00  0.002 0.00 0.40504 0.03  -0.001 0.00 0.72014 0.00  -0.002 0.00 0.39172 0.03 
 S6 M  0.005 0.00 0.01502 0.21  -0.001 0.00 0.76403 0.00  0.001 0.00 0.50714 0.02  0.001 0.00 0.75854 0.00  0.004 0.00 0.03835 0.15 
 S7 F+M  0.001 0.00 0.36458 0.01  -0.002 0.00 0.16249 0.04  0.001 0.00 0.43806 0.01  -0.000 0.00 0.71432 0.00  0.001 0.00 0.47610 0.01 
 S7 F  -0.002 0.00 0.42552 0.02  -0.003 0.00 0.19666 0.06  0.001 0.00 0.62333 0.01  -0.001 0.00 0.60195 0.01  -0.003 0.00 0.11011 0.09 
 S7 M  0.004 0.00 0.02311 0.18  -0.002 0.00 0.44117 0.02  0.001 0.00 0.56782 0.01  -0.000 0.00 0.88872 0.00  0.006 0.00 0.00310 0.31 
 S8 F+M  0.001 0.00 0.36463 0.01  -0.002 0.00 0.20311 0.03  0.001 0.00 0.47753 0.01  -0.001 0.00 0.67904 0.00  0.001 0.00 0.43103 0.01 
 S8 F  -0.002 0.00 0.33391 0.03  -0.002 0.00 0.20692 0.06  0.001 0.00 0.62442 0.01  -0.001 0.00 0.55449 0.01  -0.003 0.00 0.11344 0.09 
 S8 M  0.005 0.00 0.01351 0.22  -0.001 0.00 0.53586 0.01  0.001 0.00 0.63649 0.01  -0.000 0.00 0.89300 0.00  0.006 0.00 0.00242 0.33 
 
Table S5-1. SNP heritability estimated for use of different substances analysed using LD score correlation. Heritability in liability scale was used for binary 
trait and observed scale was used for continuous traits. Z scores were derived by dividing the heritability estimates by the standard errors (SE), assuming that 
these quotients follow a Z distribution. Two-tailed p values were calculated in R using the equation: 2*pnorm(abs(z), lower.tail = F)). 
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 SNP heritability 
Sample Substance Trait Type Sample size Prevalence  h² SE 
Lambda 
GC 
Mean 
Chisq Intercept 
Intercept 
SE 
GSCAN alcohol Drinks consumed per week continuous 185,828 NA  0.042 0.003 1.108 1.132 0.980 0.007 
GSCAN nicotine Age of initiation of regular smoking continuous 119,239 NA  0.033 0.004 1.068 1.074 0.998 0.007 
GSCAN nicotine Cigarettes smoked per day continuous 122,027 NA  0.062 0.008 1.096 1.123 0.975 0.008 
GSCAN nicotine Smoking cessation binary 125,361 0.659  0.063 0.007 1.053 1.065 0.964 0.007 
GSCAN nicotine Regular smoking initiation binary 207,726 0.539  0.109 0.006 1.204 1.236 0.957 0.008 
ICC cannabis Cannabis initiation binary 164,741 0.267  0.065 0.004 1.184 1.213 0.996 0.007 
UKB alcohol Estimated standard drinks per week continuous 296,735 NA  0.068 0.004 1.369 1.432 1.034 0.009 
UKB caffeine Caffeine consumed per day continuous 168,919 NA  0.057 0.006 1.146 1.206 1.013 0.008 
UKB nicotine Cigarettes smoked per day continuous 25,153 NA  0.088 0.023 1.047 1.057 1.014 0.007 
UKB nicotine Pack years of smoking continuous 186,411 NA  0.093 0.005 1.310 1.357 1.015 0.008 
Table S5-2. Genetic correlations (rG) between the initiation or use of different substances analysed by LD score correlation analysis. The significance threshold 
was 0.001111111 (0.05/45). Analyses that survived multiple testing are shown in blue and boldface. Details of multiple testing correction was provided in the method 
section. 
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 Trait 1  Trait 2  Genetic correlations 
No.  Sample Substance Trait  Sample Substance Trait  rG SE Z score p value 
1  UKB alcohol Estimated standard drinks per 
week 
 UKB tobacco Pack years of smoking  0.222 0.028 7.981 1.4E-15 
2  UKB tobacco Cigarettes smoked per day  UKB tobacco Pack years of smoking  0.534 0.077 6.977 3.0E-12 
3  UKB tobacco Cigarettes smoked per day  UKB alcohol Estimated standard drinks per week  0.025 0.068 0.368 7.1E-01 
4  UKB caffeine Caffeine consumed per day  UKB tobacco Pack years of smoking  0.383 0.050 7.639 2.2E-14 
5  UKB caffeine Caffeine consumed per day  UKB alcohol Estimated standard drinks per 
week 
 0.157 0.041 3.799 1.0E-04 
6  UKB caffeine Caffeine consumed per day  UKB tobacco Cigarettes smoked per day  0.475 0.094 5.059 4.2E-07 
7  ICC cannabis Cannabis initiation  UKB tobacco Pack years of smoking  0.392 0.035 11.28 1.6E-29 
8  ICC cannabis Cannabis initiation  UKB alcohol Estimated standard drinks per 
week 
 0.382 0.035 10.87 1.6E-27 
9  ICC cannabis Cannabis initiation  UKB tobacco Cigarettes smoked per day  -.225 0.077 -2.94 3.2E-03 
10  ICC cannabis Cannabis initiation  UKB caffeine Caffeine consumed per day  -.017 0.046 -.375 7.1E-01 
11  GSCAN tobacco Regular smoking initiation  UKB tobacco Pack years of smoking  0.874 0.031 28.66 1.E-180 
12  GSCAN tobacco Regular smoking initiation  UKB alcohol Estimated standard drinks per 
week 
 0.270 0.028 9.760 1.7E-22 
13  GSCAN tobacco Regular smoking initiation  UKB tobacco Cigarettes smoked per day  0.153 0.074 2.069 3.9E-02 
14  GSCAN tobacco Regular smoking initiation  UKB caffeine Caffeine consumed per day  0.280 0.039 7.136 9.6E-13 
15  GSCAN tobacco Regular smoking initiation  ICC cannabis Cannabis initiation  0.402 0.033 12.17 4.8E-34 
16  GSCAN tobacco Smoking cessation  UKB tobacco Pack years of smoking  0.462 0.045 10.28 8.3E-25 
17  GSCAN tobacco Smoking cessation  UKB alcohol Estimated standard drinks per week  0.112 0.043 2.592 9.5E-03 
18  GSCAN tobacco Smoking cessation  UKB tobacco Cigarettes smoked per day  0.533 0.116 4.595 4.3E-06 
19  GSCAN tobacco Smoking cessation  UKB caffeine Caffeine consumed per day  0.279 0.062 4.468 7.9E-06 
20  GSCAN tobacco Smoking cessation  ICC cannabis Cannabis initiation  -.061 0.052 -1.17 2.4E-01 
21  GSCAN tobacco Smoking cessation  GSCAN tobacco Regular smoking initiation  0.421 0.047 8.937 4.0E-19 
22  GSCAN alcohol Drinks consumed per week  UKB tobacco Pack years of smoking  0.256 0.038 6.818 9.2E-12 
23  GSCAN alcohol Drinks consumed per week  UKB alcohol Estimated standard drinks per 
week 
 0.911 0.042 21.91 2.E-106 
24  GSCAN alcohol Drinks consumed per week  UKB tobacco Cigarettes smoked per day  0.143 0.081 1.774 7.6E-02 
25  GSCAN alcohol Drinks consumed per week  UKB caffeine Caffeine consumed per day  0.143 0.047 3.037 2.4E-03 
26  GSCAN alcohol Drinks consumed per week  ICC cannabis Cannabis initiation  0.382 0.046 8.348 7.0E-17 
27  GSCAN alcohol Drinks consumed per week  GSCAN tobacco Regular smoking initiation  0.359 0.038 9.358 8.1E-21 
Table S5-2. Genetic correlations (rG) between the initiation or use of different substances analysed by LD score correlation analysis. The significance threshold 
was 0.001111111 (0.05/45). Analyses that survived multiple testing are shown in blue and boldface. Details of multiple testing correction was provided in the method 
section. 
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 Trait 1  Trait 2  Genetic correlations 
No.  Sample Substance Trait  Sample Substance Trait  rG SE Z score p value 
28  GSCAN alcohol Drinks consumed per week  GSCAN tobacco Smoking cessation  0.052 0.058 0.900 3.7E-01 
29  GSCAN tobacco Cigarettes smoked per day  UKB tobacco Pack years of smoking  0.696 0.041 16.84 1.3E-63 
30  GSCAN tobacco Cigarettes smoked per day  UKB alcohol Estimated standard drinks per week  0.006 0.040 0.162 8.7E-01 
31  GSCAN tobacco Cigarettes smoked per day  UKB tobacco Cigarettes smoked per day  0.941 0.117 8.036 9.3E-16 
32  GSCAN tobacco Cigarettes smoked per day  UKB caffeine Caffeine consumed per day  0.411 0.087 4.748 2.1E-06 
33  GSCAN tobacco Cigarettes smoked per day  ICC cannabis Cannabis initiation  0.005 0.048 0.100 9.2E-01 
34  GSCAN tobacco Cigarettes smoked per day  GSCAN tobacco Regular smoking initiation  0.425 0.054 7.909 2.6E-15 
35  GSCAN tobacco Cigarettes smoked per day  GSCAN tobacco Smoking cessation  0.335 0.058 5.739 9.5E-09 
36  GSCAN tobacco Cigarettes smoked per day  GSCAN alcohol Drinks consumed per week  0.121 0.056 2.185 2.9E-02 
37  GSCAN tobacco Age of initiation of regular 
smoking 
 UKB tobacco Pack years of smoking  -.821 0.061 -13.5 1.0E-41 
38  GSCAN tobacco Age of initiation of regular 
smoking 
 UKB alcohol Estimated standard drinks per week  -.130 0.052 -2.50 1.3E-02 
39  GSCAN tobacco Age of initiation of regular 
smoking 
 UKB tobacco Cigarettes smoked per day  -.245 0.112 -2.18 2.9E-02 
40  GSCAN tobacco Age of initiation of regular 
smoking 
 UKB caffeine Caffeine consumed per day  -.196 0.061 -3.20 1.4E-03 
41  GSCAN tobacco Age of initiation of regular 
smoking 
 ICC cannabis Cannabis initiation  -.196 0.057 -3.46 5.0E-04 
42  GSCAN tobacco Age of initiation of regular 
smoking 
 GSCAN tobacco Regular smoking initiation  -.785 0.056 -14.1 4.5E-45 
43  GSCAN tobacco Age of initiation of regular 
smoking 
 GSCAN tobacco Smoking cessation  -.321 0.078 -4.10 4.2E-05 
44  GSCAN tobacco Age of initiation of regular 
smoking 
 GSCAN alcohol Drinks consumed per week  -.214 0.070 -3.06 2.2E-03 
45  GSCAN tobacco Age of initiation of regular 
smoking 
 GSCAN tobacco Cigarettes smoked per day  -.443 0.062 -7.10 1.3E-12 
Table S3 Proportion of variance of exposure traits that were explained by individual genetic instruments (R²). SNP: genome-wide significant SNPs selected as 
genetic instruments for exposure traits in MR analyses. PVALUE: association p values of the instruments. A1FREQ: effect allele frequency. BETA: effect size. 
R_square_SNP: R² by individual SNPs. R² by all SNPs is shown as the last row for each exposure (SNP= Total). See supporting information for the equation 
for calculating R². 
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No. Exposure SNP β p value A1FREQ R² 
1 Regular smoking initiation rs2155646  1.03E-10 0.61252  
2 Regular smoking initiation rs7613360 -0.0183941 1.88E-9 0.602016 0.0006745746 
3 Regular smoking initiation rs62025923  2.6E-9 0.795548  
4 Regular smoking initiation rs2162965 -0.0363663 2.79E-9 0.751556 0.0020548843 
5 Regular smoking initiation rs6756212 0.00740253 4.73E-9 0.461532 0.0001133239 
6 Regular smoking initiation rs184584210  1.06E-8   
7 Regular smoking initiation rs325535 -Inf 2.02E-8 0.837055  
8 Regular smoking initiation rs951740 -0.0285353 4.58E-8 0.377472 0.0015922373 
9 Regular smoking initiation Total    0.0044350201 
10 Cannabis initiation rs1368740 -0.067282549
2080111 
1.338E-13 0.749198 0.0099061078 
11 Cannabis initiation rs9919557  6.534E-11 0.612214  
12 Cannabis initiation rs4099556 -0.071523929
0552926 
5.908E-9 0.180395 0.0088085088 
13 Cannabis initiation rs17761723 -0.036106048
7603084 
2.153E-8 0.653659 0.0034370484 
14 Cannabis initiation Total    0.022151665 
15 Caffeine consumed per day rs2472297 -15.3909 7.8E-126 0.727035 0.0032870353 
16 Caffeine consumed per day rs4410790 -9.93959 2.6E-61 0.359539 0.0015907052 
17 Caffeine consumed per day rs17685 -6.21188 2.1E-22 0.720091 0.0005438316 
18 Caffeine consumed per day rs6947616 7.45343 1.2E-16 0.878457 0.0004147409 
19 Caffeine consumed per day rs9624470 -4.57915 5.9E-15 0.420057 0.0003571719 
20 Caffeine consumed per day rs199980439 -6.12289 2.8E-12 0.874447 0.0002877979 
21 Caffeine consumed per day rs6062679 -3.92816 1E-11 0.532389 0.0002686001 
22 Caffeine consumed per day rs182565048 -19.404 3.1E-11 0.974287 0.0006595326 
23 Caffeine consumed per day rs565223578 -11.5033 1.7E-10 0.947765 0.0004580588 
24 Caffeine consumed per day rs6145633 9.40229 1.8E-10 0.931778 0.0003929328 
25 Caffeine consumed per day rs8614 -4.77086 1.8E-10 0.81981 0.0002350993 
26 Caffeine consumed per day rs11383974 3.6289 1.2E-9 0.356802 0.0002113178 
27 Caffeine consumed per day rs780093 -3.57811 1.3E-9 0.379809 0.0002108687 
28 Caffeine consumed per day rs199736118 8.25393 3.5E-9 0.919365 0.0003531402 
29 Caffeine consumed per day rs117968677 11.195 9.1E-9 0.976221 0.0002034248 
Table S3 Proportion of variance of exposure traits that were explained by individual genetic instruments (R²). SNP: genome-wide significant SNPs selected as 
genetic instruments for exposure traits in MR analyses. PVALUE: association p values of the instruments. A1FREQ: effect allele frequency. BETA: effect size. 
R_square_SNP: R² by individual SNPs. R² by all SNPs is shown as the last row for each exposure (SNP= Total). See supporting information for the equation 
for calculating R². 
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No. Exposure SNP β p value A1FREQ R² 
30 Caffeine consumed per day rs9611522 3.70119 1.1E-8 0.741721 0.000183496 
31 Caffeine consumed per day rs1481012 5.21775 1.3E-8 0.888339 0.0001888256 
32 Caffeine consumed per day rs587714234 -3.26114 1.3E-8 0.529127 0.0001852749 
33 Caffeine consumed per day rs539726870 -5.31437 1.5E-8 0.881063 0.0002069386 
34 Caffeine consumed per day rs571868206 -16.4571 2.7E-8 0.980835 0.0003559799 
35 Caffeine consumed per day rs6415788 -3.25726 4E-8 0.396426 0.0001775054 
36 Caffeine consumed per day rs199879971 3.94336 4.3E-8 0.809886 0.0001674113 
37 Caffeine consumed per day Total    0.0109396895 
38 Estimated standard drinks per week rs1229984 -3.65259 8E-155 0.0217686 0.0020994901 
39 Estimated standard drinks per week rs1260326 -0.577313 1.6E-44 0.393415 0.0005877669 
40 Estimated standard drinks per week rs11940694 -0.514113 3.2E-35 0.391387 0.0004652696 
41 Estimated standard drinks per week rs1302808 -0.532449 2.6E-25 0.800307 0.0003348231 
42 Estimated standard drinks per week rs13107325 0.696931 9.7E-20 0.924731 0.0002498337 
43 Estimated standard drinks per week rs572771346 0.442567 3.2E-16 0.809947 0.0002228072 
44 Estimated standard drinks per week rs1004787 -0.314259 7.2E-15 0.469081 0.0001817571 
45 Estimated standard drinks per week rs61873510 0.332841 2.7E-14 0.672933 0.0001801864 
46 Estimated standard drinks per week rs56094641 0.313235 2.8E-14 0.596995 0.0001744462 
47 Estimated standard drinks per week rs9822731 -0.345202 4.1E-13 0.776068 0.0001530391 
48 Estimated standard drinks per week rs13413953 0.295064 1.5E-12 0.641508 0.0001479633 
49 Estimated standard drinks per week rs11604680 0.285453 3.1E-11 0.678383 0.0001313781 
50 Estimated standard drinks per week rs528834309 -0.293752 3.6E-11 0.635621 0.0001476907 
51 Estimated standard drinks per week rs2925635 -0.281023 4.3E-11 0.400473 0.0001401218 
52 Estimated standard drinks per week rs7132908 0.257574 2.4E-10 0.615544 0.0001160245 
53 Estimated standard drinks per week rs113441031 0.333488 4.2E-10 0.827707 0.0001172046 
54 Estimated standard drinks per week rs34305371 0.404585 7.1E-10 0.898949 0.0001098842 
55 Estimated standard drinks per week rs7786376 -0.283968 7.4E-10 0.720681 0.0001199561 
56 Estimated standard drinks per week rs141769737 -0.385074 1.1E-9 0.884177 0.0001122179 
57 Estimated standard drinks per week rs11078696 -0.316889 1.3E-9 0.196746 0.000117277 
58 Estimated standard drinks per week rs11860773 0.309727 1.5E-9 0.804905 0.000111324 
59 Estimated standard drinks per week rs72726477 0.372624 1.9E-9 0.877918 0.0001099733 
60 Estimated standard drinks per week rs28929474 0.853481 2E-9 0.980066 0.0001051665 
61 Estimated standard drinks per week rs758239226 0.312353 2.3E-9 0.805912 0.0001127762 
Table S3 Proportion of variance of exposure traits that were explained by individual genetic instruments (R²). SNP: genome-wide significant SNPs selected as 
genetic instruments for exposure traits in MR analyses. PVALUE: association p values of the instruments. A1FREQ: effect allele frequency. BETA: effect size. 
R_square_SNP: R² by individual SNPs. R² by all SNPs is shown as the last row for each exposure (SNP= Total). See supporting information for the equation 
for calculating R². 
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No. Exposure SNP β p value A1FREQ R² 
62 Estimated standard drinks per week rs113443718 0.262322 3.1E-9 0.689752 0.0001088206 
63 Estimated standard drinks per week rs4480324 0.26101 3.4E-9 0.295394 0.0001047857 
64 Estimated standard drinks per week rs60180050 -0.249526 4.2E-9 0.563907 0.0001131509 
65 Estimated standard drinks per week rs322764 -0.232074 6E-9 0.440461 0.0000980913 
66 Estimated standard drinks per week rs10267593 -0.316961 7.9E-9 0.832641 0.0001034566 
67 Estimated standard drinks per week rs11696120 -0.240623 9.3E-9 0.359358 0.0000985047 
68 Estimated standard drinks per week rs34869453 -0.239079 1E-8 0.571896 0.0001034163 
69 Estimated standard drinks per week rs429150 0.236987 1.1E-8 0.558503 0.0001023392 
70 Estimated standard drinks per week rs838145 0.232882 1.1E-8 0.459182 0.0000995286 
71 Estimated standard drinks per week rs33705 0.237729 1.7E-8 0.354743 0.0000955984 
72 Estimated standard drinks per week rs6999407 -0.286874 1.9E-8 0.187039 0.000092475 
73 Estimated standard drinks per week rs67404678 -0.347545 2.8E-8 0.878894 0.0000950089 
74 Estimated standard drinks per week rs11692435 -0.418218 3.1E-8 0.916227 0.0000992093 
75 Estimated standard drinks per week rs2955256 0.234174 3.7E-8 0.674818 0.0000889263 
76 Estimated standard drinks per week rs11428617 -0.228214 3.9E-8 0.362456 0.0000889385 
77 Estimated standard drinks per week Total    0.007840628 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
GSCAN Regular smoking 
initiation 
1.0E-05  ICC Cannabis initiation  76 IVW 6.4E-06  1.185 [ 1.035 , 1.355 ] 1.36E-02 
GSCAN Regular smoking 
initiation 
1.0E-05  ICC Cannabis initiation  76 Egger 7.6E-06  0.993 [ 0.694 , 1.422 ] 9.70E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  ICC Cannabis initiation  76 W Median   1.147 [ 0.985 , 1.335 ] 7.67E-02 
GSCAN Regular smoking 
initiation 
1.0E-05  ICC Cannabis initiation  76 W Mode   1.173 [ 0.865 , 1.591 ] 3.08E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  ICC Cannabis initiation  7 IVW 8.6E-05  1.223 [ 0.697 , 2.145 ] 4.82E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  ICC Cannabis initiation  7 Egger 5.2E-05  4.696 [ 0.010 ,  2288 ] 6.45E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  ICC Cannabis initiation  7 W Median   1.090 [ 0.752 , 1.581 ] 6.49E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  ICC Cannabis initiation  7 W Mode   1.099 [ 0.706 , 1.709 ] 6.91E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 IVW 1.1E-01  15.28 [ 8.389 , 22.16 ] 1.38E-05 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 Egger 9.5E-02  9.686 [ -18.4 , 37.74 ] 5.01E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 W Median   14.12 [ 5.076 , 23.16 ] 2.21E-03 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 67 W Mode   12.33 [ -9.36 , 34.02 ] 2.69E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 IVW 8.9E-01  40.17 [ 24.01 , 56.33 ] 1.10E-06 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 Egger 8.1E-01  57.69 [  -111 , 226.2 ] 5.32E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 W Median   38.67 [ 18.27 , 59.07 ] 2.03E-04 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 7 W Mode   37.92 [ 7.917 , 67.92 ] 4.80E-02 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Cigarettes smoked per 
day 
 67 IVW 1.5E-01  1.024 [ 0.143 , 1.905 ] 2.27E-02 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Cigarettes smoked per 
day 
 67 Egger 1.4E-01  -.309 [ -3.89 , 3.277 ] 8.66E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Cigarettes smoked per 
day 
 67 W Median   0.562 [ -.628 , 1.753 ] 3.55E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Cigarettes smoked per 
day 
 67 W Mode   0.195 [ -2.53 , 2.921 ] 8.89E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Cigarettes smoked per 
day 
 7 IVW 6.2E-01  0.918 [ -1.18 , 3.012 ] 3.90E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Cigarettes smoked per 
day 
 7 Egger 5.0E-01  4.144 [ -17.8 , 26.06 ] 7.26E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Cigarettes smoked per 
day 
 7 W Median   0.633 [ -2.12 , 3.387 ] 6.52E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Cigarettes smoked per 
day 
 7 W Mode   1.274 [ -2.76 , 5.312 ] 5.59E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Estimated standard drinks 
per week 
 67 IVW 7.7E-21  1.111 [ 0.286 , 1.936 ] 8.32E-03 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Estimated standard drinks 
per week 
 67 Egger 2.6E-16  -3.75 [ -6.88 , -.612 ] 2.22E-02 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Estimated standard drinks 
per week 
 67 W Median   0.514 [ -.191 , 1.218 ] 1.53E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Estimated standard drinks 
per week 
 67 W Mode   0.389 [ -.966 , 1.743 ] 5.76E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Estimated standard drinks 
per week 
 7 IVW 4.9E-01  0.988 [ -.144 , 2.121 ] 8.72E-02 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Estimated standard drinks 
per week 
 7 Egger 3.7E-01  1.763 [ -10.5 , 14.05 ] 7.90E-01 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Estimated standard drinks 
per week 
 7 W Median   0.495 [ -1.03 , 2.023 ] 5.25E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Estimated standard drinks 
per week 
 7 W Mode   0.563 [ -1.40 , 2.528 ] 5.95E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Pack years of smoking  67 IVW 3.6E-11  4.309 [ 3.390 , 5.227 ] 3.82E-20 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Pack years of smoking  67 Egger 7.7E-10  0.447 [ -3.17 , 4.062 ] 8.09E-01 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Pack years of smoking  67 W Median   4.153 [ 3.230 , 5.075 ] 1.12E-18 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Pack years of smoking  67 W Mode   4.195 [ 2.232 , 6.157 ] 8.47E-05 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Pack years of smoking  7 IVW 1.6E-03  6.279 [ 3.483 , 9.074 ] 1.07E-05 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Pack years of smoking  7 Egger 3.8E-02  -18.0 [ -41.7 , 5.754 ] 1.98E-01 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Pack years of smoking  7 W Median   4.766 [ 2.571 , 6.961 ] 2.08E-05 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Pack years of smoking  7 W Mode   4.845 [ 2.017 , 7.672 ] 1.53E-02 
ICC Cannabis initiation 1.0E-05  GSCAN Age of initiation of 
regular smoking 
 83 IVW 7.4E-02  -.000 [ -.011 , 0.011 ] 9.63E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Age of initiation of 
regular smoking 
 83 Egger 8.8E-02  0.010 [ -.008 , 0.028 ] 2.79E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Age of initiation of 
regular smoking 
 83 W Median   0.010 [ -.006 , 0.027 ] 2.20E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Age of initiation of 
regular smoking 
 83 W Mode   0.011 [ -.006 , 0.027 ] 2.19E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Age of initiation of 
regular smoking 
 4 IVW 6.9E-01  0.006 [ -.042 , 0.054 ] 8.09E-01 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
ICC Cannabis initiation 5.0E-08  GSCAN Age of initiation of 
regular smoking 
 4 Egger 4.8E-01  -.006 [ -.349 , 0.337 ] 9.76E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Age of initiation of 
regular smoking 
 4 W Median   0.012 [ -.046 , 0.070 ] 6.85E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Age of initiation of 
regular smoking 
 4 W Mode   0.024 [ -.051 , 0.099 ] 5.80E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Cigarettes smoked per 
day 
 83 IVW 2.2E-01  0.005 [ -.005 , 0.016 ] 3.38E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Cigarettes smoked per 
day 
 83 Egger 2.0E-01  0.001 [ -.016 , 0.019 ] 8.65E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Cigarettes smoked per 
day 
 83 W Median   0.008 [ -.010 , 0.025 ] 4.02E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Cigarettes smoked per 
day 
 83 W Mode   0.008 [ -.011 , 0.026 ] 4.16E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Cigarettes smoked per 
day 
 4 IVW 6.1E-01  -.015 [ -.063 , 0.033 ] 5.33E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Cigarettes smoked per 
day 
 4 Egger 5.5E-01  -.155 [ -.498 , 0.189 ] 4.71E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Cigarettes smoked per 
day 
 4 W Median   -.023 [ -.076 , 0.029 ] 3.83E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Cigarettes smoked per 
day 
 4 W Mode   -.028 [ -.101 , 0.046 ] 5.12E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Drinks consumed per 
week 
 83 IVW 1.9E-02  0.014 [ 0.005 , 0.023 ] 3.08E-03 
ICC Cannabis initiation 1.0E-05  GSCAN Drinks consumed per 
week 
 83 Egger 8.6E-02  -.003 [ -.017 , 0.010 ] 6.45E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Drinks consumed per 
week 
 83 W Median   0.009 [ -.004 , 0.023 ] 1.85E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Drinks consumed per 
week 
 83 W Mode   0.008 [ -.005 , 0.022 ] 2.11E-01 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
ICC Cannabis initiation 5.0E-08  GSCAN Drinks consumed per 
week 
 4 IVW 2.9E-02  0.059 [ -.008 , 0.126 ] 8.25E-02 
ICC Cannabis initiation 5.0E-08  GSCAN Drinks consumed per 
week 
 4 Egger 5.2E-01  0.443 [ 0.169 , 0.717 ] 8.68E-02 
ICC Cannabis initiation 5.0E-08  GSCAN Drinks consumed per 
week 
 4 W Median   0.042 [ -.009 , 0.092 ] 1.04E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Drinks consumed per 
week 
 4 W Mode   0.006 [ -.094 , 0.106 ] 9.09E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Smoking cessation  80 IVW 3.1E-02  1.000 [ 0.996 , 1.003 ] 8.62E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Smoking cessation  80 Egger 2.7E-02  1.000 [ 0.996 , 1.004 ] 9.08E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Smoking cessation  80 W Median   1.001 [ 0.997 , 1.005 ] 5.94E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Smoking cessation  80 W Mode   1.000 [ 0.997 , 1.003 ] 8.55E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Smoking cessation  4 IVW 4.0E-02  0.992 [ 0.925 , 1.064 ] 8.32E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Smoking cessation  4 Egger 1.8E-02  0.914 [ 0.497 , 1.680 ] 8.00E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Smoking cessation  4 W Median   0.966 [ 0.915 , 1.020 ] 2.09E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Smoking cessation  4 W Mode   0.963 [ 0.906 , 1.024 ] 3.13E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Regular smoking 
initiation 
 83 IVW 8.0E-11  1.012 [ 1.000 , 1.024 ] 4.40E-02 
ICC Cannabis initiation 1.0E-05  GSCAN Regular smoking 
initiation 
 83 Egger 2.7E-07  0.985 [ 0.969 , 1.002 ] 9.47E-02 
ICC Cannabis initiation 1.0E-05  GSCAN Regular smoking 
initiation 
 83 W Median   0.991 [ 0.978 , 1.004 ] 1.90E-01 
ICC Cannabis initiation 1.0E-05  GSCAN Regular smoking 
initiation 
 83 W Mode   0.990 [ 0.975 , 1.005 ] 1.84E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Regular smoking 
initiation 
 4 IVW 9.6E-06  1.111 [ 0.997 , 1.238 ] 5.58E-02 
ICC Cannabis initiation 5.0E-08  GSCAN Regular smoking 
initiation 
 4 Egger 7.5E-06  0.907 [ 0.371 , 2.216 ] 8.50E-01 
ICC Cannabis initiation 5.0E-08  GSCAN Regular smoking 
initiation 
 4 W Median   1.106 [ 1.044 , 1.172 ] 6.73E-04 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
ICC Cannabis initiation 5.0E-08  GSCAN Regular smoking 
initiation 
 4 W Mode   1.110 [ 1.032 , 1.193 ] 6.74E-02 
ICC Cannabis initiation 1.0E-05  UKB Caffeine consumed per 
day 
 73 IVW 1.5E-02  0.244 [ -1.42 , 1.905 ] 7.73E-01 
ICC Cannabis initiation 1.0E-05  UKB Caffeine consumed per 
day 
 73 Egger 1.3E-02  0.672 [ -2.28 , 3.624 ] 6.57E-01 
ICC Cannabis initiation 1.0E-05  UKB Caffeine consumed per 
day 
 73 W Median   0.483 [ -2.03 , 2.997 ] 7.06E-01 
ICC Cannabis initiation 1.0E-05  UKB Caffeine consumed per 
day 
 73 W Mode   0.396 [ -1.90 , 2.696 ] 7.37E-01 
ICC Cannabis initiation 5.0E-08  UKB Caffeine consumed per 
day 
 4 IVW 2.2E-01  5.904 [ -2.35 , 14.16 ] 1.61E-01 
ICC Cannabis initiation 5.0E-08  UKB Caffeine consumed per 
day 
 4 Egger 1.6E-01  26.65 [ -38.8 , 92.13 ] 5.09E-01 
ICC Cannabis initiation 5.0E-08  UKB Caffeine consumed per 
day 
 4 W Median   6.881 [ -1.60 , 15.36 ] 1.12E-01 
ICC Cannabis initiation 5.0E-08  UKB Caffeine consumed per 
day 
 4 W Mode   7.966 [ -3.67 , 19.60 ] 2.72E-01 
ICC Cannabis initiation 1.0E-05  UKB Cigarettes smoked per 
day 
 73 IVW 6.1E-01  -.144 [ -.327 , 0.038 ] 1.21E-01 
ICC Cannabis initiation 1.0E-05  UKB Cigarettes smoked per 
day 
 73 Egger 5.8E-01  -.086 [ -.409 , 0.237 ] 6.03E-01 
ICC Cannabis initiation 1.0E-05  UKB Cigarettes smoked per 
day 
 73 W Median   -.101 [ -.406 , 0.205 ] 5.17E-01 
ICC Cannabis initiation 1.0E-05  UKB Cigarettes smoked per 
day 
 73 W Mode   -.109 [ -.362 , 0.145 ] 4.03E-01 
ICC Cannabis initiation 5.0E-08  UKB Cigarettes smoked per 
day 
 4 IVW 3.3E-01  -.815 [ -1.75 , 0.124 ] 8.88E-02 
ICC Cannabis initiation 5.0E-08  UKB Cigarettes smoked per 
day 
 4 Egger 1.9E-01  -2.00 [ -10.0 , 6.001 ] 6.73E-01 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
ICC Cannabis initiation 5.0E-08  UKB Cigarettes smoked per 
day 
 4 W Median   -.679 [ -1.76 , 0.398 ] 2.17E-01 
ICC Cannabis initiation 5.0E-08  UKB Cigarettes smoked per 
day 
 4 W Mode   -.546 [ -1.96 , 0.871 ] 5.05E-01 
ICC Cannabis initiation 1.0E-05  UKB Estimated standard drinks 
per week 
 73 IVW 4.2E-23  0.170 [ -.018 , 0.357 ] 7.58E-02 
ICC Cannabis initiation 1.0E-05  UKB Estimated standard drinks 
per week 
 73 Egger 7.4E-20  -.177 [ -.496 , 0.142 ] 2.80E-01 
ICC Cannabis initiation 1.0E-05  UKB Estimated standard drinks 
per week 
 73 W Median   -.065 [ -.231 , 0.100 ] 4.38E-01 
ICC Cannabis initiation 1.0E-05  UKB Estimated standard drinks 
per week 
 73 W Mode   -.001 [ -.149 , 0.148 ] 9.94E-01 
ICC Cannabis initiation 5.0E-08  UKB Estimated standard drinks 
per week 
 4 IVW 1.1E-05  1.287 [ -.103 , 2.677 ] 6.96E-02 
ICC Cannabis initiation 5.0E-08  UKB Estimated standard drinks 
per week 
 4 Egger 5.0E-02  8.840 [ 3.015 , 14.66 ] 9.69E-02 
ICC Cannabis initiation 5.0E-08  UKB Estimated standard drinks 
per week 
 4 W Median   1.041 [ 0.313 , 1.768 ] 5.06E-03 
ICC Cannabis initiation 5.0E-08  UKB Estimated standard drinks 
per week 
 4 W Mode   1.046 [ -.210 , 2.302 ] 2.01E-01 
ICC Cannabis initiation 1.0E-05  UKB Pack years of smoking  73 IVW 1.4E-09  0.219 [ 0.022 , 0.415 ] 2.96E-02 
ICC Cannabis initiation 1.0E-05  UKB Pack years of smoking  73 Egger 7.0E-09  -.034 [ -.377 , 0.308 ] 8.44E-01 
ICC Cannabis initiation 1.0E-05  UKB Pack years of smoking  73 W Median   -.020 [ -.245 , 0.206 ] 8.65E-01 
ICC Cannabis initiation 1.0E-05  UKB Pack years of smoking  73 W Mode   -.007 [ -.187 , 0.173 ] 9.36E-01 
ICC Cannabis initiation 5.0E-08  UKB Pack years of smoking  4 IVW 1.1E-03  1.267 [ -.172 , 2.705 ] 8.44E-02 
ICC Cannabis initiation 5.0E-08  UKB Pack years of smoking  4 Egger 3.4E-04  0.613 [ -11.8 , 13.07 ] 9.32E-01 
ICC Cannabis initiation 5.0E-08  UKB Pack years of smoking  4 W Median   1.689 [ 0.843 , 2.536 ] 9.17E-05 
ICC Cannabis initiation 5.0E-08  UKB Pack years of smoking  4 W Mode   2.002 [ 1.041 , 2.963 ] 2.66E-02 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 77 IVW 2.8E-03  -.024 [ -.042 , -.005 ] 1.21E-02 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 77 Egger 1.5E-02  0.018 [ -.017 , 0.053 ] 3.09E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 77 W Median   -.012 [ -.037 , 0.014 ] 3.84E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 77 W Mode   -.013 [ -.041 , 0.015 ] 3.66E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 14 IVW 2.9E-01  -.006 [ -.030 , 0.017 ] 5.90E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 14 Egger 2.6E-01  0.008 [ -.039 , 0.055 ] 7.50E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 14 W Median   -.013 [ -.043 , 0.017 ] 3.93E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 14 W Mode   -.015 [ -.044 , 0.014 ] 3.17E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 77 IVW 1.4E-17  0.026 [ -.001 , 0.052 ] 5.51E-02 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 77 Egger 6.7E-15  -.033 [ -.083 , 0.017 ] 2.03E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 77 W Median   -.005 [ -.029 , 0.020 ] 7.19E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 77 W Mode   -.013 [ -.041 , 0.015 ] 3.74E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 14 IVW 6.7E-04  -.001 [ -.037 , 0.035 ] 9.58E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 14 Egger 8.8E-04  -.030 [ -.102 , 0.041 ] 4.20E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 14 W Median   -.014 [ -.044 , 0.015 ] 3.39E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 14 W Mode   -.016 [ -.045 , 0.014 ] 3.18E-01 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Drinks consumed per 
week 
 79 IVW 4.4E-06  0.011 [ -.005 , 0.027 ] 1.69E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Drinks consumed per 
week 
 79 Egger 4.2E-06  0.001 [ -.027 , 0.030 ] 9.21E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Drinks consumed per 
week 
 79 W Median   0.028 [ 0.007 , 0.049 ] 8.57E-03 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Drinks consumed per 
week 
 79 W Mode   0.020 [ -.000 , 0.041 ] 5.69E-02 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Drinks consumed per 
week 
 14 IVW 7.8E-06  0.026 [ -.007 , 0.059 ] 1.25E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Drinks consumed per 
week 
 14 Egger 7.6E-06  0.005 [ -.062 , 0.073 ] 8.76E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Drinks consumed per 
week 
 14 W Median   0.030 [ 0.006 , 0.053 ] 1.22E-02 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Drinks consumed per 
week 
 14 W Mode   0.029 [ 0.005 , 0.052 ] 3.28E-02 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Smoking cessation  77 IVW 1.9E-04  1.008 [ 0.996 , 1.019 ] 1.79E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Smoking cessation  77 Egger 1.8E-04  1.000 [ 0.979 , 1.022 ] 9.76E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Smoking cessation  77 W Median   1.007 [ 0.994 , 1.020 ] 2.99E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Smoking cessation  77 W Mode   1.007 [ 0.993 , 1.021 ] 3.36E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Smoking cessation  14 IVW 5.1E-01  1.018 [ 1.001 , 1.035 ] 4.00E-02 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Smoking cessation  14 Egger 5.6E-01  0.998 [ 0.963 , 1.034 ] 8.96E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Smoking cessation  14 W Median   1.012 [ 0.989 , 1.035 ] 3.25E-01 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
 
 
Supplementary table page 90 
Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Smoking cessation  14 W Mode   1.008 [ 0.985 , 1.032 ] 5.04E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Regular smoking 
initiation 
 78 IVW 5.9E-06  1.020 [ 1.004 , 1.036 ] 1.17E-02 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Regular smoking 
initiation 
 78 Egger 4.1E-05  0.990 [ 0.961 , 1.020 ] 5.14E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Regular smoking 
initiation 
 78 W Median   1.014 [ 0.993 , 1.035 ] 1.95E-01 
UKB Caffeine consumed per 
day 
1.0E-05  GSCAN Regular smoking 
initiation 
 78 W Mode   1.010 [ 0.990 , 1.030 ] 3.39E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Regular smoking 
initiation 
 15 IVW 1.4E-03  1.008 [ 0.983 , 1.034 ] 5.39E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Regular smoking 
initiation 
 15 Egger 8.4E-04  1.003 [ 0.952 , 1.057 ] 9.06E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Regular smoking 
initiation 
 15 W Median   1.013 [ 0.992 , 1.036 ] 2.33E-01 
UKB Caffeine consumed per 
day 
5.0E-08  GSCAN Regular smoking 
initiation 
 15 W Mode   1.010 [ 0.990 , 1.030 ] 3.53E-01 
UKB Caffeine consumed per 
day 
1.0E-05  ICC Cannabis initiation  74 IVW 4.0E-02  0.957 [ 0.918 , 0.998 ] 4.12E-02 
UKB Caffeine consumed per 
day 
1.0E-05  ICC Cannabis initiation  74 Egger 4.0E-02  0.925 [ 0.851 , 1.004 ] 6.68E-02 
UKB Caffeine consumed per 
day 
1.0E-05  ICC Cannabis initiation  74 W Median   0.916 [ 0.856 , 0.980 ] 1.05E-02 
UKB Caffeine consumed per 
day 
1.0E-05  ICC Cannabis initiation  74 W Mode   0.917 [ 0.858 , 0.980 ] 1.22E-02 
UKB Caffeine consumed per 
day 
5.0E-08  ICC Cannabis initiation  12 IVW 7.1E-02  0.926 [ 0.866 , 0.989 ] 2.30E-02 
UKB Caffeine consumed per 
day 
5.0E-08  ICC Cannabis initiation  12 Egger 1.8E-01  0.836 [ 0.738 , 0.947 ] 1.81E-02 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
UKB Caffeine consumed per 
day 
5.0E-08  ICC Cannabis initiation  12 W Median   0.913 [ 0.850 , 0.980 ] 1.19E-02 
UKB Caffeine consumed per 
day 
5.0E-08  ICC Cannabis initiation  12 W Mode   0.905 [ 0.844 , 0.971 ] 1.80E-02 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 174 IVW 3.1E-04  -.001 [ -.004 , 0.002 ] 4.10E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 174 Egger 3.3E-04  0.001 [ -.005 , 0.008 ] 6.38E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 174 W Median   0.000 [ -.005 , 0.006 ] 9.23E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Age of initiation of 
regular smoking 
 174 W Mode   0.001 [ -.005 , 0.006 ] 8.10E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 32 IVW 1.0E-01  -.001 [ -.005 , 0.004 ] 7.68E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 32 Egger 8.1E-02  -.001 [ -.009 , 0.007 ] 7.98E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 32 W Median   0.000 [ -.005 , 0.006 ] 9.29E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Age of initiation of 
regular smoking 
 32 W Mode   0.000 [ -.006 , 0.006 ] 9.82E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 174 IVW 1.5E-05  -.002 [ -.005 , 0.001 ] 2.72E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 174 Egger 1.2E-05  -.002 [ -.009 , 0.004 ] 5.24E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 174 W Median   -.001 [ -.006 , 0.005 ] 7.58E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Cigarettes smoked per 
day 
 174 W Mode   -.003 [ -.009 , 0.002 ] 2.65E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 32 IVW 3.0E-02  -.005 [ -.009 , 0.000 ] 7.05E-02 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 32 Egger 3.0E-02  -.001 [ -.009 , 0.007 ] 7.26E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 32 W Median   -.001 [ -.007 , 0.005 ] 7.05E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Cigarettes smoked per 
day 
 32 W Mode   -.002 [ -.007 , 0.003 ] 4.56E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Smoking cessation  173 IVW 3.5E-02  1.001 [ 1.000 , 1.003 ] 1.71E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Smoking cessation  173 Egger 3.6E-02  1.000 [ 0.998 , 1.002 ] 9.16E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Smoking cessation  173 W Median   1.000 [ 0.998 , 1.003 ] 7.82E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Smoking cessation  173 W Mode   1.001 [ 0.998 , 1.003 ] 6.00E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Smoking cessation  31 IVW 8.7E-02  1.000 [ 0.998 , 1.003 ] 8.67E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Smoking cessation  31 Egger 6.9E-02  1.000 [ 0.997 , 1.003 ] 9.49E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Smoking cessation  31 W Median   1.000 [ 0.998 , 1.003 ] 7.98E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Smoking cessation  31 W Mode   1.000 [ 0.998 , 1.003 ] 7.32E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Regular smoking 
initiation 
 174 IVW 2.7E-17  1.005 [ 1.002 , 1.008 ] 1.15E-03 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Regular smoking 
initiation 
 174 Egger 2.2E-15  0.998 [ 0.992 , 1.003 ] 4.04E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Regular smoking 
initiation 
 174 W Median   0.998 [ 0.995 , 1.002 ] 2.98E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  GSCAN Regular smoking 
initiation 
 174 W Mode   0.997 [ 0.992 , 1.001 ] 1.21E-01 
Table S5-4. Two-sample Mendelian randomisation results on the causal associations between the initiation and use of different substances. Independent SNPs 
associated with exposure trait were clumped with LD window 10000 kb, R-squared 0.01.  n SNPs: Number of independent SNPs used in each exposure-outcome pair. 
p1: Significance threshold for index SNPs. Heterogeneity tests were available from MR-Egger and inverse variance weighted MR (IVW). Raw estimates (β, SE) are the 
estimates from the MR estimators. These estimates were converted to interpretable scales as described in the method (Effect size [95%CI]). Abbreviated consortia: (1) 
GSCAN: GWAS & Sequencing Consortium of Alcohol and Nicotine use, (2) ICC: international cannabis consortium, (3) UKB: UK Biobank. The significance threshold 
was 0.002173913 (0.05/23). MR analyses that survived heterogeneity tests (i.e. Q p value >= 0.05) and multiple testing are shown in blue and boldface. 
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Exposure GWAS  Outcome GWAS  Two-sample MR analysis  Converted Estimates 
Sample Trait p1  Sample Trait  n SNPs Method Q p value  Effect size [95%CI] p value 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Regular smoking 
initiation 
 32 IVW 6.6E-08  1.000 [ 0.995 , 1.005 ] 8.96E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Regular smoking 
initiation 
 32 Egger 6.3E-08  0.998 [ 0.990 , 1.006 ] 6.35E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Regular smoking 
initiation 
 32 W Median   0.997 [ 0.993 , 1.001 ] 1.60E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  GSCAN Regular smoking 
initiation 
 32 W Mode   0.997 [ 0.992 , 1.001 ] 1.39E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  ICC Cannabis initiation  176 IVW 2.7E-22  1.016 [ 1.007 , 1.026 ] 9.20E-04 
UKB Estimated standard drinks 
per week 
1.0E-05  ICC Cannabis initiation  176 Egger 3.0E-15  0.973 [ 0.956 , 0.991 ] 3.77E-03 
UKB Estimated standard drinks 
per week 
1.0E-05  ICC Cannabis initiation  176 W Median   0.998 [ 0.985 , 1.011 ] 7.52E-01 
UKB Estimated standard drinks 
per week 
1.0E-05  ICC Cannabis initiation  176 W Mode   0.982 [ 0.968 , 0.996 ] 1.40E-02 
UKB Estimated standard drinks 
per week 
5.0E-08  ICC Cannabis initiation  30 IVW 1.0E-18  0.999 [ 0.978 , 1.020 ] 9.13E-01 
UKB Estimated standard drinks 
per week 
5.0E-08  ICC Cannabis initiation  30 Egger 1.9E-14  0.968 [ 0.937 , 1.000 ] 5.74E-02 
UKB Estimated standard drinks 
per week 
5.0E-08  ICC Cannabis initiation  30 W Median   0.984 [ 0.970 , 0.998 ] 2.86E-02 
UKB Estimated standard 
drinks per week 
5.0E-08  ICC Cannabis initiation  30 W Mode   0.977 [ 0.964 , 0.990 ] 1.38E-03 
Table S5-5. Global test results of Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO). Raw estimates were obtained from the 
MR-PRESSO estimators. These estimates were converted to interpretable effect sizes and confidence intervals (Effect size [95%CI]). The significance threshold, 
corrected by Bonferroni procedure, was 0.0125 (0.05/4). Analyses that survived multiple testing are shown in blue and boldface. The global test with outliers removed is 
shown as blank if no outliers were detected. 
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Exposure GWAS  Outcome GWAS  Raw Estimates  Converted Estimates 
Sample Trait p1  Sample Trait  Method  β SD p value  Effect size[95%CI] 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed 
per day 
 MR-PRESSO global 
test 
 22.039 5.070 4.9E-05  15.28 [ 8.389 , 22.16 ] 
GSCAN Regular smoking 
initiation 
1.0E-05  UKB Caffeine consumed per 
day 
 MR-PRESSO global 
test with outliers 
removed 
      
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed 
per day 
 MR-PRESSO global 
test 
 57.956 7.394 2.3E-04  40.17 [ 30.13 , 50.22 ] 
GSCAN Regular smoking 
initiation 
5.0E-08  UKB Caffeine consumed per 
day 
 MR-PRESSO global 
test with outliers 
removed 
      
ICC Cannabis initiation 5.0E-08  GSCAN Regular smoking 
initiation 
 MR-PRESSO global 
test 
 0.152 0.079 1.5E-01  1.111 [ 0.997 , 1.238 ] 
ICC Cannabis initiation 5.0E-08  GSCAN Regular smoking 
initiation 
 MR-PRESSO global 
test with outliers 
removed 
 0.147 0.006 2.4E-02  1.107 [ 1.099 , 1.116 ] 
ICC Cannabis initiation 5.0E-08  UKB Pack years of smoking  MR-PRESSO global 
test 
 1.827 1.059 1.8E-01  1.267 [ -.172 , 2.705 ] 
ICC Cannabis initiation 5.0E-08  UKB Pack years of smoking  MR-PRESSO global 
test with outliers 
removed 
 2.744 0.415 2.2E-02  1.902 [ 1.338 , 2.466 ] 
Table S5-6. Results of Mendelian randomization leave-one-out analysis on the causal association between regular smoking initiation on caffeine consumed per 
day. SNPs that were associated with smoking initiation were clumped at p value < 1e-5 and < 5e-8. Raw estimates were obtained from the MR estimators. 
These estimates were converted to interpretable effect sizes and confidence intervals (Effect size [95%CI]).The significance thresholds, corrected by 
Bonferroni procedure, were 0.0007352941 (0.05/68) and 0.00625 (0.05/8), respectively for the clumping p value < 1e-5 and < 5e-8. Analysis that survived 
multiple testing was put in blue boldface. 
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 Exposure SNPs clumped at p value < 1e-5  Exposure SNPs clumped at p value < 5e-8 
 Raw Estimates Converted Estimates  Raw Estimates Converted Estimates 
No. SNP removed  β SE p value Effecct size [95%CI]  β SE p value Effecct size [95%CI] 
1 rs10095986  23.41 4.949 2.2E-06 16.23 [ 9.506 , 22.95 ]      
2 rs10186133  22.41 5.122 1.2E-05 15.54 [ 8.577 , 22.49 ]      
3 rs1036591  22.19 5.132 1.5E-05 15.38 [ 8.408 , 22.35 ]      
4 rs10745822  21.80 5.167 2.5E-05 15.11 [ 8.091 , 22.13 ]      
5 rs10790448  22.18 5.137 1.6E-05 15.37 [ 8.395 , 22.35 ]      
6 rs10796907  21.33 5.085 2.7E-05 14.78 [ 7.873 , 21.69 ]      
7 rs11016103  23.37 4.998 2.9E-06 16.20 [ 9.406 , 22.99 ]      
8 rs11078716  21.89 5.149 2.1E-05 15.17 [ 8.175 , 22.16 ]      
9 rs111747805  21.99 5.138 1.9E-05 15.24 [ 8.264 , 22.22 ]      
10 rs112417011  22.05 5.139 1.8E-05 15.28 [ 8.300 , 22.26 ]      
11 rs117503378  22.41 5.119 1.2E-05 15.53 [ 8.577 , 22.49 ]      
12 rs11759026  23.15 5.008 3.8E-06 16.05 [ 9.244 , 22.85 ]      
13 rs117695734  21.49 5.094 2.5E-05 14.89 [ 7.972 , 21.81 ]      
14 rs118038478  22.76 5.080 7.4E-06 15.78 [ 8.875 , 22.68 ]      
15 rs12575370  22.38 5.134 1.3E-05 15.51 [ 8.539 , 22.49 ]      
16 rs12727441  22.27 5.140 1.5E-05 15.43 [ 8.451 , 22.42 ]      
17 rs12729364  22.68 5.100 8.7E-06 15.72 [ 8.792 , 22.65 ]      
18 rs12731986  22.65 5.104 9.1E-06 15.70 [ 8.767 , 22.64 ]      
19 rs1291851  21.74 5.133 2.3E-05 15.07 [ 8.099 , 22.05 ]      
20 rs13109980  22.19 5.153 1.7E-05 15.38 [ 8.381 , 22.38 ]      
21 rs13239186  21.91 5.146 2.1E-05 15.19 [ 8.197 , 22.18 ]      
22 rs1369588  22.91 5.079 6.5E-06 15.88 [ 8.980 , 22.78 ]      
23 rs145553056  22.11 5.131 1.6E-05 15.33 [ 8.355 , 22.30 ]      
24 rs1474368  21.56 5.113 2.5E-05 14.94 [ 7.995 , 21.89 ]      
25 rs1475642  22.33 5.133 1.4E-05 15.48 [ 8.502 , 22.45 ]      
26 rs1552313  20.95 5.019 3.0E-05 14.52 [ 7.700 , 21.34 ]      
27 rs1656366  21.86 5.146 2.2E-05 15.15 [ 8.162 , 22.14 ]      
28 rs17207212  21.74 5.133 2.3E-05 15.07 [ 8.097 , 22.04 ]      
29 rs1774240  22.71 5.088 8.1E-06 15.74 [ 8.831 , 22.66 ]      
Table S5-6. Results of Mendelian randomization leave-one-out analysis on the causal association between regular smoking initiation on caffeine consumed per 
day. SNPs that were associated with smoking initiation were clumped at p value < 1e-5 and < 5e-8. Raw estimates were obtained from the MR estimators. 
These estimates were converted to interpretable effect sizes and confidence intervals (Effect size [95%CI]).The significance thresholds, corrected by 
Bonferroni procedure, were 0.0007352941 (0.05/68) and 0.00625 (0.05/8), respectively for the clumping p value < 1e-5 and < 5e-8. Analysis that survived 
multiple testing was put in blue boldface. 
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 Exposure SNPs clumped at p value < 1e-5  Exposure SNPs clumped at p value < 5e-8 
 Raw Estimates Converted Estimates  Raw Estimates Converted Estimates 
No. SNP removed  β SE p value Effecct size [95%CI]  β SE p value Effecct size [95%CI] 
30 rs186535126  22.10 5.159 1.8E-05 15.32 [ 8.309 , 22.33 ]      
31 rs2155646  21.02 5.113 3.9E-05 14.57 [ 7.622 , 21.51 ]  57.27 13.06 1.2E-05 39.70 [ 21.96 , 57.44 ] 
32 rs2158359  22.33 5.132 1.4E-05 15.48 [ 8.506 , 22.45 ]      
33 rs2162965  20.98 5.089 3.7E-05 14.54 [ 7.631 , 21.46 ]  56.00 12.87 1.4E-05 38.82 [ 21.33 , 56.31 ] 
34 rs2256012  22.31 5.129 1.4E-05 15.47 [ 8.499 , 22.44 ]      
35 rs2326213  20.99 5.016 2.9E-05 14.55 [ 7.734 , 21.36 ]      
36 rs281287  22.48 5.127 1.2E-05 15.58 [ 8.614 , 22.55 ]      
37 rs28717373  21.81 5.142 2.2E-05 15.12 [ 8.133 , 22.10 ]      
38 rs310333  22.13 5.139 1.7E-05 15.34 [ 8.356 , 22.32 ]      
39 rs325535  21.40 5.124 2.9E-05 14.84 [ 7.875 , 21.80 ]  58.27 12.71 4.5E-06 40.39 [ 23.12 , 57.65 ] 
40 rs34253747  22.64 5.117 9.7E-06 15.69 [ 8.740 , 22.64 ]      
41 rs376345767  21.77 5.159 2.4E-05 15.09 [ 8.084 , 22.10 ]      
42 rs3781295  21.34 5.097 2.8E-05 14.79 [ 7.868 , 21.72 ]      
43 rs4352629  22.18 5.148 1.6E-05 15.37 [ 8.380 , 22.37 ]      
44 rs559928  21.40 5.105 2.8E-05 14.83 [ 7.899 , 21.77 ]      
45 rs6110373  21.90 5.142 2.1E-05 15.18 [ 8.194 , 22.17 ]      
46 rs62025923  21.35 5.131 3.2E-05 14.80 [ 7.831 , 21.77 ]  58.71 12.85 4.9E-06 40.70 [ 23.24 , 58.16 ] 
47 rs62170823  22.78 5.110 8.3E-06 15.79 [ 8.848 , 22.73 ]      
48 rs6417681  21.80 5.137 2.2E-05 15.11 [ 8.134 , 22.09 ]      
49 rs6756212  20.61 5.016 4.0E-05 14.29 [ 7.471 , 21.10 ]  52.90 12.83 3.7E-05 36.67 [ 19.24 , 54.10 ] 
50 rs72782486  22.57 5.105 9.8E-06 15.64 [ 8.708 , 22.58 ]      
51 rs72906609  22.42 5.154 1.4E-05 15.54 [ 8.539 , 22.54 ]      
52 rs75082010  22.00 5.129 1.8E-05 15.25 [ 8.279 , 22.21 ]      
53 rs75177132  22.63 5.106 9.4E-06 15.68 [ 8.746 , 22.62 ]      
54 rs7613360  21.40 5.140 3.1E-05 14.83 [ 7.848 , 21.81 ]  59.37 12.91 4.2E-06 41.15 [ 23.61 , 58.69 ] 
55 rs76172101  23.04 5.019 4.4E-06 15.97 [ 9.149 , 22.79 ]      
56 rs77311064  21.19 5.102 3.3E-05 14.69 [ 7.760 , 21.62 ]      
57 rs7737703  21.65 5.120 2.4E-05 15.00 [ 8.049 , 21.96 ]      
58 rs7872818  22.36 5.129 1.3E-05 15.50 [ 8.528 , 22.46 ]      
Table S5-6. Results of Mendelian randomization leave-one-out analysis on the causal association between regular smoking initiation on caffeine consumed per 
day. SNPs that were associated with smoking initiation were clumped at p value < 1e-5 and < 5e-8. Raw estimates were obtained from the MR estimators. 
These estimates were converted to interpretable effect sizes and confidence intervals (Effect size [95%CI]).The significance thresholds, corrected by 
Bonferroni procedure, were 0.0007352941 (0.05/68) and 0.00625 (0.05/8), respectively for the clumping p value < 1e-5 and < 5e-8. Analysis that survived 
multiple testing was put in blue boldface. 
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 Exposure SNPs clumped at p value < 1e-5  Exposure SNPs clumped at p value < 5e-8 
 Raw Estimates Converted Estimates  Raw Estimates Converted Estimates 
No. SNP removed  β SE p value Effecct size [95%CI]  β SE p value Effecct size [95%CI] 
59 rs7894565  22.65 5.131 1.0E-05 15.70 [ 8.732 , 22.67 ]      
60 rs793103  23.01 5.049 5.2E-06 15.95 [ 9.090 , 22.81 ]      
61 rs7984262  22.21 5.141 1.6E-05 15.40 [ 8.412 , 22.38 ]      
62 rs883323  21.74 5.131 2.3E-05 15.07 [ 8.098 , 22.04 ]      
63 rs895632  21.38 5.099 2.7E-05 14.82 [ 7.895 , 21.75 ]      
64 rs9411438  22.23 5.138 1.5E-05 15.41 [ 8.431 , 22.39 ]      
65 rs951740  22.04 5.156 1.9E-05 15.28 [ 8.272 , 22.28 ]  63.04 12.71 7.0E-07 43.69 [ 26.43 , 60.96 ] 
66 rs9645884  21.97 5.135 1.9E-05 15.23 [ 8.250 , 22.20 ]      
67 rs9651873  20.36 4.834 2.5E-05 14.12 [ 7.548 , 20.68 ]      
68 All  22.04 5.070 1.4E-05 15.28 [ 8.389 , 22.16 ]  57.96 11.89 1.1E-06 40.17 [ 24.01 , 56.33 ] 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
1 linear regression Age at starting smoking in current 
smokers 
Caffeine consumed per day  -0.00 [ -0.00 , -0.00 ] 1.2E-07 
  Age at starting smoking in current 
smokers 
Age  0.051 [ 0.036 , 0.066 ] 1.8E-11 
  Age at starting smoking in current 
smokers 
Sex  0.429 [ 0.264 , 0.594 ] 3.6E-07 
  Age at starting smoking in current 
smokers 
Overall health rating  -0.42 [ -0.58 , -0.25 ] 5.3E-07 
  Age at starting smoking in current 
smokers 
Educational attainment  0.778 [ 0.662 , 0.895 ] 8.3E-39 
  Age at starting smoking in current 
smokers 
Townsend deprivation index  -0.00 [ -0.04 , 0.027 ] 6.3E-01 
  Age at starting smoking in current 
smokers 
PC1  -0.07 [ -0.14 , 0.003 ] 6.1E-02 
  Age at starting smoking in current 
smokers 
PC2  0.082 [ 0.002 , 0.162 ] 4.3E-02 
  Age at starting smoking in current 
smokers 
PC3  0.005 [ -0.07 , 0.081 ] 9.0E-01 
  Age at starting smoking in current 
smokers 
PC4  -0.02 [ -0.07 , 0.027 ] 3.7E-01 
  Age at starting smoking in current 
smokers 
PC5  -0.01 [ -0.03 , 0.011 ] 3.5E-01 
  Age at starting smoking in current 
smokers 
PC6  -0.03 [ -0.10 , 0.037 ] 3.7E-01 
  Age at starting smoking in current 
smokers 
PC7  0.004 [ -0.04 , 0.059 ] 8.6E-01 
  Age at starting smoking in current 
smokers 
PC8  0.046 [ -0.00 , 0.100 ] 9.0E-02 
  Age at starting smoking in current 
smokers 
PC9  0.004 [ -0.02 , 0.031 ] 7.6E-01 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Age at starting smoking in current 
smokers 
PC10  0.084 [ 0.027 , 0.142 ] 3.9E-03 
2 linear regression Age at starting smoking in current 
smokers 
Cannabis initiation  0.152 [ -0.09 , 0.401 ] 2.3E-01 
  Age at starting smoking in current 
smokers 
Age  0.049 [ 0.026 , 0.072 ] 2.9E-05 
  Age at starting smoking in current 
smokers 
Sex  0.564 [ 0.331 , 0.797 ] 2.1E-06 
  Age at starting smoking in current 
smokers 
Overall health rating  -0.45 [ -0.69 , -0.22 ] 1.1E-04 
  Age at starting smoking in current 
smokers 
Educational attainment  0.894 [ 0.719 , 1.069 ] 2.2E-23 
  Age at starting smoking in current 
smokers 
Townsend deprivation index  -0.00 [ -0.05 , 0.048 ] 9.0E-01 
  Age at starting smoking in current 
smokers 
PC1  -0.09 [ -0.19 , 0.015 ] 9.2E-02 
  Age at starting smoking in current 
smokers 
PC2  0.019 [ -0.09 , 0.131 ] 7.3E-01 
  Age at starting smoking in current 
smokers 
PC3  -0.00 [ -0.11 , 0.097 ] 8.9E-01 
  Age at starting smoking in current 
smokers 
PC4  -0.06 [ -0.13 , 0.007 ] 8.1E-02 
  Age at starting smoking in current 
smokers 
PC5  -0.00 [ -0.03 , 0.029 ] 9.7E-01 
  Age at starting smoking in current 
smokers 
PC6  0.038 [ -0.06 , 0.137 ] 4.4E-01 
  Age at starting smoking in current 
smokers 
PC7  0.001 [ -0.07 , 0.079 ] 9.7E-01 
  Age at starting smoking in current 
smokers 
PC8  0.012 [ -0.06 , 0.089 ] 7.5E-01 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Age at starting smoking in current 
smokers 
PC9  -0.01 [ -0.05 , 0.024 ] 4.9E-01 
  Age at starting smoking in current 
smokers 
PC10  0.062 [ -0.01 , 0.142 ] 1.3E-01 
3 linear regression Age at starting smoking in current 
smokers 
Estimated standard drinks per week  -0.00 [ -0.00 , 0.001 ] 2.4E-01 
  Age at starting smoking in current 
smokers 
Age  0.052 [ 0.041 , 0.062 ] 2.2E-22 
  Age at starting smoking in current 
smokers 
Sex  0.396 [ 0.275 , 0.517 ] 1.4E-10 
  Age at starting smoking in current 
smokers 
Overall health rating  -0.47 [ -0.58 , -0.36 ] 5.2E-17 
  Age at starting smoking in current 
smokers 
Educational attainment  0.750 [ 0.668 , 0.831 ] 3.5E-72 
  Age at starting smoking in current 
smokers 
Townsend deprivation index  -0.02 [ -0.04 , 0.002 ] 8.4E-02 
  Age at starting smoking in current 
smokers 
PC1  -0.07 [ -0.13 , -0.02 ] 3.5E-03 
  Age at starting smoking in current 
smokers 
PC2  0.034 [ -0.02 , 0.089 ] 2.3E-01 
  Age at starting smoking in current 
smokers 
PC3  0.000 [ -0.05 , 0.052 ] 9.9E-01 
  Age at starting smoking in current 
smokers 
PC4  -0.02 [ -0.06 , 0.008 ] 1.4E-01 
  Age at starting smoking in current 
smokers 
PC5  -0.00 [ -0.02 , 0.008 ] 3.7E-01 
  Age at starting smoking in current 
smokers 
PC6  0.013 [ -0.03 , 0.061 ] 6.0E-01 
  Age at starting smoking in current 
smokers 
PC7  0.026 [ -0.01 , 0.065 ] 1.7E-01 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Age at starting smoking in current 
smokers 
PC8  0.033 [ -0.00 , 0.071 ] 8.4E-02 
  Age at starting smoking in current 
smokers 
PC9  0.007 [ -0.01 , 0.026 ] 4.2E-01 
  Age at starting smoking in current 
smokers 
PC10  0.068 [ 0.028 , 0.108 ] 8.5E-04 
4 linear regression Caffeine consumed per day Cannabis initiation  5.788 [ 3.827 , 7.749 ] 7.2E-09 
  Caffeine consumed per day Age  -0.60 [ -0.75 , -0.44 ] 1.8E-14 
  Caffeine consumed per day Sex  -21.6 [ -23.2 , -20.0 ] 2.E-158 
  Caffeine consumed per day Overall health rating  4.479 [ 2.771 , 6.187 ] 2.8E-07 
  Caffeine consumed per day Educational attainment  -3.03 [ -4.29 , -1.76 ] 2.7E-06 
  Caffeine consumed per day Townsend deprivation index  0.849 [ 0.421 , 1.277 ] 1.0E-04 
  Caffeine consumed per day PC1  -0.62 [ -1.36 , 0.102 ] 9.2E-02 
  Caffeine consumed per day PC2  -1.15 [ -1.91 , -0.39 ] 2.9E-03 
  Caffeine consumed per day PC3  -0.80 [ -1.52 , -0.07 ] 3.1E-02 
  Caffeine consumed per day PC4  0.299 [ -0.18 , 0.784 ] 2.3E-01 
  Caffeine consumed per day PC5  0.248 [ 0.031 , 0.464 ] 2.5E-02 
  Caffeine consumed per day PC6  0.394 [ -0.28 , 1.072 ] 2.5E-01 
  Caffeine consumed per day PC7  -0.32 [ -0.85 , 0.215 ] 2.4E-01 
  Caffeine consumed per day PC8  -0.73 [ -1.27 , -0.19 ] 7.6E-03 
  Caffeine consumed per day PC9  -0.09 [ -0.34 , 0.158 ] 4.6E-01 
  Caffeine consumed per day PC10  0.342 [ -0.20 , 0.889 ] 2.2E-01 
5 linear regression Caffeine consumed per day Smoking initiation  11.41 [ 10.35 , 12.48 ] 5.8E-98 
  Caffeine consumed per day Age  -0.95 [ -1.04 , -0.86 ] 3.9E-87 
  Caffeine consumed per day Sex  -21.9 [ -22.9 , -20.8 ] 0.0E+00 
  Caffeine consumed per day Overall health rating  6.796 [ 5.702 , 7.890 ] 4.5E-34 
  Caffeine consumed per day Educational attainment  -4.46 [ -5.22 , -3.70 ] 1.6E-30 
  Caffeine consumed per day Townsend deprivation index  1.898 [ 1.625 , 2.171 ] 2.7E-42 
  Caffeine consumed per day PC1  -0.00 [ -0.49 , 0.473 ] 9.7E-01 
  Caffeine consumed per day PC2  -0.40 [ -0.90 , 0.097 ] 1.1E-01 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Caffeine consumed per day PC3  -0.34 [ -0.81 , 0.139 ] 1.6E-01 
  Caffeine consumed per day PC4  0.498 [ 0.174 , 0.822 ] 2.5E-03 
  Caffeine consumed per day PC5  0.108 [ -0.03 , 0.250 ] 1.3E-01 
  Caffeine consumed per day PC6  0.297 [ -0.14 , 0.742 ] 1.9E-01 
  Caffeine consumed per day PC7  -0.38 [ -0.74 , -0.03 ] 3.1E-02 
  Caffeine consumed per day PC8  -0.52 [ -0.87 , -0.16 ] 3.8E-03 
  Caffeine consumed per day PC9  -0.05 [ -0.22 , 0.106 ] 4.9E-01 
  Caffeine consumed per day PC10  0.252 [ -0.10 , 0.611 ] 1.7E-01 
6 logistic regression Cannabis initiation Caffeine consumed per day  1.000 [ 1.000 , 1.000 ] 1.9E-09 
  Cannabis initiation Age  0.928 [ 0.926 , 0.931 ] 0.0E+00 
  Cannabis initiation Sex  0.716 [ 0.696 , 0.736 ] 1.E-121 
  Cannabis initiation Overall health rating  1.046 [ 1.016 , 1.077 ] 2.6E-03 
  Cannabis initiation Educational attainment  1.552 [ 1.513 , 1.591 ] 5.E-259 
  Cannabis initiation Townsend deprivation index  1.156 [ 1.148 , 1.164 ] 0.0E+00 
  Cannabis initiation PC1  1.014 [ 1.001 , 1.027 ] 3.0E-02 
  Cannabis initiation PC2  1.005 [ 0.992 , 1.019 ] 4.2E-01 
  Cannabis initiation PC3  1.021 [ 1.008 , 1.034 ] 1.2E-03 
  Cannabis initiation PC4  0.989 [ 0.981 , 0.997 ] 1.2E-02 
  Cannabis initiation PC5  1.005 [ 1.002 , 1.009 ] 2.0E-03 
  Cannabis initiation PC6  1.007 [ 0.995 , 1.019 ] 2.1E-01 
  Cannabis initiation PC7  1.000 [ 0.991 , 1.009 ] 9.6E-01 
  Cannabis initiation PC8  1.002 [ 0.992 , 1.011 ] 6.4E-01 
  Cannabis initiation PC9  0.992 [ 0.988 , 0.997 ] 1.5E-03 
  Cannabis initiation PC10  0.985 [ 0.975 , 0.994 ] 2.8E-03 
7 logistic regression Cannabis initiation Estimated standard drinks per 
week 
 1.021 [ 1.020 , 1.022 ] 0.0E+00 
  Cannabis initiation Age  0.932 [ 0.930 , 0.934 ] 0.0E+00 
  Cannabis initiation Sex  0.830 [ 0.812 , 0.849 ] 3.9E-58 
  Cannabis initiation Overall health rating  1.062 [ 1.039 , 1.087 ] 1.1E-07 
  Cannabis initiation Educational attainment  1.515 [ 1.487 , 1.545 ] 0.0E+00 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Cannabis initiation Townsend deprivation index  1.147 [ 1.141 , 1.154 ] 0.0E+00 
  Cannabis initiation PC1  1.012 [ 1.002 , 1.022 ] 1.5E-02 
  Cannabis initiation PC2  1.001 [ 0.990 , 1.011 ] 8.0E-01 
  Cannabis initiation PC3  1.009 [ 0.999 , 1.019 ] 5.1E-02 
  Cannabis initiation PC4  0.982 [ 0.975 , 0.988 ] 4.5E-08 
  Cannabis initiation PC5  1.006 [ 1.003 , 1.009 ] 4.5E-06 
  Cannabis initiation PC6  1.004 [ 0.995 , 1.013 ] 3.6E-01 
  Cannabis initiation PC7  1.002 [ 0.994 , 1.009 ] 5.7E-01 
  Cannabis initiation PC8  1.004 [ 0.997 , 1.011 ] 2.0E-01 
  Cannabis initiation PC9  0.990 [ 0.987 , 0.994 ] 1.5E-07 
  Cannabis initiation PC10  0.982 [ 0.975 , 0.989 ] 3.8E-06 
8 logistic regression Cannabis initiation Smoking initiation  3.938 [ 3.827 , 4.053 ] 0.0E+00 
  Cannabis initiation Age  0.919 [ 0.917 , 0.921 ] 0.0E+00 
  Cannabis initiation Sex  0.737 [ 0.720 , 0.754 ] 1.E-150 
  Cannabis initiation Overall health rating  0.993 [ 0.969 , 1.017 ] 5.9E-01 
  Cannabis initiation Educational attainment  1.623 [ 1.591 , 1.656 ] 0.0E+00 
  Cannabis initiation Townsend deprivation index  1.140 [ 1.133 , 1.146 ] 0.0E+00 
  Cannabis initiation PC1  1.009 [ 0.999 , 1.020 ] 7.3E-02 
  Cannabis initiation PC2  1.002 [ 0.991 , 1.013 ] 6.6E-01 
  Cannabis initiation PC3  1.010 [ 0.999 , 1.020 ] 6.1E-02 
  Cannabis initiation PC4  0.986 [ 0.979 , 0.993 ] 9.5E-05 
  Cannabis initiation PC5  1.007 [ 1.004 , 1.010 ] 9.9E-07 
  Cannabis initiation PC6  1.004 [ 0.994 , 1.014 ] 4.0E-01 
  Cannabis initiation PC7  1.001 [ 0.993 , 1.009 ] 7.0E-01 
  Cannabis initiation PC8  1.001 [ 0.993 , 1.009 ] 7.2E-01 
  Cannabis initiation PC9  0.992 [ 0.988 , 0.996 ] 5.7E-05 
  Cannabis initiation PC10  0.985 [ 0.977 , 0.992 ] 2.1E-04 
9 linear regression Cigarettes per day Caffeine consumed per day  0.006 [ 0.006 , 0.007 ] 1.9E-68 
  Cigarettes per day Age  0.043 [ 0.022 , 0.063 ] 5.5E-05 
  Cigarettes per day Sex  -1.46 [ -1.68 , -1.23 ] 5.0E-36 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Cigarettes per day Overall health rating  1.840 [ 1.613 , 2.066 ] 3.0E-56 
  Cigarettes per day Educational attainment  -0.61 [ -0.77 , -0.45 ] 1.2E-13 
  Cigarettes per day Townsend deprivation index  0.188 [ 0.138 , 0.238 ] 1.6E-13 
  Cigarettes per day PC1  -0.07 [ -0.17 , 0.034 ] 1.9E-01 
  Cigarettes per day PC2  0.020 [ -0.08 , 0.131 ] 7.1E-01 
  Cigarettes per day PC3  -0.02 [ -0.13 , 0.077 ] 6.0E-01 
  Cigarettes per day PC4  0.106 [ 0.035 , 0.177 ] 3.3E-03 
  Cigarettes per day PC5  0.034 [ 0.004 , 0.063 ] 2.5E-02 
  Cigarettes per day PC6  0.059 [ -0.03 , 0.156 ] 2.3E-01 
  Cigarettes per day PC7  0.048 [ -0.02 , 0.123 ] 2.1E-01 
  Cigarettes per day PC8  0.044 [ -0.03 , 0.119 ] 2.5E-01 
  Cigarettes per day PC9  0.039 [ 0.001 , 0.077 ] 4.2E-02 
  Cigarettes per day PC10  0.009 [ -0.06 , 0.089 ] 8.1E-01 
10 linear regression Cigarettes per day Cannabis initiation  -0.78 [ -1.12 , -0.44 ] 7.3E-06 
  Cigarettes per day Age  0.029 [ -0.00 , 0.061 ] 6.8E-02 
  Cigarettes per day Sex  -1.50 [ -1.82 , -1.17 ] 1.5E-19 
  Cigarettes per day Overall health rating  1.814 [ 1.495 , 2.133 ] 1.7E-28 
  Cigarettes per day Educational attainment  -0.59 [ -0.83 , -0.34 ] 1.7E-06 
  Cigarettes per day Townsend deprivation index  0.143 [ 0.072 , 0.214 ] 7.3E-05 
  Cigarettes per day PC1  0.021 [ -0.12 , 0.170 ] 7.7E-01 
  Cigarettes per day PC2  -0.03 [ -0.19 , 0.115 ] 6.2E-01 
  Cigarettes per day PC3  -0.13 [ -0.28 , 0.007 ] 6.3E-02 
  Cigarettes per day PC4  -0.00 [ -0.10 , 0.091 ] 9.3E-01 
  Cigarettes per day PC5  0.055 [ 0.014 , 0.097 ] 8.6E-03 
  Cigarettes per day PC6  0.073 [ -0.06 , 0.210 ] 2.9E-01 
  Cigarettes per day PC7  0.105 [ -0.00 , 0.213 ] 5.4E-02 
  Cigarettes per day PC8  0.005 [ -0.10 , 0.111 ] 9.2E-01 
  Cigarettes per day PC9  0.066 [ 0.013 , 0.120 ] 1.4E-02 
  Cigarettes per day PC10  0.129 [ 0.018 , 0.240 ] 2.2E-02 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
11 linear regression Cigarettes per day Estimated standard drinks per 
week 
 0.022 [ 0.016 , 0.028 ] 9.7E-15 
  Cigarettes per day Age  0.044 [ 0.028 , 0.059 ] 2.0E-08 
  Cigarettes per day Sex  -1.44 [ -1.61 , -1.26 ] 1.0E-56 
  Cigarettes per day Overall health rating  1.736 [ 1.574 , 1.898 ] 1.5E-96 
  Cigarettes per day Educational attainment  -0.68 [ -0.80 , -0.56 ] 3.4E-29 
  Cigarettes per day Townsend deprivation index  0.201 [ 0.164 , 0.237 ] 2.1E-27 
  Cigarettes per day PC1  -0.06 [ -0.14 , 0.014 ] 1.1E-01 
  Cigarettes per day PC2  0.008 [ -0.07 , 0.089 ] 8.4E-01 
  Cigarettes per day PC3  -0.02 [ -0.10 , 0.052 ] 5.3E-01 
  Cigarettes per day PC4  0.060 [ 0.008 , 0.112 ] 2.3E-02 
  Cigarettes per day PC5  0.035 [ 0.014 , 0.057 ] 1.2E-03 
  Cigarettes per day PC6  0.015 [ -0.05 , 0.087 ] 6.6E-01 
  Cigarettes per day PC7  0.002 [ -0.05 , 0.058 ] 9.3E-01 
  Cigarettes per day PC8  0.011 [ -0.04 , 0.067 ] 6.9E-01 
  Cigarettes per day PC9  0.044 [ 0.017 , 0.072 ] 1.5E-03 
  Cigarettes per day PC10  0.019 [ -0.03 , 0.078 ] 5.1E-01 
12 linear regression Estimated standard drinks per 
week 
Cannabis initiation  3.390 [ 3.240 , 3.540 ] 0.0E+00 
  Estimated standard drinks per 
week 
Age  0.082 [ 0.071 , 0.094 ] 4.8E-44 
  Estimated standard drinks per 
week 
Sex  -6.39 [ -6.51 , -6.27 ] 0.0E+00 
  Estimated standard drinks per 
week 
Overall health rating  -0.72 [ -0.84 , -0.59 ] 4.1E-28 
  Estimated standard drinks per week Educational attainment  0.093 [ -0.00 , 0.189 ] 5.8E-02 
  Estimated standard drinks per week Townsend deprivation index  -0.00 [ -0.03 , 0.029 ] 8.7E-01 
  Estimated standard drinks per week PC1  -0.01 [ -0.07 , 0.036 ] 5.0E-01 
  Estimated standard drinks per week PC2  0.028 [ -0.03 , 0.086 ] 3.5E-01 
  Estimated standard drinks per week PC3  -0.06 [ -0.11 , -0.00 ] 3.1E-02 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Estimated standard drinks per week PC4  0.044 [ 0.007 , 0.081 ] 2.0E-02 
  Estimated standard drinks per 
week 
PC5  0.080 [ 0.064 , 0.097 ] 5.1E-22 
  Estimated standard drinks per week PC6  0.025 [ -0.02 , 0.077 ] 3.4E-01 
  Estimated standard drinks per week PC7  -0.00 [ -0.04 , 0.036 ] 8.1E-01 
  Estimated standard drinks per week PC8  0.000 [ -0.04 , 0.041 ] 9.8E-01 
  Estimated standard drinks per 
week 
PC9  0.058 [ 0.038 , 0.077 ] 3.7E-09 
  Estimated standard drinks per 
week 
PC10  0.124 [ 0.082 , 0.166 ] 7.2E-09 
13 linear regression Estimated standard drinks per 
week 
Smoking initiation  3.586 [ 3.506 , 3.665 ] 0.0E+00 
  Estimated standard drinks per 
week 
Age  -0.03 [ -0.04 , -0.02 ] 4.1E-20 
  Estimated standard drinks per 
week 
Sex  -6.99 [ -7.07 , -6.91 ] 0.0E+00 
  Estimated standard drinks per 
week 
Overall health rating  -0.82 [ -0.90 , -0.74 ] 2.4E-89 
  Estimated standard drinks per 
week 
Educational attainment  0.343 [ 0.286 , 0.400 ] 5.0E-32 
  Estimated standard drinks per week Townsend deprivation index  -0.01 [ -0.03 , 0.009 ] 3.1E-01 
  Estimated standard drinks per week PC1  -0.00 [ -0.04 , 0.028 ] 6.9E-01 
  Estimated standard drinks per week PC2  0.021 [ -0.01 , 0.059 ] 2.6E-01 
  Estimated standard drinks per 
week 
PC3  -0.06 [ -0.09 , -0.02 ] 8.6E-04 
  Estimated standard drinks per 
week 
PC4  0.050 [ 0.025 , 0.074 ] 5.1E-05 
  Estimated standard drinks per 
week 
PC5  0.093 [ 0.082 , 0.103 ] 2.5E-67 
  Estimated standard drinks per week PC6  -0.02 [ -0.05 , 0.008 ] 1.4E-01 
  Estimated standard drinks per week PC7  -0.02 [ -0.05 , -0.00 ] 3.8E-02 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Estimated standard drinks per week PC8  0.002 [ -0.02 , 0.028 ] 8.7E-01 
  Estimated standard drinks per 
week 
PC9  0.062 [ 0.050 , 0.074 ] 4.1E-23 
  Estimated standard drinks per 
week 
PC10  0.132 [ 0.105 , 0.160 ] 7.9E-22 
14 linear regression Pack years of smoking Cannabis initiation  6.332 [ 6.164 , 6.500 ] 0.0E+00 
  Pack years of smoking Age  0.345 [ 0.333 , 0.358 ] 0.0E+00 
  Pack years of smoking Sex  -1.72 [ -1.85 , -1.59 ] 8.E-150 
  Pack years of smoking Overall health rating  2.146 [ 2.011 , 2.282 ] 7.E-210 
  Pack years of smoking Educational attainment  -1.87 [ -1.97 , -1.76 ] 6.E-285 
  Pack years of smoking Townsend deprivation index  0.342 [ 0.307 , 0.376 ] 3.0E-83 
  Pack years of smoking PC1  -0.01 [ -0.07 , 0.044 ] 6.1E-01 
  Pack years of smoking PC2  0.003 [ -0.05 , 0.065 ] 9.1E-01 
  Pack years of smoking PC3  -0.02 [ -0.08 , 0.031 ] 3.6E-01 
  Pack years of smoking PC4  0.000 [ -0.03 , 0.040 ] 9.9E-01 
  Pack years of smoking PC5  0.055 [ 0.037 , 0.072 ] 6.5E-10 
  Pack years of smoking PC6  -0.00 [ -0.06 , 0.047 ] 7.8E-01 
  Pack years of smoking PC7  -0.04 [ -0.08 , -0.00 ] 4.4E-02 
  Pack years of smoking PC8  0.030 [ -0.01 , 0.074 ] 1.8E-01 
  Pack years of smoking PC9  0.016 [ -0.00 , 0.037 ] 1.2E-01 
  Pack years of smoking PC10  0.032 [ -0.01 , 0.077 ] 1.5E-01 
15 linear regression Pack years of smoking Smoking initiation  NC  
  Pack years of smoking Age  0.155 [ 0.149 , 0.161 ] 0.0E+00 
  Pack years of smoking Sex  -1.30 [ -1.36 , -1.23 ] 0.0E+00 
  Pack years of smoking Overall health rating  1.505 [ 1.438 , 1.572 ] 0.0E+00 
  Pack years of smoking Educational attainment  -0.68 [ -0.73 , -0.63 ] 3.E-175 
  Pack years of smoking Townsend deprivation index  0.266 [ 0.249 , 0.283 ] 1.E-204 
  Pack years of smoking PC1  -0.02 [ -0.05 , 0.007 ] 1.4E-01 
  Pack years of smoking PC2  0.018 [ -0.01 , 0.050 ] 2.4E-01 
  Pack years of smoking PC3  0.001 [ -0.02 , 0.031 ] 9.4E-01 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
 
 
Supplementary table page 108 
 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Pack years of smoking PC4  0.023 [ 0.002 , 0.043 ] 2.6E-02 
  Pack years of smoking PC5  0.029 [ 0.020 , 0.038 ] 3.9E-11 
  Pack years of smoking PC6  -0.02 [ -0.05 , 0.005 ] 1.1E-01 
  Pack years of smoking PC7  -0.01 [ -0.03 , 0.004 ] 1.3E-01 
  Pack years of smoking PC8  0.026 [ 0.003 , 0.048 ] 2.1E-02 
  Pack years of smoking PC9  0.008 [ -0.00 , 0.019 ] 9.1E-02 
  Pack years of smoking PC10  0.024 [ 0.001 , 0.046 ] 3.6E-02 
16 linear regression Smoking cessation Caffeine consumed per day  0.000 [ 0.000 , 0.000 ] 0.0E+00 
  Smoking cessation Age  -0.00 [ -0.00 , -0.00 ] 0.0E+00 
  Smoking cessation Sex  -0.01 [ -0.01 , -0.00 ] 8.3E-12 
  Smoking cessation Overall health rating  0.048 [ 0.044 , 0.052 ] 2.E-119 
  Smoking cessation Educational attainment  -0.01 [ -0.02 , -0.01 ] 1.3E-42 
  Smoking cessation Townsend deprivation index  0.015 [ 0.014 , 0.016 ] 7.E-218 
  Smoking cessation PC1  0.000 [ -0.00 , 0.002 ] 5.7E-01 
  Smoking cessation PC2  0.001 [ 3.085 , 0.003 ] 4.6E-02 
  Smoking cessation PC3  -0.00 [ -0.00 , 9.636 ] 6.4E-02 
  Smoking cessation PC4  0.000 [ -0.00 , 0.001 ] 6.7E-01 
  Smoking cessation PC5  0.001 [ 0.000 , 0.001 ] 8.2E-08 
  Smoking cessation PC6  0.000 [ -0.00 , 0.002 ] 2.5E-01 
  Smoking cessation PC7  -0.00 [ -0.00 , 0.001 ] 8.6E-01 
  Smoking cessation PC8  0.000 [ -0.00 , 0.002 ] 1.6E-01 
  Smoking cessation PC9  0.000 [ -9.70 , 0.001 ] 9.8E-02 
  Smoking cessation PC10  0.000 [ -0.00 , 0.001 ] 3.6E-01 
17 linear regression Smoking cessation Cannabis initiation  0.028 [ 0.022 , 0.033 ] 1.7E-24 
  Smoking cessation Age  -0.00 [ -0.00 , -0.00 ] 9.E-162 
  Smoking cessation Sex  -0.02 [ -0.02 , -0.01 ] 2.0E-21 
  Smoking cessation Overall health rating  0.039 [ 0.034 , 0.044 ] 1.2E-55 
  Smoking cessation Educational attainment  -0.01 [ -0.01 , -0.01 ] 6.6E-16 
  Smoking cessation Townsend deprivation index  0.010 [ 0.009 , 0.011 ] 2.0E-66 
  Smoking cessation PC1  -0.00 [ -0.00 , 0.001 ] 4.5E-01 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Smoking cessation PC2  -0.00 [ -0.00 , 0.001 ] 5.9E-01 
  Smoking cessation PC3  -0.00 [ -0.00 , 0.000 ] 2.6E-01 
  Smoking cessation PC4  0.000 [ -0.00 , 0.001 ] 4.8E-01 
  Smoking cessation PC5  0.000 [ 1.772 , 0.001 ] 4.4E-02 
  Smoking cessation PC6  0.000 [ -0.00 , 0.002 ] 4.3E-01 
  Smoking cessation PC7  0.001 [ -7.57 , 0.003 ] 6.2E-02 
  Smoking cessation PC8  0.001 [ -0.00 , 0.002 ] 9.6E-02 
  Smoking cessation PC9  0.000 [ -0.00 , 0.000 ] 6.8E-01 
  Smoking cessation PC10  -0.00 [ -0.00 , 0.001 ] 5.8E-01 
18 linear regression Smoking cessation Estimated standard drinks per 
week 
 0.001 [ 0.001 , 0.001 ] 2.9E-88 
  Smoking cessation Age  -0.00 [ -0.00 , -0.00 ] 0.0E+00 
  Smoking cessation Sex  -0.01 [ -0.01 , -0.00 ] 1.5E-11 
  Smoking cessation Overall health rating  0.056 [ 0.053 , 0.059 ] 4.E-270 
  Smoking cessation Educational attainment  -0.02 [ -0.02 , -0.02 ] 8.E-113 
  Smoking cessation Townsend deprivation index  0.017 [ 0.016 , 0.017 ] 0.0E+00 
  Smoking cessation PC1  -0.00 [ -0.00 , 0.001 ] 5.7E-01 
  Smoking cessation PC2  1.231 [ -0.00 , 0.001 ] 9.9E-01 
  Smoking cessation PC3  -0.00 [ -0.00 , 2.379 ] 5.4E-02 
  Smoking cessation PC4  0.000 [ -0.00 , 0.001 ] 3.6E-01 
  Smoking cessation PC5  0.001 [ 0.000 , 0.001 ] 8.8E-07 
  Smoking cessation PC6  0.000 [ -0.00 , 0.002 ] 2.1E-01 
  Smoking cessation PC7  0.000 [ -0.00 , 0.001 ] 7.7E-01 
  Smoking cessation PC8  0.001 [ -1.83 , 0.002 ] 5.0E-02 
  Smoking cessation PC9  0.000 [ -0.00 , 0.000 ] 4.2E-01 
  Smoking cessation PC10  4.573 [ -0.00 , 0.001 ] 9.3E-01 
19 logistic regression Smoking initiation Caffeine consumed per day  1.000 [ 1.000 , 1.000 ] 1.3E-98 
  Smoking initiation Age  1.014 [ 1.013 , 1.015 ] 4.E-105 
  Smoking initiation Sex  0.795 [ 0.784 , 0.806 ] 5.E-223 
  Smoking initiation Overall health rating  1.186 [ 1.168 , 1.203 ] 3.E-110 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Smoking initiation Educational attainment  0.973 [ 0.963 , 0.984 ] 6.7E-07 
  Smoking initiation Townsend deprivation index  1.057 [ 1.053 , 1.061 ] 3.E-183 
  Smoking initiation PC1  1.004 [ 0.998 , 1.011 ] 1.7E-01 
  Smoking initiation PC2  1.000 [ 0.994 , 1.007 ] 7.7E-01 
  Smoking initiation PC3  1.005 [ 0.999 , 1.012 ] 8.6E-02 
  Smoking initiation PC4  0.991 [ 0.987 , 0.996 ] 2.8E-04 
  Smoking initiation PC5  1.002 [ 1.000 , 1.004 ] 4.4E-03 
  Smoking initiation PC6  1.004 [ 0.998 , 1.010 ] 1.2E-01 
  Smoking initiation PC7  0.999 [ 0.994 , 1.004 ] 7.6E-01 
  Smoking initiation PC8  1.007 [ 1.002 , 1.012 ] 2.2E-03 
  Smoking initiation PC9  0.996 [ 0.994 , 0.999 ] 7.1E-03 
  Smoking initiation PC10  0.997 [ 0.992 , 1.002 ] 3.0E-01 
20 logistic regression Smoking initiation Cannabis initiation  3.874 [ 3.766 , 3.986 ] 0.0E+00 
  Smoking initiation Age  1.041 [ 1.039 , 1.043 ] 0.0E+00 
  Smoking initiation Sex  0.884 [ 0.868 , 0.901 ] 5.3E-38 
  Smoking initiation Overall health rating  1.163 [ 1.140 , 1.186 ] 1.9E-50 
  Smoking initiation Educational attainment  0.846 [ 0.833 , 0.858 ] 2.E-108 
  Smoking initiation Townsend deprivation index  1.021 [ 1.016 , 1.026 ] 3.4E-16 
  Smoking initiation PC1  1.004 [ 0.995 , 1.012 ] 3.3E-01 
  Smoking initiation PC2  1.001 [ 0.992 , 1.010 ] 8.0E-01 
  Smoking initiation PC3  0.998 [ 0.990 , 1.007 ] 7.6E-01 
  Smoking initiation PC4  0.991 [ 0.985 , 0.996 ] 2.4E-03 
  Smoking initiation PC5  1.003 [ 1.000 , 1.005 ] 1.5E-02 
  Smoking initiation PC6  1.002 [ 0.994 , 1.010 ] 5.6E-01 
  Smoking initiation PC7  0.998 [ 0.992 , 1.005 ] 7.3E-01 
  Smoking initiation PC8  1.008 [ 1.001 , 1.014 ] 1.1E-02 
  Smoking initiation PC9  0.998 [ 0.995 , 1.001 ] 3.2E-01 
  Smoking initiation PC10  1.003 [ 0.997 , 1.010 ] 2.6E-01 
21 logistic regression Smoking initiation Estimated standard drinks per 
week 
 1.026 [ 1.026 , 1.027 ] 0.0E+00 
Table S5-7. Phenotypic associations between use or initiation of different substances in the UK Biobank cohort. The dependent variables and independent 
variables (in blue) in the 21 logistic or linear regression models matched the outcome traits and exposure traits used in the MR analyses. Each model contained 
covariates : Age, sex, overall health rating, educational attainment, Townsend Deprivation Index, and the first 10 genetic principle components (PC1- PC10). 
Raw estimates from the modelling were converted to interpretable scales as described in the method. Results were in bold phase when the association p values 
of the predictor lower than a significance threshold, 0.002380952 (0.05/21), obtained from Bonferroni correction. 
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 Converted Estimates 
Model no. Method Outcome Predictor  Effect size (95% CI) P value 
  Smoking initiation Age  1.017 [ 1.016 , 1.018 ] 5.E-266 
  Smoking initiation Sex  0.946 [ 0.935 , 0.957 ] 2.2E-21 
  Smoking initiation Overall health rating  1.213 [ 1.199 , 1.227 ] 6.E-246 
  Smoking initiation Educational attainment  0.957 [ 0.949 , 0.964 ] 6.3E-27 
  Smoking initiation Townsend deprivation index  1.059 [ 1.056 , 1.062 ] 0.0E+00 
  Smoking initiation PC1  1.003 [ 0.998 , 1.008 ] 1.5E-01 
  Smoking initiation PC2  0.999 [ 0.994 , 1.004 ] 9.0E-01 
  Smoking initiation PC3  1.004 [ 0.999 , 1.009 ] 9.2E-02 
  Smoking initiation PC4  0.988 [ 0.985 , 0.992 ] 4.3E-11 
  Smoking initiation PC5  1.001 [ 0.999 , 1.002 ] 1.0E-01 
  Smoking initiation PC6  1.005 [ 1.000 , 1.010 ] 2.3E-02 
  Smoking initiation PC7  0.999 [ 0.995 , 1.002 ] 6.4E-01 
  Smoking initiation PC8  1.006 [ 1.003 , 1.010 ] 3.5E-04 
  Smoking initiation PC9  0.996 [ 0.994 , 0.997 ] 5.1E-06 
  Smoking initiation PC10  0.995 [ 0.991 , 0.999 ] 1.3E-02 
 
